1	R	NN	O	r	nn	3	SENT_1	[p1l19t81r45b118],
2	E	NN	O	e	nn	3	SENT_1	[p1l54t81r74b118],
3	V	NN	O	v	_	0	SENT_1	[p1l81t81r111b118],
4	I	PRP	O	I	dep	3	SENT_1	[p1l119t81r127b118],
5	E	NNP	O	E	nn	10	SENT_1	[p1l139t81r159b118],
6	W	NNP	O	W	nn	10	SENT_1	[p1l167t81r209b118],
7	nature	NN	O	nature	nn	10	SENT_1	[p1l1797t97r1888b118],
8	publishing	NN	O	publishing	nn	10	SENT_1	[p1l1897t94r2046b125],
9	group	NN	O	group	nn	10	SENT_1	[p1l2055t101r2139b125],
10	Open	NNP	MISC	Open	dep	3	SENT_1	[p1l22t153r158b216],

1	Personalized	VBN	O	personalize	_	0	SENT_2	[p1l27t291r560b367],
2	Cancer	NN	O	cancer	nn	3	SENT_2	[p1l588t294r883b367],
3	Medicine	NN	O	medicine	dobj	1	SENT_2	[p1l908t291r1320b367],
4	:	:	O	:	_	0	SENT_2	[p1l908t291r1320b367],
5	Molecular	JJ	ORGANIZATION	molecular	amod	6	SENT_2	[p1l1347t291r1770b367],
6	Diagnostics	NNPS	ORGANIZATION	Diagnostics	dep	3	SENT_2	[p1l27t406r540b499],
7	,	,	O	,	_	0	SENT_2	[p1l27t406r540b499],
8	Predictive	NNP	O	Predictive	nn	9	SENT_2	[p1l568t403r986b479],
9	Biomarkers	NNS	O	biomarker	dep	3	SENT_2	[p1l1016t403r1511b490],
10	,	,	O	,	_	0	SENT_2	[p1l1016t403r1511b490],
11	and	CC	O	and	_	0	SENT_2	[p1l1535t403r1691b479],
12	Drug	NN	O	drug	nn	13	SENT_2	[p1l1724t406r1928b499],
13	Resistance	NN	O	resistance	dep	3	SENT_2	[p1l27t518r471b590],

1	D	NN	O	d	_	0	SENT_3	[p1l20t666r55b699],
2	Gonzalez	NNP	PERSON	Gonzalez	nn	4	SENT_3	[p1l67t663r257b699],
3	de	FW	PERSON	de	nn	4	SENT_3	[p1l268t663r314b699],
4	Castro	NNP	PERSON	Castro	dep	1	SENT_3	[p1l326t658r489b705],
5	‘	CD	NUMBER	‘	dep	1	SENT_3	[p1l326t658r489b705],
6	,	,	O	,	_	0	SENT_3	[p1l326t658r489b705],
7	PA	NN	LOCATION	pa	nn	8	SENT_3	[p1l501t665r558b699],
8	Clarkez	NNP	LOCATION	Clarkez	dep	1	SENT_3	[p1l570t658r733b705],
9	,	,	O	,	_	0	SENT_3	[p1l570t658r733b705],
10	B	NNP	O	B	nn	11	SENT_3	[p1l745t666r773b699],
11	Al-Lazikaniz	NNP	O	Al-Lazikaniz	conj_and	5	SENT_3	[p1l784t658r1044b699],
12	and	CC	O	and	_	0	SENT_3	[p1l1055t663r1131b699],
13	P	NN	O	p	conj_and	5	SENT_3	[p1l1141t666r1168b699],
14	Workmanz	JJ	O	workmanz	amod	13	SENT_3	[p1l1178t658r1402b699],

1	The	DT	O	the	det	3	SENT_4	[p1l19t780r84b811],
2	progressive	JJ	O	progressive	amod	3	SENT_4	[p1l94t781r298b819],
3	elucidation	NN	O	elucidation	nsubj	11	SENT_4	[p1l307t780r504b811],
4	of	IN	O	of	_	0	SENT_4	[p1l515t780r551b811],
5	the	DT	O	the	det	7	SENT_4	[p1l557t780r615b811],
6	molecular	JJ	O	molecular	amod	7	SENT_4	[p1l625t780r801b811],
7	pathogenesis	NN	O	pathogenesis	prep_of	3	SENT_4	[p1l810t780r1047b819],
8	of	IN	O	of	_	0	SENT_4	[p1l1056t780r1093b811],
9	cancer	NN	O	cancer	prep_of	7	SENT_4	[p1l1099t789r1215b811],
10	has	VBZ	O	have	aux	11	SENT_4	[p1l1224t780r1283b811],
11	fueled	VBN	O	fuel	_	0	SENT_4	[p1l1291t780r1402b811],
12	the	DT	O	the	det	14	SENT_4	[p1l1411t780r1469b811],
13	rational	JJ	O	rational	amod	14	SENT_4	[p1l1479t780r1613b811],
14	development	NN	O	development	dobj	11	SENT_4	[p1l1623t780r1860b819],
15	of	IN	O	of	_	0	SENT_4	[p1l1869t780r1905b811],
16	targeted	VBN	O	target	amod	17	SENT_4	[p1l1911t780r2063b819],
17	drugs	NNS	O	drug	prep_of	14	SENT_4	[p1l20t833r121b873],
18	for	IN	O	for	_	0	SENT_4	[p1l129t833r179b864],
19	patient	NN	O	patient	nn	20	SENT_4	[p1l188t834r314b872],
20	populations	NNS	O	population	prep_for	11	SENT_4	[p1l324t833r536b872],
21	stratiﬁed	VBN	O	stratiﬁed	partmod	20	SENT_4	[p1l545t833r701b864],
22	by	IN	O	by	_	0	SENT_4	[p1l712t833r755b873],
23	genetic	JJ	O	genetic	amod	24	SENT_4	[p1l762t834r894b873],
24	characteristics	NNS	O	characteristic	agent	21	SENT_4	[p1l902t833r1165b864],
25	.	.	O	.	_	0	SENT_4	[p1l902t833r1165b864],

1	Here	RB	O	here	advmod	3	SENT_5	[p1l1175t835r1256b864],
2	we	PRP	O	we	nsubj	11	SENT_5	[p1l1265t842r1315b864],
3	discuss	VBP	O	discuss	_	0	SENT_5	[p1l1324t833r1449b864],
4	general	JJ	O	general	amod	5	SENT_5	[p1l1458t833r1590b873],
5	challenges	NNS	O	challenge	dobj	3	SENT_5	[p1l1601t833r1789b873],
6	relating	VBG	O	relate	xcomp	3	SENT_5	[p1l1800t833r1934b873],
7	to	TO	O	to	_	0	SENT_5	[p1l1943t838r1979b864],
8	molecular	JJ	O	molecular	amod	9	SENT_5	[p1l21t888r197b919],
9	diagnostics	NNS	O	diagnostic	prep_to	6	SENT_5	[p1l205t888r407b927],
10	and	CC	O	and	_	0	SENT_5	[p1l416t888r481b919],
11	describe	VBP	O	describe	conj_and	3	SENT_5	[p1l491t888r640b919],
12	predictive	JJ	O	predictive	amod	13	SENT_5	[p1l650t888r827b926],
13	biomarkers	NNS	O	biomarker	dobj	11	SENT_5	[p1l837t888r1036b919],
14	for	IN	O	for	_	0	SENT_5	[p1l1044t888r1094b919],
15	personalized	JJ	O	personalized	amod	17	SENT_5	[p1l1103t888r1328b926],
16	cancer	NN	O	cancer	nn	17	SENT_5	[p1l1338t897r1454b919],
17	medicine	NN	O	medicine	prep_for	11	SENT_5	[p1l1463t888r1634b919],
18	.	.	O	.	_	0	SENT_5	[p1l1463t888r1634b919],

1	We	PRP	O	we	nsubj	3	SENT_6	[p1l1640t890r1695b919],
2	also	RB	O	also	advmod	3	SENT_6	[p1l1704t888r1773b919],
3	highlight	VBP	O	highlight	_	0	SENT_6	[p1l1783t888r1944b927],
4	resistance	NN	O	resistance	nn	5	SENT_6	[p1l1954t889r2129b919],
5	mechanisms	NNS	O	mechanism	dobj	3	SENT_6	[p1l21t942r241b973],
6	for	IN	O	for	_	0	SENT_6	[p1l249t942r299b973],
7	epidermal	JJ	O	epidermal	amod	10	SENT_6	[p1l307t942r486b981],
8	growth	NN	O	growth	nn	10	SENT_6	[p1l496t942r623b981],
9	factor	NN	O	factor	nn	10	SENT_6	[p1l632t942r737b973],
10	receptor	NN	O	receptor	prep_for	5	SENT_6	[p1l746t947r895b981],
11	(	CD	NUMBER	(	num	15	SENT_6	[p1l904t943r1017b977],
12	EGFR	NN	ORGANIZATION	egfr	nn	15	SENT_6	[p1l904t943r1017b977],
13	)	NN	O	)	nn	15	SENT_6	[p1l904t943r1017b977],
14	kinase	NN	O	kinase	nn	15	SENT_6	[p1l1029t942r1140b973],
15	inhibitors	NNS	O	inhibitor	tmod	3	SENT_6	[p1l1150t942r1319b973],
16	in	IN	O	in	_	0	SENT_6	[p1l1329t943r1359b972],
17	lung	NN	O	lung	nn	18	SENT_6	[p1l1370t942r1447b981],
18	cancer	NN	O	cancer	prep_in	15	SENT_6	[p1l1457t951r1579b973],
19	.	.	O	.	_	0	SENT_6	[p1l1457t951r1579b973],

1	We	PRP	O	we	nsubj	2	SENT_7	[p1l1585t944r1640b973],
2	envisage	VBP	O	envisage	_	0	SENT_7	[p1l1649t943r1805b981],
3	a	DT	O	a	det	4	SENT_7	[p1l1814t951r1832b973],
4	future	JJ	DATE	future	dobj	2	SENT_7	[p1l1841t942r1950b973],
5	requiring	VBG	O	require	xcomp	2	SENT_7	[p1l1960t943r2121b981],
6	the	DT	O	the	det	7	SENT_7	[p1l20t995r78b1026],
7	use	NN	O	use	dobj	5	SENT_7	[p1l88t1004r146b1026],
8	of	IN	O	of	_	0	SENT_7	[p1l155t995r192b1026],
9	longitudinal	JJ	O	longitudinal	amod	11	SENT_7	[p1l199t995r413b1034],
10	genome	NN	O	genome	nn	11	SENT_7	[p1l424t1004r570b1034],
11	sequencing	NN	O	sequencing	prep_of	7	SENT_7	[p1l579t996r782b1034],
12	and	CC	O	and	_	0	SENT_7	[p1l792t995r858b1026],
13	other	JJ	O	other	amod	15	SENT_7	[p1l868t995r964b1026],
14	omics	NNS	O	omic	nn	15	SENT_7	[p1l972t996r1074b1026],
15	technologies	NNS	O	technology	prep_of	7	SENT_7	[p1l1082t995r1311b1034],
16	alongside	IN	O	alongside	_	0	SENT_7	[p1l1320t995r1493b1034],
17	combinatorial	JJ	O	combinatorial	amod	18	SENT_7	[p1l1502t995r1748b1026],
18	treatment	NN	O	treatment	prep_alongside	11	SENT_7	[p1l1758t1000r1936b1026],
19	to	TO	O	to	aux	20	SENT_7	[p1l1944t1000r1980b1026],
20	overcome	VB	O	overcome	xcomp	5	SENT_7	[p1l20t1059r195b1081],
21	cellular	JJ	O	cellular	amod	24	SENT_7	[p1l204t1050r332b1081],
22	and	CC	O	and	_	0	SENT_7	[p1l340t1050r406b1081],
23	molecular	JJ	O	molecular	conj_and	21	SENT_7	[p1l417t1050r593b1081],
24	heterogeneity	NN	O	heterogeneity	dobj	20	SENT_7	[p1l602t1050r853b1089],
25	and	CC	O	and	_	0	SENT_7	[p1l861t1050r926b1081],
26	prevent	VBP	O	prevent	conj_and	2	SENT_7	[p1l938t1054r1074b1089],
27	resistance	NN	O	resistance	dobj	26	SENT_7	[p1l1083t1051r1259b1081],
28	caused	VBN	O	cause	partmod	27	SENT_7	[p1l1268t1050r1390b1081],
29	by	IN	O	by	_	0	SENT_7	[p1l1401t1050r1443b1089],
30	clonal	JJ	O	clonal	amod	31	SENT_7	[p1l1451t1050r1555b1081],
31	evolution	NN	O	evolution	agent	28	SENT_7	[p1l1565t1050r1743b1081],
32	.	.	O	.	_	0	SENT_7	[p1l1565t1050r1743b1081],

1	Our	PRP$	O	we	poss	3	SENT_8	[p1l10t1249r143b1308],
2	molecular	JJ	O	molecular	amod	3	SENT_8	[p1l159t1245r487b1308],
3	understanding	NN	O	understanding	nsubjpass	12	SENT_8	[p1l503t1245r980b1329],
4	of	IN	O	of	_	0	SENT_8	[p1l996t1245r1067b1308],
5	cancer	NN	O	cancer	nn	6	SENT_8	[p1l1075t1268r1287b1308],
6	causation	NN	O	causation	prep_of	3	SENT_8	[p1l1304t1250r1610b1308],
7	and	CC	O	and	_	0	SENT_8	[p1l1627t1245r1749b1308],
8	progression	NN	O	progression	prep_of	3	SENT_8	[p1l1763t1250r2143b1329],
9	has	VBZ	O	have	aux	12	SENT_8	[p1l8t1348r117b1411],
10	been	VBN	O	be	auxpass	12	SENT_8	[p1l136t1348r297b1411],
11	hugely	RB	O	hugely	advmod	12	SENT_8	[p1l316t1348r539b1432],
12	enabled	VBN	O	enable	_	0	SENT_8	[p1l556t1348r816b1411],
13	by	IN	O	by	_	0	SENT_8	[p1l832t1348r915b1432],
14	genome	NN	O	genome	nn	15	SENT_8	[p1l932t1371r1196b1432],
15	sequencing	NN	O	sequencing	agent	12	SENT_8	[p1l1218t1353r1594b1432],
16	and	CC	O	and	_	0	SENT_8	[p1l1614t1348r1738b1411],
17	other	JJ	O	other	amod	20	SENT_8	[p1l1758t1348r1934b1411],
18	largescale	JJ	O	largescale	amod	20	SENT_8	[p1l1952t1348r2139b1432, p1l9t1451r163b1514],
19	omics	NNS	O	omic	nn	20	SENT_8	[p1l181t1456r373b1514],
20	approaches	NNS	O	approach	agent	12	SENT_8	[p1l392t1451r775b1534],
21	,	,	O	,	_	0	SENT_8	[p1l392t1451r775b1534],
22	leading	VBG	O	lead	dep	15	SENT_8	[p1l794t1451r1034b1535],
23	to	TO	O	to	_	0	SENT_8	[p1l1049t1463r1112b1514],
24	the	DT	O	the	det	25	SENT_8	[p1l1130t1451r1232b1514],
25	discovery	NN	O	discovery	prep_to	22	SENT_8	[p1l1251t1451r1565b1535],
26	and	CC	O	and	_	0	SENT_8	[p1l1580t1451r1702b1514],
27	development	NN	O	development	conj_and	25	SENT_8	[p1l1719t1451r2144b1534],
28	of	IN	O	of	_	0	SENT_8	[p1l9t1555r81b1618],
29	molecularly	RB	O	molecularly	advmod	30	SENT_8	[p1l89t1555r481b1639],
30	targeted	VBN	O	target	amod	31	SENT_8	[p1l494t1555r762b1639],
31	drugs	NNS	O	drug	prep_of	25	SENT_8	[p1l779t1555r964b1639],
32	and	CC	O	and	_	0	SENT_8	[p1l983t1555r1106b1618],
33	companion	NN	O	companion	nn	34	SENT_8	[p1l1123t1560r1498b1638],
34	diagnostics	NNS	O	diagnostic	prep_of	25	SENT_8	[p1l1516t1555r1882b1639],
35	for	IN	O	for	_	0	SENT_8	[p1l1897t1555r1991b1618],
36	personalized	VBN	O	personalize	prep_for	34	SENT_8	[p1l2006t1577r2139b1638, p1l9t1657r335b1729],
37	,	,	O	,	_	0	SENT_8	[p1l2006t1577r2139b1638, p1l9t1657r335b1729],
38	precision	NN	O	precision	nn	39	SENT_8	[p1l354t1662r657b1740],
39	treatment	NN	O	treatment	npadvmod	51	SENT_8	[p1l674t1649r1041b1720],
40	.1	CD	NUMBER	.1	num	39	SENT_8	[p1l674t1649r1041b1720],
41	Of	IN	O	of	_	0	SENT_8	[p1l1065t1657r1158b1721],
42	course	NN	O	course	prep_of	51	SENT_8	[p1l1167t1680r1398b1729],
43	,	,	O	,	_	0	SENT_8	[p1l1167t1680r1398b1729],
44	the	DT	O	the	det	45	SENT_8	[p1l1417t1657r1521b1720],
45	outcome	NN	O	outcome	nsubjpass	51	SENT_8	[p1l1539t1669r1827b1720],
46	of	IN	O	of	_	0	SENT_8	[p1l1846t1657r1919b1720],
47	cancer	NN	O	cancer	nn	48	SENT_8	[p1l1928t1680r2144b1720],
48	treatment	NN	O	treatment	prep_of	45	SENT_8	[p1l8t1772r339b1823],
49	is	VBZ	O	be	auxpass	51	SENT_8	[p1l358t1765r408b1823],
50	not	RB	O	not	neg	51	SENT_8	[p1l429t1772r542b1823],
51	determined	VBN	O	determine	dep	15	SENT_8	[p1l563t1760r956b1823],
52	only	RB	O	only	advmod	51	SENT_8	[p1l976t1760r1126b1844],
53	by	IN	O	by	_	0	SENT_8	[p1l1141t1760r1224b1844],
54	the	DT	O	the	det	55	SENT_8	[p1l1241t1760r1346b1823],
55	variation	NN	O	variation	agent	51	SENT_8	[p1l1364t1765r1669b1823],
56	in	IN	O	in	_	0	SENT_8	[p1l1689t1765r1756b1822],
57	the	DT	O	the	det	59	SENT_8	[p1l1775t1760r1881b1823],
58	genetic	JJ	O	genetic	amod	59	SENT_8	[p1l1902t1765r2142b1844],
59	makeup	NN	O	makeup	prep_in	55	SENT_8	[p1l8t1863r281b1946],
60	of	IN	O	of	_	0	SENT_8	[p1l304t1863r378b1926],
61	a	DT	O	a	det	62	SENT_8	[p1l390t1886r425b1926],
62	tumor	NN	O	tumor	prep_of	59	SENT_8	[p1l444t1875r669b1926],
63	.	.	O	.	_	0	SENT_8	[p1l444t1875r669b1926],

1	Interpatient	JJ	O	interpatient	amod	2	SENT_9	[p1l694t1868r1097b1946],
2	differences	NNS	O	difference	nsubj	25	SENT_9	[p1l1117t1863r1482b1926],
3	in	IN	O	in	_	0	SENT_9	[p1l1504t1868r1571b1925],
4	pharmacokinetics	NNS	O	pharmacokinetic	prep_in	2	SENT_9	[p1l1591t1863r2138b1946, p1l9t1971r94b2029],
5	and	CC	O	and	_	0	SENT_9	[p1l116t1966r240b2029],
6	changes	NNS	O	change	prep_in	2	SENT_9	[p1l261t1966r524b2050],
7	in	IN	O	in	_	0	SENT_9	[p1l545t1971r611b2028],
8	drug	NN	O	drug	nn	9	SENT_9	[p1l632t1966r792b2050],
9	levels	NNS	O	level	prep_in	4	SENT_9	[p1l810t1966r990b2029],
10	during	IN	O	during	_	0	SENT_9	[p1l1012t1966r1239b2050],
11	treatment	NN	O	treatment	nn	13	SENT_9	[p1l1257t1978r1585b2029],
12	(	CD	NUMBER	(	num	13	SENT_9	[p1l1608t1967r1872b2049],
13	aspects	NNS	O	aspect	prep_during	9	SENT_9	[p1l1608t1967r1872b2049],
14	that	WDT	O	that	nsubj	15	SENT_9	[p1l1892t1966r2023b2029],
15	are	VBP	O	be	rcmod	4	SENT_9	[p1l2043t1989r2142b2029],
16	outside	IN	O	outside	_	0	SENT_9	[p1l9t2069r257b2132],
17	the	DT	O	the	det	18	SENT_9	[p1l279t2069r386b2132],
18	scope	NN	O	scope	prep_outside	15	SENT_9	[p1l410t2091r601b2152],
19	of	IN	O	of	_	0	SENT_9	[p1l624t2069r699b2132],
20	this	DT	O	this	det	22	SENT_9	[p1l711t2069r835b2132],
21	article	NN	O	article	nn	22	SENT_9	[p1l859t2069r1095b2146],
22	)	NN	O	)	prep_of	18	SENT_9	[p1l859t2069r1095b2146],
23	are	VBP	O	be	cop	25	SENT_9	[p1l1123t2092r1223b2132],
24	also	RB	O	also	advmod	25	SENT_9	[p1l1247t2069r1378b2132],
25	likely	JJ	O	likely	_	0	SENT_9	[p1l1401t2069r1587b2153],
26	to	TO	O	to	aux	27	SENT_9	[p1l1605t2081r1671b2132],
27	contribute	VB	O	contribute	xcomp	25	SENT_9	[p1l1696t2069r2051b2132],
28	to	TO	O	to	_	0	SENT_9	[p1l2073t2081r2139b2132],
29	therapy	NN	O	therapy	nn	30	SENT_9	[p1l8t2172r259b2256],
30	resistance	NN	O	resistance	prep_to	27	SENT_9	[p1l274t2177r607b2235],
31	.	.	O	.	_	0	SENT_9	[p1l274t2177r607b2235],

1	Therefore	RB	O	therefore	advmod	31	SENT_10	[p1l628t2172r960b2244],
2	,	,	O	,	_	0	SENT_10	[p1l628t2172r960b2244],
3	personalized	JJ	O	personalized	amod	4	SENT_10	[p1l978t2172r1398b2255],
4	treatment	NN	O	treatment	nsubj	16	SENT_10	[p1l1414t2184r1736b2235],
5	requires	VBZ	O	require	parataxis	31	SENT_10	[p1l1753t2177r2016b2255],
6	not	RB	O	not	neg	5	SENT_10	[p1l2035t2184r2145b2235],
7	only	RB	O	only	advmod	5	SENT_10	[p1l9t2275r154b2359],
8	the	DT	O	the	det	9	SENT_10	[p1l167t2275r269b2338],
9	characterization	NN	O	characterization	pobj	7	SENT_10	[p1l288t2275r813b2338],
10	of	IN	O	of	_	0	SENT_10	[p1l831t2275r903b2338],
11	the	DT	O	the	det	13	SENT_10	[p1l910t2275r1012b2338],
12	tumor	NN	O	tumor	nn	13	SENT_10	[p1l1029t2287r1236b2338],
13	cells	NNS	O	cell	prep_of	5	SENT_10	[p1l1253t2275r1389b2338],
14	but	CC	O	but	_	0	SENT_10	[p1l1405t2275r1515b2338],
15	also	RB	O	also	advmod	5	SENT_10	[p1l1532t2275r1657b2338],
16	individualized	VBN	O	individualize	parataxis	31	SENT_10	[p1l1676t2275r2144b2338],
17	drug	NN	O	drug	nn	18	SENT_10	[p1l9t2377r167b2461],
18	administration	NN	O	administration	dobj	16	SENT_10	[p1l183t2377r689b2449],
19	,	,	O	,	_	0	SENT_10	[p1l183t2377r689b2449],
20	as	IN	O	as	mark	21	SENT_10	[p1l710t2400r772b2440],
21	set	VBN	O	set	dep	31	SENT_10	[p1l791t2389r880b2440],
22	out	RP	O	out	prt	21	SENT_10	[p1l897t2389r1005b2440],
23	in	IN	O	in	_	0	SENT_10	[p1l1022t2382r1086b2439],
24	the	DT	O	the	det	28	SENT_10	[p1l1103t2377r1207b2440],
25	Pharmacologic	JJ	O	pharmacologic	amod	28	SENT_10	[p1l1225t2377r1721b2461],
26	Audit	NNP	O	Audit	nn	28	SENT_10	[p1l1738t2377r1926b2440],
27	Trail	NN	O	trail	nn	28	SENT_10	[p1l1942t2369r2141b2440],
28	.2	NN	NUMBER	.2	prep_in	21	SENT_10	[p1l1942t2369r2141b2440],
29	Here	RB	O	here	advmod	31	SENT_10	[p1l83t2485r241b2543],
30	we	PRP	O	we	nsubj	31	SENT_10	[p1l258t2503r349b2543],
31	focus	VBP	O	focus	_	0	SENT_10	[p1l369t2480r541b2543],
32	on	IN	O	on	_	0	SENT_10	[p1l561t2503r645b2543],
33	the	DT	O	the	det	35	SENT_10	[p1l663t2480r766b2543],
34	current	JJ	DATE	current	amod	35	SENT_10	[p1l786t2492r1027b2543],
35	status	NN	O	status	prep_on	31	SENT_10	[p1l1046t2492r1229b2543],
36	and	CC	O	and	_	0	SENT_10	[p1l1249t2480r1372b2543],
37	issues	NNS	O	issue	prep_on	31	SENT_10	[p1l1390t2485r1576b2543],
38	facing	VBG	O	face	xcomp	31	SENT_10	[p1l1595t2480r1795b2564],
39	molecular	JJ	O	molecular	amod	41	SENT_10	[p1l1812t2480r2143b2543],
40	cancer	NN	O	cancer	nn	41	SENT_10	[p1l9t2606r222b2646],
41	diagnostics	NNS	O	diagnostic	dobj	38	SENT_10	[p1l238t2583r600b2667],
42	and	CC	O	and	_	0	SENT_10	[p1l619t2583r741b2646],
43	especially	RB	O	especially	advmod	44	SENT_10	[p1l757t2583r1071b2667],
44	discuss	VBP	O	discuss	conj_and	31	SENT_10	[p1l1085t2583r1314b2646],
45	predictive	JJ	O	predictive	amod	46	SENT_10	[p1l1331t2583r1653b2666],
46	biomarkers	NNS	O	biomarker	dobj	44	SENT_10	[p1l1669t2583r2054b2646],
47	.	.	O	.	_	0	SENT_10	[p1l1669t2583r2054b2646],

1	In	IN	O	in	_	0	SENT_11	[p1l2074t2588r2143b2645],
2	addition	NN	O	addition	prep_in	5	SENT_11	[p1l9t2686r300b2758],
3	,	,	O	,	_	0	SENT_11	[p1l9t2686r300b2758],
4	We	PRP	O	we	nsubj	5	SENT_11	[p1l318t2709r408b2749],
5	emphasize	VBP	O	emphasize	_	0	SENT_11	[p1l428t2686r771b2769],
6	mechanisms	NNS	O	mechanism	dobj	5	SENT_11	[p1l788t2686r1198b2749],
7	of	IN	O	of	_	0	SENT_11	[p1l1218t2686r1290b2749],
8	resistance	NN	O	resistance	prep_of	6	SENT_11	[p1l1298t2691r1615b2749],
9	to	TO	O	to	_	0	SENT_11	[p1l1633t2698r1697b2749],
10	EGFR	NN	ORGANIZATION	egfr	nn	12	SENT_11	[p1l1715t2690r1919b2749],
11	kinase	NN	O	kinase	nn	12	SENT_11	[p1l1933t2686r2142b2749],
12	inhibitors	NNS	O	inhibitor	prep_to	5	SENT_11	[p1l9t2789r325b2852],
13	as	IN	O	as	_	0	SENT_11	[p1l344t2812r406b2852],
14	a	DT	O	a	det	15	SENT_11	[p1l424t2812r459b2852],
15	paradigm	NN	O	paradigm	prep_as	12	SENT_11	[p1l473t2789r792b2873],
16	for	IN	O	for	_	0	SENT_11	[p1l809t2789r902b2852],
17	the	DT	O	the	det	19	SENT_11	[p1l917t2789r1020b2852],
18	major	JJ	O	major	amod	19	SENT_11	[p1l1037t2794r1232b2873],
19	challenge	NN	O	challenge	prep_for	15	SENT_11	[p1l1249t2789r1554b2873],
20	of	IN	O	of	_	0	SENT_11	[p1l1572t2789r1644b2852],
21	drug	NN	O	drug	nn	22	SENT_11	[p1l1652t2789r1809b2873],
22	resistance	NN	O	resistance	prep_of	19	SENT_11	[p1l1824t2794r2142b2852],
23	we	PRP	O	we	nsubj	25	SENT_11	[p1l7t2915r96b2955],
24	now	RB	DATE	now	advmod	25	SENT_11	[p1l113t2915r255b2955],
25	face	VBP	O	face	rcmod	22	SENT_11	[p1l268t2892r393b2955],
26	in	IN	O	in	_	0	SENT_11	[p1l409t2897r473b2954],
27	targeted	VBN	O	target	amod	28	SENT_11	[p1l488t2892r749b2976],
28	therapy	NN	O	therapy	prep_in	25	SENT_11	[p1l764t2892r1010b2976],
29	and	CC	O	and	_	0	SENT_11	[p1l1023t2892r1144b2955],
30	personalized	JJ	O	personalized	amod	31	SENT_11	[p1l1158t2892r1567b2975],
31	medicine	NN	O	medicine	prep_in	25	SENT_11	[p1l1582t2892r1894b2955],
32	.	.	O	.	_	0	SENT_11	[p1l1582t2892r1894b2955],

1	Finally	RB	O	finally	advmod	4	SENT_12	[p1l1914t2892r2141b2976],
2	,	,	O	,	_	0	SENT_12	[p1l1914t2892r2141b2976],
3	we	PRP	O	we	nsubj	4	SENT_12	[p1l7t3019r99b3059],
4	anticipate	VBP	O	anticipate	_	0	SENT_12	[p1l121t3001r443b3079],
5	a	DT	O	a	det	6	SENT_12	[p1l464t3019r499b3059],
6	future	NN	DATE	future	dobj	4	SENT_12	[p1l517t2996r719b3059],
7	in	IN	O	in	_	0	SENT_12	[p1l739t3001r805b3058],
8	which	WDT	O	which	rel	17	SENT_12	[p1l823t2996r1029b3059],
9	longitudinal	JJ	O	longitudinal	amod	11	SENT_12	[p1l1048t2996r1458b3080],
10	genome	NN	O	genome	nn	11	SENT_12	[p1l1477t3019r1743b3080],
11	sequencing	NN	O	sequencing	nsubj	17	SENT_12	[p1l1764t3001r2142b3080],
12	and	CC	O	and	_	0	SENT_12	[p1l9t3099r133b3162],
13	other	JJ	O	other	amod	15	SENT_12	[p1l152t3099r327b3162],
14	omics	NNS	O	omic	nn	15	SENT_12	[p1l346t3104r540b3162],
15	technologies	NNS	O	technology	conj_and	11	SENT_12	[p1l559t3099r973b3183],
16	will	MD	O	will	aux	17	SENT_12	[p1l992t3099r1113b3162],
17	inform	VB	O	inform	rcmod	6	SENT_12	[p1l1132t3099r1363b3162],
18	adaptive	JJ	O	adaptive	amod	20	SENT_12	[p1l1383t3099r1658b3182],
19	combinatorial	JJ	O	combinatorial	amod	20	SENT_12	[p1l1678t3099r2141b3162],
20	treatment	NN	O	treatment	dobj	17	SENT_12	[p1l8t3214r324b3265],
21	to	TO	O	to	aux	22	SENT_12	[p1l339t3214r402b3265],
22	tackle	VB	O	tackle	xcomp	17	SENT_12	[p1l419t3202r607b3265],
23	genetic	JJ	O	genetic	amod	26	SENT_12	[p1l624t3207r853b3286],
24	and	CC	O	and	_	0	SENT_12	[p1l870t3202r991b3265],
25	phenotypic	JJ	O	phenotypic	conj_and	23	SENT_12	[p1l1006t3202r1370b3286],
26	heterogeneity	NN	O	heterogeneity	dobj	22	SENT_12	[p1l1385t3202r1827b3286],
27	and	CC	O	and	_	0	SENT_12	[p1l1841t3202r1961b3265],
28	overcome	VBN	O	overcome	rcmod	6	SENT_12	[p1l1978t3225r2139b3265, p1l9t3328r187b3368],
29	drug	NN	O	drug	nn	30	SENT_12	[p1l207t3305r365b3389],
30	resistance	NN	O	resistance	dobj	28	SENT_12	[p1l382t3310r717b3368],
31	.	.	O	.	_	0	SENT_12	[p1l382t3310r717b3368],

1	We	PRP	O	we	nsubj	2	SENT_13	[p1l738t3310r846b3368],
2	begin	VBP	O	begin	_	0	SENT_13	[p1l863t3305r1048b3389],
3	by	IN	O	by	_	0	SENT_13	[p1l1066t3305r1148b3389],
4	giving	VBG	O	give	prepc_by	2	SENT_13	[p1l1164t3310r1368b3389],
5	an	DT	O	a	det	6	SENT_13	[p1l1387t3328r1465b3368],
6	overview	NN	O	overview	dobj	4	SENT_13	[p1l1485t3310r1786b3368],
7	of	IN	O	of	_	0	SENT_13	[p1l1803t3305r1875b3368],
8	some	DT	O	some	prep_of	6	SENT_13	[p1l1886t3328r2059b3368],
9	of	IN	O	of	_	0	SENT_13	[p1l2079t3305r2152b3368],
10	the	DT	O	the	det	11	SENT_13	[p1l8t3408r110b3471],
11	challenges	NNS	O	challenge	prep_of	8	SENT_13	[p1l129t3408r464b3492],
12	in	IN	O	in	_	0	SENT_13	[p1l483t3413r547b3470],
13	kinase	NN	O	kinase	nn	15	SENT_13	[p1l564t3408r773b3471],
14	inhibitor	NN	O	inhibitor	nn	15	SENT_13	[p1l791t3408r1080b3471],
15	discovery	NN	O	discovery	prep_in	4	SENT_13	[p1l1098t3408r1413b3492],
16	and	CC	O	and	_	0	SENT_13	[p1l1428t3408r1551b3471],
17	development	NN	O	development	conj_and	15	SENT_13	[p1l1569t3408r2009b3491],
18	.	.	O	.	_	0	SENT_13	[p1l1569t3408r2009b3491],

1	THE	DT	O	the	det	2	SENT_14	[p1l8t3623r147b3677],
2	EMERGENCE	NN	O	emergence	_	0	SENT_14	[p1l169t3623r609b3678],
3	OF	IN	O	of	_	0	SENT_14	[p1l628t3622r722b3678],
4	KINASE	NNP	O	KINASE	nn	5	SENT_14	[p1l744t3623r1006b3678],
5	INHIBITORS	NNP	O	INHIBITORS	prep_of	2	SENT_14	[p1l1028t3622r1444b3678],
6	FOR	IN	O	for	_	0	SENT_14	[p1l1465t3622r1607b3678],
7	CANCER	NNP	O	CANCER	prep_for	2	SENT_14	[p1l1625t3623r1918b3678],

1	TREATMENT	NN	O	treatment	_	0	SENT_15	[p1l8t3726r444b3780],

1	Protein	NN	O	protein	nn	3	SENT_16	[p2l9t32r253b90],
2	kinase	NN	O	kinase	nn	3	SENT_16	[p2l270t27r481b90],
3	inhibitors	NNS	O	inhibitor	nsubj	5	SENT_16	[p2l500t27r822b90],
4	now	RB	DATE	now	advmod	5	SENT_16	[p2l841t50r987b90],
5	play	VBP	O	play	_	0	SENT_16	[p2l1001t27r1141b111],
6	a	DT	O	a	det	8	SENT_16	[p2l1157t50r1191b90],
7	leading	VBG	O	lead	amod	8	SENT_16	[p2l1207t27r1452b111],
8	role	NN	O	role	dobj	5	SENT_16	[p2l1469t27r1594b90],
9	in	IN	O	in	_	0	SENT_16	[p2l1613t32r1678b89],
10	the	DT	O	the	det	11	SENT_16	[p2l1696t27r1800b90],
11	treatment	NN	O	treatment	prep_in	5	SENT_16	[p2l1818t39r2144b90],
12	of	IN	O	of	_	0	SENT_16	[p2l9t130r82b193],
13	cancer	NN	O	cancer	prep_of	11	SENT_16	[p2l91t153r319b202],
14	,	,	O	,	_	0	SENT_16	[p2l91t153r319b202],
15	exemplifying	VBG	O	exemplify	partmod	5	SENT_16	[p2l340t130r775b214],
16	small-molecule	JJ	O	small-molecule	amod	17	SENT_16	[p2l793t130r1304b193],
17	exploitation	NN	O	exploitation	dobj	15	SENT_16	[p2l1324t130r1720b213],
18	of	IN	O	of	_	0	SENT_16	[p2l1739t130r1812b193],
19	oncogene	NN	O	oncogene	nn	21	SENT_16	[p2l1821t153r2140b214],
20	addiction	NN	O	addiction	nn	21	SENT_16	[p2l9t224r422b296],
21	.3	NN	NUMBER	.3	prep_of	17	SENT_16	[p2l9t224r422b296],
22	’	CD	NUMBER	’	number	23	SENT_16	[p2l9t224r422b296],
23	4	CD	NUMBER	4	num	25	SENT_16	[p2l9t224r422b296],
24	A	DT	O	a	det	25	SENT_16	[p2l441t237r499b295],
25	total	NN	O	total	nsubjpass	33	SENT_16	[p2l518t232r669b296],
26	of	IN	O	of	_	0	SENT_16	[p2l689t232r762b296],
27	24	CD	NUMBER	24	num	30	SENT_16	[p2l774t239r852b295],
28	small-molecule	JJ	O	small-molecule	amod	30	SENT_16	[p2l874t232r1388b296],
29	kinase	NN	O	kinase	nn	30	SENT_16	[p2l1408t232r1621b296],
30	inhibitors	NNS	O	inhibitor	prep_of	25	SENT_16	[p2l1642t232r1967b296],
31	have	VBP	O	have	aux	33	SENT_16	[p2l1988t232r2140b296],
32	been	VBN	O	be	auxpass	33	SENT_16	[p2l6t336r169b399],
33	approved	VBN	O	approve	rcmod	21	SENT_16	[p2l191t336r504b419],
34	for	IN	O	for	_	0	SENT_16	[p2l524t336r620b399],
35	use	NN	O	use	prep_for	33	SENT_16	[p2l640t359r750b399],
36	as	IN	O	as	_	0	SENT_16	[p2l772t359r836b399],
37	therapeutic	JJ	O	therapeutic	amod	38	SENT_16	[p2l857t336r1240b419],
38	agents	NNS	O	agent	prep_as	33	SENT_16	[p2l1261t348r1489b420],
39	,	,	O	,	_	0	SENT_16	[p2l1261t348r1489b420],
40	17	CD	NUMBER	17	nsubj	43	SENT_16	[p2l1519t343r1590b399],
41	of	IN	O	of	_	0	SENT_16	[p2l1613t336r1686b399],
42	which	WDT	O	which	prep_of	40	SENT_16	[p2l1696t336r1903b399],
43	are	VBP	O	be	rcmod	38	SENT_16	[p2l1925t359r2024b399],
44	for	IN	O	for	_	0	SENT_16	[p2l2045t336r2141b399],
45	cancer	NN	O	cancer	prep_for	43	SENT_16	[p2l9t462r232b502],
46	.	.	O	.	_	0	SENT_16	[p2l9t462r232b502],

1	In	IN	O	in	_	0	SENT_17	[p2l254t444r323b501],
2	addition	NN	O	addition	prep_in	15	SENT_17	[p2l342t439r634b511],
3	,	,	O	,	_	0	SENT_17	[p2l342t439r634b511],
4	four	CD	NUMBER	four	num	6	SENT_17	[p2l654t439r792b502],
5	monoclonal	JJ	O	monoclonal	amod	6	SENT_17	[p2l809t439r1205b502],
6	antibodies	NNS	O	antibody	nsubjpass	15	SENT_17	[p2l1223t439r1562b502],
7	acting	VBG	O	act	partmod	6	SENT_17	[p2l1582t444r1783b523],
8	on	IN	O	on	_	0	SENT_17	[p2l1800t462r1883b502],
9	protein	NN	O	protein	nn	11	SENT_17	[p2l1901t444r2140b522],
10	kinase	NN	O	kinase	nn	11	SENT_17	[p2l7t542r220b605],
11	targets	NNS	O	target	prep_on	7	SENT_17	[p2l239t554r460b626],
12	have	VBP	O	have	aux	15	SENT_17	[p2l480t542r632b605],
13	also	RB	O	also	advmod	15	SENT_17	[p2l653t542r781b605],
14	been	VBN	O	be	auxpass	15	SENT_17	[p2l800t542r961b605],
15	licensed	VBN	O	license	_	0	SENT_17	[p2l979t542r1252b605],
16	for	IN	O	for	_	0	SENT_17	[p2l1271t542r1366b605],
17	cancer	NN	O	cancer	nn	18	SENT_17	[p2l1385t565r1604b605],
18	therapy	NN	O	therapy	prep_for	15	SENT_17	[p2l1621t542r1884b626],
19	.	.	O	.	_	0	SENT_17	[p2l1621t542r1884b626],

1	A	DT	O	a	det	3	SENT_18	[p2l81t649r139b707],
2	recent	JJ	O	recent	amod	3	SENT_18	[p2l171t657r397b708],
3	report	NN	O	report	nsubj	12	SENT_18	[p2l429t657r657b728],
4	from	IN	O	from	_	0	SENT_18	[p2l688t645r866b708],
5	the	DT	O	the	det	7	SENT_18	[p2l897t645r1010b708],
6	Pharmaceutical	NNP	ORGANIZATION	Pharmaceutical	nn	7	SENT_18	[p2l1043t645r1617b708],
7	Research	NNP	ORGANIZATION	Research	prep_from	3	SENT_18	[p2l1649t645r1977b708],
8	and	CC	ORGANIZATION	and	_	0	SENT_18	[p2l2010t645r2143b708],
9	Manufacturers	NNP	ORGANIZATION	Manufacturers	conj_and	3	SENT_18	[p2l8t749r494b812],
10	of	IN	ORGANIZATION	of	_	0	SENT_18	[p2l515t749r586b812],
11	America	NNP	ORGANIZATION	America	prep_of	9	SENT_18	[p2l595t753r881b812],
12	suggests	VBZ	O	suggest	_	0	SENT_18	[p2l900t761r1169b833],
13	a	DT	O	a	det	16	SENT_18	[p2l1189t772r1223b812],
14	very	RB	O	very	advmod	15	SENT_18	[p2l1238t772r1386b833],
15	conservative	JJ	O	conservative	amod	16	SENT_18	[p2l1402t754r1814b812],
16	approach	NN	O	approach	dobj	12	SENT_18	[p2l1834t749r2140b832],
17	to	TO	O	to	_	0	SENT_18	[p2l7t864r72b915],
18	drug	NN	O	drug	nn	19	SENT_18	[p2l93t852r251b936],
19	discovery	NN	O	discovery	prep_to	16	SENT_18	[p2l270t852r597b936],
20	.	.	O	.	_	0	SENT_18	[p2l270t852r597b936],

1	The	DT	O	the	det	2	SENT_19	[p2l620t852r742b915],
2	report	NN	O	report	nsubj	3	SENT_19	[p2l763t864r970b935],
3	indicated	VBD	O	indicate	_	0	SENT_19	[p2l989t852r1299b915],
4	that	IN	O	that	complm	14	SENT_19	[p2l1316t852r1446b915],
5	a	DT	O	a	det	7	SENT_19	[p2l1466t875r1499b915],
6	signiﬁcant	JJ	O	signiﬁcant	amod	7	SENT_19	[p2l1519t852r1864b936],
7	proportion	NN	O	proportion	nsubjpass	14	SENT_19	[p2l1881t874r2139b935, p2l7t960r146b1018],
8	of	IN	O	of	_	0	SENT_19	[p2l170t955r245b1018],
9	industry	NN	O	industry	nn	10	SENT_19	[p2l258t955r555b1039],
10	activity	NN	O	activity	prep_of	7	SENT_19	[p2l575t960r830b1039],
11	in	IN	O	in	_	0	SENT_19	[p2l850t960r917b1017],
12	oncology	NN	O	oncology	prep_in	10	SENT_19	[p2l941t955r1263b1039],
13	is	VBZ	O	be	auxpass	14	SENT_19	[p2l1282t960r1333b1018],
14	directed	VBN	O	direct	ccomp	3	SENT_19	[p2l1358t955r1640b1018],
15	toward	IN	O	toward	_	0	SENT_19	[p2l1661t955r1904b1018],
16	a	DT	O	a	det	19	SENT_19	[p2l1927t978r1962b1018],
17	relatively	RB	O	relatively	advmod	18	SENT_19	[p2l1984t955r2137b1018, p2l7t1058r191b1142],
18	small	JJ	O	small	amod	19	SENT_19	[p2l208t1058r385b1121],
19	number	NN	O	number	prep_toward	14	SENT_19	[p2l404t1058r672b1121],
20	of	IN	O	of	_	0	SENT_19	[p2l691t1058r763b1121],
21	targets	NNS	O	target	prep_of	19	SENT_19	[p2l773t1070r1013b1142],
22	,	,	O	,	_	0	SENT_19	[p2l773t1070r1013b1142],
23	as	IN	O	as	mark	24	SENT_19	[p2l1035t1081r1098b1121],
24	shown	VBN	O	show	advcl	14	SENT_19	[p2l1120t1058r1337b1121],
25	by	IN	O	by	_	0	SENT_19	[p2l1356t1058r1438b1142],
26	the	DT	O	the	det	27	SENT_19	[p2l1453t1058r1558b1121],
27	fact	NN	O	fact	prep_by	24	SENT_19	[p2l1578t1058r1700b1121],
28	that	IN	O	that	complm	42	SENT_19	[p2l1717t1058r1849b1121],
29	>	JJR	O	>	nsubj	42	SENT_19	[p2l1870t1063r2055b1123],
30	20	CD	PERCENT	20	number	31	SENT_19	[p2l1870t1063r2055b1123],
31	%	NN	PERCENT	%	amod	29	SENT_19	[p2l1870t1063r2055b1123],
32	of	IN	O	of	_	0	SENT_19	[p2l2077t1058r2150b1121],
33	the	DT	O	the	det	34	SENT_19	[p2l7t1161r113b1224],
34	projects	NNS	O	project	prep_of	29	SENT_19	[p2l133t1166r403b1245],
35	involving	VBG	O	involve	_	0	SENT_19	[p2l425t1161r745b1245],
36	the	DT	O	the	det	38	SENT_19	[p2l764t1161r870b1224],
37	clinical	JJ	O	clinical	amod	38	SENT_19	[p2l892t1161r1136b1224],
38	development	NN	O	development	prep_involving	34	SENT_19	[p2l1157t1161r1600b1244],
39	of	IN	O	of	_	0	SENT_19	[p2l1621t1161r1694b1224],
40	cancer	NN	O	cancer	nn	41	SENT_19	[p2l1706t1184r1929b1224],
41	drugs	NNS	O	drug	prep_of	38	SENT_19	[p2l1950t1161r2141b1245],
42	focus	VBP	O	focus	ccomp	14	SENT_19	[p2l8t1265r184b1328],
43	on	IN	O	on	_	0	SENT_19	[p2l206t1288r290b1328],
44	only	RB	O	only	quantmod	45	SENT_19	[p2l311t1265r459b1349],
45	eight	CD	NUMBER	eight	num	48	SENT_19	[p2l476t1265r641b1349],
46	common	JJ	O	common	amod	48	SENT_19	[p2l660t1288r962b1328],
47	kinase	NN	O	kinase	nn	48	SENT_19	[p2l980t1265r1194b1328],
48	targets	NNS	O	target	prep_on	42	SENT_19	[p2l1213t1277r1452b1349],
49	.	.	O	.	_	0	SENT_19	[p2l1213t1277r1452b1349],

1	In	IN	O	in	_	0	SENT_20	[p2l1476t1270r1545b1327],
2	order	NN	O	order	prep_in	8	SENT_20	[p2l1566t1265r1747b1328],
3	of	IN	O	of	_	0	SENT_20	[p2l1766t1265r1839b1328],
4	popularity	NN	O	popularity	prep_of	2	SENT_20	[p2l1848t1265r2139b1348, p2l8t1373r105b1452],
5	,	,	O	,	_	0	SENT_20	[p2l1848t1265r2139b1348, p2l8t1373r105b1452],
6	these	DT	O	these	nsubj	8	SENT_20	[p2l126t1368r301b1431],
7	are	VBP	O	be	cop	8	SENT_20	[p2l323t1391r423b1431],
8	VEGF/VEGFR	NNP	O	VEGF/VEGFR	_	0	SENT_20	[p2l442t1372r975b1440],
9	,	,	O	,	_	0	SENT_20	[p2l442t1372r975b1440],
10	the	DT	O	the	det	11	SENT_20	[p2l997t1368r1103b1431],
11	lipid	NN	O	lipid	dep	23	SENT_20	[p2l1123t1368r1278b1451],
12	kinase	NN	O	kinase	nn	13	SENT_20	[p2l1296t1368r1514b1431],
13	PI3K	NN	O	pi3k	dep	11	SENT_20	[p2l1535t1373r1726b1440],
14	,	,	O	,	_	0	SENT_20	[p2l1535t1373r1726b1440],
15	human	JJ	O	human	amod	18	SENT_20	[p2l1747t1368r1989b1431],
16	epidermal	JJ	O	epidermal	amod	18	SENT_20	[p2l2011t1373r2138b1451, p2l9t1471r251b1534],
17	growth	NN	O	growth	nn	18	SENT_20	[p2l272t1471r515b1555],
18	factor	NN	O	factor	appos	13	SENT_20	[p2l538t1471r736b1534],
19	receptor	NN	O	receptor	dep	23	SENT_20	[p2l758t1483r1042b1554],
20	2	CD	NUMBER	2	num	19	SENT_20	[p2l1063t1478r1099b1533],
21	(	CD	NUMBER	(	num	23	SENT_20	[p2l1127t1472r1408b1548],
22	HER2	NN	O	her2	nn	23	SENT_20	[p2l1127t1472r1408b1548],
23	)	NN	O	)	dep	34	SENT_20	[p2l1127t1472r1408b1548],
24	,	,	O	,	_	0	SENT_20	[p2l1127t1472r1408b1548],
25	mTOR	NN	O	mtor	appos	23	SENT_20	[p2l1431t1474r1681b1543],
26	,	,	O	,	_	0	SENT_20	[p2l1431t1474r1681b1543],
27	EGFR	NN	ORGANIZATION	egfr	appos	23	SENT_20	[p2l1706t1475r1931b1543],
28	,	,	O	,	_	0	SENT_20	[p2l1706t1475r1931b1543],
29	MET	NN	O	met	appos	23	SENT_20	[p2l1955t1474r2140b1543],
30	,	,	O	,	_	0	SENT_20	[p2l1955t1474r2140b1543],
31	PD	NN	O	pd	nn	32	SENT_20	[p2l9t1579r114b1636],
32	GF	NN	O	gf	appos	23	SENT_20	[p2l123t1578r252b1640],
33	/	:	O	/	punct	34	SENT_20	[p2l123t1578r252b1640],
34	PDGFR	NN	LOCATION	pdgfr	dep	8	SENT_20	[p2l258t1578r546b1646],
35	,	,	O	,	_	0	SENT_20	[p2l258t1578r546b1646],
36	and	CC	O	and	_	0	SENT_20	[p2l569t1574r695b1637],
37	KIT	NN	O	kit	nn	40	SENT_20	[p2l715t1577r851b1636],
38	(	CD	NUMBER	(	num	40	SENT_20	[p2l875t1574r2142b1658],
39	http://www.phrma.org/sites/default/	NN	O	http://www.phrma.org/sites/default/	nn	40	SENT_20	[p2l875t1574r2142b1658],
40	files/1000/phrmamedicinesindevelopmentcancer2012	NN	O	files/1000/phrmamedicinesindevelopmentcancer2012	conj_and	8	SENT_20	[p2l8t1677r2140b1760],
41	.	.	O	.	_	0	SENT_20	[p2l8t1677r2140b1760],

1	pdf	NN	O	pdf	_	0	SENT_21	[p2l8t1677r2140b1760],
2	;	:	O	;	_	0	SENT_21	[p2l8t1677r2140b1760],
3	http	NN	O	http	dep	1	SENT_21	[p2l7t1780r196b1863],
4	:	:	O	:	_	0	SENT_21	[p2l7t1780r196b1863],
5	/	:	O	/	punct	3	SENT_21	[p2l7t1780r196b1863],
6	/	:	O	/	punct	7	SENT_21	[p2l201t1784r225b1846],
7	www.forbes.com	NNP	O	www.forbes.com	dep	1	SENT_21	[p2l229t1780r841b1846],
8	/	:	O	/	punct	7	SENT_21	[p2l229t1780r841b1846],
9	sites/brucebooth	JJ	O	sites/brucebooth	amod	1	SENT_21	[p2l847t1780r1457b1846],
10	/	:	O	/	punct	11	SENT_21	[p2l847t1780r1457b1846],
11	2012	CD	DATE	2012	dep	1	SENT_21	[p2l1463t1784r1656b1846],
12	/	:	O	/	punct	11	SENT_21	[p2l1463t1784r1656b1846],
13	06	CD	NUMBER	06	dep	1	SENT_21	[p2l1661t1784r1769b1846],
14	/	:	O	/	punct	15	SENT_21	[p2l1661t1784r1769b1846],
15	07	CD	NUMBER	07	dep	17	SENT_21	[p2l1775t1784r1883b1846],
16	/	:	O	/	punct	15	SENT_21	[p2l1775t1784r1883b1846],
17	cancerdrug-targets-the-march-of-the-lemmings	NNS	O	cancerdrug-targets-the-march-of-the-lemming	dep	13	SENT_21	[p2l1888t1803r2140b1843, p2l9t1883r1469b1967],
18	/	:	O	/	punct	19	SENT_21	[p2l1888t1803r2140b1843, p2l9t1883r1469b1967],
19	)	CD	NUMBER	)	dep	17	SENT_21	[p2l1888t1803r2140b1843, p2l9t1883r1469b1967],
20	.	.	O	.	_	0	SENT_21	[p2l1888t1803r2140b1843, p2l9t1883r1469b1967],

1	In	IN	O	in	_	0	SENT_22	[p2l1492t1888r1561b1945],
2	fact	NN	O	fact	prep_in	23	SENT_22	[p2l1581t1883r1718b1955],
3	,	,	O	,	_	0	SENT_22	[p2l1581t1883r1718b1955],
4	with	IN	O	with	_	0	SENT_22	[p2l1738t1883r1887b1946],
5	respect	NN	O	respect	_	0	SENT_22	[p2l1906t1895r2143b1966],
6	to	TO	O	to	_	0	SENT_22	[p2l7t1998r71b2049],
7	preclinical	JJ	O	preclinical	amod	8	SENT_22	[p2l91t1986r440b2069],
8	development	NN	O	development	prep_with_respect_to	23	SENT_22	[p2l460t1986r908b2069],
9	,	,	O	,	_	0	SENT_22	[p2l460t1986r908b2069],
10	the	DT	O	the	det	13	SENT_22	[p2l928t1986r1032b2049],
11	“	NN	O	“	nn	13	SENT_22	[p2l1053t1986r1464b2070],
12	congestion	NN	O	congestion	nn	13	SENT_22	[p2l1053t1986r1464b2070],
13	”	NN	O	”	nsubj	23	SENT_22	[p2l1053t1986r1464b2070],
14	of	IN	O	of	_	0	SENT_22	[p2l1486t1986r1558b2049],
15	activity	NN	O	activity	prep_of	13	SENT_22	[p2l1569t1991r1814b2070],
16	centering	VBG	O	center	partmod	15	SENT_22	[p2l1830t1991r2143b2070],
17	on	IN	O	on	_	0	SENT_22	[p2l9t2112r94b2152],
18	these	DT	O	these	det	20	SENT_22	[p2l115t2089r290b2152],
19	same	JJ	O	same	amod	20	SENT_22	[p2l313t2112r484b2152],
20	targets	NNS	O	target	prep_on	16	SENT_22	[p2l505t2101r732b2173],
21	is	VBZ	O	be	cop	23	SENT_22	[p2l754t2094r804b2152],
22	even	RB	O	even	advmod	23	SENT_22	[p2l827t2112r983b2152],
23	greater	JJR	O	greater	_	0	SENT_22	[p2l1004t2101r1251b2173],
24	.	.	O	.	_	0	SENT_22	[p2l1004t2101r1251b2173],

1	On	IN	O	on	_	0	SENT_23	[p2l83t2196r195b2255],
2	the	DT	O	the	det	4	SENT_23	[p2l229t2192r345b2255],
3	other	JJ	O	other	amod	4	SENT_23	[p2l380t2192r580b2255],
4	hand	NN	O	hand	prep_on	23	SENT_23	[p2l612t2192r821b2264],
5	,	,	O	,	_	0	SENT_23	[p2l612t2192r821b2264],
6	our	PRP$	O	we	poss	8	SENT_23	[p2l858t2215r985b2255],
7	own	JJ	O	own	amod	8	SENT_23	[p2l1020t2215r1175b2255],
8	mining	NN	O	mining	nsubj	23	SENT_23	[p2l1209t2197r1481b2276],
9	of	IN	O	of	_	0	SENT_23	[p2l1515t2192r1594b2255],
10	data	NNS	O	datum	prep_of	8	SENT_23	[p2l1620t2192r1777b2255],
11	from	IN	O	from	_	0	SENT_23	[p2l1811t2192r1992b2255],
12	the	DT	O	the	det	16	SENT_23	[p2l2026t2192r2142b2255],
13	ChEMBL5	NN	O	chembl5	nn	16	SENT_23	[p2l10t2287r387b2357],
14	(	CD	NUMBER	(	num	16	SENT_23	[p2l424t2294r1609b2377],
15	http://www.ebi.ac.uk/chembl/	NN	O	http://www.ebi.ac.uk/chembl/	nn	16	SENT_23	[p2l424t2294r1609b2377],
16	)	NN	O	)	prep_from	10	SENT_23	[p2l424t2294r1609b2377],
17	and	CC	O	and	_	0	SENT_23	[p2l1647t2294r1781b2357],
18	canSAR6	NN	O	cansar6	nn	20	SENT_23	[p2l1814t2286r2141b2358],
19	(	CD	NUMBER	(	num	20	SENT_23	[p2l12t2397r906b2480],
20	https://cansar.icr.ac.uk	NN	O	https://cansar.icr.ac.uk	conj_and	16	SENT_23	[p2l12t2397r906b2480],
21	)	CD	NUMBER	)	num	22	SENT_23	[p2l12t2397r906b2480],
22	databases	NNS	O	database	dep	20	SENT_23	[p2l940t2397r1287b2460],
23	gives	VBZ	O	give	_	0	SENT_23	[p2l1316t2402r1495b2481],
24	us	PRP	O	we	iobj	23	SENT_23	[p2l1524t2420r1601b2460],
25	an	DT	O	a	det	26	SENT_23	[p2l1630t2420r1714b2460],
26	estimate	NN	O	estimate	dobj	23	SENT_23	[p2l1743t2402r2046b2460],
27	of	IN	O	of	_	0	SENT_23	[p2l2076t2397r2153b2460],
28	~	NN	O	~	nn	31	SENT_23	[p2l11t2507r181b2563],
29	395	CD	NUMBER	395	num	31	SENT_23	[p2l11t2507r181b2563],
30	kinase	NN	O	kinase	nn	31	SENT_23	[p2l207t2500r432b2563],
31	inhibitors	NNS	O	inhibitor	prep_of	26	SENT_23	[p2l458t2500r804b2563],
32	that	WDT	O	that	nsubj	33	SENT_23	[p2l829t2500r967b2563],
33	are	VBP	O	be	rcmod	26	SENT_23	[p2l992t2523r1095b2563],
34	in	IN	O	in	_	0	SENT_23	[p2l1120t2505r1188b2562],
35	clinical	JJ	O	clinical	amod	36	SENT_23	[p2l1215t2500r1469b2563],
36	development	NN	O	development	prep_in	33	SENT_23	[p2l1494t2500r1972b2583],
37	,	,	O	,	_	0	SENT_23	[p2l1494t2500r1972b2583],
38	representing	VBG	O	represent	xcomp	33	SENT_23	[p2l1998t2522r2140b2583, p2l9t2608r336b2687],
39	a	DT	O	a	det	42	SENT_23	[p2l358t2626r392b2666],
40	high	JJ	O	high	amod	42	SENT_23	[p2l413t2603r571b2687],
41	proportion	NN	O	proportion	nn	42	SENT_23	[p2l593t2608r982b2686],
42	(	NN	O	(	dobj	38	SENT_23	[p2l1008t2603r1210b2680],
43	33	CD	PERCENT	33	number	44	SENT_23	[p2l1008t2603r1210b2680],
44	%	NN	PERCENT	%	amod	42	SENT_23	[p2l1008t2603r1210b2680],
45	)	CD	NUMBER	)	dep	54	SENT_23	[p2l1008t2603r1210b2680],
46	of	IN	O	of	_	0	SENT_23	[p2l1238t2603r1313b2666],
47	the	DT	O	the	det	48	SENT_23	[p2l1326t2603r1435b2666],
48	total	NN	O	total	prep_of	45	SENT_23	[p2l1457t2603r1616b2666],
49	of	IN	O	of	_	0	SENT_23	[p2l1640t2603r1715b2666],
50	~	NN	O	~	prep_of	48	SENT_23	[p2l1731t2610r1965b2675],
51	1,2	CD	NUMBER	1,2	num	52	SENT_23	[p2l1731t2610r1965b2675],
52	OO	NN	O	oo	dep	54	SENT_23	[p2l1731t2610r1965b2675],
53	cancer	NN	O	cancer	nn	54	SENT_23	[p2l1990t2626r2138b2666, p2l9t2729r111b2769],
54	drugs	NNS	O	drug	dep	42	SENT_23	[p2l133t2706r326b2790],
55	currently	RB	DATE	currently	advmod	54	SENT_23	[p2l350t2706r669b2790],
56	in	IN	O	in	_	0	SENT_23	[p2l688t2711r755b2768],
57	clinical	JJ	O	clinical	amod	58	SENT_23	[p2l778t2706r1026b2769],
58	development	NN	O	development	prep_in	54	SENT_23	[p2l1049t2706r1496b2789],
59	overall	NN	O	overall	advmod	38	SENT_23	[p2l1518t2706r1766b2769],
60	.	.	O	.	_	0	SENT_23	[p2l1518t2706r1766b2769],

1	Moreover	RB	O	moreover	advmod	8	SENT_24	[p2l1791t2711r2141b2778],
2	,	,	O	,	_	0	SENT_24	[p2l1791t2711r2141b2778],
3	these	DT	O	these	det	6	SENT_24	[p2l7t2809r192b2872],
4	395	CD	NUMBER	395	num	6	SENT_24	[p2l220t2816r342b2872],
5	kinase	NN	O	kinase	nn	6	SENT_24	[p2l370t2809r599b2872],
6	inhibitors	NNS	O	inhibitor	nsubjpass	8	SENT_24	[p2l626t2809r979b2872],
7	are	VBP	O	be	auxpass	8	SENT_24	[p2l1006t2832r1111b2872],
8	believed	VBN	O	believe	_	0	SENT_24	[p2l1136t2809r1437b2872],
9	to	TO	O	to	aux	10	SENT_24	[p2l1461t2821r1530b2872],
10	act	VB	O	act	xcomp	8	SENT_24	[p2l1558t2821r1661b2872],
11	on	IN	O	on	_	0	SENT_24	[p2l1687t2832r1776b2872],
12	~	NN	O	~	nn	13	SENT_24	[p2l1805t2816r1980b2872],
13	11O	NN	O	11o	prep_on	10	SENT_24	[p2l1805t2816r1980b2872],
14	primary	JJ	O	primary	nsubj	15	SENT_24	[p2l2006t2814r2138b2892, p2l8t2935r195b2996],
15	declared	VBD	O	declare	rcmod	13	SENT_24	[p2l217t2912r516b2975],
16	targets	NNS	O	target	dobj	15	SENT_24	[p2l540t2924r796b2996],
17	,	,	O	,	_	0	SENT_24	[p2l540t2924r796b2996],
18	with	IN	O	with	_	0	SENT_24	[p2l821t2912r979b2975],
19	many	JJ	O	many	prep_with	15	SENT_24	[p2l1004t2935r1201b2996],
20	of	IN	O	of	_	0	SENT_24	[p2l1224t2912r1299b2975],
21	them	PRP	O	they	nsubj	22	SENT_24	[p2l1314t2912r1496b2975],
22	modulating	VBG	O	modulate	prepc_of	19	SENT_24	[p2l1521t2912r1935b2996],
23	more	JJR	O	more	dobj	22	SENT_24	[p2l1959t2935r2141b2975],

1	‘	RB	O	‘	advmod	7	SENT_25	[p2l21t3042r160b3068],
2	Molecular	JJ	ORGANIZATION	molecular	amod	7	SENT_25	[p2l21t3042r160b3068],
3	Diagnostics	NNPS	ORGANIZATION	Diagnostics	nn	7	SENT_25	[p2l168t3046r316b3075],
4	Department	NNP	ORGANIZATION	Department	nn	7	SENT_25	[p2l325t3046r488b3074],
5	,	,	O	,	_	0	SENT_25	[p2l325t3046r488b3074],
6	The	NNP	ORGANIZATION	The	appos	7	SENT_25	[p2l493t3045r540b3068],
7	Institute	NNP	ORGANIZATION	Institute	_	0	SENT_25	[p2l549t3046r654b3068],
8	of	IN	ORGANIZATION	of	_	0	SENT_25	[p2l661t3045r688b3068],
9	Cancer	NNP	ORGANIZATION	Cancer	nn	10	SENT_25	[p2l693t3046r782b3068],
10	Research	NNP	ORGANIZATION	Research	prep_of	7	SENT_25	[p2l789t3045r902b3068],
11	and	CC	O	and	_	0	SENT_25	[p2l910t3045r958b3068],
12	the	DT	O	the	det	17	SENT_25	[p2l965t3045r1007b3068],
13	Royal	NNP	ORGANIZATION	Royal	nn	17	SENT_25	[p2l1016t3045r1082b3075],
14	Marsden	NNP	ORGANIZATION	Marsden	nn	17	SENT_25	[p2l1091t3045r1201b3068],
15	NHS	NNP	ORGANIZATION	NHS	nn	17	SENT_25	[p2l1211t3046r1264b3068],
16	Foundation	NNP	ORGANIZATION	Foundation	nn	17	SENT_25	[p2l1272t3045r1419b3068],
17	Trust	NNP	ORGANIZATION	Trust	conj_and	7	SENT_25	[p2l1425t3046r1495b3072],
18	,	,	O	,	_	0	SENT_25	[p2l1425t3046r1495b3072],
19	London	NNP	LOCATION	London	nn	21	SENT_25	[p2l1503t3045r1607b3072],
20	,	,	O	,	_	0	SENT_25	[p2l1503t3045r1607b3072],
21	UK	NNP	LOCATION	UK	appos	17	SENT_25	[p2l1616t3046r1657b3072],
22	;	:	O	;	_	0	SENT_25	[p2l1616t3046r1657b3072],
23	2Cancer	NNP	O	2Cancer	nn	28	SENT_25	[p2l1664t3041r1765b3068],
24	Research	NNP	ORGANIZATION	Research	nn	28	SENT_25	[p2l1773t3045r1885b3068],
25	UK	NNP	ORGANIZATION	UK	nn	28	SENT_25	[p2l1895t3046r1930b3068],
26	Cancer	NNP	ORGANIZATION	Cancer	nn	28	SENT_25	[p2l1936t3046r2025b3068],
27	Therapeutics	NNPS	ORGANIZATION	Therapeutics	nn	28	SENT_25	[p2l19t3083r186b3112],
28	Unit	NNP	ORGANIZATION	Unit	dep	7	SENT_25	[p2l195t3084r253b3110],
29	,	,	O	,	_	0	SENT_25	[p2l195t3084r253b3110],
30	The	NNP	ORGANIZATION	The	nn	31	SENT_25	[p2l258t3083r306b3106],
31	Institute	NNP	ORGANIZATION	Institute	appos	28	SENT_25	[p2l314t3084r419b3106],
32	of	IN	ORGANIZATION	of	_	0	SENT_25	[p2l427t3083r453b3106],
33	Cancer	NNP	ORGANIZATION	Cancer	nn	34	SENT_25	[p2l458t3084r547b3106],
34	Research	NNP	ORGANIZATION	Research	prep_of	31	SENT_25	[p2l555t3083r675b3110],
35	,	,	O	,	_	0	SENT_25	[p2l555t3083r675b3110],
36	London	NNP	LOCATION	London	nn	38	SENT_25	[p2l683t3083r788b3110],
37	,	,	O	,	_	0	SENT_25	[p2l683t3083r788b3110],
38	UK	NNP	LOCATION	UK	appos	34	SENT_25	[p2l796t3084r837b3106],
39	.	.	O	.	_	0	SENT_25	[p2l796t3084r837b3106],

1	Correspondence	NN	O	correspondence	_	0	SENT_26	[p2l844t3083r1064b3112],
2	:	:	O	:	_	0	SENT_26	[p2l844t3083r1064b3112],
3	P	NN	PERSON	p	nn	4	SENT_26	[p2l1073t3084r1086b3106],
4	Workman	NN	PERSON	workman	dep	1	SENT_26	[p2l1092t3083r1216b3106],
5	(	CD	NUMBER	(	num	7	SENT_26	[p2l1225t3083r1561b3112],
6	pau	NN	O	pau	nn	7	SENT_26	[p2l1225t3083r1561b3112],
7	|	NN	O	|	dep	4	SENT_26	[p2l1225t3083r1561b3112],
8	.	.	O	.	_	0	SENT_26	[p2l1225t3083r1561b3112],

1	workman@icr.ac.uk	NN	O	workman@icr.ac.uk	nn	2	SENT_27	[p2l1225t3083r1561b3112],
2	)	NN	O	)	_	0	SENT_27	[p2l1225t3083r1561b3112],
3	;	:	O	;	_	0	SENT_27	[p2l1225t3083r1561b3112],
4	D	NN	PERSON	d	nn	7	SENT_27	[p2l1569t3084r1587b3106],
5	Gonzalez	NNP	PERSON	Gonzalez	nn	7	SENT_27	[p2l1594t3083r1712b3106],
6	de	FW	PERSON	de	nn	7	SENT_27	[p2l1719t3083r1750b3106],
7	Castro	NNP	PERSON	Castro	dep	9	SENT_27	[p2l1758t3084r1838b3106],
8	(	CD	NUMBER	(	num	9	SENT_27	[p2l21t3120r490b3149],
9	david	NN	O	david	dep	2	SENT_27	[p2l21t3120r490b3149],
10	.	.	O	.	_	0	SENT_27	[p2l21t3120r490b3149],

1	gonza	NN	O	gonza	_	0	SENT_28	[p2l21t3120r490b3149],
2	|	SYM	O	|	dep	4	SENT_28	[p2l21t3120r490b3149],
3	ez—de—castro@icr.ac.uk	FW	O	ez—de—castro@icr.ac.uk	nn	4	SENT_28	[p2l21t3120r490b3149],
4	)	FW	O	)	rcmod	1	SENT_28	[p2l21t3120r490b3149],
5	Received	VBN	O	receive	partmod	1	SENT_28	[p2l21t3160r130b3183],
6	20	CD	DATE	20	num	7	SENT_28	[p2l139t3162r167b3183],
7	November	NNP	DATE	November	nsubj	11	SENT_28	[p2l176t3160r306b3183],
8	201	CD	NUMBER	201	number	9	SENT_28	[p2l313t3162r351b3183],
9	2	CD	NUMBER	2	dep	7	SENT_28	[p2l358t3162r377b3187],
10	;	:	O	;	_	0	SENT_28	[p2l358t3162r377b3187],
11	accepted	VBN	O	accept	dep	5	SENT_28	[p2l384t3160r497b3189],
12	30	CD	DATE	30	num	13	SENT_28	[p2l506t3162r534b3183],
13	November	NNP	DATE	November	dobj	11	SENT_28	[p2l543t3160r673b3183],
14	201	CD	NUMBER	201	num	13	SENT_28	[p2l680t3162r719b3183],
15	2	CD	NUMBER	2	dep	13	SENT_28	[p2l726t3162r745b3187],
16	;	:	O	;	_	0	SENT_28	[p2l726t3162r745b3187],
17	advance	NN	O	advance	dep	13	SENT_28	[p2l752t3160r855b3183],
18	online	NN	O	online	prep	17	SENT_28	[p2l863t3160r939b3183],
19	publication	NN	O	publication	dep	18	SENT_28	[p2l948t3160r1085b3189],
20	30	CD	DATE	30	num	19	SENT_28	[p2l1094t3162r1123b3183],
21	January	NNP	DATE	January	tmod	11	SENT_28	[p2l1129t3161r1225b3190],
22	2013	CD	DATE	2013	num	21	SENT_28	[p2l1232t3162r1296b3183],
23	.	.	O	.	_	0	SENT_28	[p2l1232t3162r1296b3183],

1	doi	FW	O	doi	dep	29	SENT_29	[p2l1304t3160r1357b3183],
2	:	:	O	:	_	0	SENT_29	[p2l1304t3160r1357b3183],
3	l	NN	O	l	nn	5	SENT_29	[p2l1304t3160r1357b3183],
4	o.l	NN	O	o.l	nn	5	SENT_29	[p2l1365t3162r1393b3183],
5	O38/clpt	NN	O	o38/clpt	dep	15	SENT_29	[p2l1401t3160r1620b3189],
6	.20	CD	NUMBER	.20	num	7	SENT_29	[p2l1401t3160r1620b3189],
7	i2	NN	O	i2	dep	5	SENT_29	[p2l1401t3160r1620b3189],
8	.237	CD	NUMBER	.237	number	9	SENT_29	[p2l1401t3160r1620b3189],
9	252	CD	NUMBER	252	dep	7	SENT_29	[p2l20t3203r66b3224],
10	VOLUME	NN	O	volume	dep	15	SENT_29	[p2l1390t3203r1498b3224],
11	93	CD	NUMBER	93	num	10	SENT_29	[p2l1506t3203r1533b3224],
12	NUMBER	NN	O	number	nn	15	SENT_29	[p2l1544t3203r1651b3224],
13	3	CD	NUMBER	3	num	15	SENT_29	[p2l1660t3203r1672b3224],
14	|	NN	O	|	nn	15	SENT_29	[p2l1682t3201r1684b3231],
15	MARCH	NN	DATE	march	dep	29	SENT_29	[p2l1695t3203r1786b3224],
16	2013	CD	DATE	2013	num	18	SENT_29	[p2l1796t3203r1853b3224],
17	|	CD	NUMBER	|	num	18	SENT_29	[p2l1863t3201r1865b3231],
18	www.nature.com/cpt	NN	O	www.nature.com/cpt	dep	15	SENT_29	[p2l1874t3203r2139b3229],
19	than	IN	O	than	_	0	SENT_29	[p2l7t3523r166b3587],
20	one	CD	NUMBER	one	num	22	SENT_29	[p2l192t3546r318b3587],
21	kinase	NN	O	kinase	nn	22	SENT_29	[p2l342t3515r670b3587],
22	.5	NN	NUMBER	.5	prep_than	18	SENT_29	[p2l342t3515r670b3587],
23	=	JJ	O	=	amod	22	SENT_29	[p2l342t3515r670b3587],
24	6	CD	NUMBER	6	tmod	23	SENT_29	[p2l342t3515r670b3587],
25	In	IN	O	in	_	0	SENT_29	[p2l696t3528r769b3586],
26	addition	NN	O	addition	prep_in	29	SENT_29	[p2l795t3523r1113b3595],
27	,	,	O	,	_	0	SENT_29	[p2l795t3523r1113b3595],
28	there	EX	O	there	expl	29	SENT_29	[p2l1140t3523r1320b3587],
29	is	VBZ	O	be	_	0	SENT_29	[p2l1346t3528r1398b3587],
30	considerable	JJ	O	considerable	amod	32	SENT_29	[p2l1425t3523r1873b3587],
31	further	JJ	O	further	amod	32	SENT_29	[p2l1899t3523r2153b3587],
32	potential	NN	O	potential	nsubj	29	SENT_29	[p3l6t23r339b106],
33	in	IN	O	in	_	0	SENT_29	[p3l369t28r439b85],
34	this	DT	O	this	det	36	SENT_29	[p3l468t23r602b86],
35	target	NN	O	target	nn	36	SENT_29	[p3l632t35r846b107],
36	class	NN	O	class	prep_in	32	SENT_29	[p3l875t23r1042b86],
37	in	IN	O	in	_	0	SENT_29	[p3l1073t28r1144b85],
38	the	DT	O	the	det	39	SENT_29	[p3l1172t23r1286b86],
39	context	NN	O	context	prep_in	36	SENT_29	[p3l1317t35r1590b86],
40	of	IN	O	of	_	0	SENT_29	[p3l1619t23r1697b86],
41	cancer	NN	O	cancer	prep_of	39	SENT_29	[p3l1717t46r1971b86],
42	.	.	O	.	_	0	SENT_29	[p3l1717t46r1971b86],

1	Our	PRP$	O	we	poss	3	SENT_30	[p3l2005t27r2153b86],
2	recent	JJ	O	recent	amod	3	SENT_30	[p3l8t139r231b190],
3	analysis7	NN	O	analysis7	nsubj	5	SENT_30	[p3l258t119r574b211],
4	has	VBZ	O	have	aux	5	SENT_30	[p3l599t126r717b190],
5	identiﬁed	VBN	O	identiﬁed	_	0	SENT_30	[p3l744t126r1092b190],
6	42	CD	NUMBER	42	number	7	SENT_30	[p3l1117t133r1198b189],
7	actual	JJ	O	actual	dobj	5	SENT_30	[p3l1227t126r1443b190],
8	or	CC	O	or	_	0	SENT_30	[p3l1470t149r1545b190],
9	potential	JJ	O	potential	amod	11	SENT_30	[p3l1569t126r1895b210],
10	kinase	NN	O	kinase	nn	11	SENT_30	[p3l1919t126r2150b190],
11	targets	NNS	O	target	dobj	5	SENT_30	[p3l7t243r257b315],
12	with	IN	O	with	_	0	SENT_30	[p3l288t231r454b294],
13	cancer-causing	JJ	O	cancer-causing	amod	14	SENT_30	[p3l487t236r1053b315],
14	mutations	NNS	O	mutation	prep_with	5	SENT_30	[p3l1084t236r1461b294],
15	or	CC	O	or	_	0	SENT_30	[p3l1495t254r1572b294],
16	other	JJ	O	other	amod	18	SENT_30	[p3l1604t231r1802b294],
17	genomic	JJ	O	genomic	amod	18	SENT_30	[p3l1833t236r2152b315],
18	abnormalities	NNS	O	abnormality	conj_or	14	SENT_30	[p3l8t334r485b397],
19	from	IN	O	from	_	0	SENT_30	[p3l508t334r677b397],
20	the	DT	O	the	det	21	SENT_30	[p3l698t334r806b397],
21	total	NN	O	total	prep_from	5	SENT_30	[p3l828t334r984b397],
22	of	IN	O	of	_	0	SENT_30	[p3l1006t334r1080b397],
23	479	CD	NUMBER	479	num	25	SENT_30	[p3l1092t341r1213b397],
24	cancer	NN	O	cancer	nn	25	SENT_30	[p3l1238t334r1733b397],
25	—	NN	O	—	prep_of	21	SENT_30	[p3l1238t334r1733b397],
26	related	JJ	O	related	amod	27	SENT_30	[p3l1238t334r1733b397],
27	genes	NNS	O	gene	dep	25	SENT_30	[p3l1755t357r1944b418],
28	listed	VBN	O	list	partmod	27	SENT_30	[p3l1966t334r2153b397],
29	in	IN	O	in	_	0	SENT_30	[p3l8t443r75b500],
30	the	DT	O	the	det	35	SENT_30	[p3l97t437r205b501],
31	Cancer	NN	O	cancer	nn	35	SENT_30	[p3l230t441r479b501],
32	Gene	NN	O	gene	nn	35	SENT_30	[p3l502t441r683b501],
33	Census8	NN	O	census8	nn	35	SENT_30	[p3l707t429r989b501],
34	(	CD	NUMBER	(	num	35	SENT_30	[p3l1016t437r1234b521],
35	http	NN	O	http	prep_in	28	SENT_30	[p3l1016t437r1234b521],
36	:	:	O	:	_	0	SENT_30	[p3l1016t437r1234b521],
37	/	:	O	/	punct	41	SENT_30	[p3l1016t437r1234b521],
38	/	:	O	/	punct	39	SENT_30	[p3l1240t437r1927b522],
39	www.sanger.ac.uk	NN	O	www.sanger.ac.uk	dep	41	SENT_30	[p3l1240t437r1927b522],
40	/	:	O	/	punct	39	SENT_30	[p3l1240t437r1927b522],
41	genetics	NNS	O	genetics	dep	21	SENT_30	[p3l1933t450r2149b522, p3l8t545r131b607],
42	/	:	O	/	punct	43	SENT_30	[p3l1933t450r2149b522, p3l8t545r131b607],
43	CGP	NN	O	cgp	dep	41	SENT_30	[p3l139t545r340b607],
44	/	:	O	/	punct	43	SENT_30	[p3l139t545r340b607],
45	Census	NNP	O	Census	nn	46	SENT_30	[p3l348t542r659b617],
46	)	NN	O	)	dep	41	SENT_30	[p3l348t542r659b617],
47	.	.	O	.	_	0	SENT_30	[p3l348t542r659b617],

1	Also	RB	O	also	advmod	16	SENT_31	[p3l688t541r870b613],
2	,	,	O	,	_	0	SENT_31	[p3l688t541r870b613],
3	only	RB	O	only	advmod	6	SENT_31	[p3l900t541r1059b625],
4	a	DT	O	a	det	6	SENT_31	[p3l1083t564r1118b604],
5	small	JJ	O	small	amod	6	SENT_31	[p3l1145t541r1336b604],
6	proportion	NN	O	proportion	nsubj	16	SENT_31	[p3l1361t546r1765b624],
7	of	IN	O	of	_	0	SENT_31	[p3l1792t541r1869b604],
8	the	DT	O	the	det	12	SENT_31	[p3l1885t541r1998b604],
9	518	CD	NUMBER	518	num	12	SENT_31	[p3l2027t548r2150b604],
10	human	JJ	O	human	amod	12	SENT_31	[p3l7t644r251b707],
11	protein	NN	O	protein	nn	12	SENT_31	[p3l272t649r525b727],
12	kinases	NNS	O	kinase	prep_of	6	SENT_31	[p3l546t644r798b707],
13	have	VBP	O	have	aux	16	SENT_31	[p3l820t644r977b707],
14	been	VBN	O	be	cop	16	SENT_31	[p3l998t644r1163b707],
15	functionally	RB	O	functionally	advmod	16	SENT_31	[p3l1186t644r1611b728],
16	annotated	JJ	O	annotated	_	0	SENT_31	[p3l1630t644r1978b707],
17	with	IN	O	with	_	0	SENT_31	[p3l1998t644r2152b707],
18	“	CD	NUMBER	“	num	20	SENT_31	[p3l9t746r366b810],
19	selective	JJ	O	selective	amod	20	SENT_31	[p3l9t746r366b810],
20	”	NN	O	”	prep_with	16	SENT_31	[p3l9t746r366b810],
21	small	JJ	O	small	amod	24	SENT_31	[p3l393t746r937b810],
22	—	NN	O	—	nn	24	SENT_31	[p3l393t746r937b810],
23	molecule	NN	O	molecule	nn	24	SENT_31	[p3l393t746r937b810],
24	inhibitors	NNS	O	inhibitor	nsubj	25	SENT_31	[p3l962t738r1360b810],
25	.9	VBP	NUMBER	.9	rcmod	20	SENT_31	[p3l962t738r1360b810],

1	The	DT	O	the	det	3	SENT_32	[p3l81t850r205b913],
2	surprising	JJ	O	surprising	amod	3	SENT_32	[p3l227t855r572b934],
3	imbalance	NN	O	imbalance	nsubj	13	SENT_32	[p3l590t850r939b913],
4	of	IN	O	of	_	0	SENT_32	[p3l960t850r1033b913],
5	drug	NN	O	drug	nn	6	SENT_32	[p3l1044t850r1205b934],
6	discovery	NN	O	discovery	prep_of	3	SENT_32	[p3l1224t850r1551b934],
7	and	CC	O	and	_	0	SENT_32	[p3l1568t850r1693b913],
8	development	NN	O	development	nn	9	SENT_32	[p3l1713t850r2153b933],
9	activity	NN	O	activity	prep_of	3	SENT_32	[p3l8t958r258b1037],
10	may	MD	O	may	aux	13	SENT_32	[p3l275t976r421b1037],
11	well	RB	O	well	advmod	13	SENT_32	[p3l435t953r572b1016],
12	be	VB	O	be	cop	13	SENT_32	[p3l589t953r668b1016],
13	attributable	JJ	O	attributable	_	0	SENT_32	[p3l689t953r1079b1016],
14	to	TO	O	to	_	0	SENT_32	[p3l1099t965r1164b1016],
15	limitations	NNS	O	limitation	prep_to	13	SENT_32	[p3l1184t953r1550b1016],
16	in	IN	O	in	_	0	SENT_32	[p3l1571t958r1637b1015],
17	the	DT	O	the	det	18	SENT_32	[p3l1657t953r1762b1016],
18	availability	NN	O	availability	prep_in	15	SENT_32	[p3l1783t953r2153b1037],
19	of	IN	O	of	_	0	SENT_32	[p3l8t1055r84b1119],
20	knowledge	NN	O	knowledge	nn	23	SENT_32	[p3l96t1055r478b1140],
21	and	CC	O	and	_	0	SENT_32	[p3l503t1055r633b1119],
22	technical	JJ	O	technical	nn	23	SENT_32	[p3l655t1055r975b1119],
23	resources	NNS	O	resource	prep_of	18	SENT_32	[p3l998t1047r1413b1119],
24	.	.	O	.	_	0	SENT_32	[p3l998t1047r1413b1119],

1	”	NN	O	”	npadvmod	28	SENT_33	[p3l998t1047r1413b1119],
2	For	IN	O	for	_	0	SENT_33	[p3l1438t1061r1557b1119],
3	instance	NN	O	instance	prep_for	28	SENT_33	[p3l1580t1061r1889b1128],
4	,	,	O	,	_	0	SENT_33	[p3l1580t1061r1889b1128],
5	limitations	NNS	O	limitation	nsubj	28	SENT_33	[p3l1913t1055r2148b1119, p3l7t1164r181b1222],
6	in	IN	O	in	_	0	SENT_33	[p3l207t1164r276b1221],
7	the	DT	O	the	det	8	SENT_33	[p3l300t1159r411b1222],
8	understanding	NN	O	understanding	prep_in	5	SENT_33	[p3l436t1159r959b1243],
9	of	IN	O	of	_	0	SENT_33	[p3l984t1159r1060b1222],
10	the	DT	O	the	det	13	SENT_33	[p3l1075t1159r1184b1222],
11	underlying	VBG	O	underlie	amod	13	SENT_33	[p3l1210t1159r1602b1243],
12	biological	JJ	O	biological	amod	13	SENT_33	[p3l1623t1159r1973b1243],
13	processes	NNS	O	process	prep_of	8	SENT_33	[p3l1996t1181r2146b1242, p3l8t1285r216b1325],
14	and	CC	O	and	_	0	SENT_33	[p3l241t1262r372b1325],
15	the	DT	O	the	det	16	SENT_33	[p3l394t1262r504b1325],
16	lack	NN	O	lack	conj_and	13	SENT_33	[p3l528t1262r672b1325],
17	of	IN	O	of	_	0	SENT_33	[p3l694t1262r770b1325],
18	suitable	JJ	O	suitable	amod	19	SENT_33	[p3l786t1262r1056b1325],
19	assays	NNS	O	assay	prep_of	16	SENT_33	[p3l1082t1285r1313b1346],
20	,	,	O	,	_	0	SENT_33	[p3l1082t1285r1313b1346],
21	chemical	NN	O	chemical	nn	23	SENT_33	[p3l1339t1262r1656b1325],
22	tool	NN	O	tool	nn	23	SENT_33	[p3l1679t1262r1818b1325],
23	libraries	NNS	O	library	prep_of	16	SENT_33	[p3l1840t1262r2148b1334],
24	,	,	O	,	_	0	SENT_33	[p3l1840t1262r2148b1334],
25	and	CC	O	and	_	0	SENT_33	[p3l8t1365r132b1428],
26	informative	JJ	O	informative	amod	27	SENT_33	[p3l151t1365r542b1428],
27	biomarkers	NNS	O	biomarker	prep_of	16	SENT_33	[p3l560t1365r940b1428],
28	make	VBP	O	make	_	0	SENT_33	[p3l960t1365r1141b1428],
29	the	DT	O	the	det	30	SENT_33	[p3l1160t1365r1264b1428],
30	exploration	NN	O	exploration	dobj	28	SENT_33	[p3l1285t1365r1668b1448],
31	of	IN	O	of	_	0	SENT_33	[p3l1688t1365r1760b1428],
32	new	JJ	O	new	amod	33	SENT_33	[p3l1771t1388r1911b1428],
33	targets	NNS	O	target	prep_of	30	SENT_33	[p3l1927t1377r2149b1449],
34	both	CC	O	both	preconj	30	SENT_33	[p3l6t1468r164b1531],
35	more	JJR	O	more	amod	36	SENT_33	[p3l184t1491r362b1531],
36	difﬁcult	NN	O	difﬁcult	conj	30	SENT_33	[p3l383t1468r648b1531],
37	and	CC	O	and	_	0	SENT_33	[p3l668t1468r794b1531],
38	more	JJR	O	more	conj	30	SENT_33	[p3l813t1491r990b1531],
39	risky	JJ	O	risky	amod	38	SENT_33	[p3l1011t1468r1179b1552],
40	than	IN	O	than	_	0	SENT_33	[p3l1195t1468r1349b1531],
41	pursuing	VBG	O	pursue	prepc_than	28	SENT_33	[p3l1368t1473r1676b1552],
42	those	DT	O	those	dobj	41	SENT_33	[p3l1694t1468r1877b1531],
43	that	WDT	O	that	nsubjpass	52	SENT_33	[p3l1896t1468r2030b1531],
44	are	VBP	O	be	auxpass	47	SENT_33	[p3l2050t1491r2150b1531],
45	already	RB	O	already	advmod	47	SENT_33	[p3l8t1571r266b1655],
46	well	RB	O	well	advmod	47	SENT_33	[p3l284t1571r426b1634],
47	understood	VBN	O	understand	rcmod	42	SENT_33	[p3l449t1571r875b1643],
48	,	,	O	,	_	0	SENT_33	[p3l449t1571r875b1643],
49	validated	VBN	O	validate	rcmod	42	SENT_33	[p3l897t1571r1238b1643],
50	,	,	O	,	_	0	SENT_33	[p3l897t1571r1238b1643],
51	and	CC	O	and	_	0	SENT_33	[p3l1265t1571r1395b1634],
52	shown	VBN	O	show	rcmod	42	SENT_33	[p3l1418t1571r1646b1634],
53	to	TO	O	to	aux	55	SENT_33	[p3l1669t1583r1736b1634],
54	be	VB	O	be	cop	55	SENT_33	[p3l1759t1571r1841b1634],
55	successful	JJ	O	successful	xcomp	52	SENT_33	[p3l1866t1594r2147b1634, p3l7t1674r117b1737],
56	.	.	O	.	_	0	SENT_33	[p3l1866t1594r2147b1634, p3l7t1674r117b1737],

1	Less	RBR	O	less	advmod	3	SENT_34	[p3l144t1679r289b1737],
2	well	RB	O	well	advmod	3	SENT_34	[p3l311t1674r452b1737],
3	studied	VBN	O	study	amod	4	SENT_34	[p3l477t1674r733b1737],
4	kinases	NNS	O	kinase	nsubj	11	SENT_34	[p3l754t1674r1009b1737],
5	and	CC	O	and	_	0	SENT_34	[p3l1034t1674r1163b1737],
6	other	JJ	O	other	amod	8	SENT_34	[p3l1186t1674r1372b1737],
7	novel	JJ	O	novel	amod	8	SENT_34	[p3l1394t1674r1582b1737],
8	targets	NNS	O	target	conj_and	4	SENT_34	[p3l1604t1686r1836b1758],
9	not	RB	O	not	dep	10	SENT_34	[p3l1860t1686r1977b1737],
10	only	RB	O	only	advmod	11	SENT_34	[p3l2000t1674r2154b1758],
11	require	VB	O	require	_	0	SENT_34	[p3l8t1782r261b1860],
12	enhanced	VBN	O	enhance	amod	13	SENT_34	[p3l286t1777r628b1840],
13	investment	NN	O	investment	dobj	11	SENT_34	[p3l652t1782r1044b1840],
14	but	CC	O	but	cc	17	SENT_34	[p3l1065t1777r1183b1840],
15	they	PRP	O	they	nsubj	17	SENT_34	[p3l1205t1777r1361b1861],
16	also	RB	O	also	advmod	17	SENT_34	[p3l1382t1777r1518b1840],
17	carry	VBP	O	carry	rcmod	13	SENT_34	[p3l1544t1800r1730b1861],
18	greater	JJR	O	greater	amod	19	SENT_34	[p3l1751t1789r1997b1861],
19	risk	NN	O	risk	dobj	17	SENT_34	[p3l2021t1777r2154b1840],
20	of	IN	O	of	_	0	SENT_34	[p3l8t1880r83b1943],
21	failure	NN	O	failure	prep_of	19	SENT_34	[p3l97t1880r337b1952],
22	;	:	O	;	_	0	SENT_34	[p3l97t1880r337b1952],
23	these	DT	O	these	nsubj	25	SENT_34	[p3l362t1880r541b1943],
24	are	VBP	O	be	cop	25	SENT_34	[p3l565t1903r668b1943],
25	matters	NNS	O	matter	parataxis	17	SENT_34	[p3l691t1892r950b1943],
26	of	IN	O	of	_	0	SENT_34	[p3l975t1880r1050b1943],
27	major	JJ	O	major	amod	28	SENT_34	[p3l1063t1885r1270b1964],
28	concern	NN	O	concern	prep_of	25	SENT_34	[p3l1293t1903r1574b1943],
29	for	IN	O	for	_	0	SENT_34	[p3l1597t1880r1697b1943],
30	the	DT	O	the	det	32	SENT_34	[p3l1718t1880r1826b1943],
31	pharmaceutical	JJ	O	pharmaceutical	amod	32	SENT_34	[p3l1849t1880r2149b1963, p3l8t1983r271b2046],
32	industry	NN	O	industry	prep_for	28	SENT_34	[p3l293t1983r586b2067],
33	from	IN	O	from	_	0	SENT_34	[p3l606t1983r774b2046],
34	a	DT	O	a	det	36	SENT_34	[p3l797t2006r831b2046],
35	commercial	JJ	O	commercial	amod	36	SENT_34	[p3l854t1983r1260b2046],
36	point	NN	O	point	prep_from	32	SENT_34	[p3l1281t1988r1465b2066],
37	of	IN	O	of	_	0	SENT_34	[p3l1487t1983r1561b2046],
38	view	NN	O	view	prep_of	36	SENT_34	[p3l1571t1988r1741b2046],
39	.	.	O	.	_	0	SENT_34	[p3l1571t1988r1741b2046],

1	Such	JJ	O	such	amod	2	SENT_35	[p3l1768t1983r1932b2046],
2	issues	NNS	O	issue	dep	5	SENT_35	[p3l1955t1988r2150b2046],
3	must	MD	O	must	aux	5	SENT_35	[p3l7t2098r181b2149],
4	be	VB	O	be	auxpass	5	SENT_35	[p3l202t2086r283b2149],
5	addressed	VBN	O	address	_	0	SENT_35	[p3l308t2086r657b2149],
6	through	IN	O	through	_	0	SENT_35	[p3l679t2086r963b2170],
7	new	JJ	O	new	amod	8	SENT_35	[p3l987t2109r1133b2149],
8	paradigms	NNS	O	paradigm	prep_through	5	SENT_35	[p3l1152t2086r1523b2170],
9	such	JJ	O	such	_	0	SENT_35	[p3l1548t2086r1707b2149],
10	as	IN	O	as	_	0	SENT_35	[p3l1731t2109r1797b2149],
11	nonproﬁt	JJ	O	nonproﬁt	amod	13	SENT_35	[p3l1821t2086r2153b2169],
12	drug	NN	O	drug	nn	13	SENT_35	[p3l8t2190r171b2274],
13	discovery	NN	O	discovery	prep_such_as	8	SENT_35	[p3l192t2190r523b2274],
14	and	CC	O	and	_	0	SENT_35	[p3l542t2190r668b2253],
15	development	NN	O	development	nn	16	SENT_35	[p3l690t2190r1135b2273],
16	programs	NNS	O	program	prep_such_as	8	SENT_35	[p3l1155t2212r1484b2274],
17	and	CC	O	and	_	0	SENT_35	[p3l1507t2190r1634b2253],
18	public	JJ	O	public	amod	21	SENT_35	[p3l1654t2190r2151b2273],
19	—	NN	O	—	nn	21	SENT_35	[p3l1654t2190r2151b2273],
20	private	JJ	O	private	amod	21	SENT_35	[p3l1654t2190r2151b2273],
21	partnership	NN	O	partnership	prep_such_as	8	SENT_35	[p3l6t2293r423b2376],
22	,	,	O	,	_	0	SENT_35	[p3l6t2293r423b2376],
23	which	WDT	O	which	nsubj	24	SENT_35	[p3l444t2293r654b2356],
24	have	VBP	O	have	rcmod	8	SENT_35	[p3l673t2293r829b2356],
25	the	DT	O	the	det	26	SENT_35	[p3l849t2293r955b2356],
26	potential	JJ	O	potential	dobj	24	SENT_35	[p3l975t2293r1282b2376],
27	to	TO	O	to	aux	28	SENT_35	[p3l1301t2305r1367b2356],
28	increase	VB	O	increase	dep	26	SENT_35	[p3l1389t2298r1668b2356],
29	creativity	NN	O	creativity	dobj	28	SENT_35	[p3l1689t2298r2008b2377],
30	and	CC	O	and	_	0	SENT_35	[p3l2027t2293r2153b2356],
31	innovation	NN	O	innovation	dobj	28	SENT_35	[p3l8t2401r382b2459],
32	and	CC	O	and	_	0	SENT_35	[p3l404t2395r530b2459],
33	reduce	VB	O	reduce	conj_and	28	SENT_35	[p3l552t2395r780b2459],
34	unnecessary	JJ	O	unnecessary	amod	35	SENT_35	[p3l802t2418r1229b2480],
35	duplication	NN	O	duplication	dobj	33	SENT_35	[p3l1248t2387r1765b2479],
36	.9	CD	NUMBER	.9	num	39	SENT_35	[p3l1248t2387r1765b2479],
37	’	NN	O	’	nn	39	SENT_35	[p3l1248t2387r1765b2479],
38	1	CD	NUMBER	1	num	39	SENT_35	[p3l1248t2387r1765b2479],
39	°	NN	O	°	nsubjpass	5	SENT_35	[p3l1248t2387r1765b2479],

1	MOLECULAR	NNP	O	MOLECULAR	nn	2	SENT_36	[p3l10t2611r463b2667],
2	DIAGNOSTICS	NNPS	O	DIAGNOSTICS	_	0	SENT_36	[p3l484t2611r983b2667],
3	AND	CC	O	and	_	0	SENT_36	[p3l1001t2612r1162b2666],
4	PREDICTIVE	NNPS	O	PREDICTIVE	conj_and	2	SENT_36	[p3l1184t2612r1609b2667],
5	BIOMARKERS	NNPS	O	BIOMARKERS	dep	2	SENT_36	[p3l1631t2611r2110b2667],
6	From	IN	O	from	_	0	SENT_36	[p3l8t2712r200b2770],
7	the	DT	O	the	det	10	SENT_36	[p3l226t2707r336b2770],
8	initial	JJ	O	initial	amod	10	SENT_36	[p3l363t2707r572b2770],
9	pioneering	JJ	O	pioneering	amod	10	SENT_36	[p3l597t2712r986b2791],
10	experience	NN	O	experience	prep_from	5	SENT_36	[p3l1012t2712r1396b2790],
11	with	IN	O	with	_	0	SENT_36	[p3l1421t2707r1580b2770],
12	the	DT	O	the	det	15	SENT_36	[p3l1606t2707r1716b2770],
13	HER2	NN	O	her2	nn	15	SENT_36	[p3l1744t2712r1955b2770],
14	antibody	NN	O	antibody	nn	15	SENT_36	[p3l1985t2712r2148b2770, p3l6t2810r186b2894],
15	trastuzumab	NN	O	trastuzumab	prep_with	10	SENT_36	[p3l206t2810r647b2873],
16	in	IN	O	in	_	0	SENT_36	[p3l673t2815r741b2872],
17	breast	NN	O	breast	nn	18	SENT_36	[p3l763t2810r975b2873],
18	cancer	NN	O	cancer	prep_in	15	SENT_36	[p3l999t2833r1240b2882],
19	,	,	O	,	_	0	SENT_36	[p3l999t2833r1240b2882],
20	to	TO	O	to	dep	41	SENT_36	[p3l1265t2822r1333b2873],
21	the	DT	O	the	det	24	SENT_36	[p3l1357t2810r1467b2873],
22	BCR-ABL1	NN	O	bcr-abl1	nn	24	SENT_36	[p3l1491t2814r1880b2873],
23	inhibitor	NN	O	inhibitor	nn	24	SENT_36	[p3l1911t2810r2148b2873, p3l7t2925r105b2976],
24	imatinib	NN	O	imatinib	pobj	20	SENT_36	[p3l126t2913r413b2976],
25	in	IN	O	in	_	0	SENT_36	[p3l437t2918r503b2975],
26	chronic	JJ	O	chronic	amod	28	SENT_36	[p3l526t2913r783b2976],
27	myeloid	JJ	O	myeloid	amod	28	SENT_36	[p3l804t2913r1078b2997],
28	leukemia	NN	O	leukemia	prep_in	24	SENT_36	[p3l1098t2913r1411b2976],
29	and	CC	O	and	_	0	SENT_36	[p3l1432t2913r1558b2976],
30	the	DT	O	the	det	33	SENT_36	[p3l1578t2913r1684b2976],
31	EGF	NN	ORGANIZATION	egf	nn	33	SENT_36	[p3l1706t2917r1857b2976],
32	R	NN	O	r	nn	33	SENT_36	[p3l1863t2918r1915b2976],
33	kinase	NN	O	kinase	conj_and	24	SENT_36	[p3l1933t2913r2149b2976],
34	inhibitors	NNS	O	inhibitor	nn	35	SENT_36	[p3l8t3016r349b3079],
35	geﬁtinib	NN	O	geﬁtinib	dep	33	SENT_36	[p3l373t3016r661b3100],
36	and	CC	O	and	_	0	SENT_36	[p3l686t3016r816b3079],
37	erlotinib	NN	O	erlotinib	dep	33	SENT_36	[p3l839t3016r1138b3079],
38	(	CD	NUMBER	(	num	39	SENT_36	[p3l1167t3016r1432b3099],
39	Figure	NN	O	figure	dep	33	SENT_36	[p3l1167t3016r1432b3099],
40	1	CD	NUMBER	1	num	41	SENT_36	[p3l1460t3016r1521b3093],
41	)	NN	O	)	rcmod	5	SENT_36	[p3l1460t3016r1521b3093],
42	in	IN	O	in	dep	41	SENT_36	[p3l1549t3021r1618b3078],
43	non-small-cell	JJ	O	non-small-cell	pobj	42	SENT_36	[p3l1641t3016r2152b3079],
44	a	DT	O	a	det	50	SENT_36	[p3l738t3271r781b3320],
45	b	NN	O	b	nn	50	SENT_36	[p3l1822t3256r1868b3320],
46	lung	NN	O	lung	nn	50	SENT_36	[p4l6t1976r163b2060],
47	cancer	NN	O	cancer	nn	50	SENT_36	[p4l186t1999r415b2039],
48	(	CD	NUMBER	(	num	50	SENT_36	[p4l442t1977r787b2053],
49	NSCLC	NN	O	nsclc	nn	50	SENT_36	[p4l442t1977r787b2053],
50	)	NN	O	)	dep	43	SENT_36	[p4l442t1977r787b2053],
51	,	,	O	,	_	0	SENT_36	[p4l442t1977r787b2053],
52	through	IN	O	through	dep	41	SENT_36	[p4l812t1976r1097b2060],
53	to	TO	O	to	pcomp	52	SENT_36	[p4l1120t1988r1188b2039],
54	recent	JJ	O	recent	amod	55	SENT_36	[p4l1213t1988r1430b2039],
55	experience	NN	O	experience	pobj	53	SENT_36	[p4l1453t1981r1831b2059],
56	with	IN	O	with	_	0	SENT_36	[p4l1854t1976r2011b2039],
57	the	DT	O	the	det	60	SENT_36	[p4l2034t1976r2143b2039],
58	BRAF	NN	MISC	braf	nn	60	SENT_36	[p4l8t2082r214b2140],
59	inhibitor	NN	O	inhibitor	nn	60	SENT_36	[p4l238t2078r544b2141],
60	vemurafenib	NN	O	vemurafenib	prep_with	55	SENT_36	[p4l562t2078r1000b2141],
61	in	IN	O	in	_	0	SENT_36	[p4l1023t2083r1091b2140],
62	melanoma	NN	O	melanoma	prep_in	60	SENT_36	[p4l1113t2078r1479b2141],
63	and	CC	O	and	_	0	SENT_36	[p4l1501t2078r1629b2141],
64	the	DT	O	the	det	66	SENT_36	[p4l1649t2078r1757b2141],
65	dual	JJ	O	dual	amod	66	SENT_36	[p4l1780t2078r1928b2141],
66	ALKMET	NNP	O	ALKMET	prep_in	60	SENT_36	[p4l1949t2082r2140b2140, p4l7t2183r183b2242],

1	inhibitor	NN	O	inhibitor	nn	2	SENT_37	[p4l205t2180r508b2243],
2	crizotinib	NN	O	crizotinib	nsubjpass	11	SENT_37	[p4l529t2180r858b2243],
3	in	IN	O	in	_	0	SENT_37	[p4l881t2185r948b2242],
4	NSCLC	NNP	ORGANIZATION	NSCLC	prep_in	2	SENT_37	[p4l969t2172r1357b2252],
5	,1	CD	NUMBER	,1	num	4	SENT_37	[p4l969t2172r1357b2252],
6	*	CD	NUMBER	*	number	7	SENT_37	[p4l969t2172r1357b2252],
7	11	CD	NUMBER	11	num	4	SENT_37	[p4l969t2172r1357b2252],
8	it	PRP	O	it	nsubjpass	11	SENT_37	[p4l1384t2185r1430b2243],
9	has	VBZ	O	have	aux	11	SENT_37	[p4l1449t2180r1561b2243],
10	been	VBN	O	be	auxpass	11	SENT_37	[p4l1582t2180r1746b2243],
11	recognized	VBN	O	recognize	_	0	SENT_37	[p4l1768t2180r2144b2264],
12	that	IN	O	that	complm	27	SENT_37	[p4l6t2283r139b2346],
13	the	DT	O	the	det	15	SENT_37	[p4l157t2283r263b2346],
14	successful	JJ	O	successful	amod	15	SENT_37	[p4l285t2283r621b2346],
15	development	NN	O	development	nsubj	27	SENT_37	[p4l642t2283r1082b2366],
16	and	CC	O	and	_	0	SENT_37	[p4l1102t2283r1227b2346],
17	use	NN	O	use	nsubj	27	SENT_37	[p4l1247t2306r1357b2346],
18	of	IN	O	of	_	0	SENT_37	[p4l1378t2283r1452b2346],
19	kinase	NN	O	kinase	nn	20	SENT_37	[p4l1461t2283r1677b2346],
20	inhibitors	NNS	O	inhibitor	prep_of	15	SENT_37	[p4l1698t2283r2027b2346],
21	for	IN	O	for	_	0	SENT_37	[p4l2048t2283r2145b2346],
22	cancer	NN	O	cancer	nn	23	SENT_37	[p4l8t2409r224b2449],
23	therapy	NN	O	therapy	prep_for	20	SENT_37	[p4l241t2386r495b2470],
24	is	VBZ	O	be	cop	27	SENT_37	[p4l511t2391r559b2449],
25	very	RB	O	very	advmod	26	SENT_37	[p4l576t2409r725b2470],
26	much	JJ	O	much	advmod	27	SENT_37	[p4l740t2386r929b2449],
27	dependent	JJ	O	dependent	ccomp	11	SENT_37	[p4l948t2386r1301b2469],
28	on	IN	O	on	_	0	SENT_37	[p4l1319t2409r1403b2449],
29	predictive	JJ	O	predictive	amod	30	SENT_37	[p4l1421t2386r1750b2469],
30	biomarkers	NNS	O	biomarker	prep_on	27	SENT_37	[p4l1768t2386r2144b2449],
31	for	IN	O	for	_	0	SENT_37	[p4l7t2489r103b2552],
32	patient	NN	O	patient	nn	33	SENT_37	[p4l120t2494r355b2572],
33	selection	NN	O	selection	prep_for	30	SENT_37	[p4l374t2489r686b2552],
34	.	.	O	.	_	0	SENT_37	[p4l374t2489r686b2552],

1	In	IN	O	in	_	0	SENT_38	[p4l709t2494r779b2551],
2	the	DT	O	the	det	3	SENT_38	[p4l798t2489r903b2552],
3	era	NN	O	era	prep_in	12	SENT_38	[p4l923t2512r1025b2552],
4	of	IN	O	of	_	0	SENT_38	[p4l1044t2489r1117b2552],
5	personalized	JJ	O	personalized	amod	7	SENT_38	[p4l1126t2489r1556b2572],
6	cancer	NN	O	cancer	nn	7	SENT_38	[p4l1575t2512r1795b2552],
7	medicine	NN	O	medicine	prep_of	3	SENT_38	[p4l1813t2489r2142b2561],
8	,	,	O	,	_	0	SENT_38	[p4l1813t2489r2142b2561],
9	companion	NN	O	companion	nn	10	SENT_38	[p4l8t2597r390b2675],
10	diagnostics	NNS	O	diagnostic	nsubj	12	SENT_38	[p4l410t2592r786b2676],
11	have	VBP	O	have	aux	12	SENT_38	[p4l804t2592r958b2655],
12	jumped	VBN	O	jump	_	0	SENT_38	[p4l972t2592r1236b2676],
13	to	TO	O	to	_	0	SENT_38	[p4l1253t2604r1318b2655],
14	the	DT	O	the	det	16	SENT_38	[p4l1338t2592r1443b2655],
15	front	JJ	O	front	amod	16	SENT_38	[p4l1462t2592r1630b2655],
16	line	NN	O	line	prep_to	12	SENT_38	[p4l1646t2592r1770b2655],
17	of	IN	O	of	_	0	SENT_38	[p4l1790t2592r1863b2655],
18	targeted	VBN	O	target	amod	19	SENT_38	[p4l1872t2592r2146b2676],
19	prescribing	NN	O	prescribing	prep_of	16	SENT_38	[p4l6t2695r388b2779],
20	of	IN	O	of	_	0	SENT_38	[p4l406t2695r479b2758],
21	therapeutics	NNS	O	therapeutics	prep_of	19	SENT_38	[p4l488t2695r918b2778],
22	.	.	O	.	_	0	SENT_38	[p4l488t2695r918b2778],

1	In	IN	O	in	_	0	SENT_39	[p4l940t2700r1011b2757],
2	our	PRP$	O	we	poss	5	SENT_39	[p4l1031t2718r1147b2758],
3	multidisciplinary	JJ	O	multidisciplinary	amod	5	SENT_39	[p4l1165t2695r1749b2779],
4	team	NN	O	team	nn	5	SENT_39	[p4l1763t2707r1930b2758],
5	meetings	NNS	O	meeting	prep_in	10	SENT_39	[p4l1949t2707r2141b2758, p4l7t2803r145b2882],
6	We	PRP	O	we	nsubjpass	10	SENT_39	[p4l166t2821r260b2861],
7	are	VBP	O	be	auxpass	10	SENT_39	[p4l283t2821r384b2861],
8	now	RB	DATE	now	advmod	10	SENT_39	[p4l406t2821r555b2861],
9	commonly	RB	O	commonly	advmod	10	SENT_39	[p4l575t2798r949b2882],
10	faced	VBN	O	face	_	0	SENT_39	[p4l967t2798r1149b2861],
11	with	IN	O	with	_	0	SENT_39	[p4l1168t2798r1322b2861],
12	clinical	JJ	O	clinical	amod	13	SENT_39	[p4l1344t2798r1590b2861],
13	decisions	NNS	O	decision	prep_with	10	SENT_39	[p4l1612t2798r1926b2861],
14	about	IN	O	about	_	0	SENT_39	[p4l1950t2798r2144b2861],
15	individual	JJ	O	individual	amod	16	SENT_39	[p4l7t2901r367b2964],
16	patients	NNS	O	patient	prep_about	13	SENT_39	[p4l390t2906r667b2984],
17	involving	VBG	O	involve	xcomp	10	SENT_39	[p4l693t2901r1023b2985],
18	the	DT	O	the	det	20	SENT_39	[p4l1045t2901r1154b2964],
19	molecular	JJ	O	molecular	amod	20	SENT_39	[p4l1179t2901r1534b2964],
20	proﬁling	NN	O	proﬁling	dobj	17	SENT_39	[p4l1557t2901r1861b2985],
21	of	IN	O	of	_	0	SENT_39	[p4l1885t2901r1961b2964],
22	their	PRP$	O	they	poss	24	SENT_39	[p4l1975t2901r2142b2964],
23	tumor	NN	O	tumor	nn	24	SENT_39	[p4l6t3015r220b3067],
24	tissue	NN	O	tissue	prep_of	20	SENT_39	[p4l238t2995r505b3067],
25	.	.	O	.	_	0	SENT_39	[p4l238t2995r505b3067],

1	”	NN	O	”	_	0	SENT_40	[p4l238t2995r505b3067],

1	Arguably	RB	O	arguably	advmod	18	SENT_41	[p4l80t3107r416b3191],
2	,	,	O	,	_	0	SENT_41	[p4l80t3107r416b3191],
3	most	JJS	O	most	nsubjpass	18	SENT_41	[p4l441t3119r615b3170],
4	of	IN	O	of	_	0	SENT_41	[p4l638t3107r713b3170],
5	the	DT	O	the	det	7	SENT_41	[p4l726t3107r835b3170],
6	recent	JJ	O	recent	amod	7	SENT_41	[p4l859t3119r1075b3170],
7	attention	NN	O	attention	prep_of	3	SENT_41	[p4l1098t3112r1412b3170],
8	concerning	VBG	O	concern	_	0	SENT_41	[p4l1436t3112r1833b3191],
9	molecular	JJ	O	molecular	amod	11	SENT_41	[p4l1855t3107r2142b3170, p4l6t3210r98b3273],
10	cancer	NN	O	cancer	nn	11	SENT_41	[p4l121t3233r350b3273],
11	diagnostics	NNS	O	diagnostic	prep_concerning	7	SENT_41	[p4l373t3210r766b3294],
12	in	IN	O	in	_	0	SENT_41	[p4l791t3215r859b3272],
13	the	DT	O	the	det	15	SENT_41	[p4l881t3210r990b3273],
14	clinical	JJ	O	clinical	amod	15	SENT_41	[p4l1015t3210r1266b3273],
15	setting	NN	O	setting	prep_in	11	SENT_41	[p4l1290t3215r1524b3294],
16	has	VBZ	O	have	aux	18	SENT_41	[p4l1545t3210r1660b3273],
17	been	VBN	O	be	auxpass	18	SENT_41	[p4l1682t3210r1850b3273],
18	focused	VBN	O	focus	_	0	SENT_41	[p4l1873t3210r2145b3273],
19	on	IN	O	on	_	0	SENT_41	[p4l8t3336r93b3376],
20	predictive	JJ	O	predictive	amod	21	SENT_41	[p4l115t3313r456b3396],
21	biomarkers	NNS	O	biomarker	prep_on	18	SENT_41	[p4l476t3313r864b3376],
22	of	IN	O	of	_	0	SENT_41	[p4l887t3313r961b3376],
23	response	NN	O	response	prep_of	21	SENT_41	[p4l973t3335r1273b3396],
24	to	TO	O	to	_	0	SENT_41	[p4l1294t3325r1360b3376],
25	therapy	NN	O	therapy	dep	41	SENT_41	[p4l1382t3313r1653b3397],
26	,	,	O	,	_	0	SENT_41	[p4l1382t3313r1653b3397],
27	such	JJ	O	such	_	0	SENT_41	[p4l1677t3313r1832b3376],
28	as	IN	O	as	_	0	SENT_41	[p4l1855t3336r1919b3376],
29	KRAS	NNP	ORGANIZATION	KRAS	nn	30	SENT_41	[p4l1940t3317r2144b3376],
30	mutations	NNS	O	mutation	prep_such_as	25	SENT_41	[p4l7t3421r356b3480],
31	in	IN	O	in	_	0	SENT_41	[p4l380t3421r447b3479],
32	metastatic	JJ	O	metastatic	amod	35	SENT_41	[p4l470t3421r824b3480],
33	colorectal	JJ	O	colorectal	amod	35	SENT_41	[p4l848t3416r1186b3480],
34	cancer	NN	O	cancer	nn	35	SENT_41	[p4l1209t3439r1436b3480],
35	(	NN	O	(	prep_in	30	SENT_41	[p4l1461t3408r1916b3493],
36	mCRC	NN	O	mcrc	dep	41	SENT_41	[p4l1461t3408r1916b3493],
37	)	CD	NUMBER	)	num	36	SENT_41	[p4l1461t3408r1916b3493],
38	,12	CD	NUMBER	,12	number	39	SENT_41	[p4l1461t3408r1916b3493],
39	’13	CD	NUMBER	’13	num	41	SENT_41	[p4l1461t3408r1916b3493],
40	EGFR	NN	ORGANIZATION	egfr	nn	41	SENT_41	[p4l1938t3420r2144b3480],
41	mutations	NNS	O	mutation	dep	47	SENT_41	[p4l7t3523r362b3582],
42	in	IN	O	in	_	0	SENT_41	[p4l387t3523r455b3581],
43	advanced	JJ	O	advanced	amod	44	SENT_41	[p4l479t3518r812b3582],
44	NSCLC	NNP	O	NSCLC	prep_in	41	SENT_41	[p4l834t3510r1287b3590],
45	,14	CD	NUMBER	,14	num	44	SENT_41	[p4l834t3510r1287b3590],
46	‘	CD	NUMBER	‘	num	47	SENT_41	[p4l834t3510r1287b3590],
47	16	CD	NUMBER	16	prep_to	18	SENT_41	[p4l834t3510r1287b3590],
48	and	CC	O	and	_	0	SENT_41	[p4l1312t3518r1442b3582],
49	BRAF	NN	O	braf	nn	50	SENT_41	[p4l1463t3522r1678b3581],
50	mutations	NNS	O	mutation	conj_and	47	SENT_41	[p4l1696t3523r2051b3582],
51	in	IN	O	in	_	0	SENT_41	[p4l2076t3523r2144b3581],
52	metastatic	JJ	O	metastatic	amod	55	SENT_41	[p5l7t31r360b89],
53	malignant	JJ	O	malignant	amod	55	SENT_41	[p5l383t26r736b110],
54	melanoma	NN	O	melanoma	nn	55	SENT_41	[p5l758t18r1282b89],
55	.17	NN	NUMBER	.17	prep_in	18	SENT_41	[p5l758t18r1282b89],
56	=	JJ	O	=	amod	55	SENT_41	[p5l758t18r1282b89],
57	18	CD	NUMBER	18	tmod	56	SENT_41	[p5l758t18r1282b89],
58	The	DT	O	the	det	59	SENT_41	[p5l1306t26r1432b89],
59	presence	NN	O	presence	nsubjpass	68	SENT_41	[p5l1454t48r1756b109],
60	or	CC	O	or	_	0	SENT_41	[p5l1780t49r1852b89],
61	absence	NN	O	absence	conj_or	59	SENT_41	[p5l1875t26r2144b89],
62	of	IN	O	of	_	0	SENT_41	[p5l8t129r84b192],
63	these	DT	O	these	det	65	SENT_41	[p5l98t129r279b192],
64	predictive	JJ	O	predictive	amod	65	SENT_41	[p5l303t129r656b212],
65	markers	NNS	O	marker	prep_of	59	SENT_41	[p5l681t129r968b192],
66	is	VBZ	O	be	auxpass	68	SENT_41	[p5l993t134r1045b192],
67	directly	RB	O	directly	advmod	68	SENT_41	[p5l1071t129r1341b213],
68	linked	VBN	O	link	rcmod	55	SENT_41	[p5l1361t129r1585b192],
69	to	TO	O	to	_	0	SENT_41	[p5l1608t141r1675b192],
70	the	DT	O	the	det	72	SENT_41	[p5l1700t129r1810b192],
71	response	NN	O	response	nn	72	SENT_41	[p5l1835t151r2145b212],
72	rates	NNS	O	rate	prep_to	68	SENT_41	[p5l8t244r176b295],
73	of	IN	O	of	_	0	SENT_41	[p5l208t232r286b295],
74	particular	JJ	O	particular	dep	75	SENT_41	[p5l306t232r669b315],
75	targeted	VBN	O	target	amod	76	SENT_41	[p5l698t232r996b316],
76	therapies	NNS	O	therapy	prep_of	72	SENT_41	[p5l1025t232r1357b315],
77	with	IN	O	with	_	0	SENT_41	[p5l1387t232r1548b295],
78	small-molecule	JJ	O	small-molecule	amod	80	SENT_41	[p5l1580t232r2142b295],
79	kinase	NN	O	kinase	nn	80	SENT_41	[p5l6t335r223b398],
80	inhibitors	NNS	O	inhibitor	prep_with	76	SENT_41	[p5l246t335r578b398],
81	or	CC	O	or	_	0	SENT_41	[p5l602t358r673b398],
82	antibodies	NNS	O	antibody	prep_with	76	SENT_41	[p5l695t335r1066b398],
83	.	.	O	.	_	0	SENT_41	[p5l695t335r1066b398],

1	Consequently	RB	O	consequently	advmod	19	SENT_42	[p5l1092t335r1577b419],
2	,	,	O	,	_	0	SENT_42	[p5l1092t335r1577b419],
3	testing	NN	O	testing	nsubj	19	SENT_42	[p5l1599t340r1829b419],
4	for	IN	O	for	mark	10	SENT_42	[p5l1849t335r1946b398],
5	them	PRP	O	they	nsubj	10	SENT_42	[p5l1966t335r2144b398],
6	has	VBZ	O	have	aux	10	SENT_42	[p5l6t438r120b501],
7	become	VBN	O	become	cop	10	SENT_42	[p5l142t438r414b501],
8	a	DT	O	a	det	10	SENT_42	[p5l438t461r473b501],
9	critical	JJ	O	critical	amod	10	SENT_42	[p5l496t438r736b501],
10	step	NN	O	step	dep	3	SENT_42	[p5l759t450r895b521],
11	in	IN	O	in	_	0	SENT_42	[p5l920t443r987b500],
12	the	DT	O	the	det	14	SENT_42	[p5l1010t438r1118b501],
13	pathological	JJ	O	pathological	amod	14	SENT_42	[p5l1141t438r1573b522],
14	diagnosis	NN	O	diagnosis	prep_in	10	SENT_42	[p5l1596t438r1922b522],
15	of	IN	O	of	_	0	SENT_42	[p5l1947t438r2022b501],
16	the	DT	O	the	det	18	SENT_42	[p5l2035t438r2143b501],
17	aboVe	NN	O	above	nn	18	SENT_42	[p5l8t540r612b603],
18	—	NN	O	—	prep_of	14	SENT_42	[p5l8t540r612b603],
19	mentioned	VBD	O	mention	_	0	SENT_42	[p5l8t540r612b603],
20	tumors	NNS	O	tumor	dobj	19	SENT_42	[p5l631t552r893b603],
21	.	.	O	.	_	0	SENT_42	[p5l631t552r893b603],

1	Somewhat	RB	O	somewhat	advmod	13	SENT_43	[p5l82t643r442b706],
2	away	RB	O	away	advmod	13	SENT_43	[p5l465t666r637b727],
3	from	IN	O	from	dep	13	SENT_43	[p5l656t643r825b706],
4	the	DT	O	the	det	5	SENT_43	[p5l847t643r954b706],
5	spotlight	NN	O	spotlight	pobj	3	SENT_43	[p5l978t643r1298b727],
6	,	,	O	,	_	0	SENT_43	[p5l978t643r1298b727],
7	but	CC	O	but	_	0	SENT_43	[p5l1321t643r1435b706],
8	still	RB	O	still	dep	13	SENT_43	[p5l1458t643r1581b706],
9	Very	RB	O	very	advmod	10	SENT_43	[p5l1600t666r1754b727],
10	important	JJ	O	important	dep	13	SENT_43	[p5l1774t648r2141b726],
11	,	,	O	,	_	0	SENT_43	[p5l1774t648r2141b726],
12	there	EX	O	there	expl	13	SENT_43	[p5l6t746r178b809],
13	are	VBP	O	be	_	0	SENT_43	[p5l199t769r297b809],
14	many	JJ	O	many	amod	17	SENT_43	[p5l317t769r508b830],
15	other	JJ	O	other	amod	17	SENT_43	[p5l525t746r704b809],
16	clinical	JJ	O	clinical	amod	17	SENT_43	[p5l723t746r964b809],
17	applications	NNS	O	application	nsubj	13	SENT_43	[p5l984t746r1388b829],
18	of	IN	O	of	_	0	SENT_43	[p5l1409t746r1482b809],
19	molecular	JJ	O	molecular	amod	20	SENT_43	[p5l1492t746r1833b809],
20	diagnostics	NNS	O	diagnostic	prep_of	17	SENT_43	[p5l1853t746r2142b830, p5l6t854r121b912],
21	in	IN	O	in	_	0	SENT_43	[p5l145t854r211b911],
22	oncology	NN	O	oncology	nn	24	SENT_43	[p5l234t849r553b933],
23	(	CD	NUMBER	(	num	24	SENT_43	[p5l576t850r795b926],
24	Table	NNP	O	Table	prep_in	20	SENT_43	[p5l576t850r795b926],
25	1	CD	NUMBER	1	number	26	SENT_43	[p5l822t850r903b925],
26	)	CD	NUMBER	)	num	24	SENT_43	[p5l822t850r903b925],
27	.	.	O	.	_	0	SENT_43	[p5l822t850r903b925],

1	For	IN	O	for	_	0	SENT_44	[p5l930t854r1045b912],
2	example	NN	O	example	prep_for	15	SENT_44	[p5l1068t849r1369b932],
3	,	,	O	,	_	0	SENT_44	[p5l1068t849r1369b932],
4	the	DT	O	the	det	6	SENT_44	[p5l1392t849r1499b912],
5	molecular	JJ	O	molecular	amod	6	SENT_44	[p5l1521t849r1868b912],
6	characterization	NN	O	characterization	nsubj	15	SENT_44	[p5l1890t849r2141b912, p5l6t957r335b1015],
7	of	IN	O	of	_	0	SENT_44	[p5l357t952r431b1015],
8	lymphomas	NNS	O	lymphoma	prep_of	6	SENT_44	[p5l442t952r843b1036],
9	and	CC	O	and	_	0	SENT_44	[p5l867t952r993b1015],
10	leukemias	NNS	O	leukemia	prep_of	6	SENT_44	[p5l1013t952r1357b1015],
11	is	VBZ	O	be	cop	15	SENT_44	[p5l1380t957r1430b1015],
12	now	RB	DATE	now	advmod	15	SENT_44	[p5l1452t975r1600b1015],
13	an	DT	O	a	det	15	SENT_44	[p5l1620t975r1700b1015],
14	integral	JJ	O	integral	amod	15	SENT_44	[p5l1722t952r1984b1036],
15	part	NN	O	part	_	0	SENT_44	[p5l2004t964r2145b1035],
16	of	IN	O	of	_	0	SENT_44	[p5l8t1055r81b1118],
17	the	DT	O	the	det	18	SENT_44	[p5l90t1055r195b1118],
18	diagnosis	NN	O	diagnosis	prep_of	15	SENT_44	[p5l217t1055r550b1139],
19	,	,	O	,	_	0	SENT_44	[p5l217t1055r550b1139],
20	and	CC	O	and	_	0	SENT_44	[p5l573t1055r697b1118],
21	several	JJ	O	several	amod	23	SENT_44	[p5l717t1055r948b1118],
22	molecular	JJ	O	molecular	amod	23	SENT_44	[p5l967t1055r1308b1118],
23	abnormalities	NNS	O	abnormality	nsubjpass	26	SENT_44	[p5l1328t1055r1791b1118],
24	have	VBP	O	have	aux	26	SENT_44	[p5l1810t1055r1964b1118],
25	been	VBN	O	be	auxpass	26	SENT_44	[p5l1982t1055r2144b1118],
26	included	VBN	O	include	conj_and	15	SENT_44	[p5l7t1158r305b1221],
27	in	IN	O	in	_	0	SENT_44	[p5l328t1163r394b1220],
28	the	DT	O	the	det	29	SENT_44	[p5l415t1158r522b1221],
29	latest	JJS	O	latest	nn	33	SENT_44	[p5l543t1158r720b1221],
30	World	NNP	ORGANIZATION	World	nn	33	SENT_44	[p5l741t1158r957b1221],
31	Health	NNP	ORGANIZATION	Health	nn	33	SENT_44	[p5l979t1158r1208b1221],
32	Organization	NNP	ORGANIZATION	Organization	nn	33	SENT_44	[p5l1232t1162r1684b1242],
33	classiﬁcation	NN	O	classiﬁcation	prep_in	26	SENT_44	[p5l1706t1158r2144b1221],
34	of	IN	O	of	_	0	SENT_44	[p5l8t1260r80b1323],
35	hematological	JJ	O	hematological	amod	36	SENT_44	[p5l89t1260r560b1344],
36	malignancies	NNS	O	malignancy	prep_of	26	SENT_44	[p5l579t1252r1096b1344],
37	.	.	O	.	_	0	SENT_44	[p5l579t1252r1096b1344],

1	”	NN	O	”	ccomp	10	SENT_45	[p5l579t1252r1096b1344],
2	Similarly	RB	O	similarly	advmod	1	SENT_45	[p5l1118t1260r1426b1344],
3	,	,	O	,	_	0	SENT_45	[p5l1118t1260r1426b1344],
4	molecular	JJ	O	molecular	amod	5	SENT_45	[p5l1447t1260r1784b1323],
5	analysis	NN	O	analysis	nsubj	10	SENT_45	[p5l1803t1260r2061b1344],
6	of	IN	O	of	_	0	SENT_45	[p5l2081t1260r2153b1323],
7	soft-tissue	JJ	O	soft-tissue	amod	8	SENT_45	[p5l8t1363r351b1426],
8	sarcomas	NNS	O	sarcoma	prep_of	5	SENT_45	[p5l372t1386r684b1426],
9	is	VBZ	O	be	aux	10	SENT_45	[p5l705t1368r755b1426],
10	emerging	VBG	O	emerge	_	0	SENT_45	[p5l776t1368r1096b1447],
11	as	IN	O	as	_	0	SENT_45	[p5l1116t1386r1179b1426],
12	a	DT	O	a	det	14	SENT_45	[p5l1201t1386r1235b1426],
13	critical	JJ	O	critical	amod	14	SENT_45	[p5l1255t1363r1487b1426],
14	tool	NN	O	tool	prep_as	10	SENT_45	[p5l1505t1363r1638b1426],
15	for	IN	O	for	_	0	SENT_45	[p5l1657t1363r1753b1426],
16	differential	JJ	O	differential	amod	17	SENT_45	[p5l1773t1363r2143b1426],
17	diagnosis	NN	O	diagnosis	prep_for	14	SENT_45	[p5l8t1466r346b1550],
18	.	.	O	.	_	0	SENT_45	[p5l8t1466r346b1550],

1	Such	JJ	O	such	amod	2	SENT_46	[p5l372t1466r536b1529],
2	analysis	NN	O	analysis	nsubj	3	SENT_46	[p5l559t1466r824b1550],
3	includes	VBZ	O	include	_	0	SENT_46	[p5l848t1466r1131b1529],
4	SS	NN	O	ss	dobj	3	SENT_46	[p5l1155t1470r1232b1529],
5	18	CD	NUMBER	18	num	4	SENT_46	[p5l1240t1470r1485b1529],
6	.	.	O	.	_	0	SENT_46	[p5l1240t1470r1485b1529],

1	—	NN	O	—	_	0	SENT_47	[p5l1240t1470r1485b1529],
2	.	.	O	.	_	0	SENT_47	[p5l1240t1470r1485b1529],

1	SSX	NNP	O	SSX	_	0	SENT_48	[p5l1240t1470r1485b1529],
2	fusions	NNS	O	fusion	dep	1	SENT_48	[p5l1503t1466r1747b1529],
3	in	IN	O	in	_	0	SENT_48	[p5l1771t1471r1837b1528],
4	synovial	JJ	O	synovial	prep_in	2	SENT_48	[p5l1861t1466r2143b1550],

1	C	NN	O	c	_	0	SENT_49	[p5l547t1706r590b1755],

1	Figure	NNP	O	Figure	dep	15	SENT_50	[p6l22t2022r111b2053],
2	1	CD	NUMBER	1	num	4	SENT_50	[p6l121t2024r131b2046],
3	Chemical	NNP	O	Chemical	nn	4	SENT_50	[p6l159t2022r280b2046],
4	structures	NNS	O	structure	dep	1	SENT_50	[p6l289t2026r421b2046],
5	of	IN	O	of	_	0	SENT_50	[p6l429t2022r456b2046],
6	epidermal	JJ	O	epidermal	amod	9	SENT_50	[p6l462t2022r596b2053],
7	growth	NN	O	growth	nn	9	SENT_50	[p6l605t2022r699b2053],
8	factor	NN	O	factor	nn	9	SENT_50	[p6l708t2022r785b2046],
9	receptor	NN	O	receptor	prep_of	4	SENT_50	[p6l794t2026r905b2052],
10	(	CD	NUMBER	(	num	11	SENT_50	[p6l913t2022r997b2050],
11	EGFR	NN	ORGANIZATION	egfr	dep	15	SENT_50	[p6l913t2022r997b2050],
12	)	CD	NUMBER	)	num	15	SENT_50	[p6l913t2022r997b2050],
13	tyrosine	NN	O	tyrosine	nn	15	SENT_50	[p6l1005t2023r1112b2053],
14	kinase	NN	O	kinase	nn	15	SENT_50	[p6l1121t2022r1203b2046],
15	inhibitors	NNS	O	inhibitor	dep	20	SENT_50	[p6l1212t2022r1337b2046],
16	and	CC	O	and	_	0	SENT_50	[p6l1345t2022r1394b2046],
17	their	PRP$	O	they	poss	19	SENT_50	[p6l1402t2022r1464b2046],
18	molecular	JJ	O	molecular	amod	19	SENT_50	[p6l1472t2022r1604b2046],
19	modes	NNS	O	mode	conj_and	15	SENT_50	[p6l1612t2022r1701b2046],
20	of	IN	O	of	_	0	SENT_50	[p6l1709t2022r1736b2046],
21	binding	VBG	O	bind	pobj	20	SENT_50	[p6l1743t2022r1844b2053],
22	to	TO	O	to	_	0	SENT_50	[p6l1852t2026r1879b2046],
23	the	DT	O	the	det	24	SENT_50	[p6l1886t2022r1930b2046],
24	target	NN	O	target	prep_to	21	SENT_50	[p6l1937t2026r2023b2053],
25	.	.	O	.	_	0	SENT_50	[p6l1937t2026r2023b2053],

1	(	NN	O	(	_	0	SENT_51	[p6l21t2064r53b2091],
2	a	DT	O	a	det	6	SENT_51	[p6l21t2064r53b2091],
3	)	NN	O	)	nn	6	SENT_51	[p6l21t2064r53b2091],
4	Two	CD	NUMBER	two	num	6	SENT_51	[p6l59t2063r289b2087],
5	—	NN	O	—	nn	6	SENT_51	[p6l59t2063r289b2087],
6	dimensiona	NN	O	dimensiona	dep	1	SENT_51	[p6l59t2063r289b2087],
7	|	CD	NUMBER	|	number	8	SENT_51	[p6l59t2063r289b2087],
8	(	CD	NUMBER	(	dep	6	SENT_51	[p6l299t2064r352b2091],
9	2D	NN	O	2d	nn	11	SENT_51	[p6l299t2064r352b2091],
10	)	NN	O	)	nn	11	SENT_51	[p6l299t2064r352b2091],
11	structure	NN	O	structure	dep	1	SENT_51	[p6l361t2067r480b2087],
12	of	IN	O	of	_	0	SENT_51	[p6l487t2063r515b2087],
13	reversible	JJ	O	reversible	amod	15	SENT_51	[p6l522t2063r649b2087],
14	inhibitor	NN	O	inhibitor	nn	15	SENT_51	[p6l657t2063r771b2087],
15	gefitinib	NN	O	gefitinib	prep_of	11	SENT_51	[p6l778t2063r888b2094],
16	and	CC	O	and	_	0	SENT_51	[p6l896t2063r945b2087],
17	the	DT	O	the	det	21	SENT_51	[p6l953t2063r997b2087],
18	three-dimensional	JJ	O	three-dimensional	amod	21	SENT_51	[p6l1004t2063r1249b2087],
19	(	CD	NUMBER	(	num	21	SENT_51	[p6l1259t2064r1311b2091],
20	3D	NN	O	3d	nn	21	SENT_51	[p6l1259t2064r1311b2091],
21	)	NN	O	)	prep_of	11	SENT_51	[p6l1259t2064r1311b2091],
22	structure	NN	O	structure	dep	1	SENT_51	[p6l1320t2067r1439b2087],
23	in	IN	O	in	_	0	SENT_51	[p6l1448t2064r1469b2087],
24	complex	NN	O	complex	prep_in	22	SENT_51	[p6l1478t2063r1593b2094],
25	with	IN	O	with	_	0	SENT_51	[p6l1599t2063r1657b2087],
26	EGFR	NN	ORGANIZATION	egfr	nn	29	SENT_51	[p6l1667t2064r1734b2087],
27	(	CD	NUMBER	(	num	29	SENT_51	[p6l1742t2064r1804b2091],
28	PDB	NN	O	pdb	nn	29	SENT_51	[p6l1742t2064r1804b2091],
29	code	NN	O	code	prep_with	24	SENT_51	[p6l1812t2063r1877b2087],
30	3UG2	NN	O	3ug2	nn	31	SENT_51	[p6l1885t2064r1973b2091],
31	)	NN	O	)	dep	22	SENT_51	[p6l1885t2064r1973b2091],
32	.	.	O	.	_	0	SENT_51	[p6l1885t2064r1973b2091],

1	(	NN	O	(	nn	2	SENT_52	[p6l21t2104r55b2132],
2	b	NN	O	b	_	0	SENT_52	[p6l21t2104r55b2132],
3	)	CD	NUMBER	)	num	5	SENT_52	[p6l21t2104r55b2132],
4	2D	NN	O	2d	nn	5	SENT_52	[p6l64t2105r100b2128],
5	structure	NN	O	structure	dep	2	SENT_52	[p6l108t2108r227b2129],
6	of	IN	O	of	_	0	SENT_52	[p6l235t2104r263b2129],
7	reversible	JJ	O	reversible	amod	9	SENT_52	[p6l269t2104r396b2129],
8	inhibitor	NN	O	inhibitor	nn	9	SENT_52	[p6l405t2104r518b2129],
9	erlotinib	NN	O	erlotinib	prep_of	5	SENT_52	[p6l525t2104r637b2129],
10	and	CC	O	and	_	0	SENT_52	[p6l645t2104r694b2129],
11	the	DT	O	the	det	13	SENT_52	[p6l702t2104r745b2129],
12	3D	NN	O	3d	nn	13	SENT_52	[p6l753t2105r789b2129],
13	structure	NN	O	structure	conj_and	5	SENT_52	[p6l797t2108r916b2129],
14	of	IN	O	of	_	0	SENT_52	[p6l924t2104r952b2129],
15	the	DT	O	the	det	17	SENT_52	[p6l957t2104r1000b2129],
16	binding	NN	O	binding	nn	17	SENT_52	[p6l1009t2104r1110b2135],
17	site	NN	O	site	prep_of	13	SENT_52	[p6l1119t2105r1164b2129],
18	of	IN	O	of	_	0	SENT_52	[p6l1172t2104r1199b2129],
19	EGFR	NN	ORGANIZATION	egfr	prep_of	17	SENT_52	[p6l1206t2105r1273b2128],
20	in	IN	O	in	_	0	SENT_52	[p6l1281t2105r1303b2128],
21	complex	NN	O	complex	prep_in	19	SENT_52	[p6l1312t2104r1426b2135],
22	with	IN	O	with	_	0	SENT_52	[p6l1433t2104r1490b2129],
23	erlotinib	NN	O	erlotinib	nn	26	SENT_52	[p6l1499t2104r1611b2129],
24	(	CD	NUMBER	(	num	26	SENT_52	[p6l1620t2105r1682b2132],
25	PDB	NN	O	pdb	nn	26	SENT_52	[p6l1620t2105r1682b2132],
26	code	NN	O	code	prep_with	21	SENT_52	[p6l1690t2104r1754b2129],
27	4HJO	NN	O	4hjo	nn	28	SENT_52	[p6l1761t2105r1847b2132],
28	)	NN	O	)	dep	13	SENT_52	[p6l1761t2105r1847b2132],
29	.	.	O	.	_	0	SENT_52	[p6l1761t2105r1847b2132],

1	(	NN	O	(	nn	2	SENT_53	[p6l1856t2105r1885b2132],
2	c	NN	O	c	nsubj	37	SENT_53	[p6l1856t2105r1885b2132],
3	)	CD	NUMBER	)	num	5	SENT_53	[p6l1856t2105r1885b2132],
4	2D	NN	O	2d	nn	5	SENT_53	[p6l1894t2105r1930b2128],
5	structure	NN	O	structure	rcmod	2	SENT_53	[p6l1938t2108r2057b2129],
6	of	IN	O	of	_	0	SENT_53	[p6l2065t2104r2092b2129],
7	the	DT	O	the	det	14	SENT_53	[p6l20t2145r63b2169],
8	potent	JJ	O	potent	amod	9	SENT_53	[p6l72t2149r161b2175],
9	irreversible	JJ	O	irreversible	amod	14	SENT_53	[p6l169t2145r315b2169],
10	inhibitor	NN	O	inhibitor	nn	14	SENT_53	[p6l323t2145r436b2169],
11	afatinib	NN	O	afatinib	nn	14	SENT_53	[p6l443t2145r543b2169],
12	(	CD	NUMBER	(	num	14	SENT_53	[p6l552t2145r712b2173],
13	BIBW-2992	NN	O	bibw-2992	nn	14	SENT_53	[p6l552t2145r712b2173],
14	)	NN	O	)	prep_of	5	SENT_53	[p6l552t2145r712b2173],
15	and	CC	O	and	_	0	SENT_53	[p6l721t2145r769b2169],
16	the	DT	O	the	det	18	SENT_53	[p6l778t2145r821b2169],
17	3D	NN	O	3d	nn	18	SENT_53	[p6l829t2146r865b2169],
18	structure	NN	O	structure	conj_and	14	SENT_53	[p6l873t2149r992b2169],
19	of	IN	O	of	_	0	SENT_53	[p6l1000t2145r1028b2169],
20	the	DT	O	the	det	22	SENT_53	[p6l1032t2145r1076b2169],
21	binding	NN	O	binding	nn	22	SENT_53	[p6l1085t2145r1186b2175],
22	site	NN	O	site	prep_of	18	SENT_53	[p6l1195t2146r1240b2169],
23	of	IN	O	of	_	0	SENT_53	[p6l1248t2145r1275b2169],
24	EGFR	NN	ORGANIZATION	egfr	prep_of	22	SENT_53	[p6l1282t2146r1349b2169],
25	in	IN	O	in	_	0	SENT_53	[p6l1357t2146r1379b2169],
26	complex	NN	O	complex	prep_in	24	SENT_53	[p6l1388t2145r1502b2175],
27	with	IN	O	with	dep	5	SENT_53	[p6l1509t2145r1566b2169],
28	afatinib	NN	O	afatinib	pobj	27	SENT_53	[p6l1575t2145r1681b2173],
29	,	,	O	,	_	0	SENT_53	[p6l1575t2145r1681b2173],
30	showing	VBG	O	show	partmod	2	SENT_53	[p6l1689t2145r1801b2175],
31	the	DT	O	the	det	33	SENT_53	[p6l1809t2145r1853b2169],
32	covalent	JJ	O	covalent	amod	33	SENT_53	[p6l1861t2145r1974b2169],
33	interaction	NN	O	interaction	dobj	30	SENT_53	[p6l1982t2146r2124b2169],
34	with	IN	O	with	_	0	SENT_53	[p6l20t2186r77b2210],
35	Cys797	NN	O	cys797	prep_with	30	SENT_53	[p6l86t2187r186b2217],
36	,	,	O	,	_	0	SENT_53	[p6l86t2187r186b2217],
37	highlighted	VBN	O	highlight	_	0	SENT_53	[p6l195t2186r348b2217],
38	in	IN	O	in	_	0	SENT_53	[p6l358t2187r379b2210],
39	orange	JJ	O	orange	amod	44	SENT_53	[p6l388t2193r482b2217],
40	(	CD	NUMBER	(	tmod	39	SENT_53	[p6l491t2187r553b2214],
41	PDB	NN	O	pdb	nn	44	SENT_53	[p6l491t2187r553b2214],
42	code	NN	O	code	nn	44	SENT_53	[p6l561t2186r625b2210],
43	4G5J	NN	O	4g5j	nn	44	SENT_53	[p6l632t2187r714b2214],
44	)	NN	O	)	prep_in	37	SENT_53	[p6l632t2187r714b2214],
45	.	.	O	.	_	0	SENT_53	[p6l632t2187r714b2214],

1	PDB	NNP	ORGANIZATION	PDB	_	0	SENT_54	[p6l723t2187r782b2214],
2	,	,	O	,	_	0	SENT_54	[p6l723t2187r782b2214],
3	Protein	NN	ORGANIZATION	protein	nn	5	SENT_54	[p6l791t2187r883b2210],
4	Data	NNP	ORGANIZATION	Data	nn	5	SENT_54	[p6l894t2187r953b2210],
5	Bank	NNP	ORGANIZATION	Bank	appos	1	SENT_54	[p6l963t2186r1032b2210],
6	.	.	O	.	_	0	SENT_54	[p6l963t2186r1032b2210],

1	CLINICAL	JJ	O	clinical	amod	2	SENT_55	[p6l21t2285r140b2306],
2	PHARMACOLOGY	NNP	O	PHARMACOLOGY	_	0	SENT_55	[p6l149t2285r374b2306],
3	&	CC	O	&	_	0	SENT_55	[p6l381t2285r601b2306],
4	THERAPEUTlCS	NNP	O	THERAPEUTlCS	nn	6	SENT_55	[p6l381t2285r601b2306],
5	|	NNP	O	|	nn	6	SENT_55	[p6l611t2283r613b2313],
6	VOLUME	NNP	O	VOLUME	conj_and	2	SENT_55	[p6l621t2285r729b2306],
7	93	CD	NUMBER	93	num	6	SENT_55	[p6l737t2285r764b2306],
8	NUMBER	NN	O	number	nn	11	SENT_55	[p6l774t2285r882b2306],
9	3	CD	NUMBER	3	num	11	SENT_55	[p6l890t2285r902b2306],
10	|	NN	O	|	nn	11	SENT_55	[p6l912t2283r915b2313],
11	MARCH	NN	DATE	march	dep	2	SENT_55	[p6l925t2285r1017b2306],
12	2013	CD	DATE	2013	num	13	SENT_55	[p6l1026t2285r1083b2306],
13	253	CD	NUMBER	253	dep	2	SENT_55	[p6l2093t2285r2139b2306],

1	Table	NNP	O	Table	nn	3	SENT_56	[p6l19t2516r106b2544],
2	1	CD	NUMBER	1	num	3	SENT_56	[p6l115t2519r127b2544],
3	Examples	NNS	O	example	_	0	SENT_56	[p6l153t2516r305b2551],
4	of	IN	O	of	_	0	SENT_56	[p6l313t2516r346b2544],
5	molecular	JJ	O	molecular	amod	7	SENT_56	[p6l353t2516r512b2544],
6	biomarker	NN	O	biomarker	nn	7	SENT_56	[p6l520t2516r687b2544],
7	investigations	NNS	O	investigation	prep_of	3	SENT_56	[p6l695t2517r921b2551],
8	used	VBN	O	use	partmod	7	SENT_56	[p6l929t2517r1003b2544],
9	in	IN	O	in	_	0	SENT_56	[p6l1013t2517r1040b2544],
10	clinical	JJ	O	clinical	amod	11	SENT_56	[p6l1049t2516r1159b2544],
11	practice	NN	O	practice	prep_in	8	SENT_56	[p6l1168t2517r1295b2551],
12	to	TO	O	to	aux	13	SENT_56	[p6l1302t2520r1335b2544],
13	guide	VB	O	guide	xcomp	8	SENT_56	[p6l1342t2517r1434b2551],
14	diagnosis	NN	O	diagnosis	nn	17	SENT_56	[p6l1441t2517r1595b2551],
15	and	CC	O	and	_	0	SENT_56	[p6l1602t2517r1662b2544],
16	therapeutic	JJ	O	therapeutic	nn	17	SENT_56	[p6l1670t2516r1857b2551],
17	decisions	NNS	O	decision	dobj	13	SENT_56	[p6l1864t2517r2013b2544],
18	Diagnostic	JJ	O	diagnostic	amod	17	SENT_56	[p6l21t2578r178b2609],

1	PML	NN	O	pml	_	0	SENT_57	[p6l614t2644r750b2667],
2	.	.	O	.	_	0	SENT_57	[p6l614t2644r750b2667],

1	—	NN	O	—	_	0	SENT_58	[p6l614t2644r750b2667],
2	.	.	O	.	_	0	SENT_58	[p6l614t2644r750b2667],

1	RARA	NN	ORGANIZATION	rara	nn	3	SENT_59	[p6l614t2644r750b2667],
2	BCR-ABL1	NN	O	bcr-abl1	nn	3	SENT_59	[p6l614t2702r740b2725],
3	CBFB-MYH1	NN	O	cbfb-myh1	_	0	SENT_59	[p6l614t2760r769b2784],
4	1	CD	NUMBER	1	num	6	SENT_59	[p6l777t2761r785b2784],
5	ET	NNP	O	ET	nn	6	SENT_59	[p6l614t2826r647b2850],
6	V6-RUNX	NN	O	v6-runx	dep	3	SENT_59	[p6l648t2826r769b2850],
7	1	CD	NUMBER	1	dep	3	SENT_59	[p6l772t2827r779b2850],

1	Acute	JJ	O	acute	amod	2	SENT_60	[p6l59t2855r138b2879],
2	leukemias	NNS	O	leukemia	_	0	SENT_60	[p6l147t2854r284b2879],
3	WHO	WP	O	who	rcmod	2	SENT_60	[p6l1200t2855r1271b2879],
4	2008	CD	DATE	2008	num	5	SENT_60	[p6l1279t2856r1345b2879],
5	classiﬁcation	NN	O	classiﬁcation	dep	2	SENT_60	[p6l1353t2854r1527b2879],
6	of	IN	O	of	_	0	SENT_60	[p6l1535t2854r1564b2879],
7	leukemias	NNS	O	leukemia	prep_of	5	SENT_60	[p6l1570t2854r1707b2879],

1	RUNX1	NN	O	runx1	_	0	SENT_61	[p6l614t2885r805b2909],
2	.	.	O	.	_	0	SENT_61	[p6l614t2885r805b2909],

1	—	NN	O	—	_	0	SENT_62	[p6l614t2885r805b2909],
2	.	.	O	.	_	0	SENT_62	[p6l614t2885r805b2909],

1	RUNX7	NN	O	runx7	nn	2	SENT_63	[p6l614t2885r805b2909],
2	Ti	NN	O	ti	_	0	SENT_63	[p6l810t2885r837b2909],
3	MLL-rearranged	JJ	O	mll-rearranged	amod	5	SENT_63	[p6l613t2943r828b2974],
4	TCF3-PBX1	NN	O	tcf3-pbx1	nn	5	SENT_63	[p6l615t3009r753b3033],
5	RBM	NN	O	rbm	dep	2	SENT_63	[p6l614t3068r673b3092],
6	75	CD	NUMBER	75	dep	5	SENT_63	[p6l679t3068r787b3092],
7	.	.	O	.	_	0	SENT_63	[p6l679t3068r787b3092],

1	—	NN	O	—	_	0	SENT_64	[p6l679t3068r787b3092],
2	.	.	O	.	_	0	SENT_64	[p6l679t3068r787b3092],

1	MKL7	NN	O	mkl7	_	0	SENT_65	[p6l679t3068r787b3092],

1	MPD	NN	O	mpd	nn	3	SENT_66	[p6l60t3127r124b3151],
2	JAK2	NN	O	jak2	nn	3	SENT_66	[p6l612t3127r677b3151],
3	Mutations	NNS	O	mutation	nsubj	4	SENT_66	[p6l1202t3127r1340b3151],
4	conﬁrm	VBP	O	conﬁrm	_	0	SENT_66	[p6l1348t3126r1453b3151],
5	diagnosis	NN	O	diagnosis	nn	7	SENT_66	[p6l1462t3126r1591b3157],
6	ofclonal	JJ	O	ofclonal	amod	7	SENT_66	[p6l1599t3126r1713b3151],
7	MPD	NN	O	mpd	dobj	4	SENT_66	[p6l1723t3127r1787b3151],

1	SS18	NN	O	ss18	dep	7	SENT_67	[p6l613t3191r827b3216],
2	—	CD	NUMBER	—	num	3	SENT_67	[p6l613t3191r827b3216],
3	5SX1/SSX2	NN	O	5sx1/ssx2	dep	1	SENT_67	[p6l613t3191r827b3216],
4	Synovial	JJ	O	synovial	amod	5	SENT_67	[p6l1202t3190r1314b3221],
5	sarcoma	NN	O	sarcoma	dep	7	SENT_67	[p6l1323t3197r1437b3214],
6	PAX3/PAX7-FOXO	NN	O	pax3/pax7-foxo	nn	7	SENT_67	[p6l614t3249r849b3273],
7	7A	NN	O	7a	dep	11	SENT_67	[p6l855t3249r883b3272],
8	Alveolar	JJ	O	alveolar	amod	10	SENT_67	[p6l1201t3248r1314b3272],
9	rhabdomyosarcoma	NN	O	rhabdomyosarcoma	nn	10	SENT_67	[p6l1322t3248r1597b3279],
10	E	NN	O	e	dep	7	SENT_67	[p6l614t3307r630b3331],
11	WSR	NN	O	wsr	dep	14	SENT_67	[p6l632t3307r689b3331],
12	7	CD	NUMBER	7	num	11	SENT_67	[p6l695t3308r702b3331],
13	-	:	O	-	_	0	SENT_67	[p6l707t3307r767b3331],
14	FLII	CD	NUMBER	flii	_	0	SENT_67	[p6l707t3307r767b3331],

1	Ewing	NNP	PERSON	Ewing	poss	3	SENT_68	[p6l1203t3371r1302b3401],
2	's	POS	O	's	_	0	SENT_68	[p6l1203t3371r1302b3401],
3	sarcoma	NN	O	sarcoma	_	0	SENT_68	[p6l1310t3378r1423b3395],

1	E	NN	O	e	nn	2	SENT_69	[p6l614t3401r630b3424],
2	WSR	NN	O	wsr	_	0	SENT_69	[p6l632t3400r690b3424],
3	I-ERG	NN	O	i-erg	nn	6	SENT_69	[p6l695t3400r770b3424],
4	E	NN	O	e	nn	6	SENT_69	[p6l614t3458r630b3482],
5	WSR	NN	O	wsr	nn	6	SENT_69	[p6l632t3458r690b3482],
6	1-NR4A3	NN	O	1-nr4a3	dep	2	SENT_69	[p6l695t3458r805b3482],

1	Extraskeletal	JJ	O	extraskeletal	amod	3	SENT_70	[p6l1203t3522r1373b3547],
2	myxoid	JJ	O	myxoid	amod	3	SENT_70	[p6l1383t3522r1482b3554],
3	chondrosarcoma	NN	O	chondrosarcoma	_	0	SENT_70	[p6l1491t3522r1722b3547],

1	TAF15-NR4A3	NN	O	taf15-nr4a3	nn	4	SENT_71	[p6l615t3553r793b3576],
2	Sarcomas	NNS	O	sarcoma	nn	4	SENT_71	[p6l59t3617r190b3641],
3	EWSRI-ATF1	NN	O	ewsri-atf1	nn	4	SENT_71	[p6l614t3617r777b3641],
4	EWSRI-CREB7	NN	O	ewsri-creb7	_	0	SENT_71	[p6l614t3675r799b3699],
5	A$	$	MONEY	a$	dep	4	SENT_71	[p6l612t3733r803b3757],
6	P$	CD	MONEY	p$	num	5	SENT_71	[p6l612t3733r803b3757],
7	CR1	NN	O	cr1	dep	5	SENT_71	[p6l612t3733r803b3757],
8	.	.	O	.	_	0	SENT_71	[p6l612t3733r803b3757],

1	—	NN	O	—	_	0	SENT_72	[p6l612t3733r803b3757],
2	.	.	O	.	_	0	SENT_72	[p6l612t3733r803b3757],

1	TFE3	NN	O	tfe3	nn	5	SENT_73	[p6l612t3733r803b3757],
2	Alveolar	JJ	O	alveolar	amod	5	SENT_73	[p6l1201t3732r1314b3757],
3	soft	JJ	O	soft	amod	5	SENT_73	[p6l1321t3732r1440b3763],
4	—	NN	O	—	nn	5	SENT_73	[p6l1321t3732r1440b3763],
5	part	NN	O	part	_	0	SENT_73	[p6l1321t3732r1440b3763],
6	sarcoma	NN	O	sarcoma	nn	7	SENT_73	[p6l1447t3739r1561b3757],
7	(	NN	O	(	dep	5	SENT_73	[p6l1570t3732r1629b3760],
8	and	CC	O	and	_	0	SENT_73	[p6l1570t3732r1629b3760],
9	renal	JJ	O	renal	amod	12	SENT_73	[p6l1639t3732r1704b3757],
10	cell	NN	O	cell	nn	12	SENT_73	[p6l1713t3732r1757b3757],
11	carcinoma	NN	O	carcinoma	nn	12	SENT_73	[p6l1766t3733r1917b3760],
12	)	NN	O	)	dep	5	SENT_73	[p6l1766t3733r1917b3760],

1	Clear	JJ	O	clear	amod	3	SENT_74	[p6l1201t3645r1271b3670],
2	cell	NN	O	cell	nn	3	SENT_74	[p6l1278t3645r1322b3670],
3	sarcoma	NN	O	sarcoma	_	0	SENT_74	[p6l1331t3652r1445b3670],
4	(	CD	NUMBER	(	dep	3	SENT_74	[p6l1454t3645r1513b3673],
5	and	CC	O	and	_	0	SENT_74	[p6l1454t3645r1513b3673],
6	angiomatoid	JJ	O	angiomatoid	amod	9	SENT_74	[p6l1521t3645r1697b3676],
7	ﬁbrous	JJ	O	ﬁbrous	amod	9	SENT_74	[p6l1705t3645r1801b3670],
8	histiocytoma	NN	O	histiocytoma	nn	9	SENT_74	[p6l1809t3645r1996b3677],
9	)	NN	O	)	dep	3	SENT_74	[p6l1809t3645r1996b3677],

1	FU5	NN	O	fu5	_	0	SENT_75	[p7l614t19r757b42],
2	.	.	O	.	_	0	SENT_75	[p7l614t19r757b42],

1	—	NN	O	—	_	0	SENT_76	[p7l614t19r757b42],
2	.	.	O	.	_	0	SENT_76	[p7l614t19r757b42],

1	DDIT3	NN	MISC	ddit3	nn	3	SENT_77	[p7l614t19r757b42],
2	Myxoid	NN	MISC	myxoid	nn	3	SENT_77	[p7l1202t18r1301b49],
3	Iiposarcoma	NN	MISC	iiposarcoma	_	0	SENT_77	[p7l1311t18r1476b49],
4	FUS-CREB3L2	NN	MISC	fus-creb3l2	nn	8	SENT_77	[p7l614t77r791b101],
5	Low-grade	JJ	MISC	low-grade	amod	8	SENT_77	[p7l1203t76r1348b108],
6	fibromyxoid	JJ	O	fibromyxoid	amod	8	SENT_77	[p7l1355t76r1521b108],
7	sarcoma	NN	O	sarcoma	nn	8	SENT_77	[p7l1530t84r1644b101],
8	JAZF1-SUZ12	NN	O	jazf1-suz12	dep	3	SENT_77	[p7l612t136r789b159],
9	Endometrial	JJ	MISC	endometrial	amod	13	SENT_77	[p7l1203t135r1368b159],
10	stromal	JJ	O	stromal	amod	13	SENT_77	[p7l1377t135r1479b159],
11	sarcoma	NN	O	sarcoma	nn	13	SENT_77	[p7l1488t142r1602b159],
12	ET	NNP	O	ET	nn	13	SENT_77	[p7l614t199r647b222],
13	V6	NNP	O	V6	dep	8	SENT_77	[p7l648t199r777b222],
14	.	.	O	.	_	0	SENT_77	[p7l648t199r777b222],

1	—	NN	O	—	_	0	SENT_78	[p7l648t199r777b222],
2	.	.	O	.	_	0	SENT_78	[p7l648t199r777b222],

1	NTRK3	NN	O	ntrk3	_	0	SENT_79	[p7l648t199r777b222],
2	Congenital	JJ	O	congenital	amod	4	SENT_79	[p7l1201t198r1350b229],
3	fibrosarcoma	NN	O	fibrosarcoma	nn	4	SENT_79	[p7l1359t198r1539b222],
4	(	NN	O	(	dep	1	SENT_79	[p7l1548t198r1607b226],
5	and	CC	O	and	_	0	SENT_79	[p7l1548t198r1607b226],
6	secretory	JJ	O	secretory	amod	9	SENT_79	[p7l1616t202r1743b229],
7	breast	NN	O	breast	nn	9	SENT_79	[p7l1751t198r1835b222],
8	carcinoma	NN	O	carcinoma	nn	9	SENT_79	[p7l1842t198r1994b226],
9	)	NN	O	)	conj_and	4	SENT_79	[p7l1842t198r1994b226],

1	Predictive	JJ	O	predictive	amod	4	SENT_80	[p7l21t256r168b281],
2	NSCLC	NN	O	nsclc	nn	4	SENT_80	[p7l60t345r149b369],
3	EGFR	NN	O	egfr	nn	4	SENT_80	[p7l614t316r682b339],
4	Mutations	NNS	O	mutation	nsubj	5	SENT_80	[p7l1202t316r1340b339],
5	predict	VBP	O	predict	_	0	SENT_80	[p7l1349t315r1446b346],
6	response	NN	O	response	dobj	5	SENT_80	[p7l1454t322r1577b346],
7	to	TO	O	to	_	0	SENT_80	[p7l1584t319r1612b339],
8	TKI	NN	O	tkus	prep_to	5	SENT_80	[p7l1617t316r1657b339],

1	ALK	NNP	O	ALK	nn	2	SENT_81	[p7l612t374r666b397],
2	Rearrangements	NNS	O	rearrangement	nsubj	3	SENT_81	[p7l1203t374r1429b404],
3	predict	VBP	O	predict	dep	13	SENT_81	[p7l1438t373r1534b404],
4	response	NN	O	response	dobj	3	SENT_81	[p7l1542t380r1666b404],
5	to	TO	O	to	_	0	SENT_81	[p7l1673t377r1700b397],
6	ALK	NNP	O	ALK	nn	8	SENT_81	[p7l1708t373r1902b397],
7	—	CD	NUMBER	—	num	8	SENT_81	[p7l1708t373r1902b397],
8	inhibitors	NNS	O	inhibitor	prep_to	3	SENT_81	[p7l1708t373r1902b397],
9	GIST	NN	O	gist	nn	12	SENT_81	[p7l59t432r121b456],
10	KITand	NN	O	kitand	nn	12	SENT_81	[p7l614t431r710b456],
11	PDGFRA	NN	O	pdgfra	nn	12	SENT_81	[p7l718t432r826b456],
12	Mutations	NNS	O	mutation	nsubj	13	SENT_81	[p7l1202t432r1340b456],
13	predict	VBP	O	predict	_	0	SENT_81	[p7l1349t431r1446b462],
14	response	NN	O	response	dobj	13	SENT_81	[p7l1454t438r1577b462],
15	to	TO	O	to	_	0	SENT_81	[p7l1584t435r1612b456],
16	c	NN	O	c	prep_to	13	SENT_81	[p7l1619t432r1813b457],
17	.	.	O	.	_	0	SENT_81	[p7l1619t432r1813b457],

1	—	NN	O	—	_	0	SENT_82	[p7l1619t432r1813b457],
2	.	.	O	.	_	0	SENT_82	[p7l1619t432r1813b457],

1	K	NNP	O	K	nsubj	2	SENT_83	[p7l1619t432r1813b457],
2	|	VBD	O	|	_	0	SENT_83	[p7l1619t432r1813b457],
3	T/PDGFRA	NN	O	t/pdgfra	nn	4	SENT_83	[p7l1619t432r1813b457],
4	inhibitors	NNS	O	inhibitor	dobj	2	SENT_83	[p7l1822t431r1951b456],
5	mCRC	NN	O	mcrc	nn	7	SENT_83	[p7l60t490r142b514],
6	KRA5	NN	O	kra5	nn	7	SENT_83	[p7l614t490r682b514],
7	Mutations	NNS	O	mutation	nsubj	8	SENT_83	[p7l1202t490r1340b514],
8	predict	VBP	O	predict	rcmod	4	SENT_83	[p7l1349t489r1446b520],
9	lack	NN	O	lack	dobj	8	SENT_83	[p7l1454t489r1507b514],
10	of	IN	O	of	_	0	SENT_83	[p7l1513t489r1541b514],
11	response	NN	O	response	prep_of	9	SENT_83	[p7l1548t496r1671b520],
12	to	TO	O	to	_	0	SENT_83	[p7l1678t493r1706b514],
13	anti	JJ	O	anti	prep_to	8	SENT_83	[p7l1713t490r1847b514],
14	.	.	O	.	_	0	SENT_83	[p7l1713t490r1847b514],

1	—	NN	O	—	_	0	SENT_84	[p7l1713t490r1847b514],
2	.	.	O	.	_	0	SENT_84	[p7l1713t490r1847b514],

1	EGFR	NN	ORGANIZATION	egfr	nn	2	SENT_85	[p7l1713t490r1847b514],
2	antibodies	NNS	O	antibody	_	0	SENT_85	[p7l1854t489r1999b514],
3	Melanoma	NN	O	melanoma	nn	5	SENT_85	[p7l60t553r204b578],
4	BRAF	NN	O	braf	nn	5	SENT_85	[p7l614t554r683b578],
5	Mutations	NNS	O	mutation	nsubj	6	SENT_85	[p7l1202t554r1340b578],
6	predict	VBP	O	predict	rcmod	2	SENT_85	[p7l1349t553r1446b584],
7	response	NN	O	response	dobj	6	SENT_85	[p7l1454t560r1577b584],
8	to	TO	O	to	_	0	SENT_85	[p7l1584t557r1612b578],
9	specific	JJ	O	specific	amod	11	SENT_85	[p7l1620t553r1722b584],
10	BRAF	NN	O	braf	nn	11	SENT_85	[p7l1730t554r1800b578],
11	inhibitors	NNS	O	inhibitor	prep_to	6	SENT_85	[p7l1808t553r1938b578],
12	Breast	NN	O	breast	nn	15	SENT_85	[p7l60t612r143b636],
13	cancer	NN	O	cancer	nn	15	SENT_85	[p7l150t619r241b636],
14	HER2	NN	O	her2	nn	15	SENT_85	[p7l614t612r683b636],
15	Amplifications	NNS	MISC	amplification	nsubj	16	SENT_85	[p7l1201t611r1399b642],
16	predict	VBP	O	predict	rcmod	11	SENT_85	[p7l1408t611r1504b642],
17	response	NN	O	response	dobj	16	SENT_85	[p7l1513t619r1636b642],
18	to	TO	O	to	_	0	SENT_85	[p7l1643t615r1671b636],
19	anti-HER2	JJ	O	anti-her2	amod	20	SENT_85	[p7l1678t612r1812b636],
20	antibodies	NNS	O	antibody	prep_to	16	SENT_85	[p7l1821t611r1966b636],
21	Prognostic	JJ	O	prognostic	amod	24	SENT_85	[p7l21t669r178b700],
22	CLL	NN	O	cll	nn	24	SENT_85	[p7l59t763r108b787],
23	TP53	NN	O	tp53	nn	24	SENT_85	[p7l615t734r677b758],
24	Mutations	NNS	O	mutation	nsubj	26	SENT_85	[p7l1202t734r1340b758],
25	are	VBP	O	be	cop	26	SENT_85	[p7l1348t740r1389b758],
26	indicative	JJ	O	indicative	rcmod	20	SENT_85	[p7l1398t733r1530b758],
27	of	IN	O	of	_	0	SENT_85	[p7l1538t733r1566b758],
28	poor	JJ	O	poor	amod	29	SENT_85	[p7l1572t740r1637b764],
29	outcome	NN	O	outcome	prep_of	2	SENT_85	[p7l1643t737r1766b758],

1	IGHV	NN	O	ighv	nn	2	SENT_86	[p7l614t792r683b816],
2	Lack	NN	O	lack	nsubj	6	SENT_86	[p7l1203t791r1263b816],
3	of	IN	O	of	_	0	SENT_86	[p7l1269t791r1298b816],
4	mutations	NNS	O	mutation	prep_of	2	SENT_86	[p7l1304t793r1443b816],
5	is	VBZ	O	be	cop	6	SENT_86	[p7l1451t793r1469b816],
6	indicative	JJ	O	indicative	_	0	SENT_86	[p7l1478t791r1610b816],
7	of	IN	O	of	_	0	SENT_86	[p7l1618t791r1646b816],
8	poor	JJ	O	poor	amod	9	SENT_86	[p7l1653t799r1717b822],
9	outcome	NN	O	outcome	prep_of	6	SENT_86	[p7l1724t795r1847b816],

1	AML	NN	O	aml	_	0	SENT_87	[p7l59t850r120b873],
2	FLT3	NN	O	flt3	dep	1	SENT_87	[p7l614t850r728b874],
3	.	.	O	.	_	0	SENT_87	[p7l614t850r728b874],

1	—	NN	O	—	_	0	SENT_88	[p7l614t850r728b874],
2	.	.	O	.	_	0	SENT_88	[p7l614t850r728b874],

1	ITD	NNP	O	ITD	nn	2	SENT_89	[p7l614t850r728b874],
2	Mutations	NNS	O	mutation	nsubj	4	SENT_89	[p7l1202t850r1340b874],
3	are	VBP	O	be	cop	4	SENT_89	[p7l1348t856r1389b874],
4	indicative	JJ	O	indicative	_	0	SENT_89	[p7l1398t849r1530b874],
5	of	IN	O	of	_	0	SENT_89	[p7l1538t849r1566b874],
6	poor	JJ	O	poor	amod	8	SENT_89	[p7l1572t856r1637b880],
7	outcome	NN	O	outcome	nn	8	SENT_89	[p7l1643t853r1766b874],
8	mCRC	NN	O	mcrc	prep_of	4	SENT_89	[p7l60t914r142b938],
9	BRAF	NN	O	braf	nn	10	SENT_89	[p7l614t914r683b938],
10	Mutations	NNS	O	mutation	nsubj	12	SENT_89	[p7l1202t914r1340b938],
11	are	VBP	O	be	cop	12	SENT_89	[p7l1348t920r1389b938],
12	indicative	JJ	O	indicative	rcmod	8	SENT_89	[p7l1398t913r1530b938],
13	of	IN	O	of	_	0	SENT_89	[p7l1538t913r1566b938],
14	poor	JJ	O	poor	amod	15	SENT_89	[p7l1572t920r1637b944],
15	outcome	NN	O	outcome	prep_of	8	SENT_89	[p7l1643t917r1766b938],

1	OncotypeDx	NN	O	oncotypedx	nn	3	SENT_90	[p7l614t972r780b1003],
2	Risk	NN	O	risk	nn	3	SENT_90	[p7l1203t971r1255b996],
3	stratification	NN	O	stratification	dep	12	SENT_90	[p7l1262t971r1432b996],
4	(	CD	NUMBER	(	num	6	SENT_90	[p7l1442t972r1564b1003],
5	21-gene	JJ	O	21-gene	amod	6	SENT_90	[p7l1442t972r1564b1003],
6	expression	NN	O	expression	dep	3	SENT_90	[p7l1572t973r1718b1003],
7	signature	NN	O	signature	dep	12	SENT_90	[p7l1727t972r1864b1003],
8	)	CD	NUMBER	)	num	7	SENT_90	[p7l1727t972r1864b1003],
9	Breast	NN	O	breast	nn	12	SENT_90	[p7l60t1031r143b1055],
10	cancer	NN	O	cancer	nn	12	SENT_90	[p7l150t1037r241b1055],
11	Mammaprint	NNP	O	Mammaprint	nn	12	SENT_90	[p7l613t1031r792b1061],
12	Risk	NNP	O	Risk	dep	20	SENT_90	[p7l1203t1030r1255b1055],
13	stratiﬁcation	NN	O	stratiﬁcation	dep	12	SENT_90	[p7l1262t1030r1433b1055],
14	(	CD	NUMBER	(	number	15	SENT_90	[p7l1442t1031r1564b1061],
15	70	CD	NUMBER	70	num	16	SENT_90	[p7l1442t1031r1564b1061],
16	—	NN	O	—	dep	13	SENT_90	[p7l1442t1031r1564b1061],
17	gene	NN	O	gene	nn	20	SENT_90	[p7l1442t1031r1564b1061],
18	expression	NN	O	expression	nn	20	SENT_90	[p7l1572t1031r1718b1061],
19	signature	NN	O	signature	nn	20	SENT_90	[p7l1727t1031r1864b1061],
20	)	NN	O	)	_	0	SENT_90	[p7l1727t1031r1864b1061],

1	IHC4	NN	O	ihc4	nn	3	SENT_91	[p7l614t1095r676b1119],
2	Risk	NN	O	risk	nn	3	SENT_91	[p7l1203t1094r1255b1119],
3	stratiﬁcation	NN	O	stratiﬁcation	_	0	SENT_91	[p7l1262t1094r1432b1119],
4	(	CD	NUMBER	(	num	7	SENT_91	[p7l1442t1095r1577b1125],
5	4-protein	NN	O	4-protein	nn	7	SENT_91	[p7l1442t1095r1577b1125],
6	IHC	NN	O	ihc	nn	7	SENT_91	[p7l1587t1095r1632b1119],
7	expression	NN	O	expression	dep	3	SENT_91	[p7l1640t1094r1796b1125],
8	)	CD	NUMBER	)	dep	3	SENT_91	[p7l1640t1094r1796b1125],

1	Disease	NN	O	disease	nn	3	SENT_92	[p7l21t1153r132b1177],
2	monitoring	NN	O	monitoring	nn	3	SENT_92	[p7l140t1153r306b1184],
3	CML	NN	ORGANIZATION	cml	_	0	SENT_92	[p7l59t1212r119b1235],
4	BCR-ABL1	NN	O	bcr-abl1	nn	9	SENT_92	[p7l614t1212r740b1235],
5	Minimal	JJ	O	minimal	amod	9	SENT_92	[p7l1202t1211r1311b1235],
6	residual	JJ	O	residual	amod	9	SENT_92	[p7l1321t1211r1426b1235],
7	disease	NN	O	disease	nn	9	SENT_92	[p7l1435t1211r1535b1235],
8	detection	NN	O	detection	nn	9	SENT_92	[p7l1543t1211r1674b1235],
9	APML	NN	O	apml	dep	3	SENT_92	[p7l59t1275r138b1299],
10	PML-RARA	NN	O	pml-rara	nn	16	SENT_92	[p7l614t1275r750b1299],
11	Minimal	JJ	O	minimal	amod	16	SENT_92	[p7l1202t1274r1311b1299],
12	residual	JJ	O	residual	amod	16	SENT_92	[p7l1321t1274r1426b1299],
13	disease	NN	O	disease	nn	16	SENT_92	[p7l1435t1274r1535b1299],
14	detection	NN	O	detection	nn	16	SENT_92	[p7l1543t1274r1674b1299],
15	ALL	NN	O	all	nn	16	SENT_92	[p7l59t1334r109b1357],
16	IGHV	NN	O	ighv	dep	9	SENT_92	[p7l614t1334r739b1357],
17	.	.	O	.	_	0	SENT_92	[p7l614t1334r739b1357],

1	—	NN	O	—	_	0	SENT_93	[p7l614t1334r739b1357],
2	.	.	O	.	_	0	SENT_93	[p7l614t1334r739b1357],

1	TCR	NN	O	tcr	nn	2	SENT_94	[p7l614t1334r739b1357],
2	rearrangements	NNS	O	rearrangement	_	0	SENT_94	[p7l746t1337r965b1364],
3	Minimal	JJ	O	minimal	amod	5	SENT_94	[p7l1202t1333r1311b1357],
4	residual	JJ	O	residual	amod	5	SENT_94	[p7l1321t1333r1426b1357],
5	disease	NN	O	disease	dep	2	SENT_94	[p7l1435t1333r1535b1357],
6	detection	NN	O	detection	nn	7	SENT_94	[p7l1543t1333r1674b1357],
7	ALL	NN	O	all	dep	2	SENT_94	[p7l20t1391r70b1415],
8	,	,	O	,	_	0	SENT_94	[p7l20t1391r70b1415],
9	acute	JJ	O	acute	amod	11	SENT_94	[p7l76t1393r142b1412],
10	lymphoblastic	JJ	O	lymphoblastic	amod	11	SENT_94	[p7l150t1390r319b1418],
11	leukemia	NN	O	leukemia	appos	7	SENT_94	[p7l327t1390r441b1415],
12	;	:	O	;	_	0	SENT_94	[p7l327t1390r441b1415],
13	AML	NN	ORGANIZATION	aml	dep	7	SENT_94	[p7l448t1391r507b1415],
14	,	,	O	,	_	0	SENT_94	[p7l448t1391r507b1415],
15	acute	JJ	O	acute	amod	17	SENT_94	[p7l514t1394r579b1412],
16	myeloid	JJ	O	myeloid	amod	17	SENT_94	[p7l587t1390r682b1418],
17	leukaemia	NN	O	leukaemia	appos	13	SENT_94	[p7l690t1390r819b1415],
18	;	:	O	;	_	0	SENT_94	[p7l690t1390r819b1415],
19	APML	NNP	O	APML	dep	7	SENT_94	[p7l826t1391r900b1415],
20	,	,	O	,	_	0	SENT_94	[p7l826t1391r900b1415],
21	acute	JJ	O	acute	amod	23	SENT_94	[p7l907t1393r973b1412],
22	promyelocytic	JJ	O	promyelocytic	amod	23	SENT_94	[p7l980t1390r1151b1418],
23	leukemia	NN	O	leukemia	appos	19	SENT_94	[p7l1159t1390r1273b1415],
24	;	:	O	;	_	0	SENT_94	[p7l1159t1390r1273b1415],
25	CLL	NN	O	cll	dep	7	SENT_94	[p7l1280t1391r1329b1415],
26	,	,	O	,	_	0	SENT_94	[p7l1280t1391r1329b1415],
27	chronic	JJ	O	chronic	amod	29	SENT_94	[p7l1336t1390r1424b1412],
28	lymphocytic	JJ	O	lymphocytic	amod	29	SENT_94	[p7l1432t1390r1580b1418],
29	leukemia	NN	O	leukemia	appos	25	SENT_94	[p7l1588t1390r1702b1415],
30	;	:	O	;	_	0	SENT_94	[p7l1588t1390r1702b1415],
31	CML	NN	ORGANIZATION	cml	dep	7	SENT_94	[p7l1709t1391r1767b1415],
32	,	,	O	,	_	0	SENT_94	[p7l1709t1391r1767b1415],
33	chronic	JJ	O	chronic	amod	35	SENT_94	[p7l1774t1390r1863b1412],
34	myeloid	JJ	O	myeloid	amod	35	SENT_94	[p7l1870t1390r1965b1418],
35	leukemia	NN	O	leukemia	appos	31	SENT_94	[p7l1973t1390r2088b1415],
36	;	:	O	;	_	0	SENT_94	[p7l1973t1390r2088b1415],
37	EGFR	NN	ORGANIZATION	egfr	dep	7	SENT_94	[p7l21t1429r87b1453],
38	,	,	O	,	_	0	SENT_94	[p7l21t1429r87b1453],
39	epidermal	JJ	O	epidermal	amod	42	SENT_94	[p7l94t1428r215b1455],
40	growth	NN	O	growth	nn	42	SENT_94	[p7l223t1428r309b1456],
41	factor	NN	O	factor	nn	42	SENT_94	[p7l316t1428r386b1450],
42	receptor	NN	O	receptor	appos	37	SENT_94	[p7l393t1431r500b1455],
43	;	:	O	;	_	0	SENT_94	[p7l393t1431r500b1455],
44	GIST	NNP	O	GIST	dep	7	SENT_94	[p7l507t1429r564b1453],
45	,	,	O	,	_	0	SENT_94	[p7l507t1429r564b1453],
46	gastro	NN	O	gastro	nn	49	SENT_94	[p7l571t1428r766b1456],
47	—	NN	O	—	nn	49	SENT_94	[p7l571t1428r766b1456],
48	intestina	NN	O	intestina	nn	49	SENT_94	[p7l571t1428r766b1456],
49	|	NN	O	|	appos	44	SENT_94	[p7l571t1428r766b1456],
50	stromal	JJ	O	stromal	amod	51	SENT_94	[p7l774t1428r863b1450],
51	tumors	NNS	O	tumor	dep	49	SENT_94	[p7l870t1431r962b1453],
52	;	:	O	;	_	0	SENT_94	[p7l870t1431r962b1453],
53	HER2	NN	O	her2	dep	7	SENT_94	[p7l970t1429r1037b1453],
54	,	,	O	,	_	0	SENT_94	[p7l970t1429r1037b1453],
55	human	JJ	O	human	amod	58	SENT_94	[p7l1045t1428r1128b1450],
56	epidermal	JJ	O	epidermal	amod	58	SENT_94	[p7l1136t1428r1257b1455],
57	growth	NN	O	growth	nn	58	SENT_94	[p7l1265t1428r1350b1456],
58	factor	NN	O	factor	appos	53	SENT_94	[p7l1357t1428r1428b1450],
59	receptor	NN	O	receptor	dep	58	SENT_94	[p7l1435t1431r1536b1455],
60	2	CD	NUMBER	2	num	59	SENT_94	[p7l1542t1429r1561b1453],
61	;	:	O	;	_	0	SENT_94	[p7l1542t1429r1561b1453],
62	IHC	NNP	ORGANIZATION	IHC	dep	7	SENT_94	[p7l1569t1429r1615b1453],
63	,	,	O	,	_	0	SENT_94	[p7l1569t1429r1615b1453],
64	immunohistochemistry	NN	O	immunohistochemistry	appos	62	SENT_94	[p7l1623t1428r1911b1456],
65	;	:	O	;	_	0	SENT_94	[p7l1623t1428r1911b1456],
66	mCRC	NN	O	mcrc	dep	7	SENT_94	[p7l1918t1429r1996b1453],
67	,	,	O	,	_	0	SENT_94	[p7l1918t1429r1996b1453],
68	metastatic	JJ	O	metastatic	amod	70	SENT_94	[p7l2003t1429r2128b1450],
69	colorectal	JJ	O	colorectal	amod	70	SENT_94	[p7l20t1467r137b1489],
70	cancer	NN	O	cancer	appos	66	SENT_94	[p7l145t1474r230b1493],
71	;	:	O	;	_	0	SENT_94	[p7l145t1474r230b1493],
72	MPD	NN	ORGANIZATION	mpd	dep	7	SENT_94	[p7l237t1468r298b1493],
73	,	,	O	,	_	0	SENT_94	[p7l237t1468r298b1493],
74	myeloproliferative	JJ	O	myeloproliferative	amod	75	SENT_94	[p7l306t1467r524b1495],
75	diseases	NNS	O	disease	dep	93	SENT_94	[p7l531t1467r637b1493],
76	;	:	O	;	_	0	SENT_94	[p7l531t1467r637b1493],
77	NSCLC	NNP	LOCATION	NSCLC	dep	75	SENT_94	[p7l644t1468r727b1493],
78	,	,	O	,	_	0	SENT_94	[p7l644t1468r727b1493],
79	non	JJ	O	non	amod	85	SENT_94	[p7l735t1467r903b1489],
80	—	JJ	O	—	amod	85	SENT_94	[p7l735t1467r903b1489],
81	small	JJ	O	small	amod	85	SENT_94	[p7l735t1467r903b1489],
82	—	NN	O	—	nn	85	SENT_94	[p7l735t1467r903b1489],
83	cell	NN	O	cell	nn	85	SENT_94	[p7l735t1467r903b1489],
84	lung	NN	O	lung	nn	85	SENT_94	[p7l912t1467r964b1495],
85	cancer	NN	O	cancer	appos	77	SENT_94	[p7l971t1474r1056b1492],
86	;	:	O	;	_	0	SENT_94	[p7l971t1474r1056b1492],
87	TKI	NNP	O	TKI	dep	85	SENT_94	[p7l1061t1468r1103b1493],
88	,	,	O	,	_	0	SENT_94	[p7l1061t1468r1103b1493],
89	tyrosine	NN	O	tyrosine	nn	91	SENT_94	[p7l1109t1468r1206b1495],
90	kinase	NN	O	kinase	nn	91	SENT_94	[p7l1214t1467r1289b1489],
91	inhibitor	NN	O	inhibitor	appos	77	SENT_94	[p7l1296t1467r1405b1493],
92	;	:	O	;	_	0	SENT_94	[p7l1296t1467r1405b1493],
93	WHO	WP	ORGANIZATION	who	dep	72	SENT_94	[p7l1410t1468r1477b1493],
94	,	,	O	,	_	0	SENT_94	[p7l1410t1468r1477b1493],
95	World	NNP	ORGANIZATION	World	nn	97	SENT_94	[p7l1482t1467r1553b1489],
96	Health	NNP	ORGANIZATION	Health	nn	97	SENT_94	[p7l1562t1467r1638b1489],
97	Organization	NNP	ORGANIZATION	Organization	dep	72	SENT_94	[p7l1646t1468r1808b1495],
98	.	.	O	.	_	0	SENT_94	[p7l1646t1468r1808b1495],

1	254	CD	NUMBER	254	num	2	SENT_95	[p7l20t1572r67b1593],
2	VOLUME	NN	O	volume	dep	7	SENT_95	[p7l1390t1572r1498b1593],
3	93	CD	NUMBER	93	dep	2	SENT_95	[p7l1506t1572r1533b1593],
4	NUMBER	NN	O	number	dep	7	SENT_95	[p7l1544t1572r1651b1593],
5	3	CD	NUMBER	3	num	4	SENT_95	[p7l1660t1572r1672b1593],
6	|	NN	O	|	nn	7	SENT_95	[p7l1682t1570r1684b1600],
7	MARCH	NN	DATE	march	_	0	SENT_95	[p7l1695t1572r1786b1593],
8	2013	CD	DATE	2013	num	11	SENT_95	[p7l1796t1572r1853b1593],
9	|	CD	NUMBER	|	num	11	SENT_95	[p7l1863t1570r1865b1600],
10	www.nature.com/cpt	JJ	O	www.nature.com/cpt	amod	11	SENT_95	[p7l1874t1572r2139b1598],
11	sarcomas	NNS	O	sarcoma	dep	7	SENT_95	[p7l9t1902r346b1950],
12	,	,	O	,	_	0	SENT_95	[p7l9t1902r346b1950],
13	EWSR1	NN	O	ewsr1	nn	14	SENT_95	[p7l371t1884r626b1942],
14	fusions	NNS	O	fusion	appos	11	SENT_95	[p7l659t1880r906b1942],
15	in	IN	O	in	_	0	SENT_95	[p7l932t1885r998b1941],
16	Ewing	NNP	PERSON	Ewing	poss	18	SENT_95	[p7l1024t1880r1281b1962],
17	’s	POS	O	’s	_	0	SENT_95	[p7l1024t1880r1281b1962],
18	sarcoma	NN	O	sarcoma	prep_in	14	SENT_95	[p7l1308t1902r1614b1950],
19	,	,	O	,	_	0	SENT_95	[p7l1308t1902r1614b1950],
20	and	CC	O	and	_	0	SENT_95	[p7l1642t1880r1768b1942],
21	PAX3/7FKHR	NN	O	pax3/7fkhr	nn	22	SENT_95	[p7l1791t1884r2083b1945, p7l6t1985r216b2041],
22	fusions	NNS	O	fusion	conj_and	7	SENT_95	[p7l237t1980r474b2042],
23	in	IN	O	in	_	0	SENT_95	[p7l495t1985r560b2041],
24	alveolar	JJ	O	alveolar	amod	25	SENT_95	[p7l582t1980r842b2042],
25	rhabdomyosarcomaszo	NN	O	rhabdomyosarcomaszo	prep_in	22	SENT_95	[p7l862t1972r1638b2062],

1	Another	DT	O	another	det	3	SENT_96	[p7l78t2080r372b2142],
2	important	JJ	O	important	amod	3	SENT_96	[p7l397t2085r750b2161],
3	aspect	NN	O	aspect	nsubj	9	SENT_96	[p7l775t2092r991b2161],
4	of	IN	O	of	_	0	SENT_96	[p7l1017t2080r1091b2142],
5	molecular	JJ	O	molecular	amod	6	SENT_96	[p7l1107t2080r1458b2142],
6	diagnostics	NNS	O	diagnostic	prep_of	3	SENT_96	[p7l1484t2080r1874b2162],
7	is	VBZ	O	be	cop	9	SENT_96	[p7l1901t2085r1951b2142],
8	the	DT	O	the	det	9	SENT_96	[p7l1977t2080r2085b2142],
9	analysis	NN	O	analysis	_	0	SENT_96	[p7l8t2181r266b2263],
10	of	IN	O	of	_	0	SENT_96	[p7l290t2181r361b2243],
11	prognostic	JJ	O	prognostic	amod	12	SENT_96	[p7l373t2186r730b2263],
12	markers	NNS	O	marker	prep_of	9	SENT_96	[p7l752t2181r1022b2243],
13	in	IN	O	in	_	0	SENT_96	[p7l1045t2186r1110b2242],
14	certain	JJ	O	certain	amod	15	SENT_96	[p7l1132t2186r1363b2243],
15	malignancies	NNS	O	malignancy	prep_in	12	SENT_96	[p7l1384t2181r1823b2263],
16	such	JJ	O	such	_	0	SENT_96	[p7l1847t2181r1998b2243],
17	as	IN	O	as	_	0	SENT_96	[p7l2020t2203r2083b2243],
18	chronic	JJ	O	chronic	amod	21	SENT_96	[p7l8t2281r260b2343],
19	lymphocytic	JJ	O	lymphocytic	amod	21	SENT_96	[p7l278t2281r694b2363],
20	leukemia	NN	O	leukemia	nn	21	SENT_96	[p7l713t2281r1018b2343],
21	(	NN	O	(	prep_such_as	15	SENT_96	[p7l1041t2281r1384b2363],
22	including	VBG	O	include	_	0	SENT_96	[p7l1041t2281r1384b2363],
23	TP53	NN	O	tp53	nn	24	SENT_96	[p7l1408t2284r1575b2343],
24	mutations	NNS	O	mutation	prep_including	21	SENT_96	[p7l1596t2273r2085b2351],
25	,21	CD	NUMBER	,21	num	27	SENT_96	[p7l1596t2273r2085b2351],
26	=	JJ	O	=	amod	27	SENT_96	[p7l1596t2273r2085b2351],
27	22	CD	NUMBER	22	dep	24	SENT_96	[p7l1596t2273r2085b2351],
28	I	PRP	O	I	dep	31	SENT_96	[p7l6t2386r37b2442],
29	GH	NN	O	gh	nn	31	SENT_96	[p7l38t2385r157b2443],
30	V	NN	O	v	nn	31	SENT_96	[p7l161t2386r216b2443],
31	mutation	NN	O	mutation	dobj	27	SENT_96	[p7l227t2373r611b2451],
32	,	,	O	,	_	0	SENT_96	[p7l227t2373r611b2451],
33	”	NN	O	”	nn	37	SENT_96	[p7l227t2373r611b2451],
34	and	CC	O	and	_	0	SENT_96	[p7l633t2381r756b2443],
35	CLLU1	NN	O	cllu1	conj_and	33	SENT_96	[p7l778t2385r1003b2443],
36	eXpression24	NN	O	expression24	nn	37	SENT_96	[p7l1031t2373r1489b2462],
37	)	NN	O	)	dobj	27	SENT_96	[p7l1031t2373r1489b2462],
38	,	,	O	,	_	0	SENT_96	[p7l1031t2373r1489b2462],
39	and	CC	O	and	_	0	SENT_96	[p7l1511t2381r1633b2443],
40	breast	NN	O	breast	nn	41	SENT_96	[p7l1651t2381r1851b2443],
41	cancer	NN	O	cancer	dobj	27	SENT_96	[p7l1870t2403r2087b2443],
42	(	CD	NUMBER	(	dep	27	SENT_96	[p7l11t2481r354b2563],
43	including	VBG	O	include	_	0	SENT_96	[p7l11t2481r354b2563],
44	recurrence	NN	O	recurrence	nn	46	SENT_96	[p7l373t2503r731b2543],
45	risk	NN	O	risk	nn	46	SENT_96	[p7l751t2481r877b2543],
46	stratiﬁcation	NN	O	stratiﬁcation	prep_including	42	SENT_96	[p7l895t2481r1315b2543],
47	using	VBG	O	use	partmod	46	SENT_96	[p7l1335t2486r1515b2563],
48	the	DT	O	the	det	49	SENT_96	[p7l1533t2481r1636b2543],
49	OncotypeDX	NN	O	oncotypedx	dobj	47	SENT_96	[p7l1658t2485r2088b2563],
50	and	CC	O	and	_	0	SENT_96	[p7l8t2581r136b2643],
51	Mammaprint	NN	ORGANIZATION	mammaprint	nn	54	SENT_96	[p7l163t2586r634b2662],
52	gene	NN	O	gene	nn	54	SENT_96	[p7l661t2603r821b2663],
53	expression	NN	O	expression	nn	54	SENT_96	[p7l850t2586r1222b2662],
54	signatures	NNS	O	signature	dobj	47	SENT_96	[p7l1251t2586r1627b2663],
55	,	,	O	,	_	0	SENT_96	[p7l1251t2586r1627b2663],
56	or	CC	O	or	_	0	SENT_96	[p7l1657t2603r1730b2643],
57	the	DT	O	the	det	60	SENT_96	[p7l1757t2581r1865b2643],
58	IHC4	NN	O	ihc4	nn	60	SENT_96	[p7l1894t2585r2086b2643],
59	immunohistochemistry	NN	O	immunohistochemistry	nn	60	SENT_96	[p7l8t2681r784b2763],
60	method	NN	O	method	conj_or	9	SENT_96	[p7l800t2681r1055b2743],
61	that	WDT	O	that	nsubj	62	SENT_96	[p7l1073t2681r1200b2743],
62	measures	VBZ	O	measure	rcmod	60	SENT_96	[p7l1218t2703r1521b2743],
63	the	DT	O	the	det	64	SENT_96	[p7l1540t2681r1641b2743],
64	expression	NN	O	expression	dobj	62	SENT_96	[p7l1661t2686r2006b2762],
65	of	IN	O	of	_	0	SENT_96	[p7l2025t2681r2096b2743],
66	the	DT	O	the	det	68	SENT_96	[p7l7t2781r107b2843],
67	estrogen	NN	O	estrogen	nn	68	SENT_96	[p7l127t2793r400b2863],
68	receptor	NN	O	receptor	prep_of	64	SENT_96	[p7l419t2793r698b2862],
69	,	,	O	,	_	0	SENT_96	[p7l419t2793r698b2862],
70	the	DT	O	the	det	72	SENT_96	[p7l718t2781r818b2843],
71	progesterone	NN	O	progesterone	nn	72	SENT_96	[p7l837t2793r1256b2863],
72	receptor	NN	O	receptor	dobj	62	SENT_96	[p7l1276t2793r1555b2862],
73	,	,	O	,	_	0	SENT_96	[p7l1276t2793r1555b2862],
74	human	JJ	O	human	amod	75	SENT_96	[p7l1574t2781r1805b2843],
75	EGFR2	NN	O	egfr2	appos	72	SENT_96	[p7l1823t2785r2084b2845],
76	/	:	O	/	punct	77	SENT_96	[p7l1823t2785r2084b2845],
77	HER2	NN	O	her2	dep	75	SENT_96	[p7l8t2886r229b2951],
78	,	,	O	,	_	0	SENT_96	[p7l8t2886r229b2951],
79	and	CC	O	and	_	0	SENT_96	[p7l253t2881r378b2943],
80	Ki-672548	NN	O	ki-672548	nn	81	SENT_96	[p7l400t2873r789b2956],
81	)	NN	O	)	conj_and	64	SENT_96	[p7l400t2873r789b2956],
82	.	.	O	.	_	0	SENT_96	[p7l400t2873r789b2956],

1	No	DT	O	no	det	3	SENT_97	[p7l814t2886r914b2943],
2	less	RBR	O	less	advmod	3	SENT_97	[p7l936t2881r1053b2943],
3	critical	JJ	O	critical	nsubj	6	SENT_97	[p7l1076t2881r1308b2943],
4	is	VBZ	O	be	cop	6	SENT_97	[p7l1330t2886r1379b2943],
5	the	DT	O	the	det	6	SENT_97	[p7l1401t2881r1506b2943],
6	use	NN	O	use	conj_and	6	SENT_97	[p7l1529t2903r1637b2943],
7	of	IN	O	of	_	0	SENT_97	[p7l1661t2881r1733b2943],
8	molecular	JJ	O	molecular	amod	9	SENT_97	[p7l1746t2881r2087b2943],
9	monitoring	NN	O	monitoring	prep_of	6	SENT_97	[p7l7t2986r389b3063],
10	of	IN	O	of	_	0	SENT_97	[p7l410t2981r482b3043],
11	residual	JJ	O	residual	amod	12	SENT_97	[p7l495t2981r757b3043],
12	disease	NN	O	disease	prep_of	9	SENT_97	[p7l779t2981r1013b3043],
13	in	IN	O	in	_	0	SENT_97	[p7l1035t2986r1100b3042],
14	chronic	JJ	O	chronic	amod	16	SENT_97	[p7l1123t2981r1374b3043],
15	myeloid	JJ	O	myeloid	amod	16	SENT_97	[p7l1395t2981r1663b3063],
16	leukemia	NN	O	leukemia	prep_in	12	SENT_97	[p7l1683t2981r1989b3043],
17	by	IN	O	by	_	0	SENT_97	[p7l2007t2981r2089b3063],
18	determining	VBG	O	determine	prepc_by	6	SENT_97	[p7l8t3081r427b3163],
19	BCR-ABL1	NN	O	bcr-abl1	nn	20	SENT_97	[p7l446t3085r810b3143],
20	eXpression29	NN	O	expression29	dobj	18	SENT_97	[p7l840t3073r1332b3162],
21	=	JJ	O	=	amod	20	SENT_97	[p7l840t3073r1332b3162],
22	30	CD	NUMBER	30	tmod	21	SENT_97	[p7l840t3073r1332b3162],
23	and	CC	O	and	_	0	SENT_97	[p7l1355t3081r1479b3143],
24	in	IN	O	in	_	0	SENT_97	[p7l1501t3086r1566b3142],
25	pediatric	JJ	O	pediatric	amod	31	SENT_97	[p7l1587t3081r1888b3162],
26	acute	JJ	O	acute	amod	27	SENT_97	[p7l1911t3093r2086b3143],
27	lymphoblastic	JJ	O	lymphoblastic	amod	31	SENT_97	[p7l6t3181r488b3263],
28	leukemia	NN	O	leukemia	nn	31	SENT_97	[p7l509t3181r822b3243],
29	(	CD	NUMBER	(	num	31	SENT_97	[p7l847t3181r1047b3256],
30	ALL	NN	O	all	nn	31	SENT_97	[p7l847t3181r1047b3256],
31	)	NN	O	)	prep_in	6	SENT_97	[p7l847t3181r1047b3256],
32	by	IN	O	by	_	0	SENT_97	[p7l1073t3181r1156b3263],
33	assessing	VBG	O	assess	prepc_by	31	SENT_97	[p7l1176t3186r1483b3263],
34	immunoglobulin	NN	O	immunoglobulin	nn	41	SENT_97	[p7l1505t3181r2086b3263],
35	and	CC	O	and	_	0	SENT_97	[p7l8t3281r131b3343],
36	T	NN	O	t	nn	41	SENT_97	[p7l151t3281r339b3343],
37	—	NN	O	—	nn	41	SENT_97	[p7l151t3281r339b3343],
38	cell	NN	O	cell	nn	41	SENT_97	[p7l151t3281r339b3343],
39	receptor	NN	O	receptor	nn	41	SENT_97	[p7l360t3293r636b3362],
40	gene	NN	O	gene	nn	41	SENT_97	[p7l656t3303r808b3363],
41	rearrangements	NNS	O	rearrangement	nsubj	42	SENT_97	[p7l829t3273r1506b3363],
42	.31	CD	NUMBER	.31	xcomp	33	SENT_97	[p7l829t3273r1506b3363],
43	=	JJ	O	=	amod	42	SENT_97	[p7l829t3273r1506b3363],
44	32	CD	NUMBER	32	tmod	43	SENT_97	[p7l829t3273r1506b3363],

1	Given	VBN	O	give	prep	18	SENT_98	[p7l80t3385r283b3443],
2	the	DT	O	the	det	5	SENT_98	[p7l306t3381r412b3443],
3	increasingly	RB	O	increasingly	advmod	4	SENT_98	[p7l437t3381r856b3463],
4	critical	JJ	O	critical	amod	5	SENT_98	[p7l877t3381r1115b3443],
5	role	NN	O	role	dep	1	SENT_98	[p7l1139t3381r1268b3443],
6	of	IN	O	of	_	0	SENT_98	[p7l1293t3381r1367b3443],
7	molecular	JJ	O	molecular	amod	8	SENT_98	[p7l1381t3381r1728b3443],
8	investigations	NNS	O	investigation	prep_of	5	SENT_98	[p7l1752t3386r2082b3463, p7l7t3486r173b3543],
9	in	IN	O	in	_	0	SENT_98	[p7l197t3486r263b3542],
10	the	DT	O	the	det	12	SENT_98	[p7l285t3481r390b3543],
11	clinical	JJ	O	clinical	amod	12	SENT_98	[p7l414t3481r658b3543],
12	management	NN	O	management	prep_in	8	SENT_98	[p7l680t3493r1121b3563],
13	of	IN	O	of	_	0	SENT_98	[p7l1144t3481r1216b3543],
14	cancer	NN	O	cancer	nn	15	SENT_98	[p7l1231t3503r1452b3543],
15	patients	NNS	O	patient	prep_of	12	SENT_98	[p7l1473t3486r1759b3562],
16	,	,	O	,	_	0	SENT_98	[p7l1473t3486r1759b3562],
17	there	EX	O	there	expl	18	SENT_98	[p7l1783t3481r1956b3543],
18	is	VBZ	O	be	_	0	SENT_98	[p7l1979t3486r2029b3543],
19	a	DT	O	a	det	21	SENT_98	[p7l2053t3503r2087b3543],
20	clear	JJ	O	clear	amod	21	SENT_98	[p7l8t3581r167b3643],
21	need	NN	O	need	nsubj	18	SENT_98	[p7l187t3581r348b3643],
22	for	IN	O	for	_	0	SENT_98	[p7l369t3581r465b3643],
23	developing	VBG	O	develop	prepc_for	21	SENT_98	[p7l486t3581r856b3663],
24	robust	JJ	O	robust	amod	30	SENT_98	[p7l876t3581r1109b3651],
25	,	,	O	,	_	0	SENT_98	[p7l876t3581r1109b3651],
26	high	JJ	O	high	amod	27	SENT_98	[p7l1131t3581r1552b3663],
27	—	JJ	O	—	amod	30	SENT_98	[p7l1131t3581r1552b3663],
28	quality	NN	O	quality	nn	30	SENT_98	[p7l1131t3581r1552b3663],
29	diagnostic	JJ	O	diagnostic	amod	30	SENT_98	[p7l1570t3581r1918b3663],
30	tests	NNS	O	test	dobj	23	SENT_98	[p7l1939t3593r2085b3643],
31	and	CC	O	and	_	0	SENT_98	[p7l8t3681r132b3743],
32	for	IN	O	for	_	0	SENT_98	[p7l155t3681r252b3743],
33	their	PRP$	O	they	poss	35	SENT_98	[p7l273t3681r435b3743],
34	corresponding	JJ	O	corresponding	amod	35	SENT_98	[p7l458t3681r956b3763],
35	technical	JJ	O	technical	conj_and	23	SENT_98	[p7l977t3681r1286b3743],
36	and	CC	O	and	_	0	SENT_98	[p7l1310t3681r1434b3743],
37	clinical	JJ	O	clinical	amod	38	SENT_98	[p7l1457t3681r1701b3743],
38	validation	NN	O	validation	conj_and	35	SENT_98	[p7l1722t3681r2082b3743],
39	.	.	O	.	_	0	SENT_98	[p7l1722t3681r2082b3743],

1	Thorough	JJ	O	thorough	dep	103	SENT_99	[p8l7t16r346b98],
2	technical	JJ	O	technical	dep	103	SENT_99	[p8l369t16r681b78],
3	validation	NN	O	validation	dep	103	SENT_99	[p8l702t16r1049b78],
4	is	VBZ	O	be	dep	103	SENT_99	[p8l1074t21r1124b78],
5	a	DT	O	a	dep	103	SENT_99	[p8l1149t38r1183b78],
6	prerequisite	NN	O	prerequisite	dep	103	SENT_99	[p8l1205t21r1614b97],
7	for	IN	O	for	dep	103	SENT_99	[p8l1638t16r1736b78],
8	establishing	VBG	O	establish	dep	103	SENT_99	[p8l1759t16r2083b78, p8l8t121r116b198],
9	the	DT	O	the	dep	103	SENT_99	[p8l137t116r244b178],
10	performance	NN	O	performance	dep	103	SENT_99	[p8l267t116r711b197],
11	characteristics	NNS	O	characteristic	dep	103	SENT_99	[p8l736t116r1230b178],
12	of	IN	O	of	dep	103	SENT_99	[p8l1256t116r1329b178],
13	a	DT	O	a	dep	103	SENT_99	[p8l1345t138r1379b178],
14	methodology	NN	O	methodology	dep	103	SENT_99	[p8l1401t116r1883b198],
15	;	:	O	;	_	0	SENT_99	[p8l1401t116r1883b198],
16	these	DT	O	these	dep	103	SENT_99	[p8l1908t116r2085b178],
17	include	VBP	O	include	dep	103	SENT_99	[p8l8t216r255b278],
18	sensitivity	NN	O	sensitivity	dep	103	SENT_99	[p8l277t221r627b298],
19	,	,	O	,	_	0	SENT_99	[p8l277t221r627b298],
20	speciﬁcity	NN	O	speciﬁcity	dep	103	SENT_99	[p8l651t216r999b298],
21	,	,	O	,	_	0	SENT_99	[p8l651t216r999b298],
22	and	CC	O	and	dep	103	SENT_99	[p8l1023t216r1146b278],
23	limits	NNS	O	limit	dep	103	SENT_99	[p8l1165t216r1355b278],
24	of	IN	O	of	dep	103	SENT_99	[p8l1377t216r1449b278],
25	detection	NN	O	detection	dep	103	SENT_99	[p8l1462t216r1775b278],
26	and	CC	O	and	dep	103	SENT_99	[p8l1797t216r1921b278],
27	coverage	NN	O	coverage	dep	103	SENT_99	[p8l1942t238r2083b278, p8l8t338r188b398],
28	as	IN	O	as	dep	103	SENT_99	[p8l213t338r278b378],
29	part	NN	O	part	dep	103	SENT_99	[p8l302t328r443b397],
30	of	IN	O	of	dep	103	SENT_99	[p8l467t316r541b378],
31	a	DT	O	a	dep	103	SENT_99	[p8l556t338r591b378],
32	standardized	JJ	O	standardized	dep	103	SENT_99	[p8l615t316r1061b378],
33	framework	NN	O	framework	dep	103	SENT_99	[p8l1084t316r1466b378],
34	for	IN	O	for	dep	103	SENT_99	[p8l1488t316r1586b378],
35	the	DT	O	the	dep	103	SENT_99	[p8l1608t316r1715b378],
36	validation	NN	O	validation	dep	103	SENT_99	[p8l1737t316r2086b378],
37	and	CC	O	and	dep	103	SENT_99	[p8l8t416r135b478],
38	veriﬁcation	NN	O	veriﬁcation	dep	103	SENT_99	[p8l156t416r555b478],
39	of	IN	O	of	dep	103	SENT_99	[p8l580t416r654b478],
40	clinical	JJ	O	clinical	dep	103	SENT_99	[p8l669t416r920b478],
41	molecular	JJ	O	molecular	dep	103	SENT_99	[p8l944t416r1295b478],
42	genetic	JJ	O	genetic	dep	103	SENT_99	[p8l1319t421r1566b498],
43	tests	NNS	O	test	dep	103	SENT_99	[p8l1590t408r1823b478],
44	.33	CD	NUMBER	.33	dep	103	SENT_99	[p8l1590t408r1823b478],
45	Highly	RB	O	highly	dep	103	SENT_99	[p8l1850t416r2089b498],
46	sensitive	JJ	O	sensitive	dep	103	SENT_99	[p8l8t521r300b578],
47	methods	NNS	O	method	dep	103	SENT_99	[p8l324t516r622b578],
48	such	JJ	O	such	dep	103	SENT_99	[p8l648t516r803b578],
49	as	IN	O	as	dep	103	SENT_99	[p8l827t538r891b578],
50	ampliﬁcation-refractory	JJ	O	ampliﬁcation-refractory	dep	103	SENT_99	[p8l917t516r1752b598],
51	mutation	NN	O	mutation	dep	103	SENT_99	[p8l1772t521r2087b578],
52	system	NN	O	system	dep	103	SENT_99	[p8l8t628r255b698],
53	,	,	O	,	_	0	SENT_99	[p8l8t628r255b698],
54	alle1e	JJ	O	alle1e	dep	103	SENT_99	[p8l280t616r738b697],
55	—	NN	O	—	dep	103	SENT_99	[p8l280t616r738b697],
56	speciﬁc	NN	O	speciﬁc	dep	103	SENT_99	[p8l280t616r738b697],
57	real-time	JJ	O	real-time	dep	103	SENT_99	[p8l760t616r1070b678],
58	PCR	NN	O	pcr	dep	103	SENT_99	[p8l1092t620r1264b686],
59	,	,	O	,	_	0	SENT_99	[p8l1092t620r1264b686],
60	mass	NN	O	mass	dep	103	SENT_99	[p8l1287t638r1452b678],
61	spectrometry	NN	O	spectrometry	dep	103	SENT_99	[p8l1475t628r1940b698],
62	,	,	O	,	_	0	SENT_99	[p8l1475t628r1940b698],
63	and	CC	O	and	dep	103	SENT_99	[p8l1964t616r2088b678],
64	high	JJ	O	high	dep	103	SENT_99	[p8l7t716r544b798],
65	—	NN	O	—	dep	103	SENT_99	[p8l7t716r544b798],
66	resolution	NN	O	resolution	dep	103	SENT_99	[p8l7t716r544b798],
67	melting	NN	O	melting	dep	103	SENT_99	[p8l568t716r849b798],
68	,	,	O	,	_	0	SENT_99	[p8l568t716r849b798],
69	among	IN	O	among	dep	103	SENT_99	[p8l876t738r1110b798],
70	others	NNS	O	other	dep	103	SENT_99	[p8l1133t716r1364b786],
71	,	,	O	,	_	0	SENT_99	[p8l1133t716r1364b786],
72	are	VBP	O	be	dep	103	SENT_99	[p8l1390t738r1491b778],
73	now	RB	DATE	now	dep	103	SENT_99	[p8l1515t738r1662b778],
74	widely	RB	O	widely	dep	103	SENT_99	[p8l1681t716r1909b798],
75	used	VBN	O	use	dep	103	SENT_99	[p8l1930t716r2088b778],
76	to	TO	O	to	dep	103	SENT_99	[p8l7t828r71b878],
77	increase	VB	O	increase	dep	103	SENT_99	[p8l93t821r366b878],
78	the	DT	O	the	dep	103	SENT_99	[p8l386t816r490b878],
79	detection	NN	O	detection	dep	103	SENT_99	[p8l512t816r824b878],
80	rate	NN	O	rate	dep	103	SENT_99	[p8l845t828r969b878],
81	of	IN	O	of	dep	103	SENT_99	[p8l991t816r1063b878],
82	genetic	JJ	O	genetic	dep	103	SENT_99	[p8l1075t821r1313b898],
83	abnormalities	NNS	O	abnormality	dep	103	SENT_99	[p8l1335t816r1814b886],
84	,	,	O	,	_	0	SENT_99	[p8l1335t816r1814b886],
85	thereby	RB	O	thereby	dep	103	SENT_99	[p8l1836t816r2090b898],
86	reducing	VBG	O	reduce	dep	103	SENT_99	[p8l8t916r312b998],
87	the	DT	O	the	dep	103	SENT_99	[p8l333t916r439b978],
88	need	NN	O	need	dep	103	SENT_99	[p8l464t916r628b978],
89	for	IN	O	for	dep	103	SENT_99	[p8l651t916r748b978],
90	accurate	JJ	O	accurate	dep	103	SENT_99	[p8l772t928r1057b978],
91	tumor	NN	O	tumor	dep	103	SENT_99	[p8l1080t928r1296b978],
92	cell	NN	O	cell	dep	103	SENT_99	[p8l1319t916r1433b978],
93	puriﬁcationl	NN	O	puriﬁcationl	dep	103	SENT_99	[p8l1455t916r1889b997],
94	selection	NN	O	selection	dep	103	SENT_99	[p8l1896t916r2084b978, p8l7t1021r143b1078],
95	and	CC	O	and	dep	103	SENT_99	[p8l166t1016r291b1078],
96	increasing	VBG	O	increase	dep	103	SENT_99	[p8l312t1021r662b1098],
97	the	DT	O	the	dep	103	SENT_99	[p8l683t1016r788b1078],
98	clinical	JJ	O	clinical	dep	103	SENT_99	[p8l811t1016r1055b1078],
99	value	NN	O	value	dep	103	SENT_99	[p8l1074t1016r1253b1078],
100	of	IN	O	of	dep	103	SENT_99	[p8l1277t1016r1349b1078],
101	the	DT	O	the	dep	103	SENT_99	[p8l1362t1016r1467b1078],
102	analysis	NN	O	analysis	dep	103	SENT_99	[p8l1491t1008r1837b1098],
103	.34	CD	NUMBER	.34	_	0	SENT_99	[p8l1491t1008r1837b1098],

1	However	RB	O	however	advmod	3	SENT_100	[p8l80t1121r398b1186],
2	,	,	O	,	_	0	SENT_100	[p8l80t1121r398b1186],
3	increased	VBD	O	increase	_	0	SENT_100	[p8l423t1116r747b1178],
4	sensitivity	NN	O	sensitivity	nsubj	6	SENT_100	[p8l770t1121r1117b1198],
5	may	MD	O	may	aux	6	SENT_100	[p8l1136t1138r1282b1198],
6	lead	VB	O	lead	ccomp	3	SENT_100	[p8l1300t1116r1440b1178],
7	to	TO	O	to	_	0	SENT_100	[p8l1462t1128r1527b1178],
8	the	DT	O	the	det	9	SENT_100	[p8l1550t1116r1656b1178],
9	detection	NN	O	detection	prep_to	6	SENT_100	[p8l1680t1116r1998b1178],
10	of	IN	O	of	_	0	SENT_100	[p8l2022t1116r2095b1178],
11	“	CD	NUMBER	“	num	14	SENT_100	[p8l9t1216r420b1278],
12	subclinical	JJ	O	subclinical	amod	14	SENT_100	[p8l9t1216r420b1278],
13	”	NN	O	”	nn	14	SENT_100	[p8l9t1216r420b1278],
14	mutations	NNS	O	mutation	prep_of	9	SENT_100	[p8l441t1221r793b1286],
15	,	,	O	,	_	0	SENT_100	[p8l441t1221r793b1286],
16	that	DT	O	that	dep	6	SENT_100	[p8l813t1216r943b1278],
17	is	VBZ	O	be	dep	16	SENT_100	[p8l962t1221r1028b1286],
18	,	,	O	,	_	0	SENT_100	[p8l962t1221r1028b1286],
19	those	DT	O	those	dobj	6	SENT_100	[p8l1049t1216r1225b1278],
20	that	WDT	O	that	nsubj	22	SENT_100	[p8l1245t1216r1374b1278],
21	are	VBP	O	be	cop	22	SENT_100	[p8l1394t1238r1491b1278],
22	present	JJ	DATE	present	rcmod	19	SENT_100	[p8l1509t1228r1753b1297],
23	in	IN	O	in	_	0	SENT_100	[p8l1772t1221r1836b1277],
24	a	DT	O	a	det	26	SENT_100	[p8l1857t1238r1890b1278],
25	small	JJ	O	small	amod	26	SENT_100	[p8l1909t1216r2084b1278],
26	subclone	NN	O	subclone	prep_in	22	SENT_100	[p8l8t1316r301b1378],
27	of	IN	O	of	_	0	SENT_100	[p8l324t1316r396b1378],
28	the	DT	O	the	det	29	SENT_100	[p8l408t1316r511b1378],
29	tumor	NN	O	tumor	prep_of	26	SENT_100	[p8l533t1328r753b1386],
30	,	,	O	,	_	0	SENT_100	[p8l533t1328r753b1386],
31	potentially	RB	O	potentially	advmod	32	SENT_100	[p8l775t1316r1136b1398],
32	leading	VBG	O	lead	xcomp	22	SENT_100	[p8l1153t1316r1398b1398],
33	to	TO	O	to	_	0	SENT_100	[p8l1418t1328r1482b1378],
34	a	DT	O	a	det	36	SENT_100	[p8l1506t1338r1539b1378],
35	negative	JJ	O	negative	amod	36	SENT_100	[p8l1560t1321r1834b1398],
36	impact	NN	O	impact	prep_to	32	SENT_100	[p8l1857t1321r2087b1397],
37	on	IN	O	on	_	0	SENT_100	[p8l8t1439r93b1479],
38	response	NN	O	response	prep_on	36	SENT_100	[p8l116t1438r412b1498],
39	to	TO	O	to	_	0	SENT_100	[p8l435t1429r500b1479],
40	certain	JJ	O	certain	amod	41	SENT_100	[p8l524t1422r758b1479],
41	therapies	NNS	O	therapy	prep_to	6	SENT_100	[p8l780t1417r1105b1498],
42	.	.	O	.	_	0	SENT_100	[p8l780t1417r1105b1498],

1	For	IN	O	for	_	0	SENT_101	[p8l1132t1422r1246b1479],
2	example	NN	O	example	prep_for	58	SENT_101	[p8l1268t1417r1565b1498],
3	,	,	O	,	_	0	SENT_101	[p8l1268t1417r1565b1498],
4	in	IN	O	in	_	0	SENT_101	[p8l1590t1422r1656b1478],
5	a	DT	O	a	det	7	SENT_101	[p8l1679t1439r1713b1479],
6	signiﬁcant	JJ	O	signiﬁcant	amod	7	SENT_101	[p8l1736t1417r2087b1499],
7	proportion	NN	O	proportion	prep_in	58	SENT_101	[p8l6t1522r364b1598],
8	of	IN	O	of	_	0	SENT_101	[p8l384t1517r454b1579],
9	responding	VBG	O	respond	amod	10	SENT_101	[p8l464t1517r832b1599],
10	patients	NNS	O	patient	prep_of	7	SENT_101	[p8l848t1522r1120b1598],
11	,	,	O	,	_	0	SENT_101	[p8l848t1522r1120b1598],
12	concomitant	JJ	O	concomitant	amod	20	SENT_101	[p8l1141t1522r1566b1587],
13	,	,	O	,	_	0	SENT_101	[p8l1141t1522r1566b1587],
14	low	JJ	O	low	amod	20	SENT_101	[p8l1585t1517r1878b1579],
15	—	NN	O	—	nn	20	SENT_101	[p8l1585t1517r1878b1579],
16	level	NN	O	level	nn	20	SENT_101	[p8l1585t1517r1878b1579],
17	EGFR	NN	ORGANIZATION	egfr	nn	20	SENT_101	[p8l1894t1521r2088b1579],
18	p.	NN	O	p.	nn	20	SENT_101	[p8l6t1620r312b1698],
19	T790M	NN	O	t790m	nn	20	SENT_101	[p8l6t1620r312b1698],
20	mutations	NNS	O	mutation	nsubj	58	SENT_101	[p8l335t1622r670b1679],
21	associated	VBN	O	associate	partmod	20	SENT_101	[p8l694t1617r1032b1679],
22	with	IN	O	with	_	0	SENT_101	[p8l1051t1617r1200b1679],
23	a	DT	O	a	det	25	SENT_101	[p8l1223t1639r1256b1679],
24	shorter	JJR	O	shorter	amod	25	SENT_101	[p8l1278t1617r1516b1679],
25	progression	NN	O	progression	prep_with	21	SENT_101	[p8l1536t1617r2084b1699],
26	—	CD	NUMBER	—	num	28	SENT_101	[p8l1536t1617r2084b1699],
27	free	JJ	O	free	amod	28	SENT_101	[p8l1536t1617r2084b1699],
28	survival	NN	O	survival	tmod	21	SENT_101	[p8l8t1717r643b1779],
29	—	CD	NUMBER	—	num	33	SENT_101	[p8l8t1717r643b1779],
30	so-called	JJ	O	so-called	amod	33	SENT_101	[p8l8t1717r643b1779],
31	“	JJ	O	“	amod	33	SENT_101	[p8l662t1717r1040b1799],
32	gatekeeper	NN	O	gatekeeper	nn	33	SENT_101	[p8l662t1717r1040b1799],
33	mutations	NNS	O	mutation	nsubj	34	SENT_101	[p8l1059t1717r1419b1779],
34	”	VBP	O	”	rcmod	28	SENT_101	[p8l1059t1717r1419b1779],
35	that	IN	O	that	complm	47	SENT_101	[p8l1439t1717r1567b1779],
36	lead	NN	O	lead	nsubj	47	SENT_101	[p8l1584t1717r1720b1779],
37	to	TO	O	to	_	0	SENT_101	[p8l1738t1729r1801b1779],
38	reduced	VBN	O	reduce	amod	40	SENT_101	[p8l1822t1717r2086b1779],
39	drug	NN	O	drug	nn	40	SENT_101	[p8l8t1817r164b1899],
40	binding	NN	O	binding	prep_to	36	SENT_101	[p8l180t1817r438b1899],
41	and	CC	O	and	_	0	SENT_101	[p8l456t1817r578b1879],
42	resistance	NN	O	resistance	prep_to	36	SENT_101	[p8l597t1822r916b1879],
43	to	TO	O	to	_	0	SENT_101	[p8l935t1829r998b1879],
44	tyrosine	NN	O	tyrosine	nn	46	SENT_101	[p8l1018t1822r1284b1899],
45	kinase	NN	O	kinase	nn	46	SENT_101	[p8l1302t1817r1511b1879],
46	inhibitors	NNS	O	inhibitor	prep_to	42	SENT_101	[p8l1531t1817r1849b1879],
47	(	VBP	O	(	ccomp	34	SENT_101	[p8l1872t1818r2083b1892],
48	TKIs	NNS	O	tki	dobj	47	SENT_101	[p8l1872t1818r2083b1892],
49	)	CD	NUMBER	)	num	50	SENT_101	[p8l1872t1818r2083b1892],
50	geﬁtinib	NN	O	geﬁtinib	dep	48	SENT_101	[p8l7t1917r277b1999],
51	and	CC	O	and	_	0	SENT_101	[p8l299t1917r420b1979],
52	erlotinib	NN	O	erlotinib	conj_and	48	SENT_101	[p8l439t1917r719b1979],
53	in	IN	O	in	_	0	SENT_101	[p8l740t1922r804b1978],
54	patients	NNS	O	patient	prep_in	52	SENT_101	[p8l823t1922r1081b1998],
55	with	IN	O	with	_	0	SENT_101	[p8l1100t1917r1246b1979],
56	NSCLC	NN	O	nsclc	prep_with	54	SENT_101	[p8l1265t1921r1518b1979],
57	(	CD	NUMBER	(	num	56	SENT_101	[p8l1541t1918r1665b1992],
58	see	VBP	O	see	_	0	SENT_101	[p8l1541t1918r1665b1992],
59	below	IN	O	below	_	0	SENT_101	[p8l1683t1917r2084b1992],
60	)	NN	O	)	prep_below	58	SENT_101	[p8l1683t1917r2084b1992],
61	.	.	O	.	_	0	SENT_101	[p8l1683t1917r2084b1992],

1	—	NN	O	—	_	0	SENT_102	[p8l1683t1917r2084b1992],
2	.	.	O	.	_	0	SENT_102	[p8l1683t1917r2084b1992],

1	are	VBP	O	be	auxpass	2	SENT_103	[p8l1683t1917r2084b1992],
2	seen	VBN	O	see	_	0	SENT_103	[p8l8t2039r154b2079],
3	pretreatment	NN	O	pretreatment	nsubjpass	2	SENT_103	[p8l175t2029r614b2098],
4	alongside	IN	O	alongside	_	0	SENT_103	[p8l636t2017r952b2099],
5	other	JJ	O	other	amod	7	SENT_103	[p8l975t2017r1153b2079],
6	EGFR	NN	ORGANIZATION	egfr	nn	7	SENT_103	[p8l1172t2021r1371b2079],
7	mutations	NNS	O	mutation	prep_alongside	3	SENT_103	[p8l1393t2022r1730b2079],
8	that	WDT	O	that	nsubj	9	SENT_103	[p8l1752t2017r1883b2079],
9	cause	VBP	O	cause	rcmod	3	SENT_103	[p8l1905t2039r2085b2079],
10	sensitivity	NN	O	sensitivity	dobj	9	SENT_103	[p8l9t2122r360b2199],
11	to	TO	O	to	_	0	SENT_103	[p8l381t2129r446b2179],
12	these	DT	O	these	det	13	SENT_103	[p8l472t2117r649b2179],
13	agents	NNS	O	agent	prep_to	9	SENT_103	[p8l675t2109r973b2199],
14	.35	CD	NUMBER	.35	dep	13	SENT_103	[p8l675t2109r973b2199],
15	The	DT	O	the	det	16	SENT_103	[p8l999t2117r1124b2179],
16	presence	NN	O	presence	nsubj	26	SENT_103	[p8l1148t2139r1449b2198],
17	of	IN	O	of	_	0	SENT_103	[p8l1475t2117r1549b2179],
18	multiple	JJ	O	multiple	amod	19	SENT_103	[p8l1564t2117r1852b2198],
19	mutations	NNS	O	mutation	prep_of	16	SENT_103	[p8l1877t2129r2082b2179, p8l7t2222r172b2279],
20	in	IN	O	in	_	0	SENT_103	[p8l195t2222r260b2278],
21	a	DT	O	a	det	24	SENT_103	[p8l284t2239r317b2279],
22	single	JJ	O	single	amod	24	SENT_103	[p8l340t2217r532b2299],
23	tumor	NN	O	tumor	nn	24	SENT_103	[p8l554t2229r766b2279],
24	biopsy	NN	O	biopsy	prep_in	19	SENT_103	[p8l785t2217r1010b2299],
25	has	VBZ	O	have	aux	26	SENT_103	[p8l1028t2217r1137b2279],
26	become	VBN	O	become	ccomp	2	SENT_103	[p8l1158t2217r1421b2279],
27	even	RB	O	even	advmod	29	SENT_103	[p8l1445t2239r1598b2279],
28	more	RBR	O	more	advmod	29	SENT_103	[p8l1620t2239r1795b2279],
29	relevant	JJ	O	relevant	acomp	26	SENT_103	[p8l1818t2217r2087b2279],
30	with	IN	O	with	_	0	SENT_103	[p8l6t2317r154b2379],
31	the	DT	O	the	det	32	SENT_103	[p8l175t2317r279b2379],
32	advent	NN	O	advent	prep_with	26	SENT_103	[p8l302t2317r523b2379],
33	of	IN	O	of	_	0	SENT_103	[p8l545t2317r616b2379],
34	increasingly	RB	O	increasingly	advmod	35	SENT_103	[p8l629t2317r1034b2399],
35	sensitive	JJ	O	sensitive	amod	36	SENT_103	[p8l1053t2322r1335b2379],
36	methods	NNS	O	method	prep_of	32	SENT_103	[p8l1357t2317r1647b2379],
37	such	JJ	O	such	_	0	SENT_103	[p8l1671t2317r1821b2379],
38	as	IN	O	as	_	0	SENT_103	[p8l1844t2339r1906b2379],
39	deep	JJ	O	deep	amod	40	SENT_103	[p8l1930t2317r2084b2398],
40	sequencing	NN	O	sequencing	prep_such_as	36	SENT_103	[p8l8t2422r399b2499],
41	.	.	O	.	_	0	SENT_103	[p8l8t2422r399b2499],

1	This	DT	O	this	nsubj	4	SENT_104	[p8l422t2417r561b2479],
2	is	VBZ	O	be	cop	4	SENT_104	[p8l582t2422r630b2479],
3	especially	RB	O	especially	advmod	4	SENT_104	[p8l652t2417r975b2499],
4	so	RB	O	so	_	0	SENT_104	[p8l993t2439r1078b2487],
5	,	,	O	,	_	0	SENT_104	[p8l993t2439r1078b2487],
6	given	VBN	O	give	prep	4	SENT_104	[p8l1100t2422r1278b2499],
7	our	PRP$	O	we	poss	9	SENT_104	[p8l1298t2439r1413b2479],
8	growing	VBG	O	grow	amod	9	SENT_104	[p8l1432t2422r1707b2499],
9	knowledge	NN	O	knowledge	dep	6	SENT_104	[p8l1724t2417r2085b2499],
10	of	IN	O	of	_	0	SENT_104	[p8l8t2517r80b2579],
11	the	DT	O	the	det	13	SENT_104	[p8l92t2517r195b2579],
12	oligoclonal	JJ	O	oligoclonal	amod	13	SENT_104	[p8l218t2517r586b2599],
13	heterogeneity	NN	O	heterogeneity	prep_of	9	SENT_104	[p8l606t2517r1063b2599],
14	and	CC	O	and	_	0	SENT_104	[p8l1082t2517r1205b2579],
15	clonal	JJ	O	clonal	amod	16	SENT_104	[p8l1227t2517r1426b2579],
16	selection	NN	O	selection	dep	6	SENT_104	[p8l1448t2517r1741b2579],
17	in	IN	O	in	_	0	SENT_104	[p8l1763t2522r1828b2578],
18	human	JJ	O	human	amod	19	SENT_104	[p8l1849t2517r2085b2579],
19	cancers	NNS	O	cancer	prep_in	16	SENT_104	[p8l8t2609r409b2679],
20	.3637	CD	NUMBER	.3637	dep	16	SENT_104	[p8l8t2609r409b2679],

1	In	IN	O	in	_	0	SENT_105	[p8l80t2722r152b2778],
2	view	NN	O	view	prep_in	9	SENT_105	[p8l175t2722r341b2779],
3	of	IN	O	of	_	0	SENT_105	[p8l365t2717r440b2779],
4	this	DT	O	this	det	5	SENT_105	[p8l456t2717r585b2779],
5	heterogeneity	NN	O	heterogeneity	prep_of	2	SENT_105	[p8l611t2717r1108b2799],
6	,	,	O	,	_	0	SENT_105	[p8l611t2717r1108b2799],
7	one	CD	NUMBER	one	nsubj	9	SENT_105	[p8l1137t2739r1261b2779],
8	may	MD	O	may	aux	9	SENT_105	[p8l1287t2739r1436b2799],
9	contest	VB	O	contest	_	0	SENT_105	[p8l1460t2729r1711b2779],
10	whether	IN	O	whether	complm	19	SENT_105	[p8l1735t2717r2026b2779],
11	a	DT	O	a	det	13	SENT_105	[p8l2052t2739r2086b2779],
12	single	JJ	O	single	amod	13	SENT_105	[p8l8t2817r206b2899],
13	biopsy	NN	O	biopsy	nsubj	19	SENT_105	[p8l228t2817r456b2899],
14	of	IN	O	of	_	0	SENT_105	[p8l478t2817r551b2879],
15	the	DT	O	the	det	17	SENT_105	[p8l565t2817r671b2879],
16	primary	JJ	O	primary	amod	17	SENT_105	[p8l695t2822r978b2899],
17	tumor	NN	O	tumor	prep_of	13	SENT_105	[p8l998t2829r1213b2879],
18	can	MD	O	can	aux	19	SENT_105	[p8l1237t2839r1353b2879],
19	provide	VB	O	provide	ccomp	9	SENT_105	[p8l1377t2817r1638b2898],
20	the	DT	O	the	det	22	SENT_105	[p8l1662t2817r1768b2879],
21	required	VBN	O	require	amod	22	SENT_105	[p8l1793t2817r2086b2898],
22	information	NN	O	information	nsubj	24	SENT_105	[p8l8t2917r440b2979],
23	to	TO	O	to	aux	24	SENT_105	[p8l467t2929r534b2979],
24	treat	VB	O	treat	xcomp	19	SENT_105	[p8l563t2929r726b2979],
25	the	DT	O	the	det	28	SENT_105	[p8l752t2917r862b2979],
26	metastatic	JJ	O	metastatic	amod	28	SENT_105	[p8l889t2922r1255b2979],
27	disease	NN	O	disease	nn	28	SENT_105	[p8l1284t2917r1535b2979],
28	years	NNS	DATE	year	tmod	24	SENT_105	[p8l1561t2939r1743b2999],
29	later	RB	DATE	later	advmod	24	SENT_105	[p8l1770t2917r1929b2979],
30	and	CC	O	and	_	0	SENT_105	[p8l1957t2917r2086b2979],
31	whether	IN	O	whether	complm	36	SENT_105	[p8l6t3017r282b3079],
32	multiple	JJ	O	multiple	amod	33	SENT_105	[p8l302t3017r581b3098],
33	biopsies	NNS	O	biopsy	nsubjpass	36	SENT_105	[p8l601t3017r871b3098],
34	may	MD	O	may	aux	36	SENT_105	[p8l892t3039r1034b3099],
35	be	VB	O	be	auxpass	36	SENT_105	[p8l1051t3017r1128b3079],
36	needed	VBN	O	need	ccomp	9	SENT_105	[p8l1149t3017r1391b3079],
37	from	IN	O	from	_	0	SENT_105	[p8l1411t3017r1574b3079],
38	each	DT	O	each	det	39	SENT_105	[p8l1596t3017r1745b3079],
39	patient	NN	O	patient	prep_from	36	SENT_105	[p8l1765t3022r2000b3098],
40	to	TO	O	to	aux	41	SENT_105	[p8l2019t3029r2083b3079],
41	ascertain	VB	O	ascertain	xcomp	36	SENT_105	[p8l8t3122r308b3179],
42	the	DT	O	the	det	45	SENT_105	[p8l329t3117r432b3179],
43	true	JJ	O	true	amod	45	SENT_105	[p8l452t3129r588b3179],
44	molecular	JJ	O	molecular	amod	45	SENT_105	[p8l610t3117r946b3179],
45	status	NN	O	status	dobj	41	SENT_105	[p8l968t3129r1156b3179],
46	of	IN	O	of	_	0	SENT_105	[p8l1178t3117r1249b3179],
47	the	DT	O	the	det	48	SENT_105	[p8l1261t3117r1364b3179],
48	tumor	NN	O	tumor	prep_of	45	SENT_105	[p8l1385t3129r1594b3179],
49	at	IN	O	at	_	0	SENT_105	[p8l1615t3129r1672b3179],
50	the	DT	O	the	det	53	SENT_105	[p8l1692t3117r1795b3179],
51	particular	JJ	O	particular	amod	53	SENT_105	[p8l1816t3122r2084b3198, p8l6t3217r97b3279],
52	time	NN	O	time	nn	53	SENT_105	[p8l120t3222r275b3279],
53	point	NN	O	point	prep_at	48	SENT_105	[p8l299t3222r483b3298],
54	of	IN	O	of	_	0	SENT_105	[p8l508t3217r581b3279],
55	treatment	NN	O	treatment	prep_of	53	SENT_105	[p8l596t3229r935b3279],
56	with	IN	O	with	_	0	SENT_105	[p8l957t3217r1111b3279],
57	respect	NN	O	respect	prep_with	41	SENT_105	[p8l1136t3229r1382b3298],
58	to	TO	O	to	_	0	SENT_105	[p8l1405t3229r1470b3279],
59	actionable	JJ	O	actionable	amod	60	SENT_105	[p8l1497t3217r1851b3279],
60	mutations	NNS	O	mutation	prep_to	41	SENT_105	[p8l1876t3229r2082b3279, p8l7t3322r191b3379],
61	.	.	O	.	_	0	SENT_105	[p8l1876t3229r2082b3279, p8l7t3322r191b3379],

1	On	IN	O	on	_	0	SENT_106	[p8l218t3321r322b3379],
2	the	DT	O	the	det	4	SENT_106	[p8l343t3317r448b3379],
3	other	JJ	O	other	amod	4	SENT_106	[p8l472t3317r652b3379],
4	hand	NN	O	hand	prep_on	7	SENT_106	[p8l672t3317r861b3387],
5	,	,	O	,	_	0	SENT_106	[p8l672t3317r861b3387],
6	there	EX	O	there	expl	7	SENT_106	[p8l884t3317r1056b3379],
7	is	VBZ	O	be	_	0	SENT_106	[p8l1079t3322r1128b3379],
8	evidence	NN	O	evidence	nsubj	7	SENT_106	[p8l1152t3317r1449b3379],
9	that	IN	O	that	complm	17	SENT_106	[p8l1471t3317r1603b3379],
10	the	DT	O	the	det	14	SENT_106	[p8l1624t3317r1729b3379],
11	key	JJ	O	key	amod	14	SENT_106	[p8l1750t3317r1868b3399],
12	initial	JJ	O	initial	amod	14	SENT_106	[p8l1887t3317r2088b3379],
13	driver	NN	O	driver	nn	14	SENT_106	[p8l8t3417r220b3479],
14	mutations	NNS	O	mutation	nsubj	17	SENT_106	[p8l244t3422r600b3479],
15	are	VBP	O	be	cop	17	SENT_106	[p8l627t3439r729b3479],
16	generally	RB	O	generally	advmod	17	SENT_106	[p8l755t3417r1079b3499],
17	present	JJ	DATE	present	ccomp	7	SENT_106	[p8l1100t3429r1359b3498],
18	in	IN	O	in	_	0	SENT_106	[p8l1384t3422r1452b3478],
19	both	CC	O	both	preconj	21	SENT_106	[p8l1475t3417r1638b3479],
20	the	DT	O	the	det	21	SENT_106	[p8l1663t3417r1772b3479],
21	primary	JJ	O	primary	prep_in	17	SENT_106	[p8l1796t3422r2087b3499],
22	and	CC	O	and	_	0	SENT_106	[p8l8t3517r131b3579],
23	the	DT	O	the	det	26	SENT_106	[p8l151t3517r255b3579],
24	metastatic	JJ	O	metastatic	amod	26	SENT_106	[p8l277t3522r621b3579],
25	biopsy	NN	O	biopsy	nn	26	SENT_106	[p8l641t3517r865b3599],
26	specimens	NNS	O	specimen	prep_in	17	SENT_106	[p8l884t3509r1313b3598],
27	,38	CD	NUMBER	,38	tmod	17	SENT_106	[p8l884t3509r1313b3598],
28	and	CC	O	and	_	0	SENT_106	[p8l1336t3517r1459b3579],
29	clinical	JJ	O	clinical	amod	30	SENT_106	[p8l1481t3517r1723b3579],
30	trials	NNS	O	trial	nsubj	32	SENT_106	[p8l1743t3517r1912b3579],
31	have	VBP	O	have	aux	32	SENT_106	[p8l1934t3517r2086b3579],
32	demonstrated	VBN	O	demonstrate	ccomp	7	SENT_106	[p8l8t3617r480b3679],
33	that	IN	O	that	complm	35	SENT_106	[p8l500t3617r633b3679],
34	there	EX	O	there	expl	35	SENT_106	[p8l653t3617r826b3679],
35	is	VBZ	O	be	ccomp	32	SENT_106	[p8l848t3622r898b3679],
36	beneﬁt	NN	O	beneﬁt	nsubj	35	SENT_106	[p8l919t3617r1153b3679],
37	in	IN	O	in	_	0	SENT_106	[p8l1174t3622r1239b3678],
38	testing	NN	O	testing	prep_in	36	SENT_106	[p8l1261t3622r1490b3699],
39	primary	JJ	O	primary	amod	40	SENT_106	[p8l1509t3622r1790b3699],
40	resected	JJ	O	resected	amod	38	SENT_106	[p8l1809t3617r2088b3679],

1	CLINICAL	JJ	O	clinical	amod	2	SENT_107	[p9l8t74r249b115],
2	PHARMACOLOGY	NNP	O	PHARMACOLOGY	_	0	SENT_107	[p9l267t74r720b115],
3	&	CC	O	&	_	0	SENT_107	[p9l735t74r1179b115],
4	THERAPEUTlCS	NNP	O	THERAPEUTlCS	nn	6	SENT_107	[p9l735t74r1179b115],
5	|	NNP	O	|	nn	6	SENT_107	[p9l1199t70r1204b130],
6	VOLUME	NNP	O	VOLUME	conj_and	2	SENT_107	[p9l1220t74r1437b116],
7	93	CD	NUMBER	93	num	6	SENT_107	[p9l1454t75r1509b116],
8	NUMBER	NN	O	number	nn	11	SENT_107	[p9l1530t74r1747b116],
9	3	CD	NUMBER	3	num	11	SENT_107	[p9l1763t75r1788b116],
10	|	NN	O	|	nn	11	SENT_107	[p9l1809t70r1813b130],
11	MARCH	NN	DATE	march	dep	2	SENT_107	[p9l1834t74r2019b116],
12	2013	CD	DATE	2013	num	13	SENT_107	[p9l2039t75r2153b116],
13	material	NN	O	material	nsubj	15	SENT_107	[p9l8t155r296b218],
14	to	TO	O	to	aux	15	SENT_107	[p9l317t167r383b218],
15	treat	VB	O	treat	infmod	2	SENT_107	[p9l406t167r565b218],
16	metastatic	JJ	O	metastatic	amod	17	SENT_107	[p9l587t160r943b218],
17	disease	NN	O	disease	dobj	15	SENT_107	[p9l966t147r1296b218],
18	.	.	O	.	_	0	SENT_107	[p9l966t147r1296b218],

1	”	NN	O	”	nsubj	23	SENT_108	[p9l966t147r1296b218],
2	Nevertheless	RB	O	nevertheless	advmod	23	SENT_108	[p9l1317t155r1781b227],
3	,	,	O	,	_	0	SENT_108	[p9l1317t155r1781b227],
4	especially	RB	O	especially	advmod	5	SENT_108	[p9l1806t155r2145b239],
5	with	IN	O	with	dep	23	SENT_108	[p9l7t258r168b321],
6	the	DT	O	the	det	7	SENT_108	[p9l194t258r307b321],
7	discovery	NN	O	discovery	pobj	5	SENT_108	[p9l335t258r686b342],
8	of	IN	O	of	_	0	SENT_108	[p9l711t258r788b321],
9	new	JJ	O	new	amod	12	SENT_108	[p9l806t281r966b330],
10	,	,	O	,	_	0	SENT_108	[p9l806t281r966b330],
11	secondary	JJ	O	secondary	amod	12	SENT_108	[p9l996t258r1371b342],
12	mutations	NNS	O	mutation	prep_of	7	SENT_108	[p9l1394t263r1760b321],
13	and	CC	O	and	_	0	SENT_108	[p9l1790t258r1922b321],
14	other	JJ	O	other	amod	15	SENT_108	[p9l1949t258r2142b321],
15	changes	NNS	O	change	pobj	5	SENT_108	[p9l9t361r289b445],
16	that	WDT	O	that	nsubj	18	SENT_108	[p9l314t361r454b424],
17	may	MD	O	may	aux	18	SENT_108	[p9l478t384r629b445],
18	have	VB	O	have	rcmod	15	SENT_108	[p9l650t361r811b424],
19	therapeutic	JJ	O	therapeutic	amod	20	SENT_108	[p9l836t361r1243b444],
20	implications	NNS	O	implication	dobj	18	SENT_108	[p9l1269t361r1731b444],
21	,	,	O	,	_	0	SENT_108	[p9l1269t361r1731b444],
22	we	PRP	O	we	nsubj	23	SENT_108	[p9l1757t384r1852b424],
23	need	VBP	O	need	_	0	SENT_108	[p9l1878t361r2048b424],
24	to	TO	O	to	aux	25	SENT_108	[p9l2072t373r2140b424],
25	reassess	NN	O	reassess	xcomp	23	SENT_108	[p9l9t488r282b528],
26	our	PRP$	O	we	poss	27	SENT_108	[p9l307t488r428b528],
27	approach	NN	O	approach	dobj	25	SENT_108	[p9l452t465r776b548],
28	to	TO	O	to	_	0	SENT_108	[p9l800t477r867b528],
29	molecular	JJ	O	molecular	amod	30	SENT_108	[p9l892t465r1247b528],
30	proﬁling	NN	O	proﬁling	prep_to	25	SENT_108	[p9l1270t465r1575b549],
31	by	IN	O	by	_	0	SENT_108	[p9l1595t465r1680b549],
32	selecting	VBG	O	select	prepc_by	23	SENT_108	[p9l1702t465r2011b549],
33	the	DT	O	the	det	36	SENT_108	[p9l2033t465r2141b528],
34	most	RBS	O	most	advmod	35	SENT_108	[p9l8t580r180b631],
35	appropriate	JJ	O	appropriate	amod	36	SENT_108	[p9l203t573r606b651],
36	sample	NN	O	sample	dobj	32	SENT_108	[p9l630t568r871b651],
37	to	TO	O	to	_	0	SENT_108	[p9l893t580r960b631],
38	biopsy	NN	O	biopsy	prep_to	32	SENT_108	[p9l982t568r1214b652],
39	(	CD	NUMBER	(	num	38	SENT_108	[p9l1236t568r1422b645],
40	such	JJ	O	such	_	0	SENT_108	[p9l1236t568r1422b645],
41	as	IN	O	as	_	0	SENT_108	[p9l1446t591r1511b631],
42	cytological	JJ	O	cytological	amod	43	SENT_108	[p9l1535t568r1915b652],
43	specimens	NNS	O	specimen	prep_such_as	38	SENT_108	[p9l1938t573r2140b651, p9l8t694r196b734],
44	from	IN	O	from	_	0	SENT_108	[p9l223t671r397b734],
45	ﬁne-needle	JJ	O	ﬁne-needle	amod	46	SENT_108	[p9l423t671r825b734],
46	aspirates	NNS	O	aspirate	prep_from	43	SENT_108	[p9l852t676r1162b754],
47	or	CC	O	or	_	0	SENT_108	[p9l1189t694r1263b734],
48	even	RB	O	even	advmod	32	SENT_108	[p9l1289t694r1451b734],
49	circulating	VBG	O	circulate	conj_or	32	SENT_108	[p9l1478t671r1865b755],
50	plasma	NN	O	plasma	nn	52	SENT_108	[p9l1889t671r2143b754],
51	DNA	NN	MISC	dna	nn	52	SENT_108	[p9l9t774r217b849],
52	)	NN	O	)	dobj	49	SENT_108	[p9l9t774r217b849],
53	so	RB	O	so	advmod	56	SENT_108	[p9l246t796r318b836],
54	as	IN	O	as	dep	56	SENT_108	[p9l344t796r410b836],
55	to	TO	O	to	aux	56	SENT_108	[p9l433t785r501b836],
56	minimize	VB	O	minimize	xcomp	49	SENT_108	[p9l525t778r862b836],
57	invasive	JJ	O	invasive	amod	58	SENT_108	[p9l886t778r1167b836],
58	procedures	NNS	O	procedure	dobj	56	SENT_108	[p9l1190t765r1668b856],
59	.	.	O	.	_	0	SENT_108	[p9l1190t765r1668b856],

1	”	NN	O	”	_	0	SENT_109	[p9l1190t765r1668b856],

1	It	PRP	O	it	nsubj	3	SENT_110	[p9l82t880r131b939],
2	is	VBZ	O	be	cop	3	SENT_110	[p9l150t880r199b939],
3	clear	JJ	O	clear	_	0	SENT_110	[p9l220t875r391b947],
4	,	,	O	,	_	0	SENT_110	[p9l220t875r391b947],
5	therefore	RB	O	therefore	advmod	3	SENT_110	[p9l412t875r734b947],
6	,	,	O	,	_	0	SENT_110	[p9l412t875r734b947],
7	that	IN	O	that	complm	9	SENT_110	[p9l755t875r887b939],
8	there	EX	O	there	expl	9	SENT_110	[p9l905t875r1077b939],
9	is	VBZ	O	be	ccomp	3	SENT_110	[p9l1098t880r1147b939],
10	a	DT	O	a	det	11	SENT_110	[p9l1168t898r1202b939],
11	need	NN	O	need	nsubj	9	SENT_110	[p9l1221t875r1384b939],
12	to	TO	O	to	aux	13	SENT_110	[p9l1402t887r1467b939],
13	ensure	VB	O	ensure	infmod	11	SENT_110	[p9l1489t898r1709b939],
14	robust	JJ	O	robust	dobj	13	SENT_110	[p9l1730t875r1945b939],
15	clinical	JJ	O	clinical	amod	14	SENT_110	[p9l1965t875r2137b939, p9l9t979r103b1042],

1	validation	NN	O	validation	_	0	SENT_111	[p9l122t979r469b1042],
2	of	IN	O	of	_	0	SENT_111	[p9l492t979r566b1042],
3	companion	NN	O	companion	nn	4	SENT_111	[p9l580t984r970b1062],
4	diagnostics	NNS	O	diagnostic	prep_of	1	SENT_111	[p9l994t979r1398b1063],
5	,	,	O	,	_	0	SENT_111	[p9l994t979r1398b1063],
6	preferably	RB	O	preferably	advmod	4	SENT_111	[p9l1421t979r1771b1063],
7	within	IN	O	within	amod	4	SENT_111	[p9l1788t979r2012b1042],
8	the	DT	O	the	det	9	SENT_111	[p9l2035t979r2141b1042],
9	context	NN	O	context	dep	4	SENT_111	[p9l9t1093r263b1144],
10	of	IN	O	of	_	0	SENT_111	[p9l286t1081r360b1144],
11	randomized	VBN	O	randomize	prepc_of	9	SENT_111	[p9l374t1081r793b1144],
12	clinical	JJ	O	clinical	amod	13	SENT_111	[p9l815t1081r1063b1144],
13	trials	NNS	O	trial	dobj	11	SENT_111	[p9l1084t1081r1257b1144],
14	in	IN	O	in	_	0	SENT_111	[p9l1281t1086r1348b1143],
15	which	WDT	O	which	rel	31	SENT_111	[p9l1369t1081r1580b1144],
16	the	DT	O	the	det	17	SENT_111	[p9l1602t1081r1709b1144],
17	detection	NN	O	detection	nsubjpass	31	SENT_111	[p9l1733t1081r2055b1144],
18	of	IN	O	of	_	0	SENT_111	[p9l2078t1081r2153b1144],
19	particular	JJ	O	particular	amod	21	SENT_111	[p9l7t1184r340b1267],
20	molecular	JJ	O	molecular	amod	21	SENT_111	[p9l358t1184r698b1247],
21	biomarkers	NNS	O	biomarker	prep_of	17	SENT_111	[p9l714t1184r1095b1247],
22	by	IN	O	by	_	0	SENT_111	[p9l1114t1184r1196b1268],
23	means	NNS	O	means	_	0	SENT_111	[p9l1213t1207r1428b1247],
24	of	IN	O	of	_	0	SENT_111	[p9l1449t1184r1522b1247],
25	a	DT	O	a	det	27	SENT_111	[p9l1533t1207r1566b1247],
26	particular	JJ	O	particular	amod	27	SENT_111	[p9l1584t1184r1917b1267],
27	methodology	NN	O	methodology	prep_by_means_of	21	SENT_111	[p9l1935t1184r2139b1247, p9l9t1287r286b1371],
28	can	MD	O	can	aux	31	SENT_111	[p9l303t1310r419b1350],
29	be	VB	O	be	auxpass	31	SENT_111	[p9l437t1287r515b1350],
30	clearly	RB	O	clearly	advmod	31	SENT_111	[p9l536t1287r757b1371],
31	linked	VBN	O	link	rcmod	13	SENT_111	[p9l772t1287r985b1350],
32	to	TO	O	to	_	0	SENT_111	[p9l1003t1299r1068b1350],
33	patient	NN	O	patient	nn	34	SENT_111	[p9l1089t1292r1324b1370],
34	outcome	NN	O	outcome	prep_to	31	SENT_111	[p9l1344t1299r1652b1350],
35	.	.	O	.	_	0	SENT_111	[p9l1344t1299r1652b1350],

1	In	IN	O	in	_	0	SENT_112	[p9l1676t1292r1746b1349],
2	this	DT	O	this	det	3	SENT_112	[p9l1765t1287r1887b1350],
3	regard	NN	O	regard	prep_in	14	SENT_112	[p9l1908t1287r2140b1371],
4	,	,	O	,	_	0	SENT_112	[p9l1908t1287r2140b1371],
5	emerging	VBG	O	emerge	amod	6	SENT_112	[p9l9t1396r342b1475],
6	data	NNS	O	datum	nsubj	14	SENT_112	[p9l366t1391r513b1454],
7	on	IN	O	on	_	0	SENT_112	[p9l537t1414r625b1454],
8	subgroup	NN	O	subgroup	nn	9	SENT_112	[p9l651t1391r980b1475],
9	analysis	NN	O	analysis	prep_on	6	SENT_112	[p9l1006t1391r1279b1475],
10	in	IN	O	in	_	0	SENT_112	[p9l1305t1396r1373b1453],
11	retrospective	JJ	O	retrospective	amod	12	SENT_112	[p9l1397t1396r1854b1474],
12	cohorts	NNS	O	cohort	prep_in	9	SENT_112	[p9l1879t1391r2142b1454],
13	have	VBP	O	have	aux	14	SENT_112	[p9l7t1494r162b1557],
14	shown	VBN	O	show	_	0	SENT_112	[p9l186t1494r407b1557],
15	different	JJ	O	different	amod	16	SENT_112	[p9l430t1494r719b1557],
16	mutations	NNS	O	mutation	nsubj	24	SENT_112	[p9l740t1499r1084b1557],
17	in	IN	O	in	_	0	SENT_112	[p9l1107t1499r1173b1556],
18	particular	JJ	O	particular	amod	19	SENT_112	[p9l1194t1494r1533b1577],
19	genes	NNS	O	gene	prep_in	16	SENT_112	[p9l1554t1517r1741b1578],
20	may	MD	O	may	aux	24	SENT_112	[p9l1763t1517r1910b1578],
21	not	RB	O	not	neg	24	SENT_112	[p9l1928t1506r2042b1557],
22	all	DT	O	all	advmod	24	SENT_112	[p9l2064t1494r2142b1557],
23	be	VB	O	be	cop	24	SENT_112	[p9l6t1597r88b1660],
24	identical	JJ	O	identical	ccomp	14	SENT_112	[p9l112t1597r417b1660],
25	with	IN	O	with	_	0	SENT_112	[p9l438t1597r596b1660],
26	respect	NN	O	respect	prep_with	24	SENT_112	[p9l620t1609r871b1680],
27	to	TO	O	to	_	0	SENT_112	[p9l892t1609r960b1660],
28	response	NN	O	response	nn	31	SENT_112	[p9l986t1619r1295b1680],
29	and	CC	O	and	_	0	SENT_112	[p9l1320t1597r1449b1660],
30	outcome	NN	O	outcome	conj_and	28	SENT_112	[p9l1474t1609r1778b1660],
31	data	NNS	O	datum	prep_to	24	SENT_112	[p9l1804t1597r1968b1660],
32	.	.	O	.	_	0	SENT_112	[p9l1804t1597r1968b1660],

1	This	DT	O	this	nsubjpass	3	SENT_113	[p9l1995t1597r2142b1660],
2	is	VBZ	O	be	auxpass	3	SENT_113	[p9l8t1705r58b1763],
3	exempliﬁed	VBN	O	exempliﬁed	_	0	SENT_113	[p9l83t1700r482b1783],
4	by	IN	O	by	_	0	SENT_113	[p9l502t1700r587b1784],
5	recent	JJ	O	recent	amod	6	SENT_113	[p9l606t1712r818b1763],
6	data	NNS	O	datum	agent	3	SENT_113	[p9l839t1700r984b1763],
7	in	IN	O	in	_	0	SENT_113	[p9l1006t1705r1072b1762],
8	colorectal	JJ	O	colorectal	amod	9	SENT_113	[p9l1096t1700r1431b1763],
9	cancer	NN	O	cancer	prep_in	6	SENT_113	[p9l1454t1723r1678b1763],
10	showing	VBG	O	show	xcomp	3	SENT_113	[p9l1701t1700r1988b1784],
11	that	IN	O	that	complm	16	SENT_113	[p9l2009t1700r2143b1763],
12	KRAS	NNP	ORGANIZATION	KRAS	nn	15	SENT_113	[p9l7t1807r212b1866],
13	p.	NN	O	p.	nn	15	SENT_113	[p9l233t1807r501b1886],
14	G13D	NN	O	g13d	nn	15	SENT_113	[p9l233t1807r501b1886],
15	mutations	NNS	O	mutation	nsubj	16	SENT_113	[p9l525t1808r872b1866],
16	seem	VBP	O	seem	ccomp	10	SENT_113	[p9l896t1826r1070b1866],
17	to	TO	O	to	aux	18	SENT_113	[p9l1091t1815r1158b1866],
18	have	VB	O	have	xcomp	16	SENT_113	[p9l1180t1803r1337b1866],
19	less	JJR	O	less	amod	20	SENT_113	[p9l1359t1803r1477b1866],
20	impact	NN	O	impact	dobj	18	SENT_113	[p9l1501t1808r1739b1886],
21	than	IN	O	than	_	0	SENT_113	[p9l1760t1803r1915b1866],
22	KRAS	NNP	ORGANIZATION	KRAS	nn	23	SENT_113	[p9l1937t1807r2142b1866],
23	codon	NN	O	codon	prep_than	18	SENT_113	[p9l9t1906r228b1969],
24	12	CD	NUMBER	12	num	25	SENT_113	[p9l260t1913r333b1968],
25	mutations	NNS	O	mutation	tmod	16	SENT_113	[p9l359t1911r714b1969],
26	in	IN	O	in	_	0	SENT_113	[p9l740t1911r808b1968],
27	determining	VBG	O	determine	prepc_in	25	SENT_113	[p9l834t1906r1274b1990],
28	resistance	NN	O	resistance	dobj	27	SENT_113	[p9l1297t1911r1642b1969],
29	to	TO	O	to	_	0	SENT_113	[p9l1666t1918r1733b1969],
30	anti	JJ	O	anti	prep_to	27	SENT_113	[p9l1761t1910r2145b1969],
31	.	.	O	.	_	0	SENT_113	[p9l1761t1910r2145b1969],

1	—	NN	O	—	_	0	SENT_114	[p9l1761t1910r2145b1969],
2	.	.	O	.	_	0	SENT_114	[p9l1761t1910r2145b1969],

1	EGFR	NN	ORGANIZATION	egfr	dep	137	SENT_115	[p9l1761t1910r2145b1969],
2	antibody	NN	O	antibody	dep	137	SENT_115	[p9l9t2008r307b2092],
3	therapy	NN	O	therapy	dep	137	SENT_115	[p9l322t2000r647b2092],
4	.40	CD	NUMBER	.40	dep	137	SENT_115	[p9l322t2000r647b2092],
5	Similarly	RB	O	similarly	dep	137	SENT_115	[p9l668t2008r976b2092],
6	,	,	O	,	_	0	SENT_115	[p9l668t2008r976b2092],
7	in	IN	O	in	dep	137	SENT_115	[p9l997t2013r1062b2070],
8	gastrointestinal	JJ	O	gastrointestinal	dep	137	SENT_115	[p9l1081t2008r1593b2092],
9	stromal	JJ	O	stromal	dep	137	SENT_115	[p9l1613t2008r1865b2071],
10	tumors	NNS	O	tumor	dep	137	SENT_115	[p9l1883t2020r2140b2080],
11	,	,	O	,	_	0	SENT_115	[p9l1883t2020r2140b2080],
12	mutations	NNS	O	mutation	dep	137	SENT_115	[p9l8t2116r358b2174],
13	in	IN	O	in	dep	137	SENT_115	[p9l382t2116r449b2173],
14	exon	NN	O	exon	dep	137	SENT_115	[p9l473t2134r638b2174],
15	11	CD	NUMBER	11	dep	137	SENT_115	[p9l668t2118r735b2173],
16	of	IN	O	of	dep	137	SENT_115	[p9l766t2111r840b2174],
17	the	DT	O	the	dep	137	SENT_115	[p9l853t2111r961b2174],
18	KIT	NN	O	kit	dep	137	SENT_115	[p9l983t2114r1127b2173],
19	gene	NN	O	gene	dep	137	SENT_115	[p9l1143t2134r1301b2195],
20	are	VBP	O	be	dep	137	SENT_115	[p9l1326t2134r1427b2174],
21	generally	RB	O	generally	dep	137	SENT_115	[p9l1451t2111r1770b2195],
22	associated	VBN	O	associate	dep	137	SENT_115	[p9l1790t2111r2143b2174],
23	with	IN	O	with	dep	137	SENT_115	[p9l7t2214r159b2277],
24	good	JJ	O	good	dep	137	SENT_115	[p9l182t2214r354b2298],
25	response	NN	O	response	dep	137	SENT_115	[p9l376t2236r675b2297],
26	and	CC	O	and	dep	137	SENT_115	[p9l699t2214r825b2277],
27	increased	VBD	O	increase	dep	137	SENT_115	[p9l847t2214r1172b2277],
28	survival	NN	O	survival	dep	137	SENT_115	[p9l1195t2214r1466b2277],
29	at	IN	O	at	dep	137	SENT_115	[p9l1488t2226r1548b2277],
30	a	DT	O	a	dep	137	SENT_115	[p9l1569t2237r1604b2277],
31	400	CD	NUMBER	400	dep	137	SENT_115	[p9l1624t2221r1745b2277],
32	mg	NN	O	mg	dep	137	SENT_115	[p9l1768t2237r1877b2298],
33	dose	NN	O	dose	dep	137	SENT_115	[p9l1899t2214r2053b2277],
34	of	IN	O	of	dep	137	SENT_115	[p9l2076t2214r2150b2277],
35	imatinib	NN	O	imatinib	dep	137	SENT_115	[p9l8t2317r312b2389],
36	,	,	O	,	_	0	SENT_115	[p9l8t2317r312b2389],
37	whereas	IN	O	whereas	dep	137	SENT_115	[p9l332t2317r608b2380],
38	mutations	NNS	O	mutation	dep	137	SENT_115	[p9l629t2322r971b2380],
39	in	IN	O	in	dep	137	SENT_115	[p9l992t2322r1058b2379],
40	exon	NN	O	exon	dep	137	SENT_115	[p9l1079t2340r1241b2380],
41	9	CD	NUMBER	9	dep	137	SENT_115	[p9l1262t2324r1297b2380],
42	of	IN	O	of	dep	137	SENT_115	[p9l1319t2317r1393b2380],
43	the	DT	O	the	dep	137	SENT_115	[p9l1403t2317r1508b2380],
44	same	JJ	O	same	dep	137	SENT_115	[p9l1530t2340r1701b2380],
45	gene	NN	O	gene	dep	137	SENT_115	[p9l1721t2340r1876b2401],
46	require	VBP	O	require	dep	137	SENT_115	[p9l1897t2322r2140b2400],
47	either	CC	O	either	dep	137	SENT_115	[p9l9t2420r205b2483],
48	a	DT	O	a	dep	137	SENT_115	[p9l228t2443r262b2483],
49	higher	JJR	O	higher	dep	137	SENT_115	[p9l282t2420r505b2504],
50	dose	NN	O	dose	dep	137	SENT_115	[p9l526t2420r680b2483],
51	of	IN	O	of	dep	137	SENT_115	[p9l703t2420r777b2483],
52	imatinib	NN	O	imatinib	dep	137	SENT_115	[p9l789t2420r1078b2483],
53	(	NN	O	(	dep	137	SENT_115	[p9l1105t2421r1250b2496],
54	600	CD	NUMBER	600	dep	137	SENT_115	[p9l1105t2421r1250b2496],
55	mg	NN	O	mg	dep	137	SENT_115	[p9l1266t2443r1375b2504],
56	or	CC	O	or	dep	137	SENT_115	[p9l1396t2443r1467b2483],
57	800	CD	NUMBER	800	dep	137	SENT_115	[p9l1489t2427r1608b2483],
58	mg	NN	O	mg	dep	137	SENT_115	[p9l1623t2421r1756b2504],
59	)	NN	O	)	dep	137	SENT_115	[p9l1623t2421r1756b2504],
60	or	CC	O	or	dep	137	SENT_115	[p9l1783t2443r1855b2483],
61	a	DT	O	a	dep	137	SENT_115	[p9l1876t2443r1911b2483],
62	different	JJ	O	different	dep	137	SENT_115	[p9l1932t2420r2138b2483, p9l9t2534r114b2585],
63	TKI	NN	O	tkus	dep	137	SENT_115	[p9l135t2525r271b2584],
64	such	JJ	O	such	dep	137	SENT_115	[p9l295t2522r450b2585],
65	as	IN	O	as	dep	137	SENT_115	[p9l473t2545r537b2585],
66	sunitinib	NN	O	sunitinib	dep	137	SENT_115	[p9l561t2522r865b2585],
67	to	TO	O	to	dep	137	SENT_115	[p9l887t2534r953b2585],
68	achieve	VB	O	achieve	dep	137	SENT_115	[p9l977t2522r1229b2585],
69	a	DT	O	a	dep	137	SENT_115	[p9l1252t2545r1286b2585],
70	signiﬁcant	JJ	O	signiﬁcant	dep	137	SENT_115	[p9l1309t2522r1663b2606],
71	response	NN	O	response	dep	137	SENT_115	[p9l1684t2514r2141b2605],
72	/	:	O	/	dep	137	SENT_115	[p9l1684t2514r2141b2605],
73	“	CD	NUMBER	“	dep	137	SENT_115	[p9l1684t2514r2141b2605],
74	>	JJR	O	>	dep	137	SENT_115	[p9l1684t2514r2141b2605],
75	42	CD	NUMBER	42	dep	137	SENT_115	[p9l1684t2514r2141b2605],
76	This	DT	O	this	dep	137	SENT_115	[p9l8t2625r155b2688],
77	troublesome	JJ	O	troublesome	dep	137	SENT_115	[p9l179t2625r621b2688],
78	clinical	JJ	O	clinical	dep	137	SENT_115	[p9l647t2625r901b2688],
79	issue	NN	O	issue	dep	137	SENT_115	[p9l925t2630r1094b2688],
80	is	VBZ	O	be	dep	137	SENT_115	[p9l1119t2630r1171b2688],
81	not	RB	O	not	dep	137	SENT_115	[p9l1196t2637r1313b2688],
82	made	VBN	O	make	dep	137	SENT_115	[p9l1337t2625r1529b2688],
83	any	DT	O	any	dep	137	SENT_115	[p9l1555t2648r1679b2709],
84	easier	JJR	O	easier	dep	137	SENT_115	[p9l1701t2630r1903b2688],
85	by	IN	O	by	dep	137	SENT_115	[p9l1924t2625r2010b2709],
86	the	DT	O	the	dep	137	SENT_115	[p9l2031t2625r2140b2688],
87	imprecise	JJ	O	imprecise	dep	137	SENT_115	[p9l8t2733r329b2811],
88	and	CC	O	and	dep	137	SENT_115	[p9l350t2728r473b2791],
89	biologically	RB	O	biologically	dep	137	SENT_115	[p9l489t2728r878b2812],
90	ambiguous	JJ	O	ambiguous	dep	137	SENT_115	[p9l895t2728r1260b2812],
91	labeling	NN	O	labeling	dep	137	SENT_115	[p9l1279t2728r1544b2812],
92	of	IN	O	of	dep	137	SENT_115	[p9l1562t2728r1635b2791],
93	targeted	VBN	O	target	dep	137	SENT_115	[p9l1644t2728r1915b2812],
94	drugs	NNS	O	drug	dep	137	SENT_115	[p9l1934t2728r2139b2812],
95	,	,	O	,	_	0	SENT_115	[p9l1934t2728r2139b2812],
96	involving	VBG	O	involve	dep	137	SENT_115	[p9l8t2831r329b2915],
97	the	DT	O	the	dep	137	SENT_115	[p9l348t2831r454b2894],
98	use	NN	O	use	dep	137	SENT_115	[p9l475t2854r586b2894],
99	of	IN	O	of	dep	137	SENT_115	[p9l608t2831r681b2894],
100	generic	JJ	O	generic	dep	137	SENT_115	[p9l693t2836r941b2915],
101	terms	NNS	O	term	dep	137	SENT_115	[p9l962t2843r1155b2894],
102	such	JJ	O	such	dep	137	SENT_115	[p9l1178t2831r1332b2894],
103	as	IN	O	as	dep	137	SENT_115	[p9l1354t2854r1418b2894],
104	“	NN	O	“	dep	137	SENT_115	[p9l1441t2831r1845b2894],
105	mutations	NNS	O	mutation	dep	137	SENT_115	[p9l1441t2831r1845b2894],
106	”	CD	NUMBER	”	dep	137	SENT_115	[p9l1441t2831r1845b2894],
107	or	CC	O	or	dep	137	SENT_115	[p9l1869t2854r1941b2894],
108	“	CD	NUMBER	“	dep	137	SENT_115	[p9l1962t2831r2138b2894, p9l6t2939r219b3018],
109	activating	VBG	O	activate	dep	137	SENT_115	[p9l1962t2831r2138b2894, p9l6t2939r219b3018],
110	mutations	NNS	O	mutation	dep	137	SENT_115	[p9l239t2934r613b2997],
111	”	CD	NUMBER	”	dep	137	SENT_115	[p9l239t2934r613b2997],
112	instead	RB	O	instead	dep	137	SENT_115	[p9l636t2934r880b2997],
113	of	IN	O	of	dep	137	SENT_115	[p9l901t2934r975b2997],
114	a	DT	O	a	dep	137	SENT_115	[p9l987t2957r1021b2997],
115	deﬁned	JJ	O	deﬁned	dep	137	SENT_115	[p9l1042t2934r1297b2997],
116	list	NN	O	list	dep	137	SENT_115	[p9l1316t2934r1417b2997],
117	of	IN	O	of	dep	137	SENT_115	[p9l1438t2934r1511b2997],
118	speciﬁc	NN	O	speciﬁc	dep	137	SENT_115	[p9l1524t2934r1776b3017],
119	mutations	NNS	O	mutation	dep	137	SENT_115	[p9l1797t2939r2141b2997],
120	that	WDT	O	that	dep	137	SENT_115	[p9l7t3037r147b3100],
121	have	VBP	O	have	dep	137	SENT_115	[p9l173t3037r334b3100],
122	been	VBN	O	be	dep	137	SENT_115	[p9l360t3037r531b3100],
123	proven	VBN	O	prove	dep	137	SENT_115	[p9l557t3059r806b3120],
124	beyond	IN	O	beyond	dep	137	SENT_115	[p9l832t3037r1099b3121],
125	signiﬁcant	JJ	O	signiﬁcant	dep	137	SENT_115	[p9l1126t3037r1498b3121],
126	uncertainty	NN	O	uncertainty	dep	137	SENT_115	[p9l1525t3042r1943b3121],
127	to	TO	O	to	dep	137	SENT_115	[p9l1965t3049r2033b3100],
128	be	VB	O	be	dep	137	SENT_115	[p9l2060t3037r2142b3100],
129	associated	VBN	O	associate	dep	137	SENT_115	[p9l9t3140r364b3203],
130	with	IN	O	with	dep	137	SENT_115	[p9l384t3140r540b3203],
131	increased	VBN	O	increase	dep	137	SENT_115	[p9l563t3140r894b3203],
132	or	CC	O	or	dep	137	SENT_115	[p9l917t3163r990b3203],
133	decreased	VBN	O	decrease	dep	137	SENT_115	[p9l1013t3140r1356b3203],
134	response	NN	O	response	dep	137	SENT_115	[p9l1379t3162r1684b3223],
135	to	TO	O	to	dep	137	SENT_115	[p9l1706t3152r1774b3203],
136	particular	JJ	O	particular	dep	137	SENT_115	[p9l1797t3140r2143b3223],
137	therapies	NNS	O	therapy	_	0	SENT_115	[p9l7t3243r334b3326],
138	.	.	O	.	_	0	SENT_115	[p9l7t3243r334b3326],

1	With	IN	O	with	mark	11	SENT_116	[p9l80t3346r253b3409],
2	the	DT	O	the	det	3	SENT_116	[p9l273t3346r379b3409],
3	availability	NN	O	availability	nsubj	11	SENT_116	[p9l402t3346r775b3430],
4	of	IN	O	of	_	0	SENT_116	[p9l794t3346r868b3409],
5	increasing	VBG	O	increase	amod	6	SENT_116	[p9l880t3351r1232b3430],
6	numbers	NNS	O	number	prep_of	3	SENT_116	[p9l1252t3346r1553b3409],
7	of	IN	O	of	_	0	SENT_116	[p9l1575t3346r1649b3409],
8	novel	JJ	O	novel	dep	9	SENT_116	[p9l1661t3346r1844b3409],
9	targeted	VBN	O	target	amod	10	SENT_116	[p9l1865t3346r2143b3430],
10	drugs	NNS	O	drug	prep_of	6	SENT_116	[p9l9t3449r205b3533],
11	approved	VBD	O	approve	advcl	33	SENT_116	[p9l231t3449r556b3532],
12	in	IN	O	in	_	0	SENT_116	[p9l580t3454r647b3511],
13	the	DT	O	the	det	15	SENT_116	[p9l671t3449r780b3512],
14	ﬁrst-line	JJ	O	ﬁrst-line	amod	15	SENT_116	[p9l804t3449r1104b3512],
15	setting	NN	O	setting	prep_in	11	SENT_116	[p9l1130t3454r1365b3533],
16	as	RB	O	as	_	0	SENT_116	[p9l1389t3472r1454b3512],
17	well	RB	O	well	_	0	SENT_116	[p9l1478t3449r1618b3512],
18	as	IN	O	as	_	0	SENT_116	[p9l1643t3472r1708b3512],
19	experimental	JJ	O	experimental	amod	20	SENT_116	[p9l1735t3454r2138b3532, p9l7t3552r95b3615],
20	drugs	NNS	O	drug	prep_in	11	SENT_116	[p9l120t3552r317b3636],
21	in	IN	O	in	_	0	SENT_116	[p9l343t3557r411b3614],
22	phase	NN	O	phase	prep_in	11	SENT_116	[p9l435t3552r635b3635],
23	I	CD	NUMBER	i	num	22	SENT_116	[p9l661t3557r706b3624],
24	,	,	O	,	_	0	SENT_116	[p9l661t3557r706b3624],
25	II	CD	NUMBER	ii	prep_in	11	SENT_116	[p9l733t3557r808b3624],
26	,	,	O	,	_	0	SENT_116	[p9l733t3557r808b3624],
27	and	CC	O	and	_	0	SENT_116	[p9l835t3552r965b3615],
28	III	NNP	O	III	nn	30	SENT_116	[p9l990t3557r1075b3614],
29	clinical	JJ	O	clinical	amod	30	SENT_116	[p9l1102t3552r1356b3615],
30	trials	NNS	O	trial	conj_and	22	SENT_116	[p9l1379t3552r1577b3624],
31	,	,	O	,	_	0	SENT_116	[p9l1379t3552r1577b3624],
32	there	EX	O	there	expl	33	SENT_116	[p9l1602t3552r1782b3615],
33	is	VBZ	O	be	_	0	SENT_116	[p9l1808t3557r1859b3615],
34	now	RB	DATE	now	advmod	33	SENT_116	[p9l1884t3575r2036b3615],
35	an	DT	O	a	det	37	SENT_116	[p9l2059t3575r2140b3615],
36	emerging	VBG	O	emerge	amod	37	SENT_116	[p9l9t3660r338b3739],
37	need	NN	O	need	nsubj	33	SENT_116	[p9l358t3655r525b3718],
38	to	TO	O	to	aux	39	SENT_116	[p9l545t3667r612b3718],
39	move	VB	O	move	infmod	37	SENT_116	[p9l635t3678r822b3718],
40	away	RB	O	away	_	0	SENT_116	[p9l846t3678r1019b3739],
41	from	IN	O	from	_	0	SENT_116	[p9l1037t3655r1207b3718],
42	single-biomarker	JJ	O	single-biomarker	amod	43	SENT_116	[p9l1230t3655r1830b3739],
43	analysis	NN	O	analysis	prep_away_from	39	SENT_116	[p9l1851t3655r2140b3739],
44	.	.	O	.	_	0	SENT_116	[p9l1851t3655r2140b3739],

1	It	PRP	O	it	nsubj	3	SENT_117	[p10l9t21r58b79],
2	is	VBZ	O	be	cop	3	SENT_117	[p10l79t21r130b79],
3	necessary	JJ	O	necessary	_	0	SENT_117	[p10l152t39r498b100],
4	,	,	O	,	_	0	SENT_117	[p10l152t39r498b100],
5	instead	RB	O	instead	advmod	3	SENT_117	[p10l522t16r787b88],
6	,	,	O	,	_	0	SENT_117	[p10l522t16r787b88],
7	to	TO	O	to	aux	8	SENT_117	[p10l809t28r875b79],
8	perform	VB	O	perform	xcomp	3	SENT_117	[p10l897t16r1184b99],
9	“	CD	NUMBER	“	num	12	SENT_117	[p10l1207t16r1425b99],
10	panel	NN	O	panel	nn	12	SENT_117	[p10l1207t16r1425b99],
11	testing	NN	O	testing	nn	12	SENT_117	[p10l1446t16r1708b100],
12	”	NN	O	”	dobj	8	SENT_117	[p10l1446t16r1708b100],
13	for	IN	O	for	_	0	SENT_117	[p10l1732t16r1831b79],
14	a	DT	O	a	det	15	SENT_117	[p10l1852t39r1886b79],
15	variety	NN	O	variety	prep_for	8	SENT_117	[p10l1904t21r2146b100],
16	of	IN	O	of	_	0	SENT_117	[p10l9t119r83b182],
17	potentially	RB	O	potentially	advmod	18	SENT_117	[p10l94t119r467b203],
18	actionable	JJ	O	actionable	amod	19	SENT_117	[p10l486t119r838b182],
19	biomarkers	NNS	O	biomarker	prep_of	15	SENT_117	[p10l858t119r1248b182],
20	on	IN	O	on	_	0	SENT_117	[p10l1271t142r1357b182],
21	which	WDT	O	which	rel	28	SENT_117	[p10l1377t119r1587b182],
22	selection	NN	O	selection	nsubjpass	28	SENT_117	[p10l1609t119r1912b182],
23	of	IN	O	of	_	0	SENT_117	[p10l1934t119r2008b182],
24	targeted	VBN	O	target	amod	25	SENT_117	[p10l2019t131r2139b182, p10l8t221r194b305],
25	therapies	NNS	O	therapy	prep_of	22	SENT_117	[p10l216t221r533b304],
26	may	MD	O	may	aux	28	SENT_117	[p10l557t244r706b305],
27	be	VB	O	be	auxpass	28	SENT_117	[p10l724t221r804b284],
28	based	VBN	O	base	rcmod	15	SENT_117	[p10l827t213r1107b284],
29	.43	CD	NUMBER	.43	dobj	28	SENT_117	[p10l827t213r1107b284],
30	Although	IN	O	although	mark	35	SENT_117	[p10l1133t221r1465b305],
31	the	DT	O	the	det	33	SENT_117	[p10l1488t221r1596b284],
32	initial	JJ	O	initial	amod	33	SENT_117	[p10l1621t221r1826b284],
33	assumption	NN	O	assumption	nsubj	35	SENT_117	[p10l1850t244r2139b304, p10l7t329r152b387],
34	may	MD	O	may	aux	35	SENT_117	[p10l179t347r332b408],
35	be	VB	O	be	advcl	52	SENT_117	[p10l354t324r436b387],
36	that	IN	O	that	complm	41	SENT_117	[p10l463t324r604b387],
37	such	PDT	O	such	predet	39	SENT_117	[p10l631t324r794b387],
38	a	DT	O	a	det	39	SENT_117	[p10l822t347r857b387],
39	strategy	NN	O	strategy	nsubj	41	SENT_117	[p10l884t336r1171b408],
40	would	MD	O	would	aux	41	SENT_117	[p10l1193t324r1418b387],
41	increase	VB	O	increase	ccomp	35	SENT_117	[p10l1445t329r1739b387],
42	the	DT	O	the	det	43	SENT_117	[p10l1765t324r1877b387],
43	cost	NN	O	cost	dobj	41	SENT_117	[p10l1905t336r2048b387],
44	of	IN	O	of	_	0	SENT_117	[p10l2075t324r2152b387],
45	diagnostics	NNS	O	diagnostic	prep_of	43	SENT_117	[p10l9t427r434b511],
46	,	,	O	,	_	0	SENT_117	[p10l9t427r434b511],
47	a	DT	O	a	det	49	SENT_117	[p10l463t450r498b490],
48	reasonable	JJ	O	reasonable	amod	49	SENT_117	[p10l523t427r906b490],
49	argument	NN	O	argument	nsubjpass	52	SENT_117	[p10l934t439r1280b511],
50	may	MD	O	may	aux	52	SENT_117	[p10l1305t450r1458b511],
51	be	VB	O	be	auxpass	52	SENT_117	[p10l1478t427r1560b490],
52	made	VBN	O	make	rcmod	29	SENT_117	[p10l1587t427r1801b499],
53	,	,	O	,	_	0	SENT_117	[p10l1587t427r1801b499],
54	from	IN	O	from	_	0	SENT_117	[p10l1829t427r2004b490],
55	the	DT	O	the	det	58	SENT_117	[p10l2029t427r2140b490],
56	health	NN	O	health	nn	58	SENT_117	[p10l7t530r226b593],
57	economics	NNS	O	economics	nn	58	SENT_117	[p10l251t535r625b593],
58	viewpoint	NN	O	viewpoint	prep_from	52	SENT_117	[p10l647t535r1019b613],
59	,	,	O	,	_	0	SENT_117	[p10l647t535r1019b613],
60	that	IN	O	that	complm	66	SENT_117	[p10l1045t530r1182b593],
61	this	DT	DATE	this	nsubj	66	SENT_117	[p10l1205t530r1332b593],
62	may	MD	DATE	may	aux	66	SENT_117	[p10l1358t553r1507b614],
63	not	RB	O	not	neg	66	SENT_117	[p10l1528t542r1644b593],
64	be	VB	O	be	cop	66	SENT_117	[p10l1666t530r1746b593],
65	the	DT	O	the	det	66	SENT_117	[p10l1770t530r1879b593],
66	case	NN	O	case	ccomp	52	SENT_117	[p10l1905t553r2047b593],
67	in	IN	O	in	_	0	SENT_117	[p10l2072t535r2140b592],
68	terms	NNS	O	term	prep_in	66	SENT_117	[p10l7t644r204b695],
69	of	IN	O	of	_	0	SENT_117	[p10l229t632r303b695],
70	cost-effectiveness	NN	O	cost-effectiveness	prep_of	68	SENT_117	[p10l317t632r925b695],
71	overall	NN	O	overall	advmod	28	SENT_117	[p10l950t632r1200b695],
72	.	.	O	.	_	0	SENT_117	[p10l950t632r1200b695],

1	First	RB	ORDINAL	first	advmod	5	SENT_118	[p10l83t740r261b807],
2	,	,	O	,	_	0	SENT_118	[p10l83t740r261b807],
3	it	PRP	O	it	nsubj	5	SENT_118	[p10l288t740r335b798],
4	is	VBZ	O	be	cop	5	SENT_118	[p10l359t740r411b798],
5	important	JJ	O	important	_	0	SENT_118	[p10l437t740r797b818],
6	to	TO	O	to	aux	7	SENT_118	[p10l820t747r887b798],
7	keep	VB	O	keep	xcomp	5	SENT_118	[p10l912t735r1075b818],
8	in	IN	O	in	_	0	SENT_118	[p10l1102t740r1170b797],
9	mind	NN	O	mind	prep_in	7	SENT_118	[p10l1195t735r1384b798],
10	the	DT	O	the	det	11	SENT_118	[p10l1407t735r1517b798],
11	requirement	NN	O	requirement	dobj	7	SENT_118	[p10l1543t740r1982b818],
12	that	WDT	O	that	dobj	20	SENT_118	[p10l2005t735r2144b798],
13	patients	NNS	O	patient	nsubjpass	20	SENT_118	[p10l7t843r285b921],
14	with	IN	O	with	_	0	SENT_118	[p10l308t838r465b901],
15	advanced	JJ	O	advanced	amod	17	SENT_118	[p10l490t838r823b901],
16	metastatic	JJ	O	metastatic	amod	17	SENT_118	[p10l846t843r1207b901],
17	disease	NN	O	disease	prep_with	13	SENT_118	[p10l1232t838r1479b901],
18	must	MD	O	must	aux	20	SENT_118	[p10l1504t850r1679b901],
19	be	VB	O	be	auxpass	20	SENT_118	[p10l1700t838r1781b901],
20	treated	VBN	O	treat	rcmod	11	SENT_118	[p10l1805t838r2051b901],
21	as	RB	O	as	advmod	22	SENT_118	[p10l2075t861r2141b901],
22	early	RB	O	early	advmod	20	SENT_118	[p10l9t941r174b1025],
23	as	IN	O	as	_	0	SENT_118	[p10l191t964r255b1004],
24	possible	JJ	O	possible	prep_as	20	SENT_118	[p10l275t941r565b1024],
25	:	:	O	:	_	0	SENT_118	[p10l275t941r565b1024],
26	assuming	VBG	O	assume	partmod	63	SENT_118	[p10l589t946r911b1025],
27	an	DT	O	a	det	30	SENT_118	[p10l931t964r1010b1004],
28	average	JJ	O	average	amod	30	SENT_118	[p10l1031t964r1283b1025],
29	turnaround	NN	O	turnaround	nn	30	SENT_118	[p10l1303t941r1699b1004],
30	time	NN	O	time	dobj	26	SENT_118	[p10l1717t946r1870b1004],
31	of	IN	O	of	_	0	SENT_118	[p10l1892t941r1965b1004],
32	7	CD	NUMBER	7	prep_of	30	SENT_118	[p10l1978t949r2056b1004],
33	-	:	O	-	_	0	SENT_118	[p10l1978t949r2056b1004],
34	10	CD	NUMBER	10	num	36	SENT_118	[p10l2069t948r2139b1004],
35	working	VBG	O	work	amod	36	SENT_118	[p10l7t1044r302b1128],
36	days	NNS	DURATION	day	dep	30	SENT_118	[p10l325t1044r478b1128],
37	for	IN	O	for	_	0	SENT_118	[p10l503t1044r603b1107],
38	a	DT	O	a	det	40	SENT_118	[p10l627t1067r662b1107],
39	diagnostic	JJ	O	diagnostic	amod	40	SENT_118	[p10l686t1044r1049b1128],
40	test	NN	O	test	prep_for	36	SENT_118	[p10l1073t1056r1213b1116],
41	,	,	O	,	_	0	SENT_118	[p10l1073t1056r1213b1116],
42	sequential	JJ	O	sequential	amod	43	SENT_118	[p10l1240t1044r1599b1127],
43	analysis	NN	O	analysis	nsubj	63	SENT_118	[p10l1623t1044r1896b1128],
44	of	IN	O	of	_	0	SENT_118	[p10l1922t1044r1998b1107],
45	two	CD	NUMBER	two	num	48	SENT_118	[p10l2011t1056r2140b1107],
46	clinically	RB	O	clinically	advmod	47	SENT_118	[p10l9t1147r317b1231],
47	actionable	JJ	O	actionable	amod	48	SENT_118	[p10l336t1147r685b1210],
48	biomarkers	NNS	O	biomarker	prep_of	43	SENT_118	[p10l705t1147r1092b1210],
49	in	IN	O	in	_	0	SENT_118	[p10l1115t1152r1181b1209],
50	the	DT	O	the	det	52	SENT_118	[p10l1201t1147r1307b1210],
51	same	JJ	O	same	amod	52	SENT_118	[p10l1330t1170r1501b1210],
52	specimen	NN	O	specimen	prep_in	48	SENT_118	[p10l1524t1152r1848b1230],
53	(	CD	NUMBER	(	num	52	SENT_118	[p10l1873t1147r2055b1224],
54	such	JJ	O	such	_	0	SENT_118	[p10l1873t1147r2055b1224],
55	as	IN	O	as	_	0	SENT_118	[p10l2077t1170r2141b1210],
56	EGFR	NN	ORGANIZATION	egfr	prep_such_as	52	SENT_118	[p10l6t1254r209b1313],
57	and	CC	O	and	_	0	SENT_118	[p10l231t1250r357b1313],
58	ALK	NN	O	alk	conj_and	56	SENT_118	[p10l374t1254r541b1312],
59	in	IN	O	in	_	0	SENT_118	[p10l555t1255r622b1312],
60	NSCLC	NNP	ORGANIZATION	NSCLC	nn	61	SENT_118	[p10l642t1250r931b1327],
61	)	NN	O	)	prep_in	56	SENT_118	[p10l642t1250r931b1327],
62	can	MD	O	can	aux	63	SENT_118	[p10l957t1273r1074b1313],
63	take	VB	O	take	parataxis	5	SENT_118	[p10l1094t1250r1236b1313],
64	up	RP	DURATION	up	prt	63	SENT_118	[p10l1257t1272r1342b1333],
65	to	TO	DURATION	to	_	0	SENT_118	[p10l1364t1262r1430b1313],
66	one	CD	DURATION	one	num	67	SENT_118	[p10l1453t1273r1575b1313],
67	month	NN	NUMBER	month	prep_to	63	SENT_118	[p10l1597t1250r1826b1313],
68	from	IN	O	from	_	0	SENT_118	[p10l1847t1250r2014b1313],
69	the	DT	O	the	det	70	SENT_118	[p10l2035t1250r2141b1313],
70	time	NN	O	time	prep_from	67	SENT_118	[p10l7t1358r158b1416],
71	of	IN	O	of	_	0	SENT_118	[p10l178t1353r251b1416],
72	referral	NN	O	referral	prep_of	70	SENT_118	[p10l261t1353r506b1416],
73	instead	RB	O	instead	_	0	SENT_118	[p10l525t1353r764b1416],
74	of	IN	O	of	_	0	SENT_118	[p10l784t1353r856b1416],
75	the	DT	DURATION	the	det	76	SENT_118	[p10l865t1353r969b1416],
76	one	CD	DURATION	one	prep_instead_of	72	SENT_118	[p10l990t1376r1109b1416],
77	to	TO	DURATION	to	_	0	SENT_118	[p10l1128t1365r1193b1416],
78	two	CD	DURATION	two	num	79	SENT_118	[p10l1213t1365r1335b1416],
79	weeks	NNS	NUMBER	week	prep_to	63	SENT_118	[p10l1354t1353r1554b1416],
80	required	VBN	O	require	partmod	79	SENT_118	[p10l1575t1353r1860b1436],
81	for	IN	O	for	_	0	SENT_118	[p10l1878t1353r1973b1416],
82	concomitant	JJ	O	concomitant	prep_for	80	SENT_118	[p10l1992t1376r2140b1416, p10l9t1461r316b1519],
83	or	CC	O	or	_	0	SENT_118	[p10l339t1479r411b1519],
84	panel	NN	O	panel	nn	85	SENT_118	[p10l431t1456r619b1539],
85	testing	NN	O	testing	conj_or	82	SENT_118	[p10l640t1461r886b1540],
86	.	.	O	.	_	0	SENT_118	[p10l640t1461r886b1540],

1	These	DT	O	these	det	3	SENT_119	[p10l912t1456r1107b1519],
2	waiting	VBG	O	wait	amod	3	SENT_119	[p10l1129t1461r1386b1540],
3	times	NNS	O	time	nsubj	9	SENT_119	[p10l1406t1461r1592b1519],
4	associated	VBN	O	associate	partmod	3	SENT_119	[p10l1617t1456r1967b1519],
5	with	IN	O	with	_	0	SENT_119	[p10l1987t1456r2141b1519],
6	sequential	JJ	O	sequential	amod	7	SENT_119	[p10l9t1559r364b1642],
7	analysis	NN	O	analysis	prep_with	4	SENT_119	[p10l388t1559r657b1643],
8	will	MD	O	will	aux	9	SENT_119	[p10l680t1559r809b1622],
9	increase	VB	O	increase	_	0	SENT_119	[p10l831t1564r1115b1622],
10	considerably	RB	O	considerably	advmod	9	SENT_119	[p10l1139t1559r1584b1643],
11	with	IN	O	with	_	0	SENT_119	[p10l1602t1559r1758b1622],
12	the	DT	O	the	det	13	SENT_119	[p10l1780t1559r1889b1622],
13	implementation	NN	O	implementation	prep_with	9	SENT_119	[p10l1912t1559r2138b1642, p10l8t1667r356b1725],
14	of	IN	O	of	_	0	SENT_119	[p10l377t1662r450b1725],
15	further	JJ	O	further	amod	17	SENT_119	[p10l460t1662r701b1725],
16	companion	NN	O	companion	nn	17	SENT_119	[p10l721t1667r1104b1745],
17	diagnostics	NNS	O	diagnostic	prep_of	13	SENT_119	[p10l1125t1662r1503b1746],
18	for	IN	O	for	_	0	SENT_119	[p10l1523t1662r1619b1725],
19	additional	JJ	O	additional	amod	21	SENT_119	[p10l1639t1662r1982b1725],
20	new	JJ	O	new	amod	21	SENT_119	[p10l2002t1685r2143b1725],
21	drugs	NNS	O	drug	prep_for	17	SENT_119	[p10l9t1765r219b1849],
22	;	:	O	;	_	0	SENT_119	[p10l9t1765r219b1849],
23	in	IN	O	in	_	0	SENT_119	[p10l243t1770r310b1827],
24	many	JJ	O	many	amod	25	SENT_119	[p10l332t1788r526b1849],
25	cases	NNS	O	case	prep_in	28	SENT_119	[p10l545t1788r715b1828],
26	this	DT	O	this	nsubj	28	SENT_119	[p10l738t1765r861b1828],
27	would	MD	O	would	aux	28	SENT_119	[p10l883t1765r1098b1828],
28	lead	VB	O	lead	parataxis	9	SENT_119	[p10l1118t1765r1259b1828],
29	to	TO	O	to	_	0	SENT_119	[p10l1280t1777r1345b1828],
30	urgent	JJ	O	urgent	amod	32	SENT_119	[p10l1369t1777r1592b1849],
31	treatment	NN	O	treatment	nn	32	SENT_119	[p10l1613t1777r1949b1828],
32	decisions	NNS	O	decision	prep_to	28	SENT_119	[p10l1971t1765r2137b1828, p10l9t1873r178b1931],
33	needing	VBG	O	need	partmod	32	SENT_119	[p10l199t1868r472b1952],
34	to	TO	O	to	aux	36	SENT_119	[p10l489t1880r555b1931],
35	be	VB	O	be	auxpass	36	SENT_119	[p10l574t1868r653b1931],
36	made	VBN	O	make	xcomp	33	SENT_119	[p10l673t1868r858b1931],
37	without	IN	O	without	_	0	SENT_119	[p10l877t1868r1143b1931],
38	a	DT	O	a	det	41	SENT_119	[p10l1163t1891r1197b1931],
39	complete	JJ	O	complete	amod	41	SENT_119	[p10l1217t1868r1524b1951],
40	molecular	JJ	O	molecular	amod	41	SENT_119	[p10l1544t1868r1886b1931],
41	picture	NN	O	picture	prep_without	36	SENT_119	[p10l1904t1873r2143b1951],
42	being	VBG	O	be	cop	43	SENT_119	[p10l6t1971r201b2055],
43	available	JJ	O	available	xcomp	36	SENT_119	[p10l224t1971r540b2034],
44	.	.	O	.	_	0	SENT_119	[p10l224t1971r540b2034],

1	It	PRP	O	it	nsubjpass	4	SENT_120	[p10l568t1976r618b2034],
2	can	MD	O	can	aux	4	SENT_120	[p10l640t1994r760b2034],
3	be	VB	O	be	auxpass	4	SENT_120	[p10l781t1971r861b2034],
4	argued	VBN	O	argue	_	0	SENT_120	[p10l886t1971r1125b2055],
5	that	IN	O	that	complm	10	SENT_120	[p10l1146t1971r1282b2034],
6	early	JJ	O	early	amod	8	SENT_120	[p10l1305t1971r1475b2055],
7	targeted	JJ	O	targeted	amod	8	SENT_120	[p10l1493t1971r1778b2055],
8	treatment	NN	O	treatment	nsubj	10	SENT_120	[p10l1799t1983r2142b2034],
9	should	MD	O	should	aux	10	SENT_120	[p10l9t2073r244b2136],
10	translate	VB	O	translate	ccomp	4	SENT_120	[p10l265t2073r564b2136],
11	into	IN	O	into	_	0	SENT_120	[p10l587t2078r724b2136],
12	better	JJR	O	better	amod	13	SENT_120	[p10l746t2073r952b2136],
13	outcomes	NNS	O	outcome	prep_into	10	SENT_120	[p10l974t2085r1308b2136],
14	with	IN	O	with	_	0	SENT_120	[p10l1330t2073r1486b2136],
15	increased	VBN	O	increase	amod	17	SENT_120	[p10l1509t2073r1841b2136],
16	survival	NN	O	survival	nn	17	SENT_120	[p10l1864t2073r2141b2136],
17	beneﬁt	NN	O	beneﬁt	prep_with	13	SENT_120	[p10l7t2617r256b2689],
18	,	,	O	,	_	0	SENT_120	[p10l7t2617r256b2689],
19	resulting	VBG	O	result	xcomp	4	SENT_120	[p10l278t2617r574b2701],
20	in	IN	O	in	_	0	SENT_120	[p10l593t2622r658b2679],
21	more	JJR	O	more	dep	22	SENT_120	[p10l678t2640r853b2680],
22	cost-effective	JJ	O	cost-effective	amod	23	SENT_120	[p10l874t2617r1317b2680],
23	treatment	NN	O	treatment	prep_in	19	SENT_120	[p10l1336t2629r1682b2680],
24	.	.	O	.	_	0	SENT_120	[p10l1336t2629r1682b2680],

1	Second	JJ	ORDINAL	second	advmod	10	SENT_121	[p10l1706t2617r1967b2689],
2	,	,	O	,	_	0	SENT_121	[p10l1706t2617r1967b2689],
3	realtime	JJ	O	realtime	amod	5	SENT_121	[p10l1989t2617r2139b2680, p10l8t2725r165b2783],
4	multiplexed	JJ	O	multiplexed	amod	5	SENT_121	[p10l188t2720r605b2803],
5	analysis	NN	O	analysis	nsubj	10	SENT_121	[p10l629t2720r899b2804],
6	of	IN	O	of	_	0	SENT_121	[p10l923t2720r998b2783],
7	several	JJ	O	several	amod	8	SENT_121	[p10l1013t2720r1252b2783],
8	markers	NNS	O	marker	prep_of	5	SENT_121	[p10l1275t2720r1557b2783],
9	can	MD	O	can	aux	10	SENT_121	[p10l1583t2743r1701b2783],
10	increase	VB	O	increase	_	0	SENT_121	[p10l1725t2725r2008b2783],
11	the	DT	O	the	det	13	SENT_121	[p10l2031t2720r2140b2783],
12	potential	JJ	O	potential	amod	13	SENT_121	[p10l7t2823r314b2906],
13	selection	NN	O	selection	dobj	10	SENT_121	[p10l336t2823r637b2886],
14	of	IN	O	of	_	0	SENT_121	[p10l661t2823r734b2886],
15	patients	NNS	O	patient	prep_of	13	SENT_121	[p10l746t2828r1016b2906],
16	for	IN	O	for	_	0	SENT_121	[p10l1038t2823r1136b2886],
17	many	JJ	O	many	amod	20	SENT_121	[p10l1157t2846r1350b2907],
18	different	JJ	O	different	amod	20	SENT_121	[p10l1370t2823r1660b2886],
19	clinical	JJ	O	clinical	amod	20	SENT_121	[p10l1682t2823r1927b2886],
20	trials	NNS	O	trial	prep_for	15	SENT_121	[p10l1948t2823r2138b2895],
21	,	,	O	,	_	0	SENT_121	[p10l1948t2823r2138b2895],
22	thereby	RB	O	thereby	advmod	23	SENT_121	[p10l8t2926r267b3010],
23	speeding	VBG	O	speed	dep	10	SENT_121	[p10l287t2926r591b3010],
24	the	DT	O	the	det	26	SENT_121	[p10l611t2926r717b2989],
25	recruitment	NN	O	recruitment	nn	26	SENT_121	[p10l741t2931r1149b2989],
26	rate	NN	O	rate	dobj	23	SENT_121	[p10l1171t2938r1297b2989],
27	and	CC	O	and	_	0	SENT_121	[p10l1321t2926r1447b2989],
28	reducing	VBG	O	reduce	conj_and	23	SENT_121	[p10l1469t2926r1771b3010],
29	the	DT	O	the	det	30	SENT_121	[p10l1791t2926r1897b2989],
30	cost	NN	O	cost	dobj	28	SENT_121	[p10l1921t2938r2056b2989],
31	of	IN	O	of	_	0	SENT_121	[p10l2078t2926r2151b2989],
32	early	JJ	O	early	amod	33	SENT_121	[p10l9t3029r177b3113],
33	trials	NNS	O	trial	prep_of	30	SENT_121	[p10l196t3029r387b3092],
34	.	.	O	.	_	0	SENT_121	[p10l196t3029r387b3092],

1	Finally	RB	O	finally	advmod	11	SENT_122	[p10l414t3029r662b3113],
2	,	,	O	,	_	0	SENT_122	[p10l414t3029r662b3113],
3	many	JJ	O	many	nsubj	11	SENT_122	[p10l687t3052r882b3113],
4	of	IN	O	of	_	0	SENT_122	[p10l902t3029r977b3092],
5	the	DT	O	the	det	8	SENT_122	[p10l989t3029r1097b3092],
6	predictive	JJ	O	predictive	amod	8	SENT_122	[p10l1119t3029r1464b3112],
7	molecular	JJ	O	molecular	amod	8	SENT_122	[p10l1487t3029r1838b3092],
8	markers	NNS	O	marker	prep_of	3	SENT_122	[p10l1859t3029r2140b3092],
9	may	MD	O	may	aux	11	SENT_122	[p10l8t3155r159b3216],
10	also	RB	O	also	advmod	11	SENT_122	[p10l180t3132r315b3195],
11	have	VB	O	have	_	0	SENT_122	[p10l340t3132r499b3195],
12	potential	JJ	O	potential	amod	14	SENT_122	[p10l523t3132r839b3215],
13	prognostic	JJ	O	prognostic	amod	14	SENT_122	[p10l861t3137r1239b3216],
14	impact	NN	O	impact	dobj	11	SENT_122	[p10l1263t3137r1525b3215],
15	;	:	O	;	_	0	SENT_122	[p10l1263t3137r1525b3215],
16	in	IN	O	in	_	0	SENT_122	[p10l1551t3137r1619b3194],
17	the	DT	O	the	det	18	SENT_122	[p10l1643t3132r1752b3195],
18	absence	NN	O	absence	prep_in	14	SENT_122	[p10l1777t3132r2051b3195],
19	of	IN	O	of	_	0	SENT_122	[p10l2076t3132r2152b3195],
20	comprehensive	JJ	O	comprehensive	amod	21	SENT_122	[p10l9t3235r513b3318],
21	testing	NN	O	testing	prep_of	18	SENT_122	[p10l532t3240r757b3319],
22	it	PRP	O	it	nsubj	24	SENT_122	[p10l775t3240r820b3298],
23	may	MD	O	may	aux	24	SENT_122	[p10l838t3258r982b3319],
24	take	VB	O	take	rcmod	21	SENT_122	[p10l997t3235r1135b3298],
25	many	JJ	O	many	amod	27	SENT_122	[p10l1154t3258r1344b3319],
26	more	JJR	O	more	amod	27	SENT_122	[p10l1360t3258r1533b3298],
27	years	NNS	DURATION	year	tmod	24	SENT_122	[p10l1551t3258r1722b3319],
28	for	IN	O	for	_	0	SENT_122	[p10l1742t3235r1837b3298],
29	their	PRP$	O	they	poss	32	SENT_122	[p10l1855t3235r2014b3298],
30	full	JJ	O	full	amod	32	SENT_122	[p10l2033t3235r2144b3298],
31	clinical	JJ	O	clinical	amod	32	SENT_122	[p10l9t3338r254b3401],
32	value	NN	O	value	prep_for	24	SENT_122	[p10l271t3338r452b3401],
33	to	TO	O	to	aux	35	SENT_122	[p10l472t3350r538b3401],
34	become	VB	O	become	cop	35	SENT_122	[p10l559t3338r826b3401],
35	clear	JJ	O	clear	xcomp	24	SENT_122	[p10l848t3338r1020b3410],
36	,	,	O	,	_	0	SENT_122	[p10l848t3338r1020b3410],
37	which	WDT	O	which	nsubj	39	SENT_122	[p10l1042t3338r1251b3401],
38	is	VBZ	O	be	cop	39	SENT_122	[p10l1272t3343r1322b3401],
39	unacceptable	JJ	O	unacceptable	rcmod	14	SENT_122	[p10l1344t3338r1807b3421],
40	.	.	O	.	_	0	SENT_122	[p10l1344t3338r1807b3421],

1	It	PRP	O	it	nsubj	3	SENT_123	[p10l82t3446r130b3504],
2	is	VBZ	O	be	cop	3	SENT_123	[p10l147t3446r194b3504],
3	important	JJ	O	important	_	0	SENT_123	[p10l213t3446r545b3524],
4	to	TO	O	to	aux	5	SENT_123	[p10l561t3453r624b3504],
5	consider	VB	O	consider	xcomp	3	SENT_123	[p10l644t3441r922b3504],
6	the	DT	O	the	det	7	SENT_123	[p10l938t3441r1040b3504],
7	context	NN	O	context	dobj	5	SENT_123	[p10l1059t3453r1299b3504],
8	of	IN	O	of	_	0	SENT_123	[p10l1316t3441r1387b3504],
9	the	DT	O	the	det	10	SENT_123	[p10l1395t3441r1497b3504],
10	tumor	NN	O	tumor	prep_of	7	SENT_123	[p10l1514t3453r1721b3504],
11	when	WRB	O	when	advmod	12	SENT_123	[p10l1736t3441r1917b3504],
12	selecting	VBG	O	select	advcl	5	SENT_123	[p10l1935t3441r2138b3504, p10l9t3549r115b3628],
13	targeted	VBN	O	target	dep	12	SENT_123	[p10l133t3544r406b3628],
14	therapies	NNS	O	therapy	dobj	13	SENT_123	[p10l425t3544r728b3627],
15	based	VBN	O	base	_	0	SENT_123	[p10l747t3544r940b3607],
16	on	IN	O	on	prepc_based_on	13	SENT_123	[p10l961t3567r1046b3607],
17	molecular	JJ	O	molecular	amod	18	SENT_123	[p10l1066t3544r1405b3607],
18	genotyping	NN	O	genotyping	pobj	13	SENT_123	[p10l1424t3549r1816b3628],
19	.	.	O	.	_	0	SENT_123	[p10l1424t3549r1816b3628],

1	Different	JJ	O	different	amod	2	SENT_124	[p10l1841t3544r2142b3607],
2	types	NNS	O	type	nsubjpass	14	SENT_124	[p10l8t3659r177b3731],
3	of	IN	O	of	_	0	SENT_124	[p10l196t3647r267b3710],
4	tumors	NNS	O	tumor	prep_of	2	SENT_124	[p10l274t3659r509b3710],
5	may	MD	O	may	aux	6	SENT_124	[p10l527t3670r669b3731],
6	originate	VB	O	originate	_	0	SENT_124	[p10l684t3652r973b3731],
7	from	IN	O	from	_	0	SENT_124	[p10l991t3647r1152b3710],
8	different	JJ	O	different	amod	10	SENT_124	[p10l1171t3647r1446b3710],
9	cellular	JJ	O	cellular	amod	10	SENT_124	[p10l1464t3647r1702b3710],
10	types	NNS	O	type	prep_from	6	SENT_124	[p10l1717t3659r1887b3731],
11	and	CC	O	and	_	0	SENT_124	[p10l1906t3647r2028b3710],
12	are	VBP	O	be	auxpass	14	SENT_124	[p10l2045t3670r2141b3710],
13	frequently	RB	O	frequently	advmod	14	SENT_124	[p11l8t16r347b100],
14	driven	VBN	O	drive	conj_and	6	SENT_124	[p11l363t16r574b79],
15	by	IN	O	by	_	0	SENT_124	[p11l590t16r672b100],
16	different	JJ	O	different	amod	17	SENT_124	[p11l687t16r965b79],
17	combinations	NNS	O	combination	agent	14	SENT_124	[p11l983t16r1430b79],
18	of	IN	O	of	_	0	SENT_124	[p11l1449t16r1521b79],
19	genetic	JJ	O	genetic	amod	20	SENT_124	[p11l1529t21r1762b100],
20	alterations	NNS	O	alteration	prep_of	17	SENT_124	[p11l1781t16r2138b79],
21	.	.	O	.	_	0	SENT_124	[p11l1781t16r2138b79],

1	For	IN	O	for	_	0	SENT_125	[p11l9t124r121b182],
2	example	NN	O	example	prep_for	7	SENT_125	[p11l138t119r426b202],
3	,	,	O	,	_	0	SENT_125	[p11l138t119r426b202],
4	BRAF	NN	O	braf	nn	5	SENT_125	[p11l446t123r645b182],
5	inhibitors	NNS	O	inhibitor	nsubj	7	SENT_125	[p11l664t119r981b182],
6	have	VBP	O	have	aux	7	SENT_125	[p11l999t119r1148b182],
7	shown	VBN	O	show	_	0	SENT_125	[p11l1168t119r1382b182],
8	unprecedented	JJ	O	unprecedented	amod	9	SENT_125	[p11l1399t119r1890b202],
9	success	NN	O	success	dobj	7	SENT_125	[p11l1908t142r2142b182],
10	in	IN	O	in	_	0	SENT_125	[p11l9t227r72b284],
11	the	DT	O	the	det	12	SENT_125	[p11l89t222r191b285],
12	treatment	NN	O	treatment	prep_in	9	SENT_125	[p11l208t234r526b285],
13	of	IN	O	of	_	0	SENT_125	[p11l543t222r615b285],
14	malignant	JJ	O	malignant	amod	15	SENT_125	[p11l622t222r954b306],
15	melanomas	NNS	O	melanoma	prep_of	12	SENT_125	[p11l970t222r1344b285],
16	with	IN	O	with	_	0	SENT_125	[p11l1361t222r1506b285],
17	BRAF-V600	NN	O	braf-v600	nn	18	SENT_125	[p11l1525t226r1925b285],
18	mutations	NNS	O	mutation	prep_with	7	SENT_125	[p11l1943t234r2139b285, p11l8t330r186b388],
19	.	.	O	.	_	0	SENT_125	[p11l1943t234r2139b285, p11l8t330r186b388],

1	BRAF	NN	O	braf	_	0	SENT_126	[p11l209t329r617b388],
2	.	.	O	.	_	0	SENT_126	[p11l209t329r617b388],

1	—	NN	O	—	_	0	SENT_127	[p11l209t329r617b388],
2	.	.	O	.	_	0	SENT_127	[p11l209t329r617b388],

1	V600	NN	O	v600	nn	2	SENT_128	[p11l209t329r617b388],
2	mutations	NNS	O	mutation	nsubjpass	5	SENT_128	[p11l636t330r971b388],
3	are	VBP	O	be	auxpass	5	SENT_128	[p11l991t348r1088b388],
4	also	RB	O	also	advmod	5	SENT_128	[p11l1108t325r1234b388],
5	observed	VBN	O	observe	_	0	SENT_128	[p11l1255t325r1571b397],
6	,	,	O	,	_	0	SENT_128	[p11l1255t325r1571b397],
7	with	IN	O	with	_	0	SENT_128	[p11l1590t325r1738b388],
8	varying	VBG	O	vary	amod	9	SENT_128	[p11l1754t330r2009b409],
9	frequency	NN	O	frequency	prep_with	5	SENT_128	[p11l2026t325r2140b388, p11l9t451r257b512],
10	,	,	O	,	_	0	SENT_128	[p11l2026t325r2140b388, p11l9t451r257b512],
11	in	IN	O	in	_	0	SENT_128	[p11l276t433r341b490],
12	other	JJ	O	other	amod	13	SENT_128	[p11l360t428r534b491],
13	cancers	NNS	O	cancer	prep_in	5	SENT_128	[p11l552t451r810b491],
14	.	.	O	.	_	0	SENT_128	[p11l552t451r810b491],

1	In	IN	O	in	_	0	SENT_129	[p11l832t433r901b490],
2	some	DT	O	some	prep_in	21	SENT_129	[p11l920t451r1092b491],
3	of	IN	O	of	_	0	SENT_129	[p11l1111t428r1182b491],
4	these	DT	O	these	det	5	SENT_129	[p11l1190t428r1358b491],
5	cancers	NNS	O	cancer	prep_of	2	SENT_129	[p11l1377t451r1637b500],
6	,	,	O	,	_	0	SENT_129	[p11l1377t451r1637b500],
7	for	IN	O	for	_	0	SENT_129	[p11l1657t428r1751b491],
8	example	NN	O	example	prep_for	21	SENT_129	[p11l1768t428r2057b511],
9	,	,	O	,	_	0	SENT_129	[p11l1768t428r2057b511],
10	in	IN	O	in	_	0	SENT_129	[p11l2077t433r2141b490],
11	nonmelanoma	JJ	O	nonmelanoma	amod	12	SENT_129	[p11l8t530r492b593],
12	malignancies	NNS	O	malignancy	prep_in	21	SENT_129	[p11l509t530r943b614],
13	such	JJ	O	such	_	0	SENT_129	[p11l963t530r1113b593],
14	as	IN	O	as	_	0	SENT_129	[p11l1132t553r1194b593],
15	hairy-cell	JJ	O	hairy-cell	amod	16	SENT_129	[p11l1212t530r1526b614],
16	leukemia	NN	O	leukemia	prep_such_as	12	SENT_129	[p11l1542t522r1923b602],
17	,44	CD	NUMBER	,44	num	19	SENT_129	[p11l1542t522r1923b602],
18	BRAF	NN	O	braf	nn	19	SENT_129	[p11l1941t534r2141b593],
19	inhibitors	NNS	O	inhibitor	nsubj	21	SENT_129	[p11l9t633r334b696],
20	can	MD	O	can	aux	21	SENT_129	[p11l356t656r471b696],
21	achieve	VB	O	achieve	_	0	SENT_129	[p11l493t633r740b696],
22	similar	JJ	O	similar	amod	23	SENT_129	[p11l762t633r994b696],
23	degrees	NNS	O	degree	dobj	21	SENT_129	[p11l1015t633r1264b717],
24	of	IN	O	of	_	0	SENT_129	[p11l1287t633r1360b696],
25	response	NN	O	response	prep_of	23	SENT_129	[p11l1371t655r1681b716],
26	.	.	O	.	_	0	SENT_129	[p11l1371t655r1681b716],

1	In	IN	O	in	_	0	SENT_130	[p11l1706t638r1776b695],
2	other	JJ	O	other	amod	3	SENT_130	[p11l1797t633r1976b696],
3	cancers	NNS	O	cancer	prep_in	14	SENT_130	[p11l1996t656r2139b696, p11l9t759r154b808],
4	,	,	O	,	_	0	SENT_130	[p11l1996t656r2139b696, p11l9t759r154b808],
5	such	JJ	O	such	_	0	SENT_130	[p11l176t736r327b799],
6	as	IN	O	as	_	0	SENT_130	[p11l346t759r409b799],
7	colorectal	JJ	O	colorectal	amod	8	SENT_130	[p11l429t736r752b799],
8	cancer	NN	O	cancer	prep_such_as	3	SENT_130	[p11l771t759r998b808],
9	,	,	O	,	_	0	SENT_130	[p11l771t759r998b808],
10	more	RBR	O	more	advmod	11	SENT_130	[p11l1018t759r1192b799],
11	complex	JJ	O	complex	amod	13	SENT_130	[p11l1211t736r1495b819],
12	underlying	JJ	O	underlying	amod	13	SENT_130	[p11l1511t736r1877b820],
13	mechanisms	NNS	O	mechanism	appos	8	SENT_130	[p11l1893t736r2139b799, p11l8t844r199b902],
14	preclude	VBP	O	preclude	_	0	SENT_130	[p11l216t839r497b922],
15	therapeutic	JJ	O	therapeutic	amod	16	SENT_130	[p11l514t839r883b922],
16	success	NN	O	success	dobj	14	SENT_130	[p11l902t862r1152b911],
17	,	,	O	,	_	0	SENT_130	[p11l902t862r1152b911],
18	including	VBG	O	include	_	0	SENT_130	[p11l1171t839r1482b923],
19	a	DT	O	a	det	21	SENT_130	[p11l1499t862r1533b902],
20	feedback	NN	O	feedback	nn	21	SENT_130	[p11l1549t839r1840b902],
21	loop	NN	O	loop	prep_including	14	SENT_130	[p11l1853t839r1998b922],
22	that	WDT	O	that	nsubj	23	SENT_130	[p11l2016t839r2144b902],
23	increases	VBZ	O	increase	rcmod	21	SENT_130	[p11l9t947r305b1005],
24	the	DT	O	the	det	25	SENT_130	[p11l322t942r425b1005],
25	expression	NN	O	expression	dobj	23	SENT_130	[p11l444t947r791b1025],
26	of	IN	O	of	_	0	SENT_130	[p11l810t942r882b1005],
27	EGF	NN	ORGANIZATION	egf	nn	28	SENT_130	[p11l890t946r1038b1005],
28	R.	NNP	O	R.	prep_of	25	SENT_130	[p11l1042t947r1107b1005],
29	This	DT	O	this	det	31	SENT_130	[p11l1129t942r1267b1005],
30	latter	JJ	O	latter	amod	31	SENT_130	[p11l1284t942r1454b1005],
31	ﬁnding	NN	O	ﬁnding	nsubj	32	SENT_130	[p11l1471t942r1709b1026],
32	suggests	VBZ	O	suggest	rcmod	25	SENT_130	[p11l1727t954r1994b1026],
33	that	IN	O	that	complm	45	SENT_130	[p11l2012t942r2141b1005],
34	a	DT	O	a	det	36	SENT_130	[p11l9t1068r44b1108],
35	combinatorial	JJ	O	combinatorial	amod	36	SENT_130	[p11l65t1045r546b1108],
36	therapy	NN	O	therapy	nsubjpass	45	SENT_130	[p11l566t1045r828b1129],
37	against	IN	O	against	_	0	SENT_130	[p11l847t1050r1085b1129],
38	both	DT	O	both	preconj	42	SENT_130	[p11l1104t1045r1264b1108],
39	BRAF	NN	ORGANIZATION	braf	nn	42	SENT_130	[p11l1286t1049r1491b1108],
40	and	CC	O	and	_	0	SENT_130	[p11l1515t1045r1642b1108],
41	EGFR	NN	ORGANIZATION	egfr	conj_and	39	SENT_130	[p11l1662t1049r1873b1108],
42	kinases	NNS	O	kinase	prep_against	36	SENT_130	[p11l1891t1045r2140b1108],
43	should	MD	O	should	aux	45	SENT_130	[p11l9t1147r235b1210],
44	be	VB	O	be	auxpass	45	SENT_130	[p11l252t1147r331b1210],
45	adopted	VBN	O	adopt	ccomp	32	SENT_130	[p11l351t1147r622b1230],
46	in	IN	O	in	_	0	SENT_130	[p11l640t1152r706b1209],
47	such	JJ	O	such	amod	48	SENT_130	[p11l727t1147r879b1210],
48	cases	NNS	O	case	prep_in	45	SENT_130	[p11l899t1139r1144b1210],
49	.45	CD	NUMBER	.45	nsubj	14	SENT_130	[p11l899t1139r1144b1210],

1	RESISTANCE	NN	O	resistance	_	0	SENT_131	[p11l12t1362r447b1417],
2	TO	TO	O	to	infmod	1	SENT_131	[p11l461t1361r557b1417],
3	TKIS	NNP	O	TKIS	dep	1	SENT_131	[p11l571t1362r719b1417],
4	IN	IN	O	in	_	0	SENT_131	[p11l740t1362r809b1416],
5	NSCLC	NNP	O	NSCLC	prep_in	3	SENT_131	[p11l833t1362r1081b1417],
6	:	:	O	:	_	0	SENT_131	[p11l833t1362r1081b1417],
7	A	DT	O	a	det	8	SENT_131	[p11l1098t1362r1146b1416],
8	PARADIGM	NN	O	paradigm	dep	3	SENT_131	[p11l1167t1362r1558b1416],

1	After	IN	O	after	_	0	SENT_132	[p11l8t1457r182b1520],
2	the	DT	O	the	det	4	SENT_132	[p11l201t1457r306b1520],
3	initial	JJ	O	initial	amod	4	SENT_132	[p11l328t1457r523b1520],
4	promise	NN	O	promise	prep_after	13	SENT_132	[p11l543t1462r817b1540],
5	of	IN	O	of	_	0	SENT_132	[p11l839t1457r912b1520],
6	targeted	VBN	O	target	amod	7	SENT_132	[p11l923t1457r1197b1541],
7	therapies	NNS	O	therapy	prep_of	4	SENT_132	[p11l1216t1457r1539b1540],
8	,	,	O	,	_	0	SENT_132	[p11l1216t1457r1539b1540],
9	drug	NN	O	drug	nn	10	SENT_132	[p11l1563t1457r1723b1541],
10	resistance	NN	O	resistance	nsubj	13	SENT_132	[p11l1743t1462r2070b1520],
11	is	VBZ	O	be	aux	13	SENT_132	[p11l2092t1462r2141b1520],
12	now	RB	DATE	now	advmod	13	SENT_132	[p11l8t1583r155b1623],
13	emerging	VBG	O	emerge	_	0	SENT_132	[p11l174t1565r493b1644],
14	as	IN	O	as	_	0	SENT_132	[p11l513t1583r576b1623],
15	the	DT	O	the	det	17	SENT_132	[p11l597t1560r702b1623],
16	major	JJ	O	major	amod	17	SENT_132	[p11l723t1565r922b1644],
17	obstacle	NN	O	obstacle	prep_as	13	SENT_132	[p11l943t1560r1211b1623],
18	to	TO	O	to	aux	19	SENT_132	[p11l1232t1572r1297b1623],
19	progress	VB	O	progress	xcomp	13	SENT_132	[p11l1318t1582r1601b1644],
20	in	IN	O	in	_	0	SENT_132	[p11l1622t1565r1688b1622],
21	the	DT	O	the	det	22	SENT_132	[p11l1708t1560r1813b1623],
22	ﬁeld	NN	O	ﬁeld	prep_in	19	SENT_132	[p11l1834t1560r1995b1632],
23	,	,	O	,	_	0	SENT_132	[p11l1834t1560r1995b1632],
24	and	CC	O	and	_	0	SENT_132	[p11l2019t1560r2144b1623],
25	this	DT	O	this	nsubj	26	SENT_132	[p11l8t1662r127b1726],
26	includes	VBZ	O	include	conj_and	13	SENT_132	[p11l146t1662r416b1726],
27	kinase	NN	O	kinase	nn	28	SENT_132	[p11l434t1662r643b1726],
28	inhibitors	NNS	O	inhibitor	dobj	26	SENT_132	[p11l662t1662r996b1726],
29	.	.	O	.	_	0	SENT_132	[p11l662t1662r996b1726],

1	Of	IN	O	of	_	0	SENT_133	[p11l1018t1662r1110b1726],
2	note	NN	O	note	prep_of	12	SENT_133	[p11l1119t1674r1279b1734],
3	,	,	O	,	_	0	SENT_133	[p11l1119t1674r1279b1734],
4	molecular	JJ	O	molecular	amod	5	SENT_133	[p11l1299t1662r1631b1726],
5	mechanisms	NNS	O	mechanism	nsubjpass	12	SENT_133	[p11l1647t1662r2058b1726],
6	of	IN	O	of	_	0	SENT_133	[p11l2078t1662r2149b1726],
7	drug	NN	O	drug	nn	8	SENT_133	[p11l9t1766r168b1850],
8	resistance	NN	O	resistance	prep_of	5	SENT_133	[p11l185t1771r510b1829],
9	are	VBP	O	be	aux	12	SENT_133	[p11l529t1789r627b1829],
10	currently	RB	DATE	currently	advmod	12	SENT_133	[p11l647t1766r955b1850],
11	being	VBG	O	be	auxpass	12	SENT_133	[p11l968t1766r1155b1850],
12	deﬁned	VBN	O	deﬁned	_	0	SENT_133	[p11l1172t1766r1438b1838],
13	,	,	O	,	_	0	SENT_133	[p11l1172t1766r1438b1838],
14	resulting	VBG	O	result	dep	12	SENT_133	[p11l1458t1766r1751b1850],
15	in	IN	O	in	_	0	SENT_133	[p11l1768t1771r1833b1828],
16	pharmacologically	RB	O	pharmacologically	advmod	17	SENT_133	[p11l1851t1766r2139b1849, p11l9t1868r370b1952],
17	actionable	JJ	O	actionable	amod	18	SENT_133	[p11l388t1868r731b1931],
18	opportunities	NNS	O	opportunity	prep_in	14	SENT_133	[p11l753t1873r1208b1951],
19	to	TO	O	to	aux	20	SENT_133	[p11l1229t1880r1294b1931],
20	restore	VB	O	restore	xcomp	14	SENT_133	[p11l1316t1880r1543b1931],
21	sensitivity	NN	O	sensitivity	npadvmod	23	SENT_133	[p11l1566t1860r2050b1952],
22	.46	CD	NUMBER	.46	num	21	SENT_133	[p11l1566t1860r2050b1952],
23	>	JJR	O	>	acomp	20	SENT_133	[p11l1566t1860r2050b1952],
24	47	CD	NUMBER	47	dobj	12	SENT_133	[p11l1566t1860r2050b1952],
25	In	IN	O	in	_	0	SENT_133	[p11l2072t1873r2142b1930],
26	many	JJ	O	many	amod	27	SENT_133	[p11l8t1994r198b2055],
27	ways	NNS	O	way	prep_in	35	SENT_133	[p11l213t1994r393b2055],
28	,	,	O	,	_	0	SENT_133	[p11l213t1994r393b2055],
29	the	DT	O	the	det	30	SENT_133	[p11l414t1971r519b2034],
30	experience	NN	O	experience	nsubj	35	SENT_133	[p11l541t1976r901b2054],
31	with	IN	O	with	_	0	SENT_133	[p11l920t1971r1070b2034],
32	TKIs	NNS	O	tki	prep_with	30	SENT_133	[p11l1091t1974r1255b2034],
33	in	IN	O	in	_	0	SENT_133	[p11l1276t1976r1342b2033],
34	NSCLC	NN	ORGANIZATION	nsclc	prep_in	32	SENT_133	[p11l1362t1975r1621b2034],
35	exempliﬁes	VBZ	O	exempliﬁes	rcmod	24	SENT_133	[p11l1643t1971r2016b2054],
36	the	DT	O	the	det	37	SENT_133	[p11l2037t1971r2142b2034],
37	successes	NNS	O	success	dobj	35	SENT_133	[p11l9t2097r306b2137],
38	and	CC	O	and	_	0	SENT_133	[p11l325t2074r446b2137],
39	challenges	NNS	O	challenge	dobj	35	SENT_133	[p11l463t2074r795b2158],
40	of	IN	O	of	_	0	SENT_133	[p11l814t2074r885b2137],
41	personalized	JJ	O	personalized	amod	43	SENT_133	[p11l892t2074r1307b2157],
42	cancer	NN	O	cancer	nn	43	SENT_133	[p11l1324t2097r1536b2137],
43	medicine	NN	O	medicine	prep_of	37	SENT_133	[p11l1553t2074r1868b2137],
44	.	.	O	.	_	0	SENT_133	[p11l1553t2074r1868b2137],

1	NSCLC	NNP	ORGANIZATION	NSCLC	nsubj	5	SENT_134	[p11l1887t2078r2140b2137],
2	is	VBZ	O	be	cop	5	SENT_134	[p11l9t2182r60b2240],
3	a	DT	O	a	det	5	SENT_134	[p11l87t2200r121b2240],
4	major	JJ	O	major	amod	5	SENT_134	[p11l145t2182r351b2261],
5	cause	NN	O	cause	_	0	SENT_134	[p11l376t2200r564b2240],
6	of	IN	O	of	_	0	SENT_134	[p11l590t2177r665b2240],
7	death	NN	O	death	prep_of	5	SENT_134	[p11l681t2177r873b2240],
8	worldwide	RB	O	worldwide	advmod	7	SENT_134	[p11l896t2177r1285b2249],
9	,	,	O	,	_	0	SENT_134	[p11l896t2177r1285b2249],
10	estimated	VBN	O	estimate	partmod	5	SENT_134	[p11l1313t2177r1651b2240],
11	at	IN	O	at	prep	10	SENT_134	[p11l1676t2189r1736b2240],
12	1.4	CD	NUMBER	1.4	number	13	SENT_134	[p11l1767t2184r1861b2240],
13	million	CD	NUMBER	million	dep	14	SENT_134	[p11l1887t2177r2142b2240],
14	fatalities	NNS	O	fatality	dep	11	SENT_134	[p11l8t2280r303b2343],
15	per	IN	O	per	_	0	SENT_134	[p11l329t2302r445b2363],
16	annum	NN	O	annum	nn	19	SENT_134	[p11l471t2303r719b2343],
17	(	CD	NUMBER	(	num	19	SENT_134	[p11l749t2280r1893b2363],
18	http://www.who.int/cancer/en/;	NN	O	http://www.who.int/cancer/en/;	nn	19	SENT_134	[p11l749t2280r1893b2363],
19	http	NN	O	http	prep_per	14	SENT_134	[p11l1920t2280r2141b2363],
20	:	:	O	:	_	0	SENT_134	[p11l1920t2280r2141b2363],
21	/	:	O	/	punct	14	SENT_134	[p11l1920t2280r2141b2363],
22	/	:	O	/	punct	14	SENT_134	[p11l1920t2280r2141b2363],
23	globocan	NN	O	globocan	dep	14	SENT_134	[p11l8t2383r2139b2467],
24	.	.	O	.	_	0	SENT_134	[p11l8t2383r2139b2467],

1	iarc	NN	O	iarc	_	0	SENT_135	[p11l8t2383r2139b2467],
2	.	.	O	.	_	0	SENT_135	[p11l8t2383r2139b2467],

1	fr/factsheets/populations	NNS	O	fr/factsheets/populations	_	0	SENT_136	[p11l8t2383r2139b2467],
2	/	:	O	/	punct	1	SENT_136	[p11l8t2383r2139b2467],
3	factsheet	NN	O	factsheet	dep	1	SENT_136	[p11l8t2383r2139b2467],
4	.	.	O	.	_	0	SENT_136	[p11l8t2383r2139b2467],

1	asp	NN	O	asp	_	0	SENT_137	[p11l8t2383r2139b2467],
2	?	.	O	?	_	0	SENT_137	[p11l8t2383r2139b2467],

1	uno	NN	O	uno	nsubj	2	SENT_138	[p11l8t2383r2139b2467],
2	=	JJ	O	=	_	0	SENT_138	[p11l8t2383r2139b2467],
3	900	CD	NUMBER	900	num	4	SENT_138	[p11l8t2383r2139b2467],
4	)	NN	O	)	dobj	2	SENT_138	[p11l8t2383r2139b2467],
5	.	.	O	.	_	0	SENT_138	[p11l8t2383r2139b2467],

1	The	DT	O	the	det	2	SENT_139	[p11l8t2486r136b2549],
2	ﬁnding	NN	O	ﬁnding	nsubj	23	SENT_139	[p11l158t2486r409b2570],
3	that	WDT	O	that	dobj	7	SENT_139	[p11l429t2486r564b2549],
4	EGFR	NN	ORGANIZATION	egfr	nn	5	SENT_139	[p11l586t2490r798b2549],
5	TKIS	NNS	O	tki	nsubj	9	SENT_139	[p11l819t2489r987b2549],
6	were	VBD	O	be	cop	7	SENT_139	[p11l1009t2509r1172b2549],
7	effective	JJ	O	effective	rcmod	2	SENT_139	[p11l1196t2486r1478b2549],
8	and	CC	O	and	_	0	SENT_139	[p11l1503t2486r1630b2549],
9	had	VBD	O	have	conj_and	7	SENT_139	[p11l1651t2486r1780b2549],
10	particular	JJ	O	particular	amod	11	SENT_139	[p11l1801t2486r2144b2569],
11	activity	NN	O	activity	dobj	9	SENT_139	[p11l9t2594r255b2673],
12	in	IN	O	in	_	0	SENT_139	[p11l270t2594r336b2651],
13	15-30	CD	PERCENT	15-30	num	14	SENT_139	[p11l361t2595r620b2654],
14	%	NN	PERCENT	%	prep_in	11	SENT_139	[p11l361t2595r620b2654],
15	of	IN	O	of	_	0	SENT_139	[p11l642t2589r715b2652],
16	patients	NNS	O	patient	prep_of	14	SENT_139	[p11l723t2594r985b2672],
17	with	IN	O	with	_	0	SENT_139	[p11l1003t2589r1153b2652],
18	EGFR	NN	ORGANIZATION	egfr	nn	19	SENT_139	[p11l1172t2593r1378b2652],
19	mutations	NNS	O	mutation	prep_with	9	SENT_139	[p11l1394t2594r1731b2652],
20	was	VBD	O	be	cop	23	SENT_139	[p11l1749t2612r1873b2652],
21	a	DT	O	a	det	23	SENT_139	[p11l1893t2612r1927b2652],
22	major	JJ	O	major	amod	23	SENT_139	[p11l1945t2594r2143b2673],
23	advance	NN	O	advance	_	0	SENT_139	[p11l9t2693r296b2765],
24	;	:	O	;	_	0	SENT_139	[p11l9t2693r296b2765],
25	however	RB	O	however	advmod	23	SENT_139	[p11l316t2693r612b2765],
26	,	,	O	,	_	0	SENT_139	[p11l316t2693r612b2765],
27	resistance	NN	O	resistance	nn	28	SENT_139	[p11l632t2698r958b2756],
28	sets	NNS	O	set	ccomp	23	SENT_139	[p11l977t2705r1096b2756],
29	in	IN	O	in	dep	30	SENT_139	[p11l1116t2698r1182b2755],
30	after	IN	O	after	dep	28	SENT_139	[p11l1201t2693r1351b2756],
31	approximately	RB	O	approximately	quantmod	32	SENT_139	[p11l1369t2693r1849b2777],
32	one	CD	DURATION	one	num	33	SENT_139	[p11l1865t2716r1985b2756],
33	year	NN	NUMBER	year	pobj	30	SENT_139	[p11l2002t2716r2144b2777],
34	of	IN	O	of	_	0	SENT_139	[p11l9t2795r82b2858],
35	treatment	NN	O	treatment	prep_of	33	SENT_139	[p11l91t2807r434b2858],
36	.	.	O	.	_	0	SENT_139	[p11l91t2807r434b2858],

1	Resistance	NN	O	resistance	nsubj	6	SENT_140	[p11l83t2903r452b2961],
2	to	TO	O	to	_	0	SENT_140	[p11l476t2910r544b2961],
3	TKIS	NN	O	tki	prep_to	1	SENT_140	[p11l570t2901r742b2961],
4	in	IN	O	in	_	0	SENT_140	[p11l768t2903r836b2960],
5	NSCLC	NNP	ORGANIZATION	NSCLC	prep_in	3	SENT_140	[p11l860t2902r1131b2961],
6	provides	VBZ	O	provide	_	0	SENT_140	[p11l1155t2898r1458b2981],
7	a	DT	O	a	det	9	SENT_140	[p11l1484t2921r1519b2961],
8	useful	JJ	O	useful	amod	9	SENT_140	[p11l1543t2898r1756b2961],
9	paradigm	NN	O	paradigm	dobj	6	SENT_140	[p11l1780t2898r2141b2982],
10	,	,	O	,	_	0	SENT_140	[p11l1780t2898r2141b2982],
11	and	CC	O	and	_	0	SENT_140	[p11l9t3001r137b3064],
12	we	PRP	O	we	nsubj	18	SENT_140	[p11l157t3024r251b3064],
13	as	RB	O	as	advmod	14	SENT_140	[p11l275t3024r340b3064],
14	well	RB	O	well	advmod	18	SENT_140	[p11l361t3001r501b3064],
15	as	IN	O	as	_	0	SENT_140	[p11l524t3024r589b3064],
16	others	NNS	O	other	prep_as	14	SENT_140	[p11l613t3001r826b3064],
17	have	VBP	O	have	aux	18	SENT_140	[p11l849t3001r1006b3064],
18	published	VBN	O	publish	conj_and	6	SENT_140	[p11l1028t3001r1368b3084],
19	commentaries	NNS	O	commentary	dobj	18	SENT_140	[p11l1391t3006r1883b3064],
20	on	IN	O	on	_	0	SENT_140	[p11l1907t3024r1994b3064],
21	this	DT	O	this	det	22	SENT_140	[p11l2016t3001r2141b3064],
22	aspect	NN	O	aspect	npadvmod	25	SENT_140	[p11l9t3115r217b3186],
23	recently	RB	DATE	recently	advmod	22	SENT_140	[p11l236t3095r649b3187],
24	.48	CD	NUMBER	.48	pobj	23	SENT_140	[p11l236t3095r649b3187],
25	>	JJR	O	>	prep_on	18	SENT_140	[p11l236t3095r649b3187],
26	49	CD	NUMBER	49	num	28	SENT_140	[p11l236t3095r649b3187],
27	Resistance	NN	O	resistance	nn	28	SENT_140	[p11l669t3108r1018b3166],
28	mechanisms	NNS	O	mechanism	nsubjpass	31	SENT_140	[p11l1037t3103r1454b3166],
29	have	VBP	O	have	aux	31	SENT_140	[p11l1474t3103r1626b3166],
30	been	VBN	O	be	auxpass	31	SENT_140	[p11l1644t3103r1804b3166],
31	identiﬁed	VBN	O	identiﬁed	ccomp	25	SENT_140	[p11l1824t3103r2144b3166],
32	through	IN	O	through	_	0	SENT_140	[p11l8t3206r287b3290],
33	numerous	JJ	O	numerous	amod	34	SENT_140	[p11l309t3229r657b3269],
34	methods	NNS	O	method	prep_through	31	SENT_140	[p11l680t3206r998b3278],
35	,	,	O	,	_	0	SENT_140	[p11l680t3206r998b3278],
36	including	VBG	O	include	_	0	SENT_140	[p11l1023t3206r1352b3290],
37	mechanistic	JJ	O	mechanistic	amod	38	SENT_140	[p11l1372t3206r1786b3269],
38	investigation	NN	O	investigation	prep_including	18	SENT_140	[p11l1809t3211r2139b3290, p11l8t3314r144b3372],
39	of	IN	O	of	_	0	SENT_140	[p11l165t3309r238b3372],
40	laboratory	NN	O	laboratory	nn	41	SENT_140	[p11l248t3309r605b3393],
41	models	NNS	O	model	prep_of	38	SENT_140	[p11l622t3309r867b3372],
42	and	CC	O	and	_	0	SENT_140	[p11l889t3309r1014b3372],
43	proﬁling	NN	O	proﬁling	prep_including	18	SENT_140	[p11l1032t3309r1327b3393],
44	of	IN	O	of	_	0	SENT_140	[p11l1346t3309r1419b3372],
45	patients	NNS	O	patient	prep_of	43	SENT_140	[p11l1429t3309r1711b3392],
46	’	CD	NUMBER	’	num	47	SENT_140	[p11l1429t3309r1711b3392],
47	tumors	NNS	O	tumor	dep	43	SENT_140	[p11l1732t3321r1992b3372],
48	.	.	O	.	_	0	SENT_140	[p11l1732t3321r1992b3372],

1	The	DT	O	the	det	2	SENT_141	[p11l2016t3309r2140b3372],
2	investigations	NNS	O	investigation	nsubj	3	SENT_141	[p11l9t3417r470b3496],
3	reveal	VBP	O	reveal	_	0	SENT_141	[p11l491t3412r689b3475],
4	the	DT	O	the	det	5	SENT_141	[p11l708t3412r813b3475],
5	existence	NN	O	existence	dobj	3	SENT_141	[p11l833t3417r1138b3475],
6	of	IN	O	of	_	0	SENT_141	[p11l1159t3412r1232b3475],
7	a	DT	O	a	det	8	SENT_141	[p11l1243t3435r1277b3475],
8	range	NN	O	range	prep_of	5	SENT_141	[p11l1296t3435r1481b3496],
9	of	IN	O	of	_	0	SENT_141	[p11l1502t3412r1575b3475],
10	devious	JJ	O	devious	amod	12	SENT_141	[p11l1586t3412r1844b3475],
11	molecular	JJ	O	molecular	amod	12	SENT_141	[p11l1864t3412r2140b3475, p11l7t3515r100b3578],
12	tricks	NNS	O	trick	prep_of	8	SENT_141	[p11l122t3515r318b3578],
13	to	TO	O	to	aux	14	SENT_141	[p11l342t3527r409b3578],
14	elude	VB	O	elude	xcomp	3	SENT_141	[p11l435t3515r622b3578],
15	EGFR	NN	ORGANIZATION	egfr	nn	16	SENT_141	[p11l646t3519r861b3578],
16	TKIs	NNS	O	tki	dobj	14	SENT_141	[p11l882t3518r1073b3587],
17	,	,	O	,	_	0	SENT_141	[p11l882t3518r1073b3587],
18	including	VBG	O	include	_	0	SENT_141	[p11l1099t3515r1436b3599],
19	ingenious	JJ	O	ingenious	amod	20	SENT_141	[p11l1459t3520r1802b3599],
20	means	NNS	O	means	prep_including	3	SENT_141	[p11l1826t3538r2051b3578],
21	of	IN	O	of	_	0	SENT_141	[p11l2077t3515r2152b3578],
22	maintaining	VBG	O	maintain	prepc_of	20	SENT_141	[p11l8t3623r450b3702],
23	addiction	NN	O	addiction	dobj	22	SENT_141	[p11l477t3618r819b3681],
24	to	TO	O	to	_	0	SENT_141	[p11l846t3630r915b3681],
25	the	DT	O	the	det	28	SENT_141	[p11l943t3618r1054b3681],
26	canonical	JJ	O	canonical	amod	28	SENT_141	[p11l1084t3618r1429b3681],
27	signaling	NN	O	signaling	nn	28	SENT_141	[p11l1457t3618r1784b3702],
28	pathways	NNS	O	pathway	prep_to	22	SENT_141	[p11l1810t3618r2142b3702],
29	downstream	RB	O	downstream	advmod	28	SENT_141	[p11l9t3720r441b3783],
30	of	IN	O	of	_	0	SENT_141	[p11l465t3720r540b3783],
31	EGFR	NN	ORGANIZATION	egfr	prep_of	28	SENT_141	[p11l554t3724r767b3783],
32	as	RB	O	as	_	0	SENT_141	[p11l788t3743r853b3783],
33	well	RB	O	well	_	0	SENT_141	[p11l876t3720r1016b3783],
34	as	IN	O	as	_	0	SENT_141	[p11l1039t3743r1105b3783],
35	other	JJ	O	other	amod	42	SENT_141	[p11l1130t3720r1314b3783],
36	less	RBR	O	less	advmod	37	SENT_141	[p11l1335t3720r1455b3783],
37	obvious	JJ	O	obvious	amod	42	SENT_141	[p11l1480t3720r1750b3783],
38	but	CC	O	but	_	0	SENT_141	[p11l1772t3720r1888b3783],
39	no	DT	O	no	dep	40	SENT_141	[p11l1910t3743r1997b3783],
40	less	JJR	O	less	advmod	41	SENT_141	[p11l2020t3720r2141b3783],
41	effective	JJ	O	effective	amod	42	SENT_141	[p12l9t27r285b90],
42	tactics	NNS	O	tactic	conj_and	28	SENT_141	[p12l304t32r517b90],
43	(	CD	NUMBER	(	num	44	SENT_141	[p12l542t28r797b110],
44	Figure	NN	O	figure	dep	42	SENT_141	[p12l542t28r797b110],
45	2	CD	NUMBER	2	num	46	SENT_141	[p12l816t28r901b103],
46	)	NN	O	)	dep	42	SENT_141	[p12l816t28r901b103],
47	.	.	O	.	_	0	SENT_141	[p12l816t28r901b103],

1	Thus	RB	O	thus	advmod	4	SENT_142	[p12l924t27r1104b99],
2	,	,	O	,	_	0	SENT_142	[p12l924t27r1104b99],
3	we	PRP	O	we	nsubj	4	SENT_142	[p12l1124t50r1216b90],
4	see	VBP	O	see	_	0	SENT_142	[p12l1237t50r1337b90],
5	the	DT	O	the	det	9	SENT_142	[p12l1357t27r1462b90],
6	second	JJ	ORDINAL	second	amod	9	SENT_142	[p12l1483t27r1862b90],
7	—	NN	O	—	nn	9	SENT_142	[p12l1483t27r1862b90],
8	site	NN	O	site	nn	9	SENT_142	[p12l1483t27r1862b90],
9	exon	NN	O	exon	dobj	4	SENT_142	[p12l1883t50r2043b90],
10	20	CD	NUMBER	20	amod	12	SENT_142	[p12l2064t34r2141b90],
11	EGFR	NN	ORGANIZATION	egfr	nn	12	SENT_142	[p12l8t134r215b193],
12	gatekeeper	NN	O	gatekeeper	dep	9	SENT_142	[p12l233t130r595b214],
13	mutation	NN	O	mutation	nn	15	SENT_142	[p12l613t135r924b193],
14	p.	NN	O	p.	nn	15	SENT_142	[p12l943t133r1253b213],
15	T79OM	NN	O	t79om	dep	9	SENT_142	[p12l943t133r1253b213],
16	that	WDT	O	that	nsubj	17	SENT_142	[p12l1273t130r1405b193],
17	reduces	VBZ	O	reduce	rcmod	15	SENT_142	[p12l1424t130r1679b193],
18	drug	NN	O	drug	nn	19	SENT_142	[p12l1701t130r1861b214],
19	binding	NN	O	binding	dobj	17	SENT_142	[p12l1877t130r2143b214],
20	in	IN	O	in	_	0	SENT_142	[p12l9t238r77b295],
21	~	NN	O	~	prep_in	19	SENT_142	[p12l106t239r302b298],
22	50	CD	PERCENT	50	number	23	SENT_142	[p12l106t239r302b298],
23	%	NN	PERCENT	%	amod	21	SENT_142	[p12l106t239r302b298],
24	of	IN	O	of	_	0	SENT_142	[p12l331t233r407b296],
25	all	DT	O	all	det	26	SENT_142	[p12l424t233r506b296],
26	cases	NNS	O	case	prep_of	21	SENT_142	[p12l532t256r709b296],
27	of	IN	O	of	_	0	SENT_142	[p12l736t233r812b296],
28	EGFR	NN	ORGANIZATION	egfr	nn	29	SENT_142	[p12l829t237r1044b296],
29	mutation	NN	O	mutation	prep_of	26	SENT_142	[p12l1067t238r1413b305],
30	;	:	O	;	_	0	SENT_142	[p12l1067t238r1413b305],
31	the	DT	O	the	det	34	SENT_142	[p12l1440t233r1550b296],
32	p.	NN	O	p.	nn	34	SENT_142	[p12l1575t236r1900b316],
33	T79OM	NN	O	t79om	nn	34	SENT_142	[p12l1575t236r1900b316],
34	mutation	NN	O	mutation	dep	26	SENT_142	[p12l1927t245r2137b296, p12l8t341r145b399],
35	plus	CC	O	plus	prep	34	SENT_142	[p12l165t336r305b419],
36	EGFR	NN	ORGANIZATION	egfr	nn	37	SENT_142	[p12l327t340r537b399],
37	ampliﬁcation	NN	O	ampliﬁcation	dep	35	SENT_142	[p12l557t336r1007b419],
38	in	IN	O	in	_	0	SENT_142	[p12l1029t341r1096b398],
39	~	NN	O	~	prep_in	37	SENT_142	[p12l1120t341r1269b401],
40	8	CD	PERCENT	8	number	41	SENT_142	[p12l1120t341r1269b401],
41	%	NN	PERCENT	%	amod	39	SENT_142	[p12l1120t341r1269b401],
42	of	IN	O	of	_	0	SENT_142	[p12l1293t336r1367b399],
43	cases	NNS	O	case	prep_of	39	SENT_142	[p12l1380t359r1568b408],
44	;	:	O	;	_	0	SENT_142	[p12l1380t359r1568b408],
45	TK	NN	O	tk	nn	46	SENT_142	[p12l1592t339r1701b398],
46	switching	NN	O	switching	dep	26	SENT_142	[p12l1723t336r2050b420],
47	or	CC	O	or	_	0	SENT_142	[p12l2071t359r2143b399],
48	receptor	NN	O	receptor	nn	49	SENT_142	[p12l9t451r298b522],
49	dimerization	NN	O	dimerization	dep	26	SENT_142	[p12l321t439r768b502],
50	through	IN	O	through	_	0	SENT_142	[p12l791t439r1073b523],
51	MET	NN	O	met	nn	52	SENT_142	[p12l1096t442r1274b501],
52	ampliﬁcation	NN	O	ampliﬁcation	prep_through	46	SENT_142	[p12l1298t439r1757b522],
53	in	IN	O	in	_	0	SENT_142	[p12l1781t444r1848b501],
54	~	NN	O	~	prep_in	52	SENT_142	[p12l1874t447r1988b502],
55	5	CD	NUMBER	5	num	54	SENT_142	[p12l1874t447r1988b502],
56	-	:	O	-	_	0	SENT_142	[p12l1874t447r1988b502],
57	19	CD	PERCENT	19	num	58	SENT_142	[p12l2003t444r2141b504],
58	%	NN	PERCENT	%	dep	26	SENT_142	[p12l2003t444r2141b504],
59	of	IN	O	of	_	0	SENT_142	[p12l9t542r83b605],
60	cases	NNS	O	case	prep_of	58	SENT_142	[p12l97t565r286b614],
61	;	:	O	;	_	0	SENT_142	[p12l97t565r286b614],
62	overexpression	NN	O	overexpression	dep	26	SENT_142	[p12l312t547r825b625],
63	of	IN	O	of	_	0	SENT_142	[p12l848t542r922b605],
64	AXL	NNP	ORGANIZATION	AXL	prep_of	62	SENT_142	[p12l935t546r1095b604],
65	and	CC	O	and	_	0	SENT_142	[p12l1118t542r1245b605],
66	its	PRP$	O	its	poss	68	SENT_142	[p12l1267t547r1342b605],
67	ligand	NN	O	ligand	nn	68	SENT_142	[p12l1365t542r1579b626],
68	GAS6	NN	O	gas6	prep_of	21	SENT_142	[p12l1602t546r1801b605],
69	in	IN	O	in	_	0	SENT_142	[p12l1824t547r1891b604],
70	20	CD	NUMBER	20	prep_in	68	SENT_142	[p12l1914t549r1992b605],
71	and	CC	O	and	_	0	SENT_142	[p12l2017t542r2144b605],
72	25	CD	PERCENT	25	num	73	SENT_142	[p12l9t651r151b709],
73	%	NN	PERCENT	%	conj_and	19	SENT_142	[p12l9t651r151b709],
74	of	IN	O	of	_	0	SENT_142	[p12l175t645r249b708],
75	cases	NNS	O	case	prep_of	73	SENT_142	[p12l261t668r450b717],
76	,	,	O	,	_	0	SENT_142	[p12l261t668r450b717],
77	respectively	RB	O	respectively	advmod	17	SENT_142	[p12l473t645r895b729],
78	;	:	O	;	_	0	SENT_142	[p12l473t645r895b729],
79	and	CC	O	and	_	0	SENT_142	[p12l919t645r1045b708],
80	activating	VBG	O	activate	amod	81	SENT_142	[p12l1066t650r1401b729],
81	mutation	NN	O	mutation	conj_and	9	SENT_142	[p12l1420t650r1734b708],
82	of	IN	O	of	_	0	SENT_142	[p12l1756t645r1830b708],
83	the	DT	O	the	det	89	SENT_142	[p12l1841t645r1947b708],
84	PI3K	NN	O	pi3k	nn	89	SENT_142	[p12l1969t650r2143b708],
85	p110a	NN	O	p110a	nn	89	SENT_142	[p12l7t748r592b832],
86	—	CD	NUMBER	—	num	89	SENT_142	[p12l7t748r592b832],
87	encoding	NN	O	encoding	nn	89	SENT_142	[p12l7t748r592b832],
88	gene	NN	O	gene	nn	89	SENT_142	[p12l615t771r776b832],
89	PIK3CA	NN	O	pik3ca	prep_of	81	SENT_142	[p12l799t752r1089b811],
90	in	IN	O	in	_	0	SENT_142	[p12l1116t753r1184b810],
91	~	NN	O	~	prep_in	89	SENT_142	[p12l1211t754r1364b813],
92	5	CD	PERCENT	5	number	93	SENT_142	[p12l1211t754r1364b813],
93	%	NN	PERCENT	%	amod	91	SENT_142	[p12l1211t754r1364b813],
94	of	IN	O	of	_	0	SENT_142	[p12l1392t748r1468b811],
95	cases	NNS	O	case	prep_of	81	SENT_142	[p12l1483t771r1677b811],
96	.	.	O	.	_	0	SENT_142	[p12l1483t771r1677b811],

1	There	EX	O	there	expl	2	SENT_143	[p12l1705t748r1903b811],
2	is	VBZ	O	be	_	0	SENT_143	[p12l1928t753r1980b811],
3	also	RB	O	also	advmod	2	SENT_143	[p12l2006t748r2141b811],
4	evidence	NN	O	evidence	nsubj	2	SENT_143	[p12l10t1048r316b1111],
5	of	IN	O	of	_	0	SENT_143	[p12l341t1048r417b1111],
6	nuclear	JJ	O	nuclear	amod	8	SENT_143	[p12l430t1048r690b1111],
7	factor-KB	NN	O	factor-kb	nn	8	SENT_143	[p12l713t1048r1040b1111],
8	signaling	NN	O	signaling	prep_of	4	SENT_143	[p12l1066t1048r1385b1132],
9	being	VBG	O	be	auxpass	10	SENT_143	[p12l1404t1048r1601b1132],
10	implicated	VBN	O	implicate	partmod	8	SENT_143	[p12l1623t1048r1994b1131],
11	as	IN	O	as	_	0	SENT_143	[p12l2017t1071r2083b1111],
12	a	DT	O	a	det	14	SENT_143	[p12l2108t1071r2143b1111],
13	resistance	NN	O	resistance	nn	14	SENT_143	[p12l10t1156r362b1214],
14	mechanism	NN	O	mechanism	prep_as	10	SENT_143	[p12l390t1151r805b1214],
15	to	TO	O	to	aux	16	SENT_143	[p12l832t1163r901b1214],
16	avoid	VB	O	avoid	xcomp	10	SENT_143	[p12l932t1151r1124b1214],
17	TKI-induced	JJ	O	tki-induced	amod	18	SENT_143	[p12l1152t1151r1623b1214],
18	apoptosis	NN	O	apoptosis	dobj	16	SENT_143	[p12l1652t1156r2010b1234],
19	,	,	O	,	_	0	SENT_143	[p12l1652t1156r2010b1234],
20	for	IN	O	for	_	0	SENT_143	[p12l2040t1151r2142b1214],
21	example	NN	O	example	prep_for	18	SENT_143	[p12l10t1254r299b1337],
22	through	IN	O	through	_	0	SENT_143	[p12l322t1254r607b1338],
23	the	DT	O	the	det	25	SENT_143	[p12l630t1254r738b1317],
24	low	JJ	O	low	amod	25	SENT_143	[p12l761t1254r888b1317],
25	expression	NN	O	expression	prep_through	16	SENT_143	[p12l910t1259r1280b1337],
26	of	IN	O	of	_	0	SENT_143	[p12l1305t1254r1380b1317],
27	the	DT	O	the	det	29	SENT_143	[p12l1393t1254r1502b1317],
28	nuclear	JJ	O	nuclear	amod	29	SENT_143	[p12l1526t1254r1786b1317],
29	factor	NN	O	factor	prep_of	25	SENT_143	[p12l1808t1254r2141b1317],
30	.	.	O	.	_	0	SENT_143	[p12l1808t1254r2141b1317],

1	—	NN	O	—	_	0	SENT_144	[p12l1808t1254r2141b1317],
2	.	.	O	.	_	0	SENT_144	[p12l1808t1254r2141b1317],

1	KB	NN	O	kb	_	0	SENT_145	[p12l1808t1254r2141b1317],
2	inhibitory	JJ	O	inhibitory	amod	4	SENT_145	[p12l9t1356r357b1440],
3	protein	NN	O	protein	nn	4	SENT_145	[p12l373t1361r622b1439],
4	IKB	NN	O	ikb	dep	1	SENT_145	[p12l644t1348r842b1419],
5	.5	CD	NUMBER	.5	num	6	SENT_145	[p12l644t1348r842b1419],
6	°	NN	O	°	dep	1	SENT_145	[p12l644t1348r842b1419],

1	Although	IN	O	although	mark	4	SENT_146	[p12l82t1459r414b1543],
2	resistance	NN	O	resistance	nn	3	SENT_146	[p12l437t1464r775b1522],
3	mechanisms	NNS	O	mechanism	nsubj	4	SENT_146	[p12l799t1459r1231b1522],
4	are	VBP	O	be	advcl	24	SENT_146	[p12l1256t1482r1358b1522],
5	yet	RB	O	yet	advmod	4	SENT_146	[p12l1379t1471r1482b1543],
6	to	TO	O	to	aux	8	SENT_146	[p12l1504t1471r1570b1522],
7	be	VB	O	be	auxpass	8	SENT_146	[p12l1593t1459r1673b1522],
8	elucidated	VBN	O	elucidate	xcomp	4	SENT_146	[p12l1698t1459r2053b1522],
9	in	IN	O	in	_	0	SENT_146	[p12l2075t1464r2143b1521],
10	a	DT	O	a	det	12	SENT_146	[p12l10t1585r45b1625],
11	signiﬁcant	JJ	O	signiﬁcant	amod	12	SENT_146	[p12l67t1562r423b1646],
12	proportion	NN	O	proportion	prep_in	8	SENT_146	[p12l442t1567r822b1645],
13	of	IN	O	of	_	0	SENT_146	[p12l844t1562r918b1625],
14	patients	NNS	O	patient	prep_of	12	SENT_146	[p12l929t1567r1199b1645],
15	(	CD	NUMBER	(	num	16	SENT_146	[p12l1225t1563r1496b1639],
16	~	NN	O	~	dep	14	SENT_146	[p12l1225t1563r1496b1639],
17	30	CD	PERCENT	30	number	18	SENT_146	[p12l1225t1563r1496b1639],
18	%	NN	PERCENT	%	amod	16	SENT_146	[p12l1225t1563r1496b1639],
19	)	CD	NUMBER	)	dep	16	SENT_146	[p12l1225t1563r1496b1639],
20	,	,	O	,	_	0	SENT_146	[p12l1225t1563r1496b1639],
21	it	PRP	O	it	nsubj	24	SENT_146	[p12l1519t1567r1565b1625],
22	is	VBZ	O	be	cop	24	SENT_146	[p12l1586t1567r1636b1625],
23	now	RB	DATE	now	advmod	24	SENT_146	[p12l1659t1585r1808b1625],
24	clear	JJ	O	clear	_	0	SENT_146	[p12l1828t1562r1989b1625],
25	that	IN	O	that	complm	33	SENT_146	[p12l2009t1562r2144b1625],
26	tumor	NN	O	tumor	nn	27	SENT_146	[p12l8t1677r227b1728],
27	heterogeneity	NN	O	heterogeneity	nsubjpass	33	SENT_146	[p12l248t1665r724b1749],
28	and	CC	O	and	_	0	SENT_146	[p12l745t1665r873b1728],
29	drug	NN	O	drug	nn	30	SENT_146	[p12l895t1665r1060b1749],
30	resistance	NN	O	resistance	conj_and	27	SENT_146	[p12l1082t1670r1420b1728],
31	may	MD	O	may	aux	33	SENT_146	[p12l1444t1688r1592b1749],
32	be	VB	O	be	auxpass	33	SENT_146	[p12l1610t1665r1691b1728],
33	detected	VBN	O	detect	ccomp	24	SENT_146	[p12l1715t1665r2007b1728],
34	not	RB	O	not	neg	35	SENT_146	[p12l2029t1677r2145b1728],
35	only	RB	O	only	preconj	33	SENT_146	[p12l10t1768r158b1852],
36	at	IN	O	at	_	0	SENT_146	[p12l175t1780r233b1831],
37	the	DT	O	the	det	39	SENT_146	[p12l251t1768r355b1831],
38	genomic	JJ	O	genomic	amod	39	SENT_146	[p12l375t1773r663b1852],
39	level	NN	O	level	prep_at	33	SENT_146	[p12l681t1768r832b1831],
40	but	CC	O	but	_	0	SENT_146	[p12l849t1768r961b1831],
41	also	RB	O	also	_	0	SENT_146	[p12l980t1768r1108b1831],
42	at	IN	O	at	_	0	SENT_146	[p12l1130t1780r1188b1831],
43	the	DT	O	the	det	45	SENT_146	[p12l1206t1768r1310b1831],
44	morphologic	JJ	O	morphologic	amod	45	SENT_146	[p12l1330t1768r1764b1852],
45	level	NN	O	level	prep_at	33	SENT_146	[p12l1783t1768r1948b1831],
46	.	.	O	.	_	0	SENT_146	[p12l1783t1768r1948b1831],

1	It	PRP	O	it	nsubj	5	SENT_147	[p12l1972t1773r2020b1831],
2	is	VBZ	O	be	cop	5	SENT_147	[p12l2039t1773r2088b1831],
3	a	DT	O	a	det	5	SENT_147	[p12l2109t1791r2144b1831],
4	fascinating	JJ	O	fascinating	amod	5	SENT_147	[p12l9t1871r370b1955],
5	ﬁnding	NN	O	ﬁnding	_	0	SENT_147	[p12l387t1871r627b1955],
6	that	WDT	O	that	det	7	SENT_147	[p12l643t1871r773b1934],
7	transformation	NN	O	transformation	dobj	19	SENT_147	[p12l789t1871r1291b1934],
8	of	IN	O	of	_	0	SENT_147	[p12l1310t1871r1383b1934],
9	NSCLC	NNP	O	NSCLC	prep_of	7	SENT_147	[p12l1391t1875r1647b1934],
10	into	IN	O	into	_	0	SENT_147	[p12l1666t1876r1796b1934],
11	the	DT	O	the	det	16	SENT_147	[p12l1815t1871r1918b1934],
12	smallcell	NN	O	smallcell	nn	16	SENT_147	[p12l1938t1871r2139b1934, p12l10t1974r124b2037],
13	lung	NN	O	lung	nn	16	SENT_147	[p12l144t1974r298b2058],
14	cancer	NN	O	cancer	nn	16	SENT_147	[p12l319t1997r543b2037],
15	(	CD	NUMBER	(	num	16	SENT_147	[p12l568t1975r820b2050],
16	SCLC	NN	ORGANIZATION	sclc	prep_into	7	SENT_147	[p12l568t1975r820b2050],
17	)	CD	NUMBER	)	num	18	SENT_147	[p12l568t1975r820b2050],
18	phenotype	NN	O	phenotype	nsubj	19	SENT_147	[p12l845t1974r1211b2058],
19	emerges	VBZ	O	emerge	rcmod	5	SENT_147	[p12l1234t1997r1514b2058],
20	in	IN	O	in	_	0	SENT_147	[p12l1537t1979r1604b2036],
21	5	CD	PERCENT	5	number	22	SENT_147	[p12l1628t1979r1857b2038],
22	—	CD	PERCENT	—	prep_in	19	SENT_147	[p12l1628t1979r1857b2038],
23	15	CD	PERCENT	15	num	24	SENT_147	[p12l1628t1979r1857b2038],
24	%	NN	PERCENT	%	dobj	19	SENT_147	[p12l1628t1979r1857b2038],
25	of	IN	O	of	_	0	SENT_147	[p12l1882t1974r1956b2037],
26	cases	NNS	O	case	prep_of	24	SENT_147	[p12l1969t1997r2140b2037],
27	receiving	VBG	O	receive	partmod	26	SENT_147	[p12l10t2081r314b2160],
28	treatment	NN	O	treatment	dobj	27	SENT_147	[p12l330t2088r658b2139],
29	with	IN	O	with	_	0	SENT_147	[p12l674t2076r823b2139],
30	TKIs	NNS	O	tki	prep_with	27	SENT_147	[p12l842t2068r1080b2139],
31	.51	CD	NUMBER	.51	num	30	SENT_147	[p12l842t2068r1080b2139],
32	This	DT	DATE	this	nsubj	34	SENT_147	[p12l1103t2076r1244b2139],
33	may	MD	DATE	may	aux	34	SENT_147	[p12l1263t2099r1408b2160],
34	indicate	VB	O	indicate	rcmod	30	SENT_147	[p12l1423t2076r1687b2139],
35	that	IN	O	that	complm	37	SENT_147	[p12l1704t2076r1835b2139],
36	there	EX	O	there	expl	37	SENT_147	[p12l1852t2076r2022b2139],
37	is	VBZ	O	be	ccomp	34	SENT_147	[p12l2041t2081r2090b2139],
38	a	DT	O	a	det	41	SENT_147	[p12l2110t2099r2144b2139],
39	minority	NN	O	minority	nn	41	SENT_147	[p12l9t2184r309b2263],
40	SCLC	NN	ORGANIZATION	sclc	nn	41	SENT_147	[p12l327t2183r522b2242],
41	subpopulation	NN	O	subpopulation	nsubj	37	SENT_147	[p12l544t2179r1029b2262],
42	originally	RB	O	originally	advmod	43	SENT_147	[p12l1051t2179r1375b2263],
43	present	JJ	DATE	present	amod	41	SENT_147	[p12l1391t2191r1638b2262],
44	that	IN	O	that	nsubjpass	46	SENT_147	[p12l1657t2179r1788b2242],
45	is	VBZ	O	be	auxpass	46	SENT_147	[p12l1809t2184r1858b2242],
46	selected	VBN	O	select	rcmod	41	SENT_147	[p12l1880t2179r2145b2242],
47	for	IN	O	for	prep	46	SENT_147	[p12l9t2282r107b2345],
48	by	IN	O	by	pcomp	47	SENT_147	[p12l125t2282r210b2366],
49	therapy	NN	O	therapy	pobj	48	SENT_147	[p12l228t2282r497b2366],
50	.	.	O	.	_	0	SENT_147	[p12l228t2282r497b2366],

1	Alternatively	RB	O	alternatively	advmod	7	SENT_148	[p12l521t2282r975b2366],
2	,	,	O	,	_	0	SENT_148	[p12l521t2282r975b2366],
3	the	DT	O	the	det	4	SENT_148	[p12l998t2282r1105b2345],
4	ﬁnding	NN	O	ﬁnding	nsubj	7	SENT_148	[p12l1126t2282r1375b2366],
5	may	MD	O	may	aux	7	SENT_148	[p12l1395t2305r1543b2366],
6	be	VB	O	be	cop	7	SENT_148	[p12l1559t2282r1639b2345],
7	attributable	JJ	O	attributable	_	0	SENT_148	[p12l1662t2282r2055b2345],
8	to	TO	O	to	_	0	SENT_148	[p12l2076t2294r2143b2345],
9	tumor	NN	O	tumor	nn	10	SENT_148	[p12l8t2397r228b2448],
10	plasticity	NN	O	plasticity	prep_to	7	SENT_148	[p12l250t2385r569b2469],
11	via	IN	O	via	_	0	SENT_148	[p12l587t2390r690b2448],
12	unknown	JJ	O	unknown	amod	13	SENT_148	[p12l714t2385r1050b2448],
13	mechanisms	NNS	O	mechanism	prep_via	10	SENT_148	[p12l1075t2385r1527b2448],
14	.	.	O	.	_	0	SENT_148	[p12l1075t2385r1527b2448],

1	A	DT	O	a	det	2	SENT_149	[p12l1554t2389r1612b2447],
2	ﬁnding	NN	O	ﬁnding	nsubj	7	SENT_149	[p12l1636t2385r1889b2469],
3	from	IN	O	from	_	0	SENT_149	[p12l1911t2385r2082b2448],
4	a	DT	O	a	det	6	SENT_149	[p12l2108t2408r2143b2448],
5	recent	JJ	O	recent	amod	6	SENT_149	[p12l10t2500r221b2551],
6	study	NN	O	study	prep_from	2	SENT_149	[p12l243t2488r430b2572],
7	illustrates	VBZ	O	illustrate	ccomp	32	SENT_149	[p12l449t2488r778b2551],
8	another	DT	O	another	det	10	SENT_149	[p12l802t2488r1069b2551],
9	interesting	JJ	O	interesting	amod	10	SENT_149	[p12l1090t2493r1456b2572],
10	form	NN	O	form	dobj	7	SENT_149	[p12l1476t2488r1645b2551],
11	of	IN	O	of	_	0	SENT_149	[p12l1668t2488r1743b2551],
12	phenotypic	JJ	O	phenotypic	amod	13	SENT_149	[p12l1754t2488r2141b2572],
13	heterogeneity	NN	O	heterogeneity	prep_of	10	SENT_149	[p12l8t2591r486b2675],
14	;	:	O	;	_	0	SENT_149	[p12l8t2591r486b2675],
15	NSCLC	NN	O	nsclc	dep	10	SENT_149	[p12l508t2595r769b2654],
16	with	IN	O	with	_	0	SENT_149	[p12l788t2591r939b2654],
17	squamous	JJ	O	squamous	amod	18	SENT_149	[p12l961t2614r1302b2674],
18	morphology	NN	O	morphology	prep_with	15	SENT_149	[p12l1323t2591r1746b2675],
19	and	CC	O	and	_	0	SENT_149	[p12l1764t2591r1889b2654],
20	immunophenotype	NN	O	immunophenotype	nn	21	SENT_149	[p12l1909t2596r2140b2654, p12l9t2694r445b2778],
21	(	NN	O	(	conj_and	18	SENT_149	[p12l467t2694r571b2778],
22	by	IN	O	by	dep	15	SENT_149	[p12l467t2694r571b2778],
23	immunohistochemistry	NN	O	immunohistochemistry	nn	24	SENT_149	[p12l586t2694r1411b2778],
24	)	NN	O	)	pobj	22	SENT_149	[p12l586t2694r1411b2778],
25	,	,	O	,	_	0	SENT_149	[p12l586t2694r1411b2778],
26	and	CC	O	and	_	0	SENT_149	[p12l1431t2694r1554b2757],
27	containing	VBG	O	contain	dep	15	SENT_149	[p12l1571t2699r1924b2778],
28	EGFR	NN	ORGANIZATION	egfr	nn	29	SENT_149	[p12l1940t2698r2144b2757],
29	mutations	NNS	O	mutation	dobj	27	SENT_149	[p12l9t2802r376b2869],
30	,	,	O	,	_	0	SENT_149	[p12l9t2802r376b2869],
31	was	VBD	O	be	auxpass	32	SENT_149	[p12l398t2820r526b2860],
32	reclassiﬁed	VBN	O	reclassiﬁed	_	0	SENT_149	[p12l549t2797r929b2860],
33	after	IN	O	after	_	0	SENT_149	[p12l951t2797r1105b2860],
34	a	DT	O	a	det	36	SENT_149	[p12l1128t2820r1163b2860],
35	secondary	JJ	O	secondary	amod	36	SENT_149	[p12l1185t2797r1541b2881],
36	biopsy	NN	O	biopsy	prep_after	32	SENT_149	[p12l1558t2797r1788b2881],
37	as	IN	O	as	_	0	SENT_149	[p12l1808t2820r1872b2860],
38	“	NN	O	“	prep_as	36	SENT_149	[p12l1897t2797r2145b2860],
39	mixed	JJ	O	mixed	amod	40	SENT_149	[p12l1897t2797r2145b2860],
40	adeno-squamous	JJ	O	adeno-squamous	amod	36	SENT_149	[p12l10t2901r582b2984],
41	or	CC	O	or	_	0	SENT_149	[p12l602t2924r673b2964],
42	adenocarcinomas	NNS	O	adenocarcinoma	amod	36	SENT_149	[p12l691t2901r1277b2964],
43	with	IN	O	with	_	0	SENT_149	[p12l1294t2901r1444b2964],
44	squamous	JJ	O	squamous	amod	45	SENT_149	[p12l1463t2924r1800b2984],
45	morphology	NN	O	morphology	prep_with	42	SENT_149	[p12l1819t2901r2138b2984, p12l10t2995r229b3087],
46	”	CD	NUMBER	”	num	47	SENT_149	[p12l1819t2901r2138b2984, p12l10t2995r229b3087],
47	.52	CD	NUMBER	.52	dep	40	SENT_149	[p12l1819t2901r2138b2984, p12l10t2995r229b3087],
48	Furthermore	RB	O	furthermore	advmod	47	SENT_149	[p12l252t3003r702b3075],
49	,	,	O	,	_	0	SENT_149	[p12l252t3003r702b3075],
50	in	IN	O	in	_	0	SENT_149	[p12l724t3008r790b3065],
51	~	NN	O	~	prep_in	32	SENT_149	[p12l813t3009r1001b3068],
52	20	CD	PERCENT	20	number	53	SENT_149	[p12l813t3009r1001b3068],
53	%	NN	PERCENT	%	amod	51	SENT_149	[p12l813t3009r1001b3068],
54	of	IN	O	of	_	0	SENT_149	[p12l1024t3003r1097b3066],
55	patients	NNS	O	patient	prep_of	51	SENT_149	[p12l1107t3008r1370b3086],
56	there	EX	O	there	expl	57	SENT_149	[p12l1391t3003r1561b3066],
57	is	VBZ	O	be	rcmod	51	SENT_149	[p12l1583t3008r1632b3066],
58	also	RB	O	also	advmod	57	SENT_149	[p12l1654t3003r1782b3066],
59	intriguing	JJ	O	intriguing	amod	60	SENT_149	[p12l1805t3008r2143b3087],
60	evidence	NN	O	evidence	nsubj	57	SENT_149	[p12l10t3106r308b3169],
61	of	IN	O	of	_	0	SENT_149	[p12l330t3106r404b3169],
62	the	DT	O	the	det	63	SENT_149	[p12l415t3106r521b3169],
63	emergence	NN	O	emergence	prep_of	60	SENT_149	[p12l544t3129r910b3190],
64	of	IN	O	of	_	0	SENT_149	[p12l933t3106r1007b3169],
65	a	DT	O	a	det	67	SENT_149	[p12l1020t3129r1054b3169],
66	drug	NN	O	drug	nn	67	SENT_149	[p12l1076t3106r1555b3190],
67	—	NN	O	—	prep_of	63	SENT_149	[p12l1076t3106r1555b3190],
68	resistant	JJ	O	resistant	amod	77	SENT_149	[p12l1076t3106r1555b3190],
69	and	CC	O	and	_	0	SENT_149	[p12l1576t3106r1702b3169],
70	more	RBR	O	more	advmod	71	SENT_149	[p12l1723t3129r1900b3169],
71	malignant	JJ	O	malignant	amod	77	SENT_149	[p12l1922t3106r2140b3190, p12l9t3221r172b3281],
72	,	,	O	,	_	0	SENT_149	[p12l1922t3106r2140b3190, p12l9t3221r172b3281],
73	invasive	JJ	O	invasive	amod	77	SENT_149	[p12l192t3214r467b3281],
74	,	,	O	,	_	0	SENT_149	[p12l192t3214r467b3281],
75	and	CC	O	and	_	0	SENT_149	[p12l487t3209r609b3272],
76	metastatic	JJ	O	metastatic	amod	77	SENT_149	[p12l625t3214r958b3272],
77	phenotype	NN	O	phenotype	nsubjpass	32	SENT_149	[p12l974t3209r1322b3293],
78	with	IN	O	with	_	0	SENT_149	[p12l1338t3209r1485b3272],
79	stem	NN	O	stem	nn	81	SENT_149	[p12l1503t3221r1657b3272],
80	cell	NN	O	cell	nn	81	SENT_149	[p12l1675t3209r1943b3272],
81	—	NN	O	—	prep_with	77	SENT_149	[p12l1675t3209r1943b3272],
82	like	IN	O	like	_	0	SENT_149	[p12l1675t3209r1943b3272],
83	traits	NNS	O	trait	prep_like	81	SENT_149	[p12l1960t3214r2139b3272],
84	.	.	O	.	_	0	SENT_149	[p12l1960t3214r2139b3272],

1	This	DT	O	this	nsubjpass	14	SENT_150	[p12l9t3312r149b3375],
2	is	VBZ	O	be	auxpass	3	SENT_150	[p12l169t3317r217b3375],
3	known	VBN	O	know	dep	24	SENT_150	[p12l235t3312r468b3375],
4	as	IN	O	as	_	0	SENT_150	[p12l487t3335r550b3375],
5	the	DT	O	the	det	9	SENT_150	[p12l568t3312r672b3375],
6	epithelial	JJ	O	epithelial	amod	9	SENT_150	[p12l691t3312r1501b3396],
7	—	NN	O	—	nn	9	SENT_150	[p12l691t3312r1501b3396],
8	mesenchymal	JJ	O	mesenchymal	amod	9	SENT_150	[p12l691t3312r1501b3396],
9	transition	NN	O	transition	prep_as	3	SENT_150	[p12l1517t3317r1841b3375],
10	and	CC	O	and	_	0	SENT_150	[p12l1861t3312r1984b3375],
11	may	MD	O	may	aux	14	SENT_150	[p12l2002t3335r2146b3396],
12	be	VB	O	be	auxpass	14	SENT_150	[p12l7t3414r88b3477],
13	partly	RB	O	partly	advmod	14	SENT_150	[p12l109t3414r316b3498],
14	linked	VBN	O	link	conj_and	3	SENT_150	[p12l333t3414r552b3477],
15	to	TO	O	to	_	0	SENT_150	[p12l573t3426r639b3477],
16	AXL	NNP	ORGANIZATION	AXL	nn	17	SENT_150	[p12l662t3418r825b3476],
17	activation	NN	O	activation	prep_to	14	SENT_150	[p12l848t3406r1264b3477],
18	.51	CD	NUMBER	.51	num	20	SENT_150	[p12l848t3406r1264b3477],
19	Epithelial	JJ	O	epithelial	amod	20	SENT_150	[p12l1291t3414r2144b3498],
20	—	NN	O	—	dobj	3	SENT_150	[p12l1291t3414r2144b3498],
21	mesenchymal	JJ	O	mesenchymal	amod	22	SENT_150	[p12l1291t3414r2144b3498],
22	transition	NN	O	transition	dep	20	SENT_150	[p12l8t3522r347b3580],
23	is	VBZ	O	be	auxpass	24	SENT_150	[p12l370t3522r421b3580],
24	regulated	VBN	O	regulate	_	0	SENT_150	[p12l445t3517r768b3601],
25	by	IN	O	by	_	0	SENT_150	[p12l788t3517r874b3601],
26	a	DT	O	a	det	27	SENT_150	[p12l894t3540r929b3580],
27	variety	NN	O	variety	nsubj	35	SENT_150	[p12l948t3522r1190b3601],
28	of	IN	O	of	_	0	SENT_150	[p12l1210t3517r1285b3580],
29	factors	NNS	O	factor	prep_of	27	SENT_150	[p12l1299t3517r1550b3589],
30	,	,	O	,	_	0	SENT_150	[p12l1299t3517r1550b3589],
31	including	VBG	O	include	_	0	SENT_150	[p12l1574t3517r1906b3601],
32	receptor	NN	O	receptor	nn	33	SENT_150	[p12l1928t3539r2141b3600, p12l8t3632r106b3683],
33	TKs	NNS	O	tk	prep_including	35	SENT_150	[p12l124t3623r279b3692],
34	,	,	O	,	_	0	SENT_150	[p12l124t3623r279b3692],
35	transforming	VBG	O	transform	agent	24	SENT_150	[p12l299t3620r743b3704],
36	growth	NN	O	growth	nn	37	SENT_150	[p12l761t3620r999b3704],
37	factor	NN	O	factor	dobj	35	SENT_150	[p12l1019t3620r1300b3704],
38	—	CD	NUMBER	—	num	37	SENT_150	[p12l1019t3620r1300b3704],
39	[	NN	O	[	nsubjpass	24	SENT_150	[p12l1019t3620r1300b3704],
40	3	CD	NUMBER	3	num	39	SENT_150	[p12l1019t3620r1300b3704],
41	,	,	O	,	_	0	SENT_150	[p12l1019t3620r1300b3704],
42	Notch	NN	O	notch	nn	47	SENT_150	[p12l1320t3620r1544b3692],
43	,	,	O	,	_	0	SENT_150	[p12l1320t3620r1544b3692],
44	Snail	NN	PERSON	snail	dep	47	SENT_150	[p12l1566t3620r1728b3683],
45	family	NN	O	family	nn	47	SENT_150	[p12l1747t3620r1960b3704],
46	transcription	NN	O	transcription	nn	47	SENT_150	[p12l1975t3632r2140b3683, p12l10t3728r312b3806],
47	factors	NNS	O	factor	nsubjpass	24	SENT_150	[p12l333t3723r579b3795],
48	,	,	O	,	_	0	SENT_150	[p12l333t3723r579b3795],
49	and	CC	O	and	_	0	SENT_150	[p12l603t3723r729b3786],
50	tumor	NN	O	tumor	nn	51	SENT_150	[p12l749t3723r1268b3786],
51	—	NN	O	—	nsubjpass	24	SENT_150	[p12l749t3723r1268b3786],
52	stromal	JJ	O	stromal	amod	53	SENT_150	[p12l749t3723r1268b3786],
53	interactions	NNS	O	interaction	dep	51	SENT_150	[p12l1289t3728r1708b3786],
54	.	.	O	.	_	0	SENT_150	[p12l1289t3728r1708b3786],

1	Suppression	NN	O	suppression	_	0	SENT_151	[p12l1734t3727r2144b3806],
2	of	IN	O	of	_	0	SENT_151	[p13l10t17r83b80],
3	cell	NN	O	cell	nn	4	SENT_151	[p13l95t17r207b80],
4	adhesion	NN	O	adhesion	prep_of	1	SENT_151	[p13l228t17r531b80],
5	protein	NN	O	protein	dep	4	SENT_151	[p13l550t22r795b100],
6	E-cadherin	NN	MISC	e-cadherin	dobj	5	SENT_151	[p13l816t17r1193b80],
7	and	CC	O	and	_	0	SENT_151	[p13l1215t17r1340b80],
8	increased	VBN	O	increase	amod	9	SENT_151	[p13l1361t17r1680b80],
9	expression	NN	O	expression	dobj	5	SENT_151	[p13l1701t22r2057b100],
10	of	IN	O	of	_	0	SENT_151	[p13l2078t17r2152b80],
11	Vimentin	NN	LOCATION	vimentin	prep_of	9	SENT_151	[p13l7t125r314b183],
12	and	CC	O	and	_	0	SENT_151	[p13l336t120r487b186],
13	/	:	O	/	punct	19	SENT_151	[p13l336t120r487b186],
14	or	CC	O	or	_	0	SENT_151	[p13l492t143r563b183],
15	ﬁbronectin	NN	O	ﬁbronectin	nsubj	19	SENT_151	[p13l582t120r954b183],
16	are	VBP	O	be	cop	19	SENT_151	[p13l976t143r1075b183],
17	common	JJ	O	common	amod	19	SENT_151	[p13l1096t143r1400b183],
18	end	NN	O	end	nn	19	SENT_151	[p13l1422t120r1546b183],
19	points	NNS	O	point	dep	6	SENT_151	[p13l1565t125r1774b203],
20	and	CC	O	and	_	0	SENT_151	[p13l1796t120r1922b183],
21	useful	JJ	O	useful	amod	22	SENT_151	[p13l1941t120r2144b183],
22	epithelial	JJ	O	epithelial	amod	26	SENT_151	[p13l10t222r824b306],
23	—	NN	O	—	nn	26	SENT_151	[p13l10t222r824b306],
24	mesenchymal	JJ	O	mesenchymal	amod	26	SENT_151	[p13l10t222r824b306],
25	transition	NN	O	transition	nn	26	SENT_151	[p13l842t227r1168b285],
26	markers	NNS	O	marker	dep	6	SENT_151	[p13l1187t214r1615b285],
27	.53	CD	NUMBER	.53	num	28	SENT_151	[p13l1187t214r1615b285],
28	>	JJR	O	>	conj_and	6	SENT_151	[p13l1187t214r1615b285],
29	54	CD	NUMBER	54	dep	28	SENT_151	[p13l1187t214r1615b285],

1	Of	IN	O	of	_	0	SENT_152	[p13l84t325r179b388],
2	note	NN	O	note	prep_of	15	SENT_152	[p13l193t337r362b397],
3	,	,	O	,	_	0	SENT_152	[p13l193t337r362b397],
4	many	JJ	O	many	nsubj	15	SENT_152	[p13l386t348r582b409],
5	of	IN	O	of	_	0	SENT_152	[p13l602t325r677b388],
6	these	DT	O	these	det	7	SENT_152	[p13l689t325r867b388],
7	mechanisms	NNS	O	mechanism	prep_of	4	SENT_152	[p13l890t325r1322b388],
8	that	WDT	O	that	nsubj	9	SENT_152	[p13l1344t325r1480b388],
9	cause	VBP	O	cause	rcmod	7	SENT_152	[p13l1503t348r1689b388],
10	resistance	NN	O	resistance	dobj	9	SENT_152	[p13l1712t330r2050b388],
11	to	TO	O	to	_	0	SENT_152	[p13l2073t337r2140b388],
12	TKIs	NNS	O	tki	prep_to	9	SENT_152	[p13l9t431r175b491],
13	in	IN	O	in	_	0	SENT_152	[p13l196t433r262b490],
14	NSCLC	NNP	ORGANIZATION	NSCLC	prep_in	12	SENT_152	[p13l282t432r543b491],
15	suggest	VBP	O	suggest	_	0	SENT_152	[p13l565t440r812b512],
16	the	DT	O	the	det	17	SENT_152	[p13l830t428r936b491],
17	use	NN	O	use	dobj	15	SENT_152	[p13l956t451r1067b491],
18	of	IN	O	of	_	0	SENT_152	[p13l1088t428r1161b491],
19	various	JJ	O	various	amod	22	SENT_152	[p13l1169t433r1419b491],
20	actionable	JJ	O	actionable	amod	22	SENT_152	[p13l1441t428r1788b491],
21	therapeutic	JJ	O	therapeutic	amod	22	SENT_152	[p13l1808t428r2138b511, p13l8t536r92b594],
22	maneuvers	NNS	O	maneuver	prep_of	17	SENT_152	[p13l115t554r489b594],
23	depending	VBG	O	depend	_	0	SENT_152	[p13l513t531r881b615],
24	on	IN	O	on	prepc_depending_on	15	SENT_152	[p13l903t554r989b594],
25	the	DT	O	the	det	29	SENT_152	[p13l1010t531r1118b594],
26	molecular	JJ	O	molecular	amod	29	SENT_152	[p13l1140t531r1488b594],
27	or	CC	O	or	_	0	SENT_152	[p13l1510t554r1583b594],
28	phenotypic	JJ	O	phenotypic	conj_or	26	SENT_152	[p13l1603t531r1991b615],
29	evidence	NN	O	evidence	pobj	15	SENT_152	[p13l2014t536r2139b594, p13l10t634r225b697],
30	.	.	O	.	_	0	SENT_152	[p13l2014t536r2139b594, p13l10t634r225b697],

1	These	DT	O	these	det	3	SENT_153	[p13l251t634r447b697],
2	therapeutic	JJ	O	therapeutic	amod	3	SENT_153	[p13l469t634r860b717],
3	approaches	NNS	O	approach	nsubj	4	SENT_153	[p13l884t634r1270b717],
4	include	VBP	O	include	_	0	SENT_153	[p13l1293t634r1546b697],
5	the	DT	O	the	det	7	SENT_153	[p13l1568t634r1675b697],
6	use	NN	O	use	nn	7	SENT_153	[p13l1698t657r1809b697],
7	(	NN	O	(	dobj	4	SENT_153	[p13l1836t634r2047b710],
8	alone	RB	O	alone	dep	7	SENT_153	[p13l1836t634r2047b710],
9	or	CC	O	or	_	0	SENT_153	[p13l2071t657r2143b697],
10	in	IN	O	in	dep	7	SENT_153	[p13l10t742r77b799],
11	combination	NN	O	combination	pobj	10	SENT_153	[p13l101t737r545b801],
12	with	IN	O	with	_	0	SENT_153	[p13l567t737r722b800],
13	EGFR	NN	ORGANIZATION	egfr	nn	14	SENT_153	[p13l745t741r959b801],
14	TKIs	NNS	O	tki	nsubj	43	SENT_153	[p13l979t738r1176b814],
15	)	CD	NUMBER	)	dep	14	SENT_153	[p13l979t738r1176b814],
16	of	IN	O	of	_	0	SENT_153	[p13l1204t737r1279b801],
17	inhibitors	NNS	O	inhibitor	prep_of	15	SENT_153	[p13l1293t737r1632b800],
18	of	IN	O	of	_	0	SENT_153	[p13l1657t737r1732b800],
19	MET	NN	O	met	prep_of	17	SENT_153	[p13l1745t740r1934b809],
20	,	,	O	,	_	0	SENT_153	[p13l1745t740r1934b809],
21	AXL	NNP	ORGANIZATION	AXL	conj_or	19	SENT_153	[p13l1958t741r2139b809],
22	,	,	O	,	_	0	SENT_153	[p13l1958t741r2139b809],
23	PI3	NN	O	pi3	nn	25	SENT_153	[p13l10t845r121b903],
24	kinase	NN	O	kinase	nn	25	SENT_153	[p13l144t840r361b903],
25	(	NN	O	(	conj_or	19	SENT_153	[p13l385t840r484b917],
26	or	CC	O	or	_	0	SENT_153	[p13l385t840r484b917],
27	downstream	JJ	O	downstream	amod	28	SENT_153	[p13l504t840r928b903],
28	targets	NNS	O	target	conj_or	19	SENT_153	[p13l947t852r1173b924],
29	thereof	RB	O	thereof	advmod	17	SENT_153	[p13l1194t840r1491b917],
30	)	RB	O	)	advmod	15	SENT_153	[p13l1194t840r1491b917],
31	,	,	O	,	_	0	SENT_153	[p13l1194t840r1491b917],
32	and	CC	O	and	_	0	SENT_153	[p13l1514t840r1640b903],
33	IKKB	NN	O	ikkb	conj_and	14	SENT_153	[p13l1661t845r1869b912],
34	,	,	O	,	_	0	SENT_153	[p13l1661t845r1869b912],
35	and	CC	O	and	_	0	SENT_153	[p13l1892t840r2018b903],
36	the	DT	O	the	det	37	SENT_153	[p13l2037t840r2143b903],
37	introduction	NN	O	introduction	conj_and	14	SENT_153	[p13l9t943r441b1006],
38	of	IN	O	of	_	0	SENT_153	[p13l462t943r536b1006],
39	SCLC	NNP	ORGANIZATION	SCLC	nn	40	SENT_153	[p13l547t947r742b1006],
40	chemotherapy	NN	O	chemotherapy	prep_of	37	SENT_153	[p13l764t943r1253b1027],
41	or	CC	O	or	_	0	SENT_153	[p13l1270t966r1341b1006],
42	drugs	NNS	O	drug	prep_of	37	SENT_153	[p13l1361t943r1551b1027],
43	acting	VBG	O	act	prepc_with	4	SENT_153	[p13l1573t948r1781b1027],
44	on	IN	O	on	_	0	SENT_153	[p13l1800t966r1885b1006],
45	epithelial	JJ	O	epithelial	amod	49	SENT_153	[p13l1906t943r2140b1026, p13l8t1045r627b1129],
46	—	NN	O	—	nn	49	SENT_153	[p13l1906t943r2140b1026, p13l8t1045r627b1129],
47	mesenchymal	JJ	O	mesenchymal	amod	49	SENT_153	[p13l1906t943r2140b1026, p13l8t1045r627b1129],
48	transition	NN	O	transition	nn	49	SENT_153	[p13l646t1050r978b1108],
49	cel1s53	NN	O	cel1s53	prep_on	43	SENT_153	[p13l999t1037r1223b1117],
50	,	,	O	,	_	0	SENT_153	[p13l999t1037r1223b1117],
51	together	RB	O	together	_	0	SENT_153	[p13l1244t1045r1528b1129],
52	with	IN	O	with	_	0	SENT_153	[p13l1546t1045r1698b1108],
53	inhibition	NN	O	inhibition	prep_together_with	49	SENT_153	[p13l1718t1045r2057b1108],
54	of	IN	O	of	_	0	SENT_153	[p13l2078t1045r2151b1108],
55	transforming	VBG	O	transform	prepc_of	53	SENT_153	[p13l8t1147r462b1231],
56	growth	NN	O	growth	nn	57	SENT_153	[p13l482t1147r725b1231],
57	factor	NN	O	factor	dobj	55	SENT_153	[p13l746t1140r1078b1231],
58	—	CD	NUMBER	—	num	57	SENT_153	[p13l746t1140r1078b1231],
59	[	NN	O	[	dep	49	SENT_153	[p13l746t1140r1078b1231],
60	355	CD	NUMBER	355	num	59	SENT_153	[p13l746t1140r1078b1231],

1	New	NNP	O	New	_	0	SENT_154	[p13l82t1255r266b1313],
2	-	:	O	-	_	0	SENT_154	[p13l82t1255r266b1313],
3	generation	NN	O	generation	nn	5	SENT_154	[p13l273t1255r638b1334],
4	irreversible	JJ	O	irreversible	amod	5	SENT_154	[p13l660t1250r1043b1313],
5	inhibitors	NNS	O	inhibitor	dep	1	SENT_154	[p13l1065t1250r1397b1313],
6	such	JJ	O	such	_	0	SENT_154	[p13l1421t1250r1576b1313],
7	as	IN	O	as	_	0	SENT_154	[p13l1598t1273r1663b1313],
8	afatinib	JJ	O	afatinib	amod	11	SENT_154	[p13l1686t1250r1943b1313],
9	show	NN	O	show	nn	11	SENT_154	[p13l1967t1250r2146b1313],
10	potent	JJ	O	potent	amod	11	SENT_154	[p13l8t1365r244b1436],
11	activity	NN	O	activity	prep_such_as	5	SENT_154	[p13l275t1358r544b1437],
12	against	IN	O	against	_	0	SENT_154	[p13l574t1358r827b1437],
13	mutant	JJ	O	mutant	amod	14	SENT_154	[p13l858t1365r1119b1416],
14	EGFR	NN	ORGANIZATION	egfr	prep_against	11	SENT_154	[p13l1150t1357r1369b1416],
15	with	IN	O	with	_	0	SENT_154	[p13l1396t1353r1557b1416],
16	the	DT	O	the	det	21	SENT_154	[p13l1588t1353r1700b1416],
17	second-site	JJ	O	second-site	amod	21	SENT_154	[p13l1733t1353r2142b1416],
18	p.	NN	O	p.	nn	21	SENT_154	[p13l8t1459r315b1539],
19	T79OM	NN	O	t79om	nn	21	SENT_154	[p13l8t1459r315b1539],
20	gatekeeper	NN	O	gatekeeper	nn	21	SENT_154	[p13l335t1456r692b1540],
21	mutation	NN	O	mutation	prep_with	14	SENT_154	[p13l709t1461r1016b1519],
22	that	WDT	O	that	nsubj	23	SENT_154	[p13l1033t1456r1164b1519],
23	reduces	VBZ	O	reduce	rcmod	5	SENT_154	[p13l1181t1456r1434b1519],
24	drug	NN	O	drug	nn	25	SENT_154	[p13l1453t1456r1612b1540],
25	binding	NN	O	binding	dobj	23	SENT_154	[p13l1627t1456r1905b1540],
26	,	,	O	,	_	0	SENT_154	[p13l1627t1456r1905b1540],
27	as	RB	O	as	_	0	SENT_154	[p13l1926t1479r1989b1519],
28	well	RB	O	well	_	0	SENT_154	[p13l2007t1456r2141b1519],
29	as	IN	O	as	_	0	SENT_154	[p13l10t1582r72b1622],
30	against	IN	O	against	_	0	SENT_154	[p13l92t1564r322b1643],
31	wild	JJ	O	wild	amod	32	SENT_154	[p13l338t1559r655b1643],
32	—	NN	O	—	prep_against	33	SENT_154	[p13l338t1559r655b1643],
33	type	NN	O	type	amod	34	SENT_154	[p13l338t1559r655b1643],
34	EGFR	NN	ORGANIZATION	egfr	conj_and	25	SENT_154	[p13l673t1563r877b1622],
35	(	CD	NUMBER	(	num	36	SENT_154	[p13l896t1559r1146b1642],
36	Figure	NN	O	figure	dep	34	SENT_154	[p13l896t1559r1146b1642],
37	1	CD	NUMBER	1	num	38	SENT_154	[p13l1169t1560r1246b1635],
38	)	NN	O	)	dep	34	SENT_154	[p13l1169t1560r1246b1635],
39	.	.	O	.	_	0	SENT_154	[p13l1169t1560r1246b1635],

1	Although	IN	O	although	dep	128	SENT_155	[p13l1266t1559r1583b1643],
2	activity	NN	O	activity	dep	128	SENT_155	[p13l1602t1564r1844b1643],
3	has	VBZ	O	have	dep	128	SENT_155	[p13l1858t1559r1967b1622],
4	been	VBN	O	be	dep	128	SENT_155	[p13l1984t1559r2143b1622],
5	observed	VBN	O	observe	dep	128	SENT_155	[p13l10t1662r322b1725],
6	in	IN	O	in	dep	128	SENT_155	[p13l343t1667r410b1724],
7	preclinical	JJ	O	preclinical	dep	128	SENT_155	[p13l431t1662r792b1745],
8	models	NNS	O	model	dep	128	SENT_155	[p13l812t1662r1080b1734],
9	,	,	O	,	_	0	SENT_155	[p13l812t1662r1080b1734],
10	clinical	JJ	O	clinical	dep	128	SENT_155	[p13l1104t1662r1350b1725],
11	activity	NN	O	activity	dep	128	SENT_155	[p13l1371t1667r1625b1746],
12	in	IN	O	in	dep	128	SENT_155	[p13l1643t1667r1710b1724],
13	geﬁtinib	NN	O	geﬁtinib	dep	128	SENT_155	[p13l1732t1662r2043b1746],
14	-	:	O	-	_	0	SENT_155	[p13l1732t1662r2043b1746],
15	or	CC	O	or	dep	128	SENT_155	[p13l2069t1685r2142b1725],
16	erlotinib	JJ	O	erlotinib	dep	128	SENT_155	[p13l10t1764r600b1827],
17	—	NN	O	—	dep	128	SENT_155	[p13l10t1764r600b1827],
18	resistant	JJ	O	resistant	dep	128	SENT_155	[p13l10t1764r600b1827],
19	tumors	NNS	O	tumor	dep	128	SENT_155	[p13l617t1776r854b1827],
20	is	VBZ	O	be	dep	128	SENT_155	[p13l874t1769r922b1827],
21	yet	RB	O	yet	dep	128	SENT_155	[p13l939t1776r1038b1848],
22	to	TO	O	to	dep	128	SENT_155	[p13l1054t1776r1118b1827],
23	be	VB	O	be	dep	128	SENT_155	[p13l1136t1764r1214b1827],
24	observed	VBN	O	observe	dep	128	SENT_155	[p13l1233t1756r1611b1827],
25	.56	CD	NUMBER	.56	dep	128	SENT_155	[p13l1233t1756r1611b1827],
26	Of	IN	O	of	dep	128	SENT_155	[p13l1632t1764r1725b1827],
27	note	NN	O	note	dep	128	SENT_155	[p13l1733t1776r1894b1836],
28	,	,	O	,	_	0	SENT_155	[p13l1733t1776r1894b1836],
29	studies	NNS	O	study	dep	128	SENT_155	[p13l1915t1764r2142b1827],
30	in	IN	O	in	dep	128	SENT_155	[p13l9t1872r75b1929],
31	a	DT	O	a	dep	128	SENT_155	[p13l94t1890r129b1930],
32	human	JJ	O	human	dep	128	SENT_155	[p13l146t1867r384b1930],
33	NSCLC	NN	O	nsclc	dep	128	SENT_155	[p13l402t1871r661b1930],
34	xenograft	NN	O	xenograft	dep	128	SENT_155	[p13l678t1867r999b1951],
35	model	NN	O	model	dep	128	SENT_155	[p13l1017t1867r1229b1930],
36	showed	VBD	O	show	dep	128	SENT_155	[p13l1249t1867r1501b1930],
37	that	IN	O	that	dep	128	SENT_155	[p13l1518t1867r1649b1930],
38	sensitive	JJ	O	sensitive	dep	128	SENT_155	[p13l1668t1872r1950b1930],
39	wildtype	JJ	O	wildtype	dep	128	SENT_155	[p13l1967t1867r2140b1930, p13l8t1982r151b2054],
40	and	CC	O	and	dep	128	SENT_155	[p13l172t1970r295b2033],
41	drug	NN	O	drug	dep	128	SENT_155	[p13l314t1970r784b2054],
42	—	CD	NUMBER	—	dep	128	SENT_155	[p13l314t1970r784b2054],
43	resistant	JJ	O	resistant	dep	128	SENT_155	[p13l314t1970r784b2054],
44	EGFR-mutant	JJ	O	egfr-mutant	dep	128	SENT_155	[p13l802t1974r1277b2033],
45	cells	NNS	O	cell	dep	128	SENT_155	[p13l1296t1970r1435b2033],
46	exhibited	VBD	O	exhibit	dep	128	SENT_155	[p13l1455t1970r1765b2033],
47	differences	NNS	O	difference	dep	128	SENT_155	[p13l1784t1970r2143b2033],
48	in	IN	O	in	dep	128	SENT_155	[p13l10t2078r77b2135],
49	growth	NN	O	growth	dep	128	SENT_155	[p13l99t2073r344b2157],
50	kinetics	NNS	O	kinetics	dep	128	SENT_155	[p13l365t2073r651b2145],
51	,	,	O	,	_	0	SENT_155	[p13l365t2073r651b2145],
52	with	IN	O	with	dep	128	SENT_155	[p13l673t2073r827b2136],
53	EGF	NN	ORGANIZATION	egf	dep	128	SENT_155	[p13l849t2077r1003b2136],
54	R	NN	O	r	dep	128	SENT_155	[p13l1008t2078r1061b2136],
55	p.	NN	O	p.	dep	128	SENT_155	[p13l1080t2076r1397b2156],
56	T79OM	NN	O	t79om	dep	128	SENT_155	[p13l1080t2076r1397b2156],
57	mutant	JJ	O	mutant	dep	128	SENT_155	[p13l1419t2085r1670b2136],
58	cells	NNS	O	cell	dep	128	SENT_155	[p13l1691t2073r1836b2136],
59	growing	VBG	O	grow	dep	128	SENT_155	[p13l1859t2078r2144b2157],
60	more	RBR	O	more	dep	128	SENT_155	[p13l9t2199r188b2239],
61	slowly	RB	O	slowly	dep	128	SENT_155	[p13l211t2176r427b2260],
62	than	IN	O	than	dep	128	SENT_155	[p13l444t2176r600b2239],
63	wild	JJ	O	wild	dep	128	SENT_155	[p13l620t2176r949b2260],
64	—	NN	O	—	dep	128	SENT_155	[p13l620t2176r949b2260],
65	type	NN	O	type	dep	128	SENT_155	[p13l620t2176r949b2260],
66	ones	NNS	O	one	dep	128	SENT_155	[p13l972t2199r1144b2248],
67	;	:	O	;	_	0	SENT_155	[p13l972t2199r1144b2248],
68	based	VBN	O	base	dep	128	SENT_155	[p13l1166t2176r1363b2239],
69	on	IN	O	on	dep	128	SENT_155	[p13l1385t2199r1472b2239],
70	this	DT	O	this	dep	128	SENT_155	[p13l1492t2176r1617b2239],
71	ﬁnding	NN	O	ﬁnding	dep	128	SENT_155	[p13l1639t2176r1904b2260],
72	,	,	O	,	_	0	SENT_155	[p13l1639t2176r1904b2260],
73	evolutionary	JJ	O	evolutionary	dep	128	SENT_155	[p13l1928t2176r2140b2239, p13l8t2284r263b2363],
74	modeling	NN	O	modeling	dep	128	SENT_155	[p13l282t2279r613b2363],
75	led	VBD	O	lead	dep	128	SENT_155	[p13l632t2279r737b2342],
76	to	TO	O	to	dep	128	SENT_155	[p13l757t2291r824b2342],
77	optimization	NN	O	optimization	dep	128	SENT_155	[p13l848t2284r1293b2362],
78	of	IN	O	of	dep	128	SENT_155	[p13l1315t2279r1390b2342],
79	dosing	NN	O	dosing	dep	128	SENT_155	[p13l1404t2279r1635b2363],
80	to	TO	O	to	dep	128	SENT_155	[p13l1655t2291r1721b2342],
81	prolong	VB	O	prolong	dep	128	SENT_155	[p13l1744t2279r2016b2363],
82	the	DT	O	the	dep	128	SENT_155	[p13l2036t2279r2144b2342],
83	clinical	JJ	O	clinical	dep	128	SENT_155	[p13l10t2382r251b2445],
84	beneﬁt	NN	O	beneﬁt	dep	128	SENT_155	[p13l270t2382r504b2445],
85	of	IN	O	of	dep	128	SENT_155	[p13l525t2382r598b2445],
86	TKIs	NNS	O	tki	dep	128	SENT_155	[p13l610t2385r775b2445],
87	against	IN	O	against	dep	128	SENT_155	[p13l798t2387r1035b2466],
88	EGFR-mutant	JJ	O	egfr-mutant	dep	128	SENT_155	[p13l1054t2386r1536b2445],
89	NSCLC	NN	O	nsclc	dep	128	SENT_155	[p13l1555t2386r1817b2445],
90	by	IN	O	by	dep	128	SENT_155	[p13l1837t2382r1921b2466],
91	delaying	VBG	O	delay	dep	128	SENT_155	[p13l1939t2382r2140b2466, p13l10t2489r118b2568],
92	the	DT	O	the	dep	128	SENT_155	[p13l136t2484r243b2547],
93	development	NN	O	development	dep	128	SENT_155	[p13l265t2484r708b2567],
94	of	IN	O	of	dep	128	SENT_155	[p13l729t2484r803b2547],
95	resistance	NN	O	resistance	dep	128	SENT_155	[p13l815t2477r1229b2547],
96	.57	CD	NUMBER	.57	dep	128	SENT_155	[p13l815t2477r1229b2547],
97	Furthermore	RB	O	furthermore	dep	128	SENT_155	[p13l1251t2484r1709b2556],
98	,	,	O	,	_	0	SENT_155	[p13l1251t2484r1709b2556],
99	the	DT	O	the	dep	128	SENT_155	[p13l1731t2484r1838b2547],
100	research	NN	O	research	dep	128	SENT_155	[p13l1860t2484r2143b2547],
101	showed	VBD	O	show	dep	128	SENT_155	[p13l10t2587r260b2650],
102	the	DT	O	the	dep	128	SENT_155	[p13l277t2587r380b2650],
103	effectiveness	NN	O	effectiveness	dep	128	SENT_155	[p13l400t2587r810b2650],
104	of	IN	O	of	dep	128	SENT_155	[p13l830t2587r902b2650],
105	using	VBG	O	use	dep	128	SENT_155	[p13l911t2592r1090b2671],
106	high-dose	JJ	O	high-dose	dep	128	SENT_155	[p13l1106t2587r1454b2671],
107	,	,	O	,	_	0	SENT_155	[p13l1106t2587r1454b2671],
108	pulsed	JJ	O	pulsed	dep	128	SENT_155	[p13l1474t2587r1707b2670],
109	,	,	O	,	_	0	SENT_155	[p13l1474t2587r1707b2670],
110	once-weekly	JJ	O	once-weekly	dep	128	SENT_155	[p13l1728t2587r2145b2671],
111	afatinib	NN	O	afatinib	dep	128	SENT_155	[p13l10t2690r261b2753],
112	with	IN	O	with	dep	128	SENT_155	[p13l280t2690r430b2753],
113	daily	JJ	SET	daily	dep	128	SENT_155	[p13l451t2690r621b2774],
114	,	,	O	,	_	0	SENT_155	[p13l451t2690r621b2774],
115	low	JJ	O	low	dep	128	SENT_155	[p13l641t2690r946b2753],
116	—	NN	O	—	dep	128	SENT_155	[p13l641t2690r946b2753],
117	dose	NN	O	dose	dep	128	SENT_155	[p13l641t2690r946b2753],
118	erlotinib	NN	O	erlotinib	dep	128	SENT_155	[p13l967t2690r1251b2753],
119	in	IN	O	in	dep	128	SENT_155	[p13l1272t2695r1337b2752],
120	delaying	VBG	O	delay	dep	128	SENT_155	[p13l1359t2690r1640b2774],
121	the	DT	O	the	dep	128	SENT_155	[p13l1657t2690r1761b2753],
122	emergence	NN	O	emergence	dep	128	SENT_155	[p13l1783t2713r2143b2774],
123	of	IN	O	of	dep	128	SENT_155	[p13l10t2793r81b2856],
124	p.	NN	O	p.	dep	128	SENT_155	[p13l88t2793r723b2876],
125	T79OM	NN	O	t79om	dep	128	SENT_155	[p13l88t2793r723b2876],
126	—	NN	O	—	dep	128	SENT_155	[p13l88t2793r723b2876],
127	mediated	VBD	O	mediate	dep	128	SENT_155	[p13l88t2793r723b2876],
128	resistance	NN	O	resistance	_	0	SENT_155	[p13l740t2798r1069b2856],
129	.	.	O	.	_	0	SENT_155	[p13l740t2798r1069b2856],

1	However	RB	O	however	advmod	11	SENT_156	[p13l1090t2798r1394b2865],
2	,	,	O	,	_	0	SENT_156	[p13l1090t2798r1394b2865],
3	the	DT	O	the	det	4	SENT_156	[p13l1412t2793r1514b2856],
4	combination	NN	O	combination	nsubj	11	SENT_156	[p13l1532t2793r1945b2856],
5	of	IN	O	of	_	0	SENT_156	[p13l1963t2793r2034b2856],
6	the	DT	O	the	det	9	SENT_156	[p13l2041t2793r2143b2856],
7	two	CD	NUMBER	two	num	9	SENT_156	[p13l8t2908r132b2959],
8	EGFR	NN	ORGANIZATION	egfr	nn	9	SENT_156	[p13l153t2900r360b2959],
9	TKIs	NNS	O	tki	prep_of	4	SENT_156	[p13l378t2899r541b2959],
10	could	MD	O	could	aux	11	SENT_156	[p13l563t2896r750b2959],
11	lead	VB	O	lead	_	0	SENT_156	[p13l768t2896r906b2959],
12	to	TO	O	to	_	0	SENT_156	[p13l925t2908r990b2959],
13	overlapping	VBG	O	overlap	amod	14	SENT_156	[p13l1012t2896r1408b2980],
14	toxicities	NNS	O	toxicity	prep_to	11	SENT_156	[p13l1426t2901r1742b2968],
15	,	,	O	,	_	0	SENT_156	[p13l1426t2901r1742b2968],
16	comprising	VBG	O	comprise	partmod	14	SENT_156	[p13l1765t2901r2144b2980],

1	VOLUME	NN	O	volume	_	0	SENT_157	[p13l590t3114r813b3156],
2	93	CD	NUMBER	93	num	1	SENT_157	[p13l831t3115r887b3156],
3	NUMBER	NN	O	number	nn	6	SENT_157	[p13l908t3114r1131b3156],
4	3	CD	NUMBER	3	num	6	SENT_157	[p13l1149t3115r1174b3156],
5	|	NN	O	|	nn	6	SENT_157	[p13l1195t3110r1199b3171],
6	MARCH	NN	DATE	march	dep	1	SENT_157	[p13l1221t3114r1411b3156],
7	2013	CD	DATE	2013	num	9	SENT_157	[p13l1431t3115r1549b3156],
8	|	CD	NUMBER	|	num	9	SENT_157	[p13l1570t3110r1575b3171],
9	www.nature.com/cpt	NN	O	www.nature.com/cpt	dep	1	SENT_157	[p13l1593t3114r2143b3167],

1	GAS6	NN	O	gas6	nn	2	SENT_158	[p13l815t3374r880b3393],
2	overe	NN	O	overe	_	0	SENT_158	[p13l815t3409r875b3423],
3	25	CD	PERCENT	25	num	4	SENT_158	[p13l815t3435r864b3453],
4	%	NN	PERCENT	%	dep	2	SENT_158	[p13l815t3435r864b3453],

1	5	CD	NUMBER	5	num	2	SENT_159	[p14l1390t71r1394b79],
2	EGFR	NN	ORGANIZATION	egfr	_	0	SENT_159	[p14l1406t52r1473b71],
3	29-40	CD	PERCENT	29-40	num	4	SENT_159	[p14l1405t83r1495b101],
4	%	NN	PERCENT	%	dep	2	SENT_159	[p14l1405t83r1495b101],
5	EGFR	NN	O	egfr	dep	4	SENT_159	[p14l1505t76r1637b101],
6	"	''	O	"	punct	4	SENT_159	[p14l1505t76r1637b101],
7	-	:	O	-	_	0	SENT_159	[p14l1505t76r1637b101],
8	‘	NN	O	‘	dep	4	SENT_159	[p14l1505t76r1637b101],
9	79	CD	NUMBER	79	num	10	SENT_159	[p14l1505t76r1637b101],
10	°	CD	NUMBER	°	dep	8	SENT_159	[p14l1505t76r1637b101],
11	"	``	O	"	punct	10	SENT_159	[p14l1505t76r1637b101],
12	‘	NN	O	‘	dep	10	SENT_159	[p14l1505t76r1637b101],
13	8	CD	PERCENT	8	number	14	SENT_159	[p14l1405t113r1440b131],
14	%	NN	PERCENT	%	amod	15	SENT_159	[p14l1405t113r1440b131],
15	EGFRp	NN	O	egfrp	dep	4	SENT_159	[p14l1449t106r1627b131],
16	.	.	O	.	_	0	SENT_159	[p14l1449t106r1627b131],

1	T79OM	NN	O	t79om	_	0	SENT_160	[p14l1449t106r1627b131],
2	+	CC	O	+	rcmod	1	SENT_160	[p14l1449t106r1627b131],
3	AMF	NN	O	amf	dep	1	SENT_160	[p14l1449t106r1627b131],
4	'	''	O	'	_	0	SENT_160	[p14l1449t106r1627b131],

1	o	NN	O	o	_	0	SENT_161	[p14l738t23r798b83],
2	AXL	NNP	O	AXL	prep	1	SENT_161	[p14l815t37r861b56],
3	MET	NN	O	met	dep	2	SENT_161	[p14l1169t46r1220b65],
4	.	.	O	.	_	0	SENT_161	[p14l1334t51r1337b54],
5	'	''	O	'	_	0	SENT_161	[p14l1346t39r1349b42],

1	overexpression	NN	O	overexpression	nn	2	SENT_162	[p14l815t67r981b91],
2	amplification	NN	O	amplification	_	0	SENT_162	[p14l1168t76r1305b100],
3	‘	CD	NUMBER	‘	number	4	SENT_162	[p14l1322t71r1338b87],
4	-6	CD	NUMBER	-6	num	2	SENT_162	[p14l1322t71r1338b87],
5	.	.	O	.	_	0	SENT_162	[p14l1322t71r1338b87],

1	.	.	O	.	_	0	SENT_163	[p14l1322t71r1338b87],

1	20	CD	PERCENT	20	num	2	SENT_164	[p14l815t98r864b116],
2	%	NN	PERCENT	%	_	0	SENT_164	[p14l815t98r864b116],
3	5-1	CD	PERCENT	5-1	dep	2	SENT_164	[p14l1168t106r1204b125],
4	9	CD	PERCENT	9	number	5	SENT_164	[p14l1210t106r1244b125],
5	%	NN	PERCENT	%	amod	3	SENT_164	[p14l1210t106r1244b125],

1	FAS-R/CD95	NN	O	fas-r/cd95	_	0	SENT_165	[p14l383t105r525b124],

1	Pathway	NN	O	pathway	_	0	SENT_166	[p14l397t359r489b383],
2	5-1	CD	PERCENT	5-1	num	1	SENT_166	[p14l1720t360r1757b378],
3	5	CD	PERCENT	5	number	4	SENT_166	[p14l1762t360r1797b378],
4	%	NN	PERCENT	%	amod	1	SENT_166	[p14l1762t360r1797b378],
5	activated	VBN	O	activate	partmod	1	SENT_166	[p14l364t389r462b408],
6	in	IN	O	in	_	0	SENT_166	[p14l471t389r488b407],
7	EGFREX19DEL/MUT	NN	O	egfrex19del/mut	nn	8	SENT_166	[p14l308t424r489b450],
8	tumors	NNS	O	tumor	prep_in	5	SENT_166	[p14l413t457r489b475],

1	Proliferation	NN	O	proliferation	_	0	SENT_167	[p14l935t924r1064b943],
2	and	CC	O	and	_	0	SENT_167	[p14l1073t924r1113b943],
3	survival	NN	O	survival	conj_and	1	SENT_167	[p14l1122t924r1204b943],

1	Figure	NN	O	figure	_	0	SENT_168	[p14l21t1012r112b1042],
2	2	CD	NUMBER	2	num	4	SENT_168	[p14l120t1013r135b1035],
3	Biochemical	JJ	O	biochemical	amod	4	SENT_168	[p14l161t1011r321b1035],
4	pathways	NNS	O	pathway	dep	1	SENT_168	[p14l331t1011r458b1042],
5	leading	VBG	O	lead	partmod	1	SENT_168	[p14l467t1011r565b1042],
6	to	TO	O	to	_	0	SENT_168	[p14l573t1015r601b1035],
7	resistance	NN	O	resistance	prep_to	5	SENT_168	[p14l610t1012r742b1035],
8	to	TO	O	to	_	0	SENT_168	[p14l749t1015r777b1035],
9	sma	NN	O	sma	nn	11	SENT_168	[p14l785t1011r989b1035],
10	|	CD	NUMBER	|	num	11	SENT_168	[p14l785t1011r989b1035],
11	|	NN	O	|	prep_to	5	SENT_168	[p14l785t1011r989b1035],
12	.	.	O	.	_	0	SENT_168	[p14l785t1011r989b1035],

1	—	NN	O	—	_	0	SENT_169	[p14l785t1011r989b1035],
2	.	.	O	.	_	0	SENT_169	[p14l785t1011r989b1035],

1	mo	NN	DURATION	mo	nn	3	SENT_170	[p14l785t1011r989b1035],
2	|	NN	O	|	nn	3	SENT_170	[p14l785t1011r989b1035],
3	ecule	NN	O	ecule	_	0	SENT_170	[p14l785t1011r989b1035],
4	epidermal	JJ	O	epidermal	amod	10	SENT_170	[p14l997t1011r1132b1041],
5	growth	NN	O	growth	nn	10	SENT_170	[p14l1142t1011r1237b1042],
6	factor	NN	O	factor	nn	10	SENT_170	[p14l1246t1011r1324b1035],
7	receptor	NN	O	receptor	nn	10	SENT_170	[p14l1333t1015r1445b1041],
8	(	CD	NUMBER	(	num	10	SENT_170	[p14l1454t1012r1674b1042],
9	EGFR	NN	ORGANIZATION	egfr	nn	10	SENT_170	[p14l1454t1012r1674b1042],
10	)	NN	O	)	dep	3	SENT_170	[p14l1454t1012r1674b1042],
11	.	.	O	.	_	0	SENT_170	[p14l1454t1012r1674b1042],

1	—	NN	O	—	_	0	SENT_171	[p14l1454t1012r1674b1042],
2	.	.	O	.	_	0	SENT_171	[p14l1454t1012r1674b1042],

1	targeting	VBG	O	target	amod	2	SENT_172	[p14l1454t1012r1674b1042],
2	drugs	NNS	O	drug	_	0	SENT_172	[p14l1684t1011r1759b1042],
3	such	JJ	O	such	_	0	SENT_172	[p14l1768t1011r1828b1035],
4	as	IN	O	as	_	0	SENT_172	[p14l1837t1018r1864b1035],
5	gefitinib	NN	O	gefitinib	prep_such_as	2	SENT_172	[p14l1872t1011r1984b1042],
6	and	CC	O	and	_	0	SENT_172	[p14l1992t1011r2041b1035],
7	erlotinib	NN	O	erlotinib	prep_such_as	2	SENT_172	[p14l20t1052r133b1076],
8	in	IN	O	in	_	0	SENT_172	[p14l142t1054r164b1076],
9	non	JJ	O	non	amod	14	SENT_172	[p14l174t1052r361b1076],
10	—	JJ	O	—	amod	14	SENT_172	[p14l174t1052r361b1076],
11	small	JJ	O	small	amod	14	SENT_172	[p14l174t1052r361b1076],
12	—	NN	O	—	nn	14	SENT_172	[p14l174t1052r361b1076],
13	cell	NN	O	cell	nn	14	SENT_172	[p14l174t1052r361b1076],
14	lung	NN	O	lung	prep_in	5	SENT_172	[p14l372t1052r430b1083],
15	cancer	NN	O	cancer	nn	18	SENT_172	[p14l439t1059r527b1076],
16	(	CD	NUMBER	(	num	18	SENT_172	[p14l535t1053r648b1080],
17	NSCLC	NN	O	nsclc	nn	18	SENT_172	[p14l535t1053r648b1080],
18	)	NN	O	)	dep	14	SENT_172	[p14l535t1053r648b1080],
19	.	.	O	.	_	0	SENT_172	[p14l535t1053r648b1080],

1	Simplified	VBN	O	simplify	csubj	12	SENT_173	[p14l656t1052r789b1082],
2	pathway	NN	O	pathway	nn	3	SENT_173	[p14l799t1052r914b1083],
3	diagram	NN	O	diagram	dobj	1	SENT_173	[p14l921t1052r1031b1083],
4	showing	VBG	O	show	partmod	3	SENT_173	[p14l1040t1052r1154b1083],
5	EGFR	NN	ORGANIZATION	egfr	nn	6	SENT_173	[p14l1164t1053r1231b1076],
6	signaling	NN	O	signaling	dobj	4	SENT_173	[p14l1239t1052r1360b1083],
7	through	IN	O	through	_	0	SENT_173	[p14l1368t1052r1477b1083],
8	the	DT	O	the	det	9	SENT_173	[p14l1486t1052r1529b1076],
9	RAS/MEK/ERK	NN	O	ras/mek/erk	prep_through	4	SENT_173	[p14l1539t1053r1723b1077],
10	and	CC	O	and	_	0	SENT_173	[p14l1730t1052r1779b1076],
11	P	NN	O	p	prep_through	4	SENT_173	[p14l1790t1053r1997b1077],
12	|	VBP	O	|	_	0	SENT_173	[p14l1790t1053r1997b1077],
13	3K/PDK1/AKT	NN	O	3k/pdk1/akt	nn	14	SENT_173	[p14l1790t1053r1997b1077],
14	pathways	NNS	O	pathway	dobj	12	SENT_173	[p14l2005t1052r2138b1083],
15	,	,	O	,	_	0	SENT_173	[p14l2005t1052r2138b1083],
16	illustrating	VBG	O	illustrate	partmod	12	SENT_173	[p14l21t1094r162b1125],
17	the	DT	O	the	det	18	SENT_173	[p14l171t1094r215b1118],
18	points	NNS	O	point	dobj	16	SENT_173	[p14l224t1095r306b1125],
19	of	IN	O	of	_	0	SENT_173	[p14l314t1094r342b1118],
20	mutation/ampli	JJ	O	mutation/ampli	amod	21	SENT_173	[p14l349t1094r660b1125],
21	ﬁcation	NN	O	ﬁcation	prep_of	18	SENT_173	[p14l349t1094r660b1125],
22	in	IN	O	in	_	0	SENT_173	[p14l670t1095r691b1118],
23	EGFRTKI	NNP	O	EGFRTKI	nn	24	SENT_173	[p14l702t1095r814b1118],
24	resistance	NN	O	resistance	prep_in	21	SENT_173	[p14l825t1095r963b1122],
25	,	,	O	,	_	0	SENT_173	[p14l825t1095r963b1122],
26	along	IN	O	along	_	0	SENT_173	[p14l971t1094r1046b1125],
27	with	IN	O	with	_	0	SENT_173	[p14l1054t1094r1112b1118],
28	other	JJ	O	other	amod	29	SENT_173	[p14l1121t1094r1194b1118],
29	mechanisms	NNS	O	mechanism	prep_along_with	21	SENT_173	[p14l1202t1094r1431b1118],
30	.	.	O	.	_	0	SENT_173	[p14l1202t1094r1431b1118],

1	The	DT	O	the	det	3	SENT_174	[p14l1202t1094r1431b1118],
2	resistance	NN	O	resistance	nn	3	SENT_174	[p14l1440t1095r1572b1118],
3	mechanisms	NNS	O	mechanism	nsubj	4	SENT_174	[p14l1581t1094r1748b1118],
4	include	VBP	O	include	_	0	SENT_174	[p14l1757t1094r1855b1118],
5	the	DT	O	the	det	10	SENT_174	[p14l1862t1094r1906b1118],
6	EGFR	NN	ORGANIZATION	egfr	nn	10	SENT_174	[p14l1915t1095r1983b1118],
7	p.	NN	O	p.	nn	10	SENT_174	[p14l1992t1095r2105b1125],
8	T790M	NN	O	t790m	nn	10	SENT_174	[p14l1992t1095r2105b1125],
9	gatekeeper	NN	O	gatekeeper	nn	10	SENT_174	[p14l20t1136r173b1167],
10	mutation	NN	O	mutation	dobj	4	SENT_174	[p14l181t1137r310b1164],
11	,	,	O	,	_	0	SENT_174	[p14l181t1137r310b1164],
12	ampliﬁcation	NN	O	ampliﬁcation	conj_and	10	SENT_174	[p14l319t1136r494b1167],
13	of	IN	O	of	_	0	SENT_174	[p14l503t1136r530b1161],
14	EGFR	NN	ORGANIZATION	egfr	nn	16	SENT_174	[p14l537t1137r605b1160],
15	p.	NN	O	p.	nn	16	SENT_174	[p14l614t1137r734b1167],
16	T790M	NN	O	t790m	prep_of	12	SENT_174	[p14l614t1137r734b1167],
17	,	,	O	,	_	0	SENT_174	[p14l614t1137r734b1167],
18	MET	NN	O	met	nn	19	SENT_174	[p14l743t1137r801b1160],
19	ampliﬁcation	NN	O	ampliﬁcation	conj_and	10	SENT_174	[p14l807t1136r990b1167],
20	,	,	O	,	_	0	SENT_174	[p14l807t1136r990b1167],
21	P	NN	O	p	nn	24	SENT_174	[p14l1000t1137r1094b1161],
22	|	CD	NUMBER	|	num	24	SENT_174	[p14l1000t1137r1094b1161],
23	3KCA	NN	O	3kca	nn	24	SENT_174	[p14l1000t1137r1094b1161],
24	mutation	NN	O	mutation	conj_and	10	SENT_174	[p14l1103t1138r1232b1164],
25	,	,	O	,	_	0	SENT_174	[p14l1103t1138r1232b1164],
26	and	CC	O	and	_	0	SENT_174	[p14l1241t1136r1290b1161],
27	an	DT	O	a	det	35	SENT_174	[p14l1299t1143r1330b1161],
28	at	IN	O	at	quantmod	31	SENT_174	[p14l1339t1140r1363b1161],
29	least	JJS	O	least	mwe	28	SENT_174	[p14l1372t1136r1433b1161],
30	two	CD	NUMBER	two	number	31	SENT_174	[p14l1440t1136r1554b1161],
31	—	CD	NUMBER	—	num	32	SENT_174	[p14l1440t1136r1554b1161],
32	fo	NN	O	fo	nn	35	SENT_174	[p14l1440t1136r1554b1161],
33	|	NN	O	|	nn	35	SENT_174	[p14l1440t1136r1554b1161],
34	d	NN	O	d	nn	35	SENT_174	[p14l1440t1136r1554b1161],
35	increase	NN	O	increase	dobj	4	SENT_174	[p14l1564t1137r1672b1161],
36	in	IN	O	in	_	0	SENT_174	[p14l1681t1137r1703b1160],
37	the	DT	O	the	det	38	SENT_174	[p14l1712t1136r1756b1161],
38	expression	NN	O	expression	prep_in	35	SENT_174	[p14l1764t1137r1906b1167],
39	of	IN	O	of	_	0	SENT_174	[p14l1916t1136r1943b1161],
40	GAS6	NN	O	gas6	prep_of	38	SENT_174	[p14l1949t1137r2021b1161],
41	and	CC	O	and	_	0	SENT_174	[p14l2029t1136r2078b1161],
42	its	PRP$	O	its	poss	44	SENT_174	[p14l2088t1137r2116b1161],
43	receptor	NN	O	receptor	nn	44	SENT_174	[p14l21t1181r134b1208],
44	AXL	NN	ORGANIZATION	axl	prep_of	38	SENT_174	[p14l141t1179r199b1202],
45	.	.	O	.	_	0	SENT_174	[p14l141t1179r199b1202],

1	Incidence	NN	O	incidence	nn	2	SENT_175	[p14l208t1177r337b1202],
2	rates	NNS	O	rate	nsubjpass	4	SENT_175	[p14l346t1181r409b1202],
3	are	VBP	O	be	auxpass	4	SENT_175	[p14l417t1184r457b1202],
4	given	VBN	O	give	_	0	SENT_175	[p14l466t1179r538b1208],
5	where	WRB	O	where	advmod	6	SENT_175	[p14l546t1177r630b1202],
6	known	VBN	O	know	advcl	4	SENT_175	[p14l639t1177r791b1202],
7	.	.	O	.	_	0	SENT_175	[p14l639t1177r791b1202],

1	The	DT	O	the	det	3	SENT_176	[p14l639t1177r791b1202],
2	FAS/nuclear	NN	O	fas/nuclear	nn	3	SENT_176	[p14l801t1177r959b1203],
3	factor	NN	O	factor	dep	9	SENT_176	[p14l966t1177r1089b1202],
4	—	CD	NUMBER	—	dep	3	SENT_176	[p14l966t1177r1089b1202],
5	i	FW	O	i	dep	4	SENT_176	[p14l966t1177r1089b1202],
6	<	JJR	O	<	amod	7	SENT_176	[p14l966t1177r1089b1202],
7	B	NN	O	b	dep	9	SENT_176	[p14l966t1177r1089b1202],
8	(	CD	NUMBER	(	num	9	SENT_176	[p14l1098t1178r1196b1205],
9	NF-KB	NN	O	nf-kb	dep	22	SENT_176	[p14l1098t1178r1196b1205],
10	)	NN	O	)	nn	12	SENT_176	[p14l1098t1178r1196b1205],
11	signaling	NN	O	signaling	nn	12	SENT_176	[p14l1205t1177r1325b1208],
12	arm	NN	O	arm	dep	9	SENT_176	[p14l1334t1184r1385b1202],
13	downstream	RB	O	downstream	advmod	12	SENT_176	[p14l1394t1177r1562b1202],
14	of	IN	O	of	_	0	SENT_176	[p14l1571t1177r1599b1202],
15	the	DT	O	the	det	18	SENT_176	[p14l1604t1177r1648b1202],
16	FAS	NN	O	fa	nn	18	SENT_176	[p14l1657t1178r1703b1202],
17	death	NN	O	death	nn	18	SENT_176	[p14l1712t1177r1787b1202],
18	receptor	NN	O	receptor	prep_of	12	SENT_176	[p14l1798t1181r1910b1208],
19	has	VBZ	O	have	aux	22	SENT_176	[p14l1919t1177r1962b1202],
20	also	RB	O	also	advmod	22	SENT_176	[p14l1970t1177r2022b1202],
21	been	VBN	O	be	auxpass	22	SENT_176	[p14l2032t1177r2097b1202],
22	shown	VBN	O	show	_	0	SENT_176	[p14l20t1219r108b1243],
23	to	TO	O	to	aux	31	SENT_176	[p14l116t1223r143b1243],
24	be	VB	O	be	cop	31	SENT_176	[p14l152t1219r184b1243],
25	important	JJ	O	important	amod	31	SENT_176	[p14l193t1220r328b1250],
26	in	IN	O	in	_	0	SENT_176	[p14l337t1220r359b1243],
27	EGFR	NN	ORGANIZATION	egfr	nn	29	SENT_176	[p14l369t1220r437b1243],
28	tyrosine	NN	O	tyrosine	nn	29	SENT_176	[p14l444t1220r552b1250],
29	kinase	NN	O	kinase	prep_in	25	SENT_176	[p14l561t1219r644b1243],
30	inhibitor	NN	O	inhibitor	nn	31	SENT_176	[p14l653t1219r768b1243],
31	resistance	NN	O	resistance	xcomp	22	SENT_176	[p14l776t1220r914b1243],
32	.	.	O	.	_	0	SENT_176	[p14l776t1220r914b1243],

1	In	IN	O	in	dep	5	SENT_177	[p14l924t1220r946b1243],
2	addition	NN	O	addition	pobj	1	SENT_177	[p14l955t1219r1074b1247],
3	,	,	O	,	_	0	SENT_177	[p14l955t1219r1074b1247],
4	epithelia	NN	O	epithelium	nn	5	SENT_177	[p14l1082t1219r1442b1250],
5	|	NN	O	|	_	0	SENT_177	[p14l1082t1219r1442b1250],
6	.	.	O	.	_	0	SENT_177	[p14l1082t1219r1442b1250],

1	—	NN	O	—	_	0	SENT_178	[p14l1082t1219r1442b1250],
2	.	.	O	.	_	0	SENT_178	[p14l1082t1219r1442b1250],

1	to	TO	O	to	_	0	SENT_179	[p14l1082t1219r1442b1250],
2	.	.	O	.	_	0	SENT_179	[p14l1082t1219r1442b1250],

1	—	NN	O	—	_	0	SENT_180	[p14l1082t1219r1442b1250],
2	.	.	O	.	_	0	SENT_180	[p14l1082t1219r1442b1250],

1	mesenchyma	NN	O	mesenchyma	nsubj	10	SENT_181	[p14l1082t1219r1442b1250],
2	|	SYM	O	|	dep	4	SENT_181	[p14l1082t1219r1442b1250],
3	(	CD	NUMBER	(	num	4	SENT_181	[p14l1453t1220r1527b1247],
4	EMT	NN	O	emt	rcmod	1	SENT_181	[p14l1453t1220r1527b1247],
5	)	CD	NUMBER	)	num	7	SENT_181	[p14l1453t1220r1527b1247],
6	transition	NN	O	transition	nn	7	SENT_181	[p14l1536t1220r1663b1243],
7	changes	NNS	O	change	dep	1	SENT_181	[p14l1672t1219r1790b1250],
8	,	,	O	,	_	0	SENT_181	[p14l1672t1219r1790b1250],
9	perhaps	RB	O	perhaps	advmod	10	SENT_181	[p14l1799t1219r1907b1250],
10	associated	VBN	O	associate	_	0	SENT_181	[p14l1915t1219r2054b1243],
11	with	IN	O	with	_	0	SENT_181	[p14l20t1261r77b1286],
12	increased	VBN	O	increase	amod	13	SENT_181	[p14l87t1261r214b1286],
13	activity	NN	O	activity	prep_with	10	SENT_181	[p14l223t1262r320b1292],
14	of	IN	O	of	_	0	SENT_181	[p14l328t1261r355b1286],
15	AXL	NNP	ORGANIZATION	AXL	prep_of	13	SENT_181	[p14l361t1262r419b1289],
16	,	,	O	,	_	0	SENT_181	[p14l361t1262r419b1289],
17	and	CC	O	and	_	0	SENT_181	[p14l427t1261r476b1286],
18	transformation	NN	O	transformation	conj_and	13	SENT_181	[p14l485t1261r685b1286],
19	from	IN	O	from	_	0	SENT_181	[p14l693t1261r756b1285],
20	the	DT	O	the	det	21	SENT_181	[p14l764t1261r808b1286],
21	NSCLC	NN	O	nsclc	prep_from	18	SENT_181	[p14l818t1262r904b1286],
22	to	TO	O	to	_	0	SENT_181	[p14l911t1265r938b1286],
23	the	DT	O	the	det	30	SENT_181	[p14l946t1261r990b1286],
24	small	JJ	O	small	amod	30	SENT_181	[p14l998t1261r1122b1286],
25	—	NN	O	—	nn	30	SENT_181	[p14l998t1261r1122b1286],
26	cell	NN	O	cell	nn	30	SENT_181	[p14l998t1261r1122b1286],
27	lung	NN	O	lung	nn	30	SENT_181	[p14l1133t1261r1190b1292],
28	cancer	NN	O	cancer	nn	30	SENT_181	[p14l1199t1268r1288b1286],
29	(	CD	NUMBER	(	num	30	SENT_181	[p14l1296t1262r1379b1289],
30	SCLC	NN	ORGANIZATION	sclc	prep_to	21	SENT_181	[p14l1296t1262r1379b1289],
31	)	CD	NUMBER	)	num	32	SENT_181	[p14l1296t1262r1379b1289],
32	phenotype	NN	O	phenotype	nsubj	34	SENT_181	[p14l1389t1261r1536b1292],
33	can	MD	O	can	aux	34	SENT_181	[p14l1544t1268r1589b1286],
34	lead	VB	O	lead	rcmod	18	SENT_181	[p14l1600t1261r1654b1286],
35	to	TO	O	to	_	0	SENT_181	[p14l1662t1265r1689b1285],
36	decreased	VBN	O	decrease	amod	37	SENT_181	[p14l1697t1261r1833b1286],
37	responsiveness	NN	O	responsiveness	prep_to	34	SENT_181	[p14l1844t1261r2108b1292],
38	.	.	O	.	_	0	SENT_181	[p14l1844t1261r2108b1292],

1	The	DT	O	the	det	5	SENT_182	[p14l1844t1261r2108b1292],
2	identification	NN	O	identification	nn	5	SENT_182	[p14l21t1302r197b1326],
3	ofvarious	JJ	O	ofvarious	amod	5	SENT_182	[p14l206t1302r336b1326],
4	resistance	NN	O	resistance	nn	5	SENT_182	[p14l345t1304r477b1326],
5	mechanisms	NNS	O	mechanism	nsubj	6	SENT_182	[p14l486t1302r653b1326],
6	suggests	VBZ	O	suggest	_	0	SENT_182	[p14l662t1306r780b1333],
7	that	IN	O	that	complm	15	SENT_182	[p14l787t1302r841b1326],
8	a	DT	O	a	det	9	SENT_182	[p14l849t1309r862b1326],
9	range	NN	O	range	nsubjpass	15	SENT_182	[p14l872t1309r948b1333],
10	ofclinically	RB	O	ofclinically	advmod	15	SENT_182	[p14l956t1302r1105b1333],
11	actionable	JJ	O	actionable	amod	12	SENT_182	[p14l1112t1302r1253b1326],
12	therapies	NNS	O	therapy	nsubjpass	15	SENT_182	[p14l1260t1302r1385b1332],
13	could	MD	O	could	aux	15	SENT_182	[p14l1394t1302r1467b1326],
14	be	VB	O	be	auxpass	15	SENT_182	[p14l1477t1302r1509b1326],
15	used	VBN	O	use	ccomp	6	SENT_182	[p14l1518t1302r1579b1326],
16	to	TO	O	to	aux	17	SENT_182	[p14l1588t1306r1615b1326],
17	overcome	VB	O	overcome	xcomp	15	SENT_182	[p14l1623t1309r1756b1326],
18	the	DT	O	the	det	19	SENT_182	[p14l1764t1302r1808b1326],
19	resistance	NN	O	resistance	dobj	17	SENT_182	[p14l1817t1304r1955b1326],
20	.	.	O	.	_	0	SENT_182	[p14l1817t1304r1955b1326],

1	For	IN	O	for	_	0	SENT_183	[p14l1965t1304r2006b1326],
2	more	JJR	O	more	amod	3	SENT_183	[p14l2014t1309r2083b1326],
3	details	NNS	O	detail	prep_for	5	SENT_183	[p14l6t1354r192b1409],
4	,	,	O	,	_	0	SENT_183	[p14l6t1354r192b1409],
5	see	VBP	O	see	_	0	SENT_183	[p14l208t1368r294b1402],
6	text	NN	O	text	dobj	5	SENT_183	[p14l309t1362r425b1402],
7	.	.	O	.	_	0	SENT_183	[p14l309t1362r425b1402],

1	Initial	JJ	O	initial	_	0	SENT_184	[p14l1062t2245r1207b2293],
2	profiling	VBG	O	profile	dep	1	SENT_184	[p14l1233t2244r1458b2307],
3	First-line	JJ	MISC	first-line	amod	4	SENT_184	[p14l1660t2245r1906b2293],
4	therapy	NN	O	therapy	dobj	2	SENT_184	[p14l1928t2245r2145b2307],

1	Adaptive	JJ	O	adaptive	amod	2	SENT_185	[p15l473t2585r915b2692],
2	therapy	NN	O	therapy	nsubj	17	SENT_185	[p15l953t2585r1332b2692],
3	in	IN	O	in	_	0	SENT_185	[p15l1372t2585r1448b2668],
4	response	NN	O	response	prep_in	2	SENT_185	[p15l361t2744r825b2830],
5	to	TO	O	to	_	0	SENT_185	[p15l861t2728r953b2808],
6	longitudinal	JJ	O	longitudinal	amod	7	SENT_185	[p15l996t2723r1568b2832],
7	profiling	NN	O	profiling	prep_to	4	SENT_185	[p15l767t2860r1161b2971],
8	to	TO	O	to	_	0	SENT_185	[p15l20t3067r47b3087],
9	information	NN	O	information	prep_to	4	SENT_185	[p15l55t3063r210b3087],
10	from	IN	O	from	_	0	SENT_185	[p15l218t3063r280b3087],
11	tumor	NN	O	tumor	nn	12	SENT_185	[p15l289t3067r372b3087],
12	proﬁling	NN	O	proﬁling	prep_from	9	SENT_185	[p15l380t3063r490b3094],
13	using	VBG	O	use	_	0	SENT_185	[p15l500t3065r570b3094],
14	multiple	JJ	O	multiple	amod	15	SENT_185	[p15l579t3063r689b3093],
15	technologies	NNS	O	technology	dobj	13	SENT_185	[p15l696t3063r875b3094],
16	,	,	O	,	_	0	SENT_185	[p15l696t3063r875b3094],
17	including	VBG	O	include	conj_and	13	SENT_185	[p15l883t3063r1006b3094],
18	next	JJ	O	next	amod	21	SENT_185	[p15l1016t3065r1229b3094],
19	—	NN	O	—	nn	21	SENT_185	[p15l1016t3065r1229b3094],
20	generation	NN	O	generation	nn	21	SENT_185	[p15l1016t3065r1229b3094],
21	sequencing	NN	O	sequencing	dobj	17	SENT_185	[p15l1239t3065r1392b3094],
22	to	TO	O	to	aux	23	SENT_185	[p15l1400t3067r1427b3087],
23	identify	VB	O	identify	xcomp	17	SENT_185	[p15l1436t3063r1536b3094],
24	predictive	JJ	O	predictive	amod	27	SENT_185	[p15l1544t3063r1676b3093],
25	and	CC	O	and	_	0	SENT_185	[p15l1683t3063r1732b3087],
26	resistance	NN	O	resistance	amod	27	SENT_185	[p15l1742t3065r1873b3087],
27	biomarkers	NNS	O	biomarker	dobj	23	SENT_185	[p15l1881t3063r2036b3091],
28	,	,	O	,	_	0	SENT_185	[p15l1881t3063r2036b3091],
29	and	CC	O	and	_	0	SENT_185	[p15l2043t3063r2092b3087],
30	incorporating	VBG	O	incorporate	conj_and	13	SENT_185	[p15l21t3105r201b3135],
31	analyses	NNS	O	analysis	dobj	30	SENT_185	[p15l210t3104r321b3135],
32	ofclonal	JJ	O	ofclonal	amod	34	SENT_185	[p15l329t3104r447b3132],
33	,	,	O	,	_	0	SENT_185	[p15l329t3104r447b3132],
34	morphological	JJ	O	morphological	amod	31	SENT_185	[p15l456t3104r656b3135],
35	,	,	O	,	_	0	SENT_185	[p15l456t3104r656b3135],
36	and	CC	O	and	_	0	SENT_185	[p15l664t3104r713b3128],
37	anatomical	JJ	O	anatomical	amod	38	SENT_185	[p15l722t3104r867b3128],
38	heterogeneity	NN	O	heterogeneity	dep	42	SENT_185	[p15l877t3104r1065b3135],
39	and	CC	O	and	_	0	SENT_185	[p15l1072t3104r1121b3128],
40	their	PRP$	O	they	poss	41	SENT_185	[p15l1129t3104r1191b3128],
41	variations	NNS	O	variation	dep	42	SENT_185	[p15l1198t3105r1327b3128],
42	longitudinally	RB	O	longitudinally	conj_and	13	SENT_185	[p15l1336t3104r1520b3135],
43	in	IN	O	in	_	0	SENT_185	[p15l1528t3105r1549b3128],
44	real	JJ	O	real	amod	45	SENT_185	[p15l1559t3104r1604b3128],
45	time	NN	O	time	prep_in	42	SENT_185	[p15l1613t3105r1679b3128],
46	.	.	O	.	_	0	SENT_185	[p15l1613t3105r1679b3128],

1	rashes	NNS	O	rash	_	0	SENT_186	[p15l21t3200r120b3231],
2	and	CC	O	and	_	0	SENT_186	[p15l130t3200r190b3231],
3	diarrhea	NN	O	diarrhea	conj_and	1	SENT_186	[p15l200t3200r343b3231],
4	.	.	O	.	_	0	SENT_186	[p15l200t3200r343b3231],

1	Alternative	JJ	O	alternative	amod	3	SENT_187	[p15l353t3200r533b3231],
2	dosing	NN	O	dosing	nn	3	SENT_187	[p15l543t3200r651b3241],
3	strategies	NNS	O	strategy	nsubj	6	SENT_187	[p15l661t3202r809b3241],
4	were	VBD	O	be	cop	6	SENT_187	[p15l818t3211r894b3231],
5	therefore	RB	O	therefore	advmod	6	SENT_187	[p15l904t3200r1049b3231],
6	patient	NN	O	patient	_	0	SENT_187	[p15l1110t3202r1240b3241],
7	.	.	O	.	_	0	SENT_187	[p15l1110t3202r1240b3241],

1	Together	RB	O	together	_	0	SENT_188	[p15l1254t3200r1408b3241],
2	with	IN	O	with	_	0	SENT_188	[p15l1419t3200r1496b3231],
3	the	DT	O	the	det	4	SENT_188	[p15l1509t3200r1562b3231],
4	reality	NN	O	reality	prep_together_with	7	SENT_188	[p15l1575t3200r1685b3241],
5	that	WDT	O	that	dep	6	SENT_188	[p15l1696t3200r1763b3231],
6	logical	JJ	O	logical	rcmod	4	SENT_188	[p15l1775t3200r1889b3241],
7	therapies	NNS	O	therapy	_	0	SENT_188	[p15l1901t3200r2059b3241],
8	that	WDT	O	that	nsubj	9	SENT_188	[p15l2071t3200r2139b3231],
9	recommended	VBD	O	recommend	rcmod	7	SENT_188	[p15l21t3250r257b3281],
10	for	IN	O	for	_	0	SENT_188	[p15l265t3250r312b3281],
11	erlotinib	NN	O	erlotinib	prep_for	9	SENT_188	[p15l321t3250r458b3281],
12	versus	CC	O	versus	prep	11	SENT_188	[p15l467t3261r568b3281],
13	afatinib	JJ	O	afatinib	dep	12	SENT_188	[p15l578t3250r706b3281],
14	.	.	O	.	_	0	SENT_188	[p15l578t3250r706b3281],

1	can	MD	O	can	aux	3	SENT_189	[p15l1111t3261r1169b3281],
2	be	VB	O	be	auxpass	3	SENT_189	[p15l1180t3250r1219b3281],
3	derived	VBN	O	derive	ccomp	26	SENT_189	[p15l1232t3250r1360b3281],
4	from	IN	O	from	_	0	SENT_189	[p15l1371t3250r1455b3281],
5	known	JJ	O	known	amod	7	SENT_189	[p15l1466t3250r1584b3281],
6	resistance	NN	O	resistance	nn	7	SENT_189	[p15l1596t3252r1764b3281],
7	mechanisms	NNS	O	mechanism	prep_from	3	SENT_189	[p15l1776t3250r1988b3281],
8	may	MD	O	may	dep	7	SENT_189	[p15l2001t3261r2073b3291],
9	not	RB	O	not	neg	8	SENT_189	[p15l2083t3256r2140b3281],
10	Given	VBN	O	give	prep	3	SENT_189	[p15l57t3302r163b3331],
11	the	DT	O	the	det	12	SENT_189	[p15l179t3300r234b3331],
12	multiplicity	NN	O	multiplicity	dep	10	SENT_189	[p15l250t3300r465b3341],
13	of	IN	O	of	_	0	SENT_189	[p15l480t3300r518b3331],
14	mechanisms	NNS	O	mechanism	prep_of	12	SENT_189	[p15l530t3300r754b3331],
15	of	IN	O	of	_	0	SENT_189	[p15l771t3300r809b3331],
16	resistance	NN	O	resistance	prep_of	14	SENT_189	[p15l821t3303r1000b3331],
17	to	TO	O	to	aux	19	SENT_189	[p15l1016t3306r1050b3331],
18	always	RB	O	always	advmod	19	SENT_189	[p15l1111t3300r1220b3341],
19	hold	VB	O	hold	infmod	12	SENT_189	[p15l1230t3300r1306b3331],
20	up	RP	O	up	prt	19	SENT_189	[p15l1316t3311r1358b3341],
21	in	IN	O	in	_	0	SENT_189	[p15l1369t3302r1402b3331],
22	the	DT	O	the	det	23	SENT_189	[p15l1412t3300r1464b3331],
23	clinic	NN	O	clinic	prep_in	19	SENT_189	[p15l1475t3300r1575b3335],
24	,	,	O	,	_	0	SENT_189	[p15l1475t3300r1575b3335],
25	this	DT	O	this	nsubj	26	SENT_189	[p15l1586t3300r1647b3331],
26	highlights	VBZ	O	highlight	ccomp	35	SENT_189	[p15l1658t3300r1826b3341],
27	the	DT	O	the	det	28	SENT_189	[p15l1837t3300r1889b3331],
28	need	NN	O	need	dobj	26	SENT_189	[p15l1900t3300r1980b3331],
29	for	IN	O	for	_	0	SENT_189	[p15l1991t3300r2038b3331],
30	novel	JJ	O	novel	amod	31	SENT_189	[p15l2049t3300r2139b3331],
31	TKIs	NNS	O	tki	prep_for	28	SENT_189	[p15l21t3351r115b3385],
32	,	,	O	,	_	0	SENT_189	[p15l21t3351r115b3385],
33	it	PRP	O	it	nsubj	35	SENT_189	[p15l128t3353r151b3381],
34	is	VBZ	O	be	cop	35	SENT_189	[p15l163t3353r189b3381],
35	likely	JJ	O	likely	_	0	SENT_189	[p15l201t3350r297b3391],
36	that	IN	O	that	complm	44	SENT_189	[p15l307t3350r375b3381],
37	the	DT	O	the	det	40	SENT_189	[p15l387t3350r440b3381],
38	optimal	JJ	O	optimal	amod	40	SENT_189	[p15l453t3350r588b3391],
39	therapeutic	JJ	O	therapeutic	amod	40	SENT_189	[p15l600t3350r799b3391],
40	tactics	NNS	O	tactic	nsubj	44	SENT_189	[p15l811t3352r922b3381],
41	will	MD	O	will	aux	44	SENT_189	[p15l934t3350r998b3381],
42	be	VB	O	be	cop	44	SENT_189	[p15l1009t3350r1049b3381],
43	therapeutic	JJ	O	therapeutic	amod	44	SENT_189	[p15l1110t3350r1307b3391],
44	strategies	NNS	O	strategy	ccomp	35	SENT_189	[p15l1319t3352r1480b3391],
45	based	VBN	O	base	partmod	44	SENT_189	[p15l1491t3350r1590b3381],
46	on	IN	O	on	_	0	SENT_189	[p15l1602t3361r1645b3381],
47	detailed	JJ	O	detailed	amod	49	SENT_189	[p15l1657t3350r1794b3381],
48	molecular	JJ	O	molecular	amod	49	SENT_189	[p15l1806t3350r1980b3381],
49	proﬁling	NN	O	proﬁling	prep_on	45	SENT_189	[p15l1991t3350r2140b3391],
50	highly	RB	O	highly	advmod	51	SENT_189	[p15l20t3400r127b3441],
51	dependent	JJ	O	dependent	amod	49	SENT_189	[p15l136t3400r313b3441],
52	on	IN	O	on	_	0	SENT_189	[p15l323t3411r365b3431],
53	the	DT	O	the	det	55	SENT_189	[p15l375t3400r427b3431],
54	actual	JJ	O	actual	amod	55	SENT_189	[p15l438t3400r537b3431],
55	mechanism	NN	O	mechanism	prep_on	45	SENT_189	[p15l547t3400r740b3431],
56	in	IN	O	in	_	0	SENT_189	[p15l750t3403r783b3431],
57	each	DT	O	each	det	58	SENT_189	[p15l794t3400r868b3431],
58	individual	NN	O	individual	prep_in	55	SENT_189	[p15l879t3400r1050b3431],
59	of	IN	O	of	_	0	SENT_189	[p15l1111t3400r1147b3431],
60	individual	JJ	O	individual	prep_of	58	SENT_189	[p15l1154t3400r1328b3431],
61	relapsed	VBD	O	relapse	partmod	60	SENT_189	[p15l1339t3400r1480b3441],
62	tumors	NNS	O	tumor	dobj	61	SENT_189	[p15l1491t3406r1621b3431],
63	.	.	O	.	_	0	SENT_189	[p15l1491t3406r1621b3431],

1	CLINICAL	JJ	O	clinical	amod	2	SENT_190	[p15l21t3506r140b3527],
2	PHARMACOLOGY	NNP	O	PHARMACOLOGY	_	0	SENT_190	[p15l149t3506r374b3527],
3	&	CC	O	&	_	0	SENT_190	[p15l381t3506r601b3527],
4	THERAPEUTlCS	NNP	O	THERAPEUTlCS	nn	6	SENT_190	[p15l381t3506r601b3527],
5	|	NNP	O	|	nn	6	SENT_190	[p15l611t3504r613b3534],
6	VOLUME	NNP	O	VOLUME	conj_and	2	SENT_190	[p15l621t3506r729b3527],
7	93	CD	NUMBER	93	num	6	SENT_190	[p15l737t3506r764b3527],
8	NUMBER	NN	O	number	nn	11	SENT_190	[p15l774t3506r882b3527],
9	3	CD	NUMBER	3	num	11	SENT_190	[p15l890t3506r902b3527],
10	|	NN	O	|	nn	11	SENT_190	[p15l912t3504r915b3534],
11	MARCH	NN	DATE	march	dep	2	SENT_190	[p15l925t3506r1017b3527],
12	2013	CD	DATE	2013	number	13	SENT_190	[p15l1026t3506r1083b3527],
13	257	CD	NUMBER	257	dep	11	SENT_190	[p15l2093t3506r2139b3527],

1	FUTURE	JJ	DATE	future	amod	2	SENT_191	[p16l11t86r292b141],
2	HORIZON	NN	O	horizon	_	0	SENT_191	[p16l314t85r648b141],
3	FOR	IN	O	for	_	0	SENT_191	[p16l672t85r813b141],
4	PRECISION	NN	O	precision	prep_for	2	SENT_191	[p16l834t85r1217b141],
5	CANCER	NNP	O	CANCER	nn	6	SENT_191	[p16l1238t86r1531b141],
6	MEDICINE	NNP	O	MEDICINE	dep	2	SENT_191	[p16l1551t86r1907b141],

1	Progressively	RB	O	progressively	advmod	5	SENT_192	[p16l8t181r471b265],
2	,	,	O	,	_	0	SENT_192	[p16l8t181r471b265],
3	and	CC	O	and	dep	4	SENT_192	[p16l496t181r623b244],
4	with	IN	O	with	dep	1	SENT_192	[p16l643t181r796b244],
5	increasing	VBG	O	increase	_	0	SENT_192	[p16l819t186r1173b265],
6	rapidity	NN	O	rapidity	dobj	5	SENT_192	[p16l1194t181r1473b265],
7	,	,	O	,	_	0	SENT_192	[p16l1194t181r1473b265],
8	the	DT	O	the	det	9	SENT_192	[p16l1496t181r1603b244],
9	power	NN	O	power	appos	6	SENT_192	[p16l1625t203r1841b264],
10	of	IN	O	of	_	0	SENT_192	[p16l1862t181r1936b244],
11	largescale	JJ	O	largescale	amod	12	SENT_192	[p16l1948t181r2142b265, p16l8t284r167b347],
12	whole	NN	O	whole	prep_of	9	SENT_192	[p16l185t284r414b347],
13	-	:	O	-	_	0	SENT_192	[p16l185t284r414b347],
14	genome	NN	O	genome	nn	15	SENT_192	[p16l421t307r686b368],
15	sequencing	NN	O	sequencing	dep	5	SENT_192	[p16l707t289r1087b368],
16	and	CC	O	and	_	0	SENT_192	[p16l1105t284r1229b347],
17	other	JJ	O	other	amod	19	SENT_192	[p16l1249t284r1427b347],
18	“	NN	O	“	nn	19	SENT_192	[p16l1447t284r1699b347],
19	omics	NNS	O	omic	dep	5	SENT_192	[p16l1447t284r1699b347],
20	”	CD	NUMBER	”	num	21	SENT_192	[p16l1447t284r1699b347],
21	technologies	NNS	O	technology	nsubj	32	SENT_192	[p16l1720t284r2142b368],
22	being	VBG	O	be	auxpass	23	SENT_192	[p16l6t387r196b471],
23	used	VBN	O	use	partmod	21	SENT_192	[p16l215t387r373b450],
24	in	IN	O	in	_	0	SENT_192	[p16l392t392r459b449],
25	discovery	NN	O	discovery	nn	26	SENT_192	[p16l480t387r809b471],
26	mode	NN	O	mode	prep_in	23	SENT_192	[p16l825t387r1018b450],
27	in	IN	O	in	_	0	SENT_192	[p16l1039t392r1105b449],
28	thousands	NNS	O	thousand	prep_in	23	SENT_192	[p16l1125t387r1475b450],
29	of	IN	O	of	_	0	SENT_192	[p16l1497t387r1571b450],
30	patients	NNS	O	patient	prep_of	28	SENT_192	[p16l1581t392r1849b470],
31	is	VBZ	O	be	aux	32	SENT_192	[p16l1870t392r1920b450],
32	deﬁning	VBG	O	deﬁning	rcmod	15	SENT_192	[p16l1941t387r2141b450, p16l8t495r117b574],
33	large	JJ	O	large	amod	34	SENT_192	[p16l137t490r304b574],
34	numbers	NNS	O	number	dobj	32	SENT_192	[p16l327t490r632b553],
35	of	IN	O	of	_	0	SENT_192	[p16l657t490r732b553],
36	pathogenic	JJ	O	pathogenic	amod	38	SENT_192	[p16l744t490r1129b574],
37	driver	NN	O	driver	nn	38	SENT_192	[p16l1152t490r1361b553],
38	mutations	NNS	O	mutation	prep_of	15	SENT_192	[p16l1382t495r1731b553],
39	that	WDT	O	that	nsubj	42	SENT_192	[p16l1754t490r1890b553],
40	are	VBP	O	be	cop	42	SENT_192	[p16l1912t513r2014b553],
41	the	DT	O	the	det	42	SENT_192	[p16l2036t490r2144b553],
42	focus	NN	O	focus	rcmod	38	SENT_192	[p16l7t593r191b656],
43	of	IN	O	of	_	0	SENT_192	[p16l216t593r291b656],
44	addiction	NN	O	addiction	prep_of	42	SENT_192	[p16l305t593r637b656],
45	for	IN	O	for	_	0	SENT_192	[p16l660t593r760b656],
46	cancer	NN	O	cancer	nn	47	SENT_192	[p16l783t616r1010b656],
47	cells	NNS	O	cell	prep_for	44	SENT_192	[p16l1033t593r1197b656],
48	.	.	O	.	_	0	SENT_192	[p16l1033t593r1197b656],

1	These	DT	O	these	det	2	SENT_193	[p16l1224t593r1421b656],
2	addictions	NNS	O	addiction	nsubj	15	SENT_193	[p16l1446t593r1828b665],
3	,	,	O	,	_	0	SENT_193	[p16l1446t593r1828b665],
4	together	RB	O	together	rcmod	2	SENT_193	[p16l1853t593r2145b677],
5	with	IN	O	with	dep	4	SENT_193	[p16l6t696r159b759],
6	genetics-related	JJ	O	genetics-related	amod	8	SENT_193	[p16l180t696r721b780],
7	synthetic	JJ	O	synthetic	amod	8	SENT_193	[p16l743t696r1052b780],
8	lethalities	NNS	O	lethality	pobj	5	SENT_193	[p16l1072t696r1401b759],
9	and	CC	O	and	_	0	SENT_193	[p16l1424t696r1550b759],
10	other	JJ	O	other	amod	12	SENT_193	[p16l1572t696r1753b759],
11	tumor	NN	O	tumor	nn	12	SENT_193	[p16l1773t708r1988b759],
12	vulnerabilities	NNS	O	vulnerability	pobj	5	SENT_193	[p16l2006t696r2141b759, p16l7t799r412b871],
13	,	,	O	,	_	0	SENT_193	[p16l2006t696r2141b759, p16l7t799r412b871],
14	have	VBP	O	have	aux	15	SENT_193	[p16l436t799r594b862],
15	yielded	VBN	O	yield	_	0	SENT_193	[p16l615t799r869b883],
16	new	JJ	O	new	amod	17	SENT_193	[p16l891t822r1037b862],
17	targets	NNS	O	target	dobj	15	SENT_193	[p16l1056t811r1287b883],
18	for	IN	O	for	_	0	SENT_193	[p16l1311t799r1410b862],
19	the	DT	O	the	det	23	SENT_193	[p16l1431t799r1540b862],
20	current	JJ	DATE	current	amod	23	SENT_193	[p16l1564t811r1821b862],
21	and	CC	O	and	_	0	SENT_193	[p16l1844t799r1972b862],
22	next	JJ	O	next	conj_and	20	SENT_193	[p16l1994t811r2145b862],
23	generation	NN	O	generation	prep_for	15	SENT_193	[p16l8t907r391b986],
24	of	IN	O	of	_	0	SENT_193	[p16l420t902r497b965],
25	molecular	JJ	O	molecular	amod	27	SENT_193	[p16l515t902r878b965],
26	therapeutic	JJ	O	therapeutic	amod	27	SENT_193	[p16l904t902r1314b985],
27	drugs	NNS	O	drug	prep_of	23	SENT_193	[p16l1342t902r1543b986],
28	to	TO	O	to	aux	29	SENT_193	[p16l1570t914r1639b965],
29	treat	VB	O	treat	xcomp	15	SENT_193	[p16l1667t914r1832b965],
30	deﬁned	VBN	O	deﬁned	dep	29	SENT_193	[p16l1859t902r2144b974],
31	,	,	O	,	_	0	SENT_193	[p16l1859t902r2144b974],
32	genetically	RB	O	genetically	acomp	29	SENT_193	[p16l7t1005r366b1089],
33	stratiﬁed	VBD	O	stratiﬁed	ccomp	32	SENT_193	[p16l383t1005r676b1068],
34	subgroups	NNS	O	subgroup	dobj	33	SENT_193	[p16l696t1005r1039b1089],
35	of	IN	O	of	_	0	SENT_193	[p16l1059t1005r1131b1068],
36	patients	NNS	O	patient	prep_of	34	SENT_193	[p16l1141t1010r1402b1088],
37	with	IN	O	with	_	0	SENT_193	[p16l1421t1005r1570b1068],
38	cancer	NN	O	cancer	prep_with	33	SENT_193	[p16l1589t1028r1816b1068],
39	.	.	O	.	_	0	SENT_193	[p16l1589t1028r1816b1068],

1	The	DT	O	the	det	2	SENT_194	[p16l1839t1005r1961b1068],
2	hope	NN	O	hope	nsubj	3	SENT_194	[p16l1980t1005r2145b1088],
3	is	VBZ	O	be	_	0	SENT_194	[p16l8t1113r59b1171],
4	that	IN	O	that	complm	18	SENT_194	[p16l83t1108r221b1171],
5	such	PDT	O	such	predet	8	SENT_194	[p16l246t1108r405b1171],
6	a	DT	O	a	det	8	SENT_194	[p16l430t1131r465b1171],
7	personalized	JJ	O	personalized	amod	8	SENT_194	[p16l488t1108r940b1191],
8	strategy	NN	O	strategy	nsubj	18	SENT_194	[p16l964t1120r1244b1192],
9	in	IN	O	in	_	0	SENT_194	[p16l1265t1113r1333b1170],
10	cancer	NN	O	cancer	nn	11	SENT_194	[p16l1358t1131r1588b1171],
11	therapy	NN	O	therapy	prep_in	8	SENT_194	[p16l1611t1108r1881b1192],
12	will	MD	O	will	aux	18	SENT_194	[p16l1900t1108r2048b1180],
13	,	,	O	,	_	0	SENT_194	[p16l1900t1108r2048b1180],
14	in	IN	O	in	_	0	SENT_194	[p16l2075t1113r2143b1170],
15	due	JJ	O	due	amod	16	SENT_194	[p16l8t1211r131b1274],
16	course	NN	O	course	prep_in	18	SENT_194	[p16l154t1234r394b1283],
17	,	,	O	,	_	0	SENT_194	[p16l154t1234r394b1283],
18	replace	VB	O	replace	ccomp	3	SENT_194	[p16l419t1211r660b1294],
19	the	DT	O	the	det	24	SENT_194	[p16l682t1211r789b1274],
20	conventional	JJ	O	conventional	amod	24	SENT_194	[p16l812t1211r1256b1274],
21	one-size-ﬁts-all	JJ	O	one-size-ﬁts-all	amod	24	SENT_194	[p16l1279t1211r1808b1274],
22	cytotoxic	JJ	O	cytotoxic	amod	24	SENT_194	[p16l1831t1216r2143b1295],
23	chemotherapy	NN	O	chemotherapy	nn	24	SENT_194	[p16l8t1315r501b1399],
24	approach	NN	O	approach	dobj	18	SENT_194	[p16l520t1315r852b1398],
25	.	.	O	.	_	0	SENT_194	[p16l520t1315r852b1398],

1	However	RB	O	however	dep	100	SENT_195	[p16l82t1423r412b1490],
2	,	,	O	,	_	0	SENT_195	[p16l82t1423r412b1490],
3	extraordinary	JJ	O	extraordinary	dep	100	SENT_195	[p16l440t1418r932b1502],
4	genetic	JJ	O	genetic	dep	100	SENT_195	[p16l954t1423r1206b1502],
5	heterogeneity	NN	O	heterogeneity	dep	100	SENT_195	[p16l1231t1418r1727b1502],
6	,	,	O	,	_	0	SENT_195	[p16l1231t1418r1727b1502],
7	both	CC	O	both	dep	100	SENT_195	[p16l1752t1418r1916b1481],
8	intratumor	NN	O	intratumor	dep	100	SENT_195	[p16l1942t1423r2141b1481, p16l7t1533r225b1584],
9	and	CC	O	and	dep	100	SENT_195	[p16l248t1521r375b1584],
10	intertumor	NN	O	intertumor	dep	100	SENT_195	[p16l397t1526r793b1593],
11	,	,	O	,	_	0	SENT_195	[p16l397t1526r793b1593],
12	is	VBZ	O	be	dep	100	SENT_195	[p16l818t1526r869b1584],
13	being	VBG	O	be	dep	100	SENT_195	[p16l891t1521r1085b1605],
14	revealed	VBN	O	reveal	dep	100	SENT_195	[p16l1106t1521r1396b1584],
15	in	IN	O	in	dep	100	SENT_195	[p16l1418t1526r1485b1583],
16	cancers	NNS	O	cancer	dep	100	SENT_195	[p16l1509t1544r1784b1593],
17	,	,	O	,	_	0	SENT_195	[p16l1509t1544r1784b1593],
18	especially	RB	O	especially	dep	100	SENT_195	[p16l1810t1521r2147b1605],
19	through	IN	O	through	dep	100	SENT_195	[p16l7t1623r283b1707],
20	deep	JJ	O	deep	dep	100	SENT_195	[p16l305t1623r463b1706],
21	sequencing	NN	O	sequencing	dep	100	SENT_195	[p16l486t1615r1029b1707],
22	.36	CD	NUMBER	.36	dep	100	SENT_195	[p16l486t1615r1029b1707],
23	>	JJR	O	>	dep	100	SENT_195	[p16l486t1615r1029b1707],
24	37	CD	NUMBER	37	dep	100	SENT_195	[p16l486t1615r1029b1707],
25	Together	RB	O	together	dep	100	SENT_195	[p16l1049t1623r1353b1707],
26	with	IN	O	with	dep	100	SENT_195	[p16l1370t1623r1523b1686],
27	alterations	NNS	O	alteration	dep	100	SENT_195	[p16l1544t1623r1900b1686],
28	in	IN	O	in	dep	100	SENT_195	[p16l1921t1628r1987b1685],
29	biochemical	JJ	O	biochemical	dep	100	SENT_195	[p16l2006t1623r2142b1686, p16l8t1726r325b1789],
30	signaling	NN	O	signaling	dep	100	SENT_195	[p16l350t1726r672b1810],
31	pathways	NNS	O	pathway	dep	100	SENT_195	[p16l695t1726r1023b1810],
32	and	CC	O	and	dep	100	SENT_195	[p16l1049t1726r1180b1789],
33	feedback	NN	O	feedback	dep	100	SENT_195	[p16l1204t1726r1520b1789],
34	loops	NNS	O	loop	dep	100	SENT_195	[p16l1540t1726r1885b1809],
35	—	RB	O	—	dep	100	SENT_195	[p16l1540t1726r1885b1809],
36	as	RB	O	as	dep	100	SENT_195	[p16l1540t1726r1885b1809],
37	well	RB	O	well	dep	100	SENT_195	[p16l1909t1726r2051b1789],
38	as	IN	O	as	dep	100	SENT_195	[p16l2077t1749r2143b1789],
39	morphological	JJ	O	morphological	dep	100	SENT_195	[p16l7t1829r506b1913],
40	variations	NNS	O	variation	dep	100	SENT_195	[p16l522t1834r876b1901],
41	,	,	O	,	_	0	SENT_195	[p16l522t1834r876b1901],
42	which	WDT	O	which	dep	100	SENT_195	[p16l896t1829r1102b1892],
43	will	MD	O	will	dep	100	SENT_195	[p16l1121t1829r1245b1892],
44	also	RB	O	also	dep	100	SENT_195	[p16l1265t1829r1394b1892],
45	have	VB	O	have	dep	100	SENT_195	[p16l1415t1829r1568b1892],
46	a	DT	O	a	dep	100	SENT_195	[p16l1589t1852r1623b1892],
47	genetic	JJ	O	genetic	dep	100	SENT_195	[p16l1642t1834r1882b1913],
48	basis	NN	O	basis	dep	100	SENT_195	[p16l1900t1829r2141b1892],
49	—	NN	O	—	dep	100	SENT_195	[p16l1900t1829r2141b1892],
50	this	DT	O	this	dep	100	SENT_195	[p16l7t1932r128b1995],
51	genetic	JJ	O	genetic	dep	100	SENT_195	[p16l148t1937r385b2016],
52	heterogeneity	NN	O	heterogeneity	dep	100	SENT_195	[p16l403t1932r861b2016],
53	and	CC	O	and	dep	100	SENT_195	[p16l878t1932r1002b1995],
54	Darwinian	JJ	MISC	darwinian	dep	100	SENT_195	[p16l1020t1937r1382b1995],
55	clonal	JJ	O	clonal	dep	100	SENT_195	[p16l1402t1932r1601b1995],
56	evolution	NN	O	evolution	dep	100	SENT_195	[p16l1621t1932r1935b1995],
57	in	IN	O	in	dep	100	SENT_195	[p16l1954t1937r2019b1994],
58	the	DT	O	the	dep	100	SENT_195	[p16l2038t1932r2142b1995],
59	face	NN	O	face	dep	100	SENT_195	[p16l7t2036r139b2099],
60	of	IN	O	of	dep	100	SENT_195	[p16l161t2036r234b2099],
61	the	DT	O	the	dep	100	SENT_195	[p16l244t2036r349b2099],
62	selective	JJ	O	selective	dep	100	SENT_195	[p16l371t2036r654b2099],
63	pressure	NN	O	pressure	dep	100	SENT_195	[p16l673t2058r956b2119],
64	of	IN	O	of	dep	100	SENT_195	[p16l978t2036r1051b2099],
65	therapy	NN	O	therapy	dep	100	SENT_195	[p16l1061t2036r1321b2120],
66	provides	VBZ	O	provide	dep	100	SENT_195	[p16l1336t2036r1626b2119],
67	an	DT	O	a	dep	100	SENT_195	[p16l1648t2059r1727b2099],
68	explanation	NN	O	explanation	dep	100	SENT_195	[p16l1748t2036r2146b2119],
69	for	IN	O	for	dep	100	SENT_195	[p16l7t2139r105b2202],
70	de	FW	O	de	dep	100	SENT_195	[p16l127t2139r201b2202],
71	novo	FW	O	novo	dep	100	SENT_195	[p16l225t2162r382b2202],
72	and	CC	O	and	dep	100	SENT_195	[p16l406t2139r532b2202],
73	acquired	VBN	O	acquire	dep	100	SENT_195	[p16l555t2139r852b2222],
74	resistance	NN	O	resistance	dep	100	SENT_195	[p16l873t2144r1225b2211],
75	,	,	O	,	_	0	SENT_195	[p16l873t2144r1225b2211],
76	which	WDT	O	which	dep	100	SENT_195	[p16l1247t2139r1456b2202],
77	is	VBZ	O	be	dep	100	SENT_195	[p16l1479t2144r1528b2202],
78	now	RB	DATE	now	dep	100	SENT_195	[p16l1552t2162r1700b2202],
79	known	VBN	O	know	dep	100	SENT_195	[p16l1718t2139r1955b2202],
80	to	TO	O	to	dep	100	SENT_195	[p16l1976t2151r2042b2202],
81	be	VB	O	be	dep	100	SENT_195	[p16l2064t2139r2144b2202],
82	the	DT	O	the	dep	100	SENT_195	[p16l7t2242r114b2305],
83	major	JJ	O	major	dep	100	SENT_195	[p16l137t2247r340b2326],
84	limitation	NN	O	limitation	dep	100	SENT_195	[p16l361t2242r702b2305],
85	of	IN	O	of	dep	100	SENT_195	[p16l726t2242r800b2305],
86	molecularly	RB	O	molecularly	dep	100	SENT_195	[p16l813t2242r1225b2326],
87	targeted	VBN	O	target	dep	100	SENT_195	[p16l1243t2242r1524b2326],
88	drugs	NNS	O	drug	dep	100	SENT_195	[p16l1547t2242r1759b2326],
89	,	,	O	,	_	0	SENT_195	[p16l1547t2242r1759b2326],
90	just	RB	O	just	dep	100	SENT_195	[p16l1779t2247r1906b2326],
91	as	RB	O	as	dep	100	SENT_195	[p16l1929t2265r1993b2305],
92	was	VBD	O	be	dep	100	SENT_195	[p16l2015t2265r2142b2305],
93	the	DT	O	the	dep	100	SENT_195	[p16l7t2344r113b2407],
94	case	NN	O	case	dep	100	SENT_195	[p16l135t2367r274b2407],
95	with	IN	O	with	dep	100	SENT_195	[p16l294t2344r447b2407],
96	cytotoxic	JJ	O	cytotoxic	dep	100	SENT_195	[p16l469t2349r781b2428],
97	chemotherapy	NN	O	chemotherapy	dep	100	SENT_195	[p16l803t2336r1445b2428],
98	.46	CD	NUMBER	.46	dep	100	SENT_195	[p16l803t2336r1445b2428],
99	>	JJR	O	>	dep	100	SENT_195	[p16l803t2336r1445b2428],
100	47	CD	NUMBER	47	_	0	SENT_195	[p16l803t2336r1445b2428],

1	The	DT	O	the	det	2	SENT_196	[p16l81t2447r208b2510],
2	solution	NN	O	solution	nsubj	12	SENT_196	[p16l232t2447r514b2510],
3	to	TO	O	to	_	0	SENT_196	[p16l537t2459r604b2510],
4	the	DT	O	the	det	6	SENT_196	[p16l627t2447r735b2510],
5	inevitable	JJ	O	inevitable	amod	6	SENT_196	[p16l759t2447r1097b2510],
6	challenge	NN	O	challenge	prep_to	2	SENT_196	[p16l1122t2447r1447b2531],
7	of	IN	O	of	_	0	SENT_196	[p16l1471t2447r1546b2510],
8	polygenic	JJ	O	polygenic	amod	11	SENT_196	[p16l1558t2447r1896b2531],
9	cancer	NN	O	cancer	nn	11	SENT_196	[p16l1919t2470r2147b2510],
10	drug	NN	O	drug	nn	11	SENT_196	[p16l8t2550r170b2634],
11	resistance	NN	O	resistance	prep_of	6	SENT_196	[p16l192t2555r525b2613],
12	is	VBZ	O	be	_	0	SENT_196	[p16l549t2555r598b2613],
13	to	TO	O	to	aux	14	SENT_196	[p16l621t2562r686b2613],
14	identify	VB	O	identify	ccomp	12	SENT_196	[p16l711t2550r978b2634],
15	not	RB	O	not	neg	16	SENT_196	[p16l997t2562r1111b2613],
16	only	RB	O	only	preconj	20	SENT_196	[p16l1133t2550r1284b2634],
17	all	DT	O	all	det	20	SENT_196	[p16l1304t2550r1383b2613],
18	exploitable	JJ	O	exploitable	amod	20	SENT_196	[p16l1405t2550r1776b2633],
19	molecular	JJ	O	molecular	amod	20	SENT_196	[p16l1799t2550r2145b2613],
20	abnormalities	NNS	O	abnormality	dobj	14	SENT_196	[p16l8t2653r480b2716],
21	but	CC	O	but	_	0	SENT_196	[p16l501t2653r615b2716],
22	also	RB	O	also	_	0	SENT_196	[p16l637t2653r769b2716],
23	the	DT	O	the	det	25	SENT_196	[p16l792t2653r899b2716],
24	full	JJ	O	full	amod	25	SENT_196	[p16l922t2653r1036b2716],
25	range	NN	O	range	conj_and	20	SENT_196	[p16l1058t2676r1247b2737],
26	of	IN	O	of	_	0	SENT_196	[p16l1271t2653r1345b2716],
27	resistance	NN	O	resistance	nn	28	SENT_196	[p16l1358t2658r1693b2716],
28	mechanisms	NNS	O	mechanism	prep_of	25	SENT_196	[p16l1716t2653r2145b2716],
29	and	CC	O	and	_	0	SENT_196	[p16l8t2756r134b2819],
30	thereafter	RB	O	thereafter	advmod	14	SENT_196	[p16l152t2756r481b2819],
31	to	TO	O	to	aux	32	SENT_196	[p16l499t2768r565b2819],
32	employ	VB	O	employ	conj_and	14	SENT_196	[p16l587t2756r839b2840],
33	precision	NN	O	precision	nsubj	35	SENT_196	[p16l855t2761r1167b2839],
34	combinatorial	JJ	O	combinatorial	dep	35	SENT_196	[p16l1188t2756r1665b2819],
35	targeted	VBN	O	target	xcomp	32	SENT_196	[p16l1684t2756r1960b2840],
36	therapy	NN	O	therapy	dobj	35	SENT_196	[p16l1979t2756r2141b2819, p16l8t2880r127b2942],
37	matched	VBD	O	match	rcmod	36	SENT_196	[p16l145t2858r440b2921],
38	speciﬁcally	RB	O	speciﬁcally	advmod	37	SENT_196	[p16l461t2858r839b2942],
39	to	TO	O	to	prep	37	SENT_196	[p16l856t2870r922b2921],
40	the	DT	O	the	det	41	SENT_196	[p16l943t2858r1050b2921],
41	fully	RB	O	fully	pobj	39	SENT_196	[p16l1071t2858r1227b2942],
42	deﬁned	VBN	O	deﬁned	partmod	41	SENT_196	[p16l1246t2858r1500b2921],
43	tumor	NN	O	tumor	nn	44	SENT_196	[p16l1520t2870r1736b2921],
44	proﬁle	NN	O	proﬁle	dobj	42	SENT_196	[p16l1755t2850r2057b2941],
45	,46	CD	NUMBER	,46	num	44	SENT_196	[p16l1755t2850r2057b2941],
46	as	IN	O	as	mark	47	SENT_196	[p16l2079t2881r2143b2921],
47	depicted	VBN	O	depict	advcl	42	SENT_196	[p16l8t2961r310b3044],
48	in	IN	O	in	_	0	SENT_196	[p16l334t2966r402b3023],
49	Figure	NNP	O	Figure	prep_in	47	SENT_196	[p16l427t2966r666b3044],
50	3	CD	NUMBER	3	num	49	SENT_196	[p16l690t2968r747b3024],
51	.	.	O	.	_	0	SENT_196	[p16l690t2968r747b3024],

1	The	DT	DATE	the	det	2	SENT_197	[p16l775t2961r903b3024],
2	future	NN	DATE	future	nsubj	9	SENT_197	[p16l928t2961r1141b3024],
3	of	IN	O	of	_	0	SENT_197	[p16l1166t2961r1242b3024],
4	such	JJ	O	such	amod	7	SENT_197	[p16l1258t2961r1417b3024],
5	truly	RB	O	truly	advmod	6	SENT_197	[p16l1440t2961r1613b3045],
6	individualized	JJ	O	individualized	amod	7	SENT_197	[p16l1635t2961r2144b3024],
7	therapies	NNS	O	therapy	prep_of	2	SENT_197	[p16l7t3064r312b3147],
8	will	MD	O	will	aux	9	SENT_197	[p16l332t3064r456b3127],
9	require	VB	O	require	_	0	SENT_197	[p16l475t3069r716b3147],
10	not	RB	O	not	neg	12	SENT_197	[p16l737t3076r849b3127],
11	only	RB	O	only	advmod	12	SENT_197	[p16l869t3064r1018b3148],
12	complete	JJ	O	complete	amod	13	SENT_197	[p16l1035t3064r1341b3147],
13	drugging	NN	O	drugging	dobj	9	SENT_197	[p16l1363t3064r1673b3148],
14	of	IN	O	of	_	0	SENT_197	[p16l1692t3064r1765b3127],
15	all	DT	O	all	det	17	SENT_197	[p16l1776t3064r1853b3127],
16	possible	JJ	O	possible	amod	17	SENT_197	[p16l1872t3064r2144b3147],
17	targets	NNS	O	target	prep_of	13	SENT_197	[p16l7t3178r236b3250],
18	in	IN	O	in	_	0	SENT_197	[p16l260t3171r328b3228],
19	the	DT	O	the	det	21	SENT_197	[p16l350t3166r458b3229],
20	cancer	NN	O	cancer	nn	21	SENT_197	[p16l481t3189r708b3229],
21	genome1	NN	O	genome1	prep_in	9	SENT_197	[p16l730t3158r1155b3250],
22	’	CD	NUMBER	’	number	23	SENT_197	[p16l730t3158r1155b3250],
23	8	CD	NUMBER	8	npadvmod	24	SENT_197	[p16l730t3158r1155b3250],
24	>	JJR	O	>	amod	21	SENT_197	[p16l730t3158r1155b3250],
25	11	CD	NUMBER	11	dep	21	SENT_197	[p16l730t3158r1155b3250],
26	but	CC	O	but	_	0	SENT_197	[p16l1181t3166r1296b3229],
27	also	RB	O	also	_	0	SENT_197	[p16l1319t3166r1451b3229],
28	the	DT	O	the	det	29	SENT_197	[p16l1475t3166r1582b3229],
29	development	NN	O	development	prep_in	9	SENT_197	[p16l1607t3166r2056b3249],
30	of	IN	O	of	_	0	SENT_197	[p16l2079t3166r2153b3229],
31	an	DT	O	a	det	34	SENT_197	[p16l8t3293r88b3333],
32	enhanced	VBN	O	enhance	amod	34	SENT_197	[p16l109t3270r438b3333],
33	comprehensive	JJ	O	comprehensive	amod	34	SENT_197	[p16l458t3270r970b3353],
34	portfolio	NN	O	portfolio	prep_of	29	SENT_197	[p16l990t3270r1290b3353],
35	of	IN	O	of	_	0	SENT_197	[p16l1313t3270r1386b3333],
36	companion	NN	O	companion	nn	38	SENT_197	[p16l1398t3275r1784b3353],
37	predictive	JJ	O	predictive	amod	38	SENT_197	[p16l1803t3270r2142b3353],
38	biomarkers	NNS	O	biomarker	prep_of	34	SENT_197	[p16l6t3364r521b3436],
39	.2	NN	NUMBER	.2	dep	38	SENT_197	[p16l6t3364r521b3436],
40	’58	CD	NUMBER	’58	num	39	SENT_197	[p16l6t3364r521b3436],

1	Although	IN	O	although	mark	6	SENT_198	[p17l80t27r416b111],
2	whole-exome	JJ	O	whole-exome	amod	3	SENT_198	[p17l437t27r913b90],
3	sequencing	NN	O	sequencing	nsubj	6	SENT_198	[p17l937t32r1334b111],
4	is	VBZ	O	be	aux	6	SENT_198	[p17l1356t32r1407b90],
5	fast	JJ	O	fast	advmod	6	SENT_198	[p17l1431t27r1553b90],
6	becoming	VBG	O	become	advcl	29	SENT_198	[p17l1573t27r1924b111],
7	much	RB	O	much	advmod	9	SENT_198	[p17l1946t27r2144b90],
8	more	RBR	O	more	advmod	9	SENT_198	[p17l7t153r182b193],
9	affordable	JJ	O	affordable	acomp	6	SENT_198	[p17l203t130r536b193],
10	and	CC	O	and	_	0	SENT_198	[p17l557t130r681b193],
11	is	VBZ	O	be	cop	13	SENT_198	[p17l700t135r749b193],
12	increasingly	RB	O	increasingly	advmod	13	SENT_198	[p17l770t130r1178b214],
13	common	JJ	O	common	advcl	29	SENT_198	[p17l1195t153r1498b193],
14	in	IN	O	in	_	0	SENT_198	[p17l1517t135r1583b192],
15	clinical	JJ	O	clinical	amod	17	SENT_198	[p17l1604t130r1844b193],
16	research	NN	O	research	nn	17	SENT_198	[p17l1863t130r2142b193],
17	(	NN	O	(	prep_in	13	SENT_198	[p17l11t233r136b310],
18	for	IN	O	for	_	0	SENT_198	[p17l11t233r136b310],
19	example	NN	O	example	prep_for	17	SENT_198	[p17l158t233r460b316],
20	,	,	O	,	_	0	SENT_198	[p17l158t233r460b316],
21	to	TO	O	to	aux	22	SENT_198	[p17l484t245r550b296],
22	identify	VB	O	identify	xcomp	13	SENT_198	[p17l575t233r844b317],
23	resistance	NN	O	resistance	nn	24	SENT_198	[p17l863t238r1199b296],
24	mechanisms	NNS	O	mechanism	nsubj	25	SENT_198	[p17l1222t233r1700b310],
25	)	VBP	O	)	ccomp	22	SENT_198	[p17l1222t233r1700b310],
26	,	,	O	,	_	0	SENT_198	[p17l1222t233r1700b310],
27	it	PRP	O	it	nsubj	29	SENT_198	[p17l1725t238r1771b296],
28	is	VBZ	O	be	cop	29	SENT_198	[p17l1793t238r1843b296],
29	unlikely	JJ	O	unlikely	_	0	SENT_198	[p17l1866t233r2147b317],
30	to	TO	O	to	aux	31	SENT_198	[p17l7t348r72b399],
31	enter	VB	O	enter	xcomp	29	SENT_198	[p17l94t348r266b399],
32	routine	JJ	O	routine	amod	34	SENT_198	[p17l285t341r530b399],
33	clinical	JJ	O	clinical	amod	34	SENT_198	[p17l551t336r793b399],
34	practice	NN	O	practice	dobj	31	SENT_198	[p17l811t341r1080b419],
35	in	IN	O	in	_	0	SENT_198	[p17l1101t341r1166b398],
36	the	DT	DURATION	the	det	39	SENT_198	[p17l1185t336r1291b399],
37	next	JJ	DURATION	next	amod	39	SENT_198	[p17l1311t348r1458b399],
38	few	JJ	DURATION	few	amod	39	SENT_198	[p17l1477t336r1596b399],
39	years	NNS	DURATION	year	prep_in	31	SENT_198	[p17l1611t359r1800b420],
40	.	.	O	.	_	0	SENT_198	[p17l1611t359r1800b420],

1	However	RB	O	however	advmod	15	SENT_199	[p17l1825t341r2140b408],
2	,	,	O	,	_	0	SENT_199	[p17l1825t341r2140b408],
3	with	IN	O	with	_	0	SENT_199	[p17l6t439r163b502],
4	DNA	NN	O	dna	nn	6	SENT_199	[p17l187t443r371b502],
5	sequencing	NN	O	sequencing	nn	6	SENT_199	[p17l396t444r794b523],
6	costs	NNS	O	cost	prep_with	15	SENT_199	[p17l817t451r987b502],
7	plummeting	VBG	O	plummet	partmod	6	SENT_199	[p17l1011t439r1466b523],
8	,	,	O	,	_	0	SENT_199	[p17l1011t439r1466b523],
9	the	DT	O	the	det	10	SENT_199	[p17l1491t439r1600b502],
10	pace	NN	O	pace	nsubj	15	SENT_199	[p17l1623t461r1782b522],
11	of	IN	O	of	_	0	SENT_199	[p17l1807t439r1883b502],
12	change	NN	O	change	prep_of	10	SENT_199	[p17l1897t439r2142b523],
13	may	MD	O	may	aux	15	SENT_199	[p17l7t565r155b626],
14	well	RB	O	well	advmod	15	SENT_199	[p17l173t542r312b605],
15	surprise	VB	O	surprise	_	0	SENT_199	[p17l335t547r612b625],
16	us	PRP	O	we	dobj	15	SENT_199	[p17l635t565r727b605],
17	.	.	O	.	_	0	SENT_199	[p17l635t565r727b605],

1	An	DT	O	a	det	2	SENT_200	[p17l752t546r856b604],
2	approach	NN	O	approach	nsubj	16	SENT_200	[p17l880t542r1199b625],
3	that	WDT	O	that	nsubj	7	SENT_200	[p17l1221t542r1357b605],
4	is	VBZ	O	be	cop	7	SENT_200	[p17l1379t547r1429b605],
5	more	RBR	O	more	advmod	7	SENT_200	[p17l1452t565r1631b605],
6	rapidly	RB	O	rapidly	advmod	7	SENT_200	[p17l1655t542r1900b626],
7	implementable	JJ	O	implementable	rcmod	2	SENT_200	[p17l1919t542r2141b625, p17l7t644r313b707],
8	in	IN	O	in	_	0	SENT_200	[p17l333t649r398b706],
9	the	DT	O	the	det	13	SENT_200	[p17l416t644r519b707],
10	short	JJ	O	short	amod	13	SENT_200	[p17l540t644r736b707],
11	-	:	O	-	_	0	SENT_200	[p17l540t644r736b707],
12	to	TO	O	to	dep	13	SENT_200	[p17l758t656r822b707],
13	mid-term	JJ	O	mid-term	prep_in	7	SENT_200	[p17l842t644r1165b707],
14	is	VBZ	O	be	cop	16	SENT_200	[p17l1185t649r1233b707],
15	the	DT	O	the	det	16	SENT_200	[p17l1252t644r1356b707],
16	assessment	NN	O	assessment	_	0	SENT_200	[p17l1376t656r1741b707],
17	of	IN	O	of	_	0	SENT_200	[p17l1760t644r1832b707],
18	a	DT	O	a	det	20	SENT_200	[p17l1843t667r1876b707],
19	deﬁned	JJ	O	deﬁned	amod	20	SENT_200	[p17l1895t644r2143b707],
20	panel	NN	O	panel	prep_of	16	SENT_200	[p17l6t747r199b830],
21	of	IN	O	of	_	0	SENT_200	[p17l224t747r299b810],
22	known	JJ	O	known	amod	24	SENT_200	[p17l313t747r557b810],
23	actionable	JJ	O	actionable	amod	24	SENT_200	[p17l583t747r945b810],
24	biomarkers	NNS	O	biomarker	prep_of	20	SENT_200	[p17l968t747r1369b810],
25	in	IN	O	in	_	0	SENT_200	[p17l1395t752r1463b809],
26	tumor	NN	O	tumor	nn	27	SENT_200	[p17l1487t759r1709b810],
27	tissue	NN	O	tissue	prep_in	24	SENT_200	[p17l1731t752r1930b810],
28	using	VBG	O	use	partmod	27	SENT_200	[p17l1955t752r2147b831],
29	neXt	NN	O	next	nn	32	SENT_200	[p17l7t856r544b935],
30	—	NN	O	—	nn	32	SENT_200	[p17l7t856r544b935],
31	generation	NN	O	generation	nn	32	SENT_200	[p17l7t856r544b935],
32	sequencing	NN	O	sequencing	dobj	28	SENT_200	[p17l564t856r958b935],
33	.	.	O	.	_	0	SENT_200	[p17l564t856r958b935],

1	There	EX	O	there	expl	2	SENT_201	[p17l981t851r1171b914],
2	is	VBZ	O	be	_	0	SENT_201	[p17l1191t856r1240b914],
3	also	RB	O	also	advmod	2	SENT_201	[p17l1261t851r1389b914],
4	potential	JJ	O	potential	acomp	2	SENT_201	[p17l1409t851r1710b934],
5	for	IN	O	for	_	0	SENT_201	[p17l1729t851r1824b914],
6	sequencing	NN	O	sequencing	prep_for	4	SENT_201	[p17l1844t874r2140b934, p17l8t958r119b1037],
7	of	IN	O	of	_	0	SENT_201	[p17l142t953r218b1016],
8	circulating	VBG	O	circulate	prepc_of	6	SENT_201	[p17l233t953r612b1037],
9	tumor	NN	O	tumor	nn	10	SENT_201	[p17l634t965r856b1016],
10	cells	NNS	O	cell	nsubj	27	SENT_201	[p17l880t953r1028b1016],
11	or	CC	O	or	_	0	SENT_201	[p17l1054t976r1127b1016],
12	cell-free	JJ	O	cell-free	amod	13	SENT_201	[p17l1151t953r1436b1016],
13	DNA39	NN	O	dna39	conj_or	10	SENT_201	[p17l1461t945r1707b1016],
14	to	TO	O	to	aux	15	SENT_201	[p17l1731t965r1798b1016],
15	capture	VB	O	capture	xcomp	8	SENT_201	[p17l1825t965r2085b1036],
16	a	DT	O	a	det	18	SENT_201	[p17l2110t976r2145b1016],
17	wider	JJR	O	wider	amod	18	SENT_201	[p17l6t1056r199b1119],
18	picture	NN	O	picture	dobj	15	SENT_201	[p17l217t1061r455b1139],
19	of	IN	O	of	_	0	SENT_201	[p17l476t1056r549b1119],
20	the	DT	O	the	dep	22	SENT_201	[p17l558t1056r663b1119],
21	multiple	JJ	O	multiple	amod	22	SENT_201	[p17l684t1056r965b1139],
22	primary	JJ	O	primary	prep_of	18	SENT_201	[p17l984t1061r1264b1140],
23	and	CC	O	and	_	0	SENT_201	[p17l1281t1056r1406b1119],
24	metastatic	JJ	O	metastatic	amod	25	SENT_201	[p17l1424t1061r1769b1119],
25	clones	NNS	O	clone	prep_of	18	SENT_201	[p17l1790t1056r1998b1119],
26	and	CC	O	and	_	0	SENT_201	[p17l2020t1056r2145b1119],
27	facilitate	VB	O	facilitate	xcomp	8	SENT_201	[p17l7t1159r291b1222],
28	repeat	NN	O	repeat	nn	29	SENT_201	[p17l312t1171r519b1242],
29	analysis	NN	O	analysis	dobj	27	SENT_201	[p17l538t1159r816b1243],
30	,	,	O	,	_	0	SENT_201	[p17l538t1159r816b1243],
31	which	WDT	O	which	nsubj	35	SENT_201	[p17l836t1159r1042b1222],
32	might	MD	O	might	aux	35	SENT_201	[p17l1061t1159r1261b1243],
33	also	RB	O	also	advmod	35	SENT_201	[p17l1281t1159r1409b1222],
34	be	VB	O	be	cop	35	SENT_201	[p17l1428t1159r1506b1222],
35	further	JJ	O	further	rcmod	29	SENT_201	[p17l1527t1159r1766b1222],
36	enabled	VBN	O	enable	partmod	35	SENT_201	[p17l1785t1159r2046b1222],
37	by	IN	O	by	_	0	SENT_201	[p17l2063t1159r2146b1243],
38	metabolomics	NNS	O	metabolomic	agent	36	SENT_201	[p17l7t1261r490b1324],
39	or	CC	O	or	_	0	SENT_201	[p17l512t1284r584b1324],
40	molecular	JJ	O	molecular	amod	42	SENT_201	[p17l604t1261r950b1324],
41	imaging	NN	O	imaging	nn	42	SENT_201	[p17l970t1253r1408b1345],
42	.46	NN	NUMBER	.46	agent	36	SENT_201	[p17l970t1253r1408b1345],
43	=	JJ	O	=	amod	42	SENT_201	[p17l970t1253r1408b1345],
44	59	CD	NUMBER	59	tmod	43	SENT_201	[p17l970t1253r1408b1345],

1	We	PRP	O	we	nsubj	3	SENT_202	[p17l80t1369r188b1427],
2	therefore	RB	O	therefore	advmod	3	SENT_202	[p17l207t1364r513b1427],
3	envisage	VBP	O	envisage	_	0	SENT_202	[p17l534t1369r817b1448],
4	a	DT	O	a	det	5	SENT_202	[p17l838t1387r872b1427],
5	future	JJ	DATE	future	dobj	3	SENT_202	[p17l891t1364r1094b1427],
6	requiring	VBG	O	require	xcomp	3	SENT_202	[p17l1115t1369r1432b1448],
7	adaptive	JJ	O	adaptive	amod	9	SENT_202	[p17l1451t1364r1733b1447],
8	combinatorial	JJ	O	combinatorial	amod	9	SENT_202	[p17l1754t1364r2141b1427, p17l8t1466r121b1529],
9	treatment	NN	O	treatment	dobj	6	SENT_202	[p17l142t1478r478b1529],
10	to	TO	O	to	aux	11	SENT_202	[p17l499t1478r565b1529],
11	counteract	VB	O	counteract	dep	6	SENT_202	[p17l589t1478r954b1529],
12	the	DT	O	the	det	16	SENT_202	[p17l975t1466r1081b1529],
13	cellular	JJ	O	cellular	amod	16	SENT_202	[p17l1105t1466r1356b1529],
14	and	CC	O	and	_	0	SENT_202	[p17l1378t1466r1505b1529],
15	molecular	JJ	O	molecular	amod	16	SENT_202	[p17l1526t1466r1872b1529],
16	heterogeneity	NN	O	heterogeneity	dobj	11	SENT_202	[p17l1893t1466r2141b1529, p17l7t1574r262b1653],
17	of	IN	O	of	_	0	SENT_202	[p17l283t1569r358b1632],
18	cancer	NN	O	cancer	prep_of	16	SENT_202	[p17l372t1592r601b1632],
19	and	CC	O	and	_	0	SENT_202	[p17l624t1569r753b1632],
20	to	TO	O	to	aux	21	SENT_202	[p17l774t1581r842b1632],
21	prevent	VB	O	prevent	dep	6	SENT_202	[p17l865t1581r1131b1652],
22	or	CC	O	or	_	0	SENT_202	[p17l1154t1592r1227b1632],
23	overcome	VB	O	overcome	conj_or	21	SENT_202	[p17l1251t1592r1590b1632],
24	drug	NN	O	drug	nn	25	SENT_202	[p17l1615t1569r1781b1653],
25	resistance	NN	O	resistance	dobj	21	SENT_202	[p17l1803t1574r2145b1632],
26	caused	VBN	O	cause	partmod	25	SENT_202	[p17l8t1672r242b1735],
27	by	IN	O	by	_	0	SENT_202	[p17l262t1672r347b1756],
28	clonal	JJ	O	clonal	amod	29	SENT_202	[p17l367t1672r574b1735],
29	evolution	NN	O	evolution	agent	26	SENT_202	[p17l598t1672r924b1735],
30	(	CD	NUMBER	(	num	33	SENT_202	[p17l950t1673r1212b1755],
31	Figure	NNP	O	Figure	nn	33	SENT_202	[p17l950t1673r1212b1755],
32	3	CD	NUMBER	3	num	33	SENT_202	[p17l1235t1673r1322b1749],
33	)	NN	O	)	dep	26	SENT_202	[p17l1235t1673r1322b1749],
34	.	.	O	.	_	0	SENT_202	[p17l1235t1673r1322b1749],

1	In	IN	O	in	_	0	SENT_203	[p17l1348t1677r1420b1734],
2	addition	NN	O	addition	_	0	SENT_203	[p17l1444t1672r1735b1735],
3	to	TO	O	to	_	0	SENT_203	[p17l1757t1684r1824b1735],
4	tailoring	VBG	O	tailor	prepc_in_addition_to	18	SENT_203	[p17l1847t1672r2146b1756],
5	drug	NN	O	drug	nn	6	SENT_203	[p17l8t1776r170b1860],
6	dosages	NNS	O	dosage	dobj	4	SENT_203	[p17l192t1776r455b1860],
7	and	CC	O	and	_	0	SENT_203	[p17l479t1776r605b1839],
8	schedules	NNS	O	schedule	dobj	4	SENT_203	[p17l628t1776r955b1839],
9	to	TO	O	to	aux	10	SENT_203	[p17l978t1788r1043b1839],
10	optimize	VB	O	optimize	xcomp	4	SENT_203	[p17l1068t1781r1368b1859],
11	pharmacokinetic	JJ	O	pharmacokinetic	amod	12	SENT_203	[p17l1390t1776r1974b1859],
12	proﬁles	NNS	O	proﬁles	dobj	10	SENT_203	[p17l1995t1798r2140b1859, p17l7t1879r164b1951],
13	,	,	O	,	_	0	SENT_203	[p17l1995t1798r2140b1859, p17l7t1879r164b1951],
14	this	DT	O	this	det	16	SENT_203	[p17l190t1879r319b1942],
15	adaptive	JJ	O	adaptive	amod	16	SENT_203	[p17l345t1879r641b1962],
16	approach	NN	O	approach	nsubj	18	SENT_203	[p17l667t1879r995b1962],
17	will	MD	O	will	aux	18	SENT_203	[p17l1018t1879r1148b1942],
18	require	VB	O	require	_	0	SENT_203	[p17l1173t1884r1426b1962],
19	not	RB	O	not	neg	21	SENT_203	[p17l1451t1891r1569b1942],
20	only	RB	O	only	advmod	21	SENT_203	[p17l1593t1879r1749b1963],
21	consideration	NN	O	consideration	dobj	18	SENT_203	[p17l1772t1879r2142b1942, p17l7t1987r144b2045],
22	of	IN	O	of	_	0	SENT_203	[p17l168t1982r242b2045],
23	anatomic	JJ	O	anatomic	amod	24	SENT_203	[p17l256t1987r572b2045],
24	heterogeneity	NN	O	heterogeneity	prep_of	21	SENT_203	[p17l594t1982r1065b2066],
25	but	CC	O	but	_	0	SENT_203	[p17l1082t1982r1196b2045],
26	also	RB	O	also	_	0	SENT_203	[p17l1218t1982r1350b2045],
27	the	DT	O	the	det	28	SENT_203	[p17l1373t1982r1479b2045],
28	use	NN	O	use	conj_and	21	SENT_203	[p17l1502t2005r1613b2045],
29	of	IN	O	of	_	0	SENT_203	[p17l1637t1982r1711b2045],
30	longitudinal	JJ	O	longitudinal	amod	32	SENT_203	[p17l1722t1982r2145b2066],
31	genome	NN	O	genome	nn	32	SENT_203	[p17l7t2109r273b2170],
32	sequencing	NN	O	sequencing	prep_of	28	SENT_203	[p17l294t2091r673b2170],
33	or	CC	O	or	_	0	SENT_203	[p17l692t2109r762b2149],
34	other	JJ	O	other	amod	38	SENT_203	[p17l782t2086r960b2149],
35	large	JJ	O	large	amod	38	SENT_203	[p17l977t2086r1332b2170],
36	—	NN	O	—	nn	38	SENT_203	[p17l977t2086r1332b2170],
37	scale	NN	O	scale	nn	38	SENT_203	[p17l977t2086r1332b2170],
38	omics	NNS	O	omic	prep_of	28	SENT_203	[p17l1352t2091r1549b2149],
39	proﬁling	VBG	O	proﬁling	partmod	32	SENT_203	[p17l1568t2086r1859b2170],
40	coupled	VBN	O	couple	prep	39	SENT_203	[p17l1878t2086r2144b2169],
41	to	TO	O	to	pcomp	40	SENT_203	[p17l7t2201r72b2252],
42	iterative	JJ	O	iterative	amod	43	SENT_203	[p17l96t2194r371b2252],
43	switching	NN	O	switching	pobj	41	SENT_203	[p17l394t2189r722b2273],
44	of	IN	O	of	_	0	SENT_203	[p17l744t2189r817b2252],
45	therapy	NN	O	therapy	prep_of	43	SENT_203	[p17l829t2189r1091b2273],
46	in	IN	O	in	mark	49	SENT_203	[p17l1110t2194r1177b2251],
47	order	NN	O	order	dep	49	SENT_203	[p17l1200t2189r1385b2252],
48	to	TO	O	to	aux	49	SENT_203	[p17l1405t2201r1471b2252],
49	match	VB	O	match	purpcl	18	SENT_203	[p17l1494t2189r1706b2252],
50	the	DT	O	the	det	53	SENT_203	[p17l1727t2189r1833b2252],
51	evolving	VBG	O	evolve	amod	53	SENT_203	[p17l1857t2189r2146b2273],
52	tumor	NN	O	tumor	nn	53	SENT_203	[p17l7t2304r222b2355],
53	proﬁle	NN	O	proﬁle	dobj	49	SENT_203	[p17l241t2292r462b2375],
54	and	CC	O	and	_	0	SENT_203	[p17l484t2292r610b2355],
55	the	DT	O	the	det	57	SENT_203	[p17l630t2292r736b2355],
56	resulting	VBG	O	result	amod	57	SENT_203	[p17l759t2292r1059b2376],
57	vulnerabilities	NNS	O	vulnerability	conj_and	53	SENT_203	[p17l1076t2292r1582b2355],
58	.	.	O	.	_	0	SENT_203	[p17l1076t2292r1582b2355],

1	258	CD	NUMBER	258	num	2	SENT_204	[p17l7t2512r104b2554],
2	ACKNOWLEDGMENTS	NNS	O	acknowledgment	_	0	SENT_204	[p17l8t2591r693b2640],
3	P.A.C.	NNP	O	P.A.C.	dep	2	SENT_204	[p17l11t2677r167b2734],
4	,	,	O	,	_	0	SENT_204	[p17l11t2677r167b2734],
5	B.A.-L.	NNP	O	B.A.-L.	dep	2	SENT_204	[p17l185t2677r363b2734],
6	,	,	O	,	_	0	SENT_204	[p17l185t2677r363b2734],
7	and	CC	O	and	_	0	SENT_204	[p17l378t2675r481b2726],
8	RW	NN	O	rw	dep	2	SENT_204	[p17l501t2677r603b2726],
9	.	.	O	.	_	0	SENT_204	[p17l501t2677r603b2726],

1	are	VBP	O	be	cop	2	SENT_205	[p17l617t2690r702b2726],
2	grateful	JJ	O	grateful	_	0	SENT_205	[p17l717t2674r931b2740],
3	for	IN	O	for	_	0	SENT_205	[p17l947t2674r1025b2726],
4	major	JJ	O	major	amod	6	SENT_205	[p17l1040t2677r1201b2740],
5	core	NN	O	core	nn	6	SENT_205	[p17l1215t2690r1334b2726],
6	support	NN	O	support	prep_for	2	SENT_205	[p17l1349t2683r1571b2739],
7	from	IN	O	from	_	0	SENT_205	[p17l1584t2674r1715b2726],
8	Cancer	NNP	ORGANIZATION	Cancer	nn	15	SENT_205	[p17l1732t2677r1925b2726],
9	Research	NNP	ORGANIZATION	Research	nn	15	SENT_205	[p17l11t2761r256b2812],
10	UK	NNP	ORGANIZATION	UK	nn	15	SENT_205	[p17l276t2764r354b2812],
11	(	NNP	O	(	nn	15	SENT_205	[p17l368t2762r720b2826],
12	programme	NN	O	programme	nn	15	SENT_205	[p17l368t2762r720b2826],
13	grant	NN	O	grant	nn	15	SENT_205	[p17l734t2769r883b2826],
14	C309/A8725	NN	O	c309/a8725	nn	15	SENT_205	[p17l897t2762r1276b2820],
15	)	NN	O	)	prep_from	6	SENT_205	[p17l897t2762r1276b2820],
16	.	.	O	.	_	0	SENT_205	[p17l897t2762r1276b2820],

1	P.W.	NNP	PERSON	P.W.	nsubj	8	SENT_206	[p17l1293t2763r1395b2812],
2	is	VBZ	O	be	cop	8	SENT_206	[p17l1411t2764r1448b2812],
3	a	DT	O	a	det	8	SENT_206	[p17l1463t2776r1490b2812],
4	Cancer	NNP	O	Cancer	nn	8	SENT_206	[p17l1507t2763r1700b2812],
5	Research	NNP	O	Research	nn	8	SENT_206	[p17l1716t2761r1962b2812],
6	UK	NNP	O	UK	nn	8	SENT_206	[p17l1982t2764r2059b2812],
7	Life	NNP	O	Life	nn	8	SENT_206	[p17l11t2847r105b2899],
8	Fellow	NNP	O	Fellow	_	0	SENT_206	[p17l122t2848r311b2899],
9	.	.	O	.	_	0	SENT_206	[p17l122t2848r311b2899],

1	D.G.d.C.	NNP	O	D.G.d.C.	nn	5	SENT_207	[p17l328t2848r541b2899],
2	thanks	NNS	O	thanks	nn	5	SENT_207	[p17l555t2848r742b2899],
3	Cancer	NNP	O	Cancer	nn	5	SENT_207	[p17l757t2849r950b2899],
4	Research	NNP	O	Research	nn	5	SENT_207	[p17l966t2848r1212b2899],
5	UKfor	NNP	O	UKfor	_	0	SENT_207	[p17l1232t2847r1397b2899],
6	funding	VBG	O	fund	partmod	5	SENT_207	[p17l1409t2847r1630b2912],
7	through	IN	O	through	_	0	SENT_207	[p17l1645t2848r1873b2912],
8	the	DT	O	the	det	11	SENT_207	[p17l1889t2848r1981b2899],
9	Stratified	NNP	ORGANIZATION	Stratified	nn	11	SENT_207	[p17l9t2932r257b2984],
10	Medicine	NNP	ORGANIZATION	Medicine	nn	11	SENT_207	[p17l276t2933r532b2984],
11	Programme	NNP	ORGANIZATION	Programme	prep_through	6	SENT_207	[p17l550t2935r878b2998],
12	(	CD	NUMBER	(	num	14	SENT_207	[p17l895t2933r1507b2992],
13	C21807/A13641	NN	O	c21807/a13641	nn	14	SENT_207	[p17l895t2933r1507b2992],
14	)	NN	O	)	dep	11	SENT_207	[p17l895t2933r1507b2992],
15	.	.	O	.	_	0	SENT_207	[p17l895t2933r1507b2992],

1	The	DT	O	the	det	2	SENT_208	[p17l895t2933r1507b2992],
2	authors	NNS	O	author	nsubj	3	SENT_208	[p17l1522t2933r1735b2984],
3	acknowledge	VBP	O	acknowledge	_	0	SENT_208	[p17l1750t2933r2128b2998],
4	funding	VBG	O	fund	conj_and	4	SENT_208	[p17l7t3019r227b3084],
5	toThe	NNP	O	toThe	nn	6	SENT_208	[p17l243t3019r413b3070],
6	Institute	NNP	ORGANIZATION	Institute	dobj	4	SENT_208	[p17l431t3022r659b3070],
7	of	IN	ORGANIZATION	of	_	0	SENT_208	[p17l675t3019r733b3070],
8	Cancer	NNP	ORGANIZATION	Cancer	nn	9	SENT_208	[p17l742t3021r936b3070],
9	Research	NNP	ORGANIZATION	Research	prep_of	6	SENT_208	[p17l952t3019r1198b3070],
10	and	CC	O	and	_	0	SENT_208	[p17l1215t3019r1318b3070],
11	the	DT	O	the	det	14	SENT_208	[p17l1334t3019r1426b3070],
12	Royal	NNP	ORGANIZATION	Royal	nn	14	SENT_208	[p17l1443t3019r1588b3084],
13	Marsden	NNP	ORGANIZATION	Marsden	nn	14	SENT_208	[p17l1607t3019r1847b3070],
14	Hospital	NNP	ORGANIZATION	Hospital	conj_and	9	SENT_208	[p17l11t3106r236b3170],
15	as	IN	O	as	_	0	SENT_208	[p17l253t3121r309b3157],
16	a	DT	O	a	det	20	SENT_208	[p17l324t3121r351b3157],
17	Cancer	NNP	O	Cancer	nn	20	SENT_208	[p17l368t3107r561b3157],
18	Research	NNP	O	Research	nn	20	SENT_208	[p17l578t3106r823b3157],
19	UK	NNP	LOCATION	UK	nn	20	SENT_208	[p17l843t3108r920b3157],
20	Centre	NNP	O	Centre	prep_as	4	SENT_208	[p17l932t3107r1117b3157],
21	and	CC	O	and	_	0	SENT_208	[p17l1132t3106r1235b3157],
22	from	IN	O	from	_	0	SENT_208	[p17l1251t3105r1381b3157],
23	the	DT	O	the	det	25	SENT_208	[p17l1397t3106r1489b3157],
24	National	NNP	ORGANIZATION	National	nn	25	SENT_208	[p17l1507t3106r1737b3157],
25	Institute	NNP	ORGANIZATION	Institute	prep_from	4	SENT_208	[p17l1757t3108r1985b3157],
26	of	IN	ORGANIZATION	of	_	0	SENT_208	[p17l8t3190r67b3242],
27	Health	NNP	ORGANIZATION	Health	nn	28	SENT_208	[p17l79t3191r257b3242],
28	Research	NNP	ORGANIZATION	Research	prep_of	25	SENT_208	[p17l278t3191r523b3242],
29	to	TO	O	to	_	0	SENT_208	[p17l539t3199r596b3242],
30	our	PRP$	O	we	poss	33	SENT_208	[p17l611t3206r705b3242],
31	Biomedical	NNP	O	Biomedical	nn	33	SENT_208	[p17l721t3191r1027b3242],
32	Research	NNP	O	Research	nn	33	SENT_208	[p17l1047t3191r1292b3242],
33	Centre	NNP	O	Centre	prep_to	4	SENT_208	[p17l1309t3193r1507b3242],
34	.	.	O	.	_	0	SENT_208	[p17l1309t3193r1507b3242],

1	We	PRP	O	we	nsubj	2	SENT_209	[p17l1518t3193r1605b3242],
2	apologize	VBP	O	apologize	_	0	SENT_209	[p17l1620t3191r1894b3256],
3	to	TO	O	to	_	0	SENT_209	[p17l1908t3199r1965b3242],
4	the	DT	O	the	det	5	SENT_209	[p17l7t3277r99b3328],
5	authors	NNS	O	author	prep_to	2	SENT_209	[p17l113t3277r326b3328],
6	of	IN	O	of	_	0	SENT_209	[p17l341t3277r400b3328],
7	numerous	JJ	O	numerous	amod	9	SENT_209	[p17l412t3292r696b3328],
8	excellent	JJ	O	excellent	amod	9	SENT_209	[p17l711t3277r961b3328],
9	papers	NNS	O	papers	prep_of	5	SENT_209	[p17l978t3292r1165b3341],
10	that	WDT	O	that	nsubjpass	14	SENT_209	[p17l1178t3277r1292b3328],
11	could	MD	O	could	aux	14	SENT_209	[p17l1306t3277r1459b3328],
12	not	RB	O	not	neg	14	SENT_209	[p17l1479t3285r1571b3328],
13	be	VB	O	be	auxpass	14	SENT_209	[p17l1587t3277r1654b3328],
14	cited	VBN	O	cite	rcmod	9	SENT_209	[p17l1669t3277r1803b3328],
15	because	IN	O	because	_	0	SENT_209	[p17l1823t3277r2051b3328],
16	of	IN	O	of	prepc_because_of	14	SENT_209	[p17l8t3363r67b3415],
17	space	NN	O	space	nn	18	SENT_209	[p17l77t3379r235b3428],
18	constraints	NNS	O	constraint	pobj	14	SENT_209	[p17l250t3366r570b3415],
19	.	.	O	.	_	0	SENT_209	[p17l250t3366r570b3415],

1	We	PRP	O	we	nsubj	2	SENT_210	[p17l581t3366r669b3415],
2	thank	VBP	O	thank	_	0	SENT_210	[p17l682t3364r845b3415],
3	our	PRP$	O	we	poss	7	SENT_210	[p17l857t3379r952b3415],
4	many	JJ	O	many	amod	7	SENT_210	[p17l967t3379r1122b3429],
5	colleagues	NNS	O	colleague	nn	7	SENT_210	[p17l1135t3364r1447b3428],
6	,	,	O	,	_	0	SENT_210	[p17l1135t3364r1447b3428],
7	collaborators	NNS	O	collaborator	dobj	2	SENT_210	[p17l1462t3364r1841b3423],
8	,	,	O	,	_	0	SENT_210	[p17l1462t3364r1841b3423],
9	and	CC	O	and	_	0	SENT_210	[p17l1856t3364r1959b3415],
10	laboratory	NN	O	laboratory	nn	11	SENT_210	[p17l11t3449r300b3514],
11	staff	NN	O	staff	dobj	2	SENT_210	[p17l314t3448r435b3500],
12	for	IN	O	for	_	0	SENT_210	[p17l444t3448r522b3500],
13	valuable	JJ	O	valuable	amod	14	SENT_210	[p17l533t3449r771b3500],
14	discussions	NNS	O	discussion	prep_for	2	SENT_210	[p17l786t3449r1115b3500],
15	.	.	O	.	_	0	SENT_210	[p17l786t3449r1115b3500],

1	We	PRP	O	we	nsubj	2	SENT_211	[p17l1126t3451r1213b3500],
2	thankVa	VBP	O	thankva	_	0	SENT_211	[p17l1227t3449r1477b3500],
3	|	CD	NUMBER	|	num	4	SENT_211	[p17l1227t3449r1477b3500],
4	Cornwell	NNP	PERSON	Cornwell	dobj	2	SENT_211	[p17l1495t3449r1739b3500],
5	for	IN	O	for	_	0	SENT_211	[p17l1755t3448r1832b3500],
6	excellent	JJ	O	excellent	amod	8	SENT_211	[p17l1846t3449r2097b3500],
7	administrative	JJ	O	administrative	amod	8	SENT_211	[p17l8t3535r409b3586],
8	support	NN	O	support	prep_for	4	SENT_211	[p17l425t3543r659b3599],
9	.	.	O	.	_	0	SENT_211	[p17l425t3543r659b3599],

1	CONFLICT	NN	O	conflict	_	0	SENT_212	[p17l9t3711r322b3760],
2	OF	IN	O	of	_	0	SENT_212	[p17l337t3711r420b3760],
3	INTEREST	NN	O	interest	prep_of	1	SENT_212	[p17l439t3711r738b3759],

1	PW.	NNP	O	PW.	nsubj	12	SENT_213	[p18l11t26r128b83],
2	,	,	O	,	_	0	SENT_213	[p18l11t26r128b83],
3	B.	NNP	O	B.	nn	4	SENT_213	[p18l146t26r189b75],
4	A.-L.	NNP	O	A.-L.	nsubj	12	SENT_213	[p18l205t27r338b83],
5	,	,	O	,	_	0	SENT_213	[p18l205t27r338b83],
6	and	CC	O	and	_	0	SENT_213	[p18l354t24r458b75],
7	PA.	NNP	O	PA.	nn	8	SENT_213	[p18l479t26r623b75],
8	C.	NNP	O	C.	nsubj	12	SENT_213	[p18l479t26r623b75],
9	are	VBP	O	be	cop	12	SENT_213	[p18l638t39r723b75],
10	employees	NNS	O	employee	nn	12	SENT_213	[p18l739t24r1047b89],
11	ofThe	NNP	O	ofThe	nn	12	SENT_213	[p18l1063t24r1232b75],
12	Institute	NNP	ORGANIZATION	Institute	_	0	SENT_213	[p18l1251t27r1482b75],
13	of	IN	ORGANIZATION	of	_	0	SENT_213	[p18l1498t24r1556b75],
14	Cancer	NNP	ORGANIZATION	Cancer	nn	15	SENT_213	[p18l1566t26r1762b75],
15	Research	NNP	ORGANIZATION	Research	prep_of	12	SENT_213	[p18l1779t24r2043b83],
16	,	,	O	,	_	0	SENT_213	[p18l1779t24r2043b83],
17	which	WDT	O	which	nsubj	18	SENT_213	[p18l7t111r176b162],
18	has	VBZ	O	have	rcmod	15	SENT_213	[p18l196t111r288b162],
19	a	DT	O	a	det	21	SENT_213	[p18l303t126r331b162],
20	commercial	JJ	O	commercial	amod	21	SENT_213	[p18l348t111r677b162],
21	interest	NN	O	interest	dobj	18	SENT_213	[p18l697t113r908b162],
22	in	IN	O	in	_	0	SENT_213	[p18l925t113r970b161],
23	the	DT	O	the	det	24	SENT_213	[p18l987t111r1079b162],
24	discovery	NN	O	discovery	prep_in	21	SENT_213	[p18l1095t111r1366b176],
25	and	CC	O	and	_	0	SENT_213	[p18l1379t111r1483b162],
26	development	NN	O	development	prep_in	21	SENT_213	[p18l1501t111r1883b175],
27	of	IN	O	of	_	0	SENT_213	[p18l1898t110r1956b162],
28	anticancer	JJ	O	anticancer	amod	29	SENT_213	[p18l8t198r304b247],
29	drugs	NNS	O	drug	prep_of	24	SENT_213	[p18l318t196r493b261],
30	,	,	O	,	_	0	SENT_213	[p18l318t196r493b261],
31	including	VBG	O	include	_	0	SENT_213	[p18l510t196r772b261],
32	kinase	NN	O	kinase	nn	33	SENT_213	[p18l792t196r968b247],
33	inhibitors	NNS	O	inhibitor	prep_including	21	SENT_213	[p18l985t196r1265b255],
34	,	,	O	,	_	0	SENT_213	[p18l985t196r1265b255],
35	and	CC	O	and	_	0	SENT_213	[p18l1281t196r1384b247],
36	operates	VBZ	O	operate	conj_and	18	SENT_213	[p18l1403t204r1648b260],
37	a	DT	O	a	det	38	SENT_213	[p18l1664t211r1691b247],
38	Rewards	NNS	MISC	reward	dobj	36	SENT_213	[p18l1711t196r1947b247],
39	to	TO	O	to	_	0	SENT_213	[p18l1962t204r2019b247],
40	Inventors	NNS	O	inventor	nn	41	SENT_213	[p18l11t285r272b333],
41	scheme	NN	O	scheme	prep_to	36	SENT_213	[p18l289t282r520b333],
42	.	.	O	.	_	0	SENT_213	[p18l289t282r520b333],

1	P.W.	NNP	PERSON	P.W.	nsubj	9	SENT_214	[p18l538t284r641b333],
2	is	VBZ	O	be	cop	5	SENT_214	[p18l658t285r695b333],
3	a	DT	O	a	det	5	SENT_214	[p18l711t297r738b333],
4	former	JJ	O	former	amod	5	SENT_214	[p18l754t282r947b333],
5	employee	NN	O	employee	ccomp	34	SENT_214	[p18l961t282r1242b347],
6	of	IN	O	of	_	0	SENT_214	[p18l1257t282r1316b333],
7	AstraZeneca	NNP	ORGANIZATION	AstraZeneca	prep_of	5	SENT_214	[p18l1326t285r1675b333],
8	and	CC	O	and	_	0	SENT_214	[p18l1692t282r1796b333],
9	declares	VBZ	O	declare	conj_and	5	SENT_214	[p18l1814t282r2046b333],
10	relevant	JJ	O	relevant	amod	12	SENT_214	[p18l10t368r238b418],
11	commercial	JJ	O	commercial	amod	12	SENT_214	[p18l253t368r581b418],
12	interactions	NNS	O	interaction	dobj	9	SENT_214	[p18l601t370r934b418],
13	with	IN	O	with	_	0	SENT_214	[p18l949t368r1071b418],
14	Yamanouchi	NNP	PERSON	Yamanouchi	nn	15	SENT_214	[p18l1084t368r1434b418],
15	(	NNP	O	(	prep_with	9	SENT_214	[p18l1454t369r1595b425],
16	now	RB	DATE	now	advmod	17	SENT_214	[p18l1454t369r1595b425],
17	Astellas	NNPS	O	Astellas	rcmod	15	SENT_214	[p18l1609t368r1856b426],
18	)	CD	NUMBER	)	dep	17	SENT_214	[p18l1609t368r1856b426],
19	,	,	O	,	_	0	SENT_214	[p18l1609t368r1856b426],
20	Piramed	NNP	PERSON	Piramed	nn	22	SENT_214	[p18l11t453r239b504],
21	Pharma	NNP	PERSON	Pharma	nn	22	SENT_214	[p18l260t453r472b504],
22	(	NNP	O	(	appos	15	SENT_214	[p18l491t453r753b517],
23	acquired	VBN	O	acquire	partmod	22	SENT_214	[p18l491t453r753b517],
24	by	IN	O	by	_	0	SENT_214	[p18l774t453r840b518],
25	Roche	NNP	PERSON	Roche	nn	26	SENT_214	[p18l856t453r1061b512],
26	)	NNP	O	)	agent	23	SENT_214	[p18l856t453r1061b512],
27	,	,	O	,	_	0	SENT_214	[p18l856t453r1061b512],
28	Genentech	NNP	ORGANIZATION	Genentech	appos	26	SENT_214	[p18l1077t453r1649b512],
29	,	,	O	,	_	0	SENT_214	[p18l1077t453r1649b512],
30	Verna	NNP	PERSON	Verna	nn	31	SENT_214	[p18l1077t453r1649b512],
31	|	NNP	O	|	nsubj	34	SENT_214	[p18l1077t453r1649b512],
32	is	VBZ	O	be	cop	34	SENT_214	[p18l1077t453r1649b512],
33	,	,	O	,	_	0	SENT_214	[p18l1077t453r1649b512],
34	Novartis	NNP	ORGANIZATION	Novartis	_	0	SENT_214	[p18l1666t455r1911b512],
35	,	,	O	,	_	0	SENT_214	[p18l1666t455r1911b512],
36	Chroma	NNP	ORGANIZATION	Chroma	nn	37	SENT_214	[p18l8t539r231b590],
37	Therapeutics	NNPS	ORGANIZATION	Therapeutics	conj_and	34	SENT_214	[p18l242t539r624b603],
38	,	,	O	,	_	0	SENT_214	[p18l242t539r624b603],
39	Astex	NNP	ORGANIZATION	Astex	nn	40	SENT_214	[p18l639t542r794b590],
40	Pharmaceuticals	NNP	ORGANIZATION	Pharmaceuticals	conj_and	34	SENT_214	[p18l811t539r1286b598],
41	,	,	O	,	_	0	SENT_214	[p18l811t539r1286b598],
42	AstraZeneca	NNP	ORGANIZATION	AstraZeneca	conj_and	34	SENT_214	[p18l1301t542r1667b598],
43	,	,	O	,	_	0	SENT_214	[p18l1301t542r1667b598],
44	Cyclacel	NNP	O	Cyclacel	conj_and	34	SENT_214	[p18l1682t539r1922b604],
45	,	,	O	,	_	0	SENT_214	[p18l1682t539r1922b604],
46	Onyx	NNP	ORGANIZATION	Onyx	nn	47	SENT_214	[p18l8t627r154b691],
47	Pharmaceuticals	NNP	ORGANIZATION	Pharmaceuticals	conj_and	34	SENT_214	[p18l171t626r647b684],
48	,	,	O	,	_	0	SENT_214	[p18l171t626r647b684],
49	Merck	NNP	ORGANIZATION	Merck	nn	56	SENT_214	[p18l664t626r836b677],
50	Serono	NNP	ORGANIZATION	Serono	nn	56	SENT_214	[p18l850t627r1061b685],
51	,	,	O	,	_	0	SENT_214	[p18l850t627r1061b685],
52	Sareum	NNP	O	Sareum	appos	56	SENT_214	[p18l1078t627r1306b684],
53	,	,	O	,	_	0	SENT_214	[p18l1078t627r1306b684],
54	Janssen	NNP	PERSON	Janssen	appos	56	SENT_214	[p18l1319t628r1555b684],
55	,	,	O	,	_	0	SENT_214	[p18l1319t628r1555b684],
56	Wilex	NNP	PERSON	Wilex	conj_and	34	SENT_214	[p18l1567t626r1733b684],
57	,	,	O	,	_	0	SENT_214	[p18l1567t626r1733b684],
58	and	CC	O	and	_	0	SENT_214	[p18l1749t626r1852b677],
59	Nextech	NNP	ORGANIZATION	Nextech	nn	60	SENT_214	[p18l11t711r240b762],
60	Ventures	NNP	ORGANIZATION	Ventures	conj_and	34	SENT_214	[p18l253t713r517b762],
61	.	.	O	.	_	0	SENT_214	[p18l253t713r517b762],

1	B.	NNP	O	B.	nn	2	SENT_215	[p18l535t713r578b762],
2	A.-L	NNP	O	A.-L	_	0	SENT_215	[p18l593t713r713b762],
3	.	.	O	.	_	0	SENT_215	[p18l593t713r713b762],

1	is	VBZ	O	be	cop	4	SENT_216	[p18l731t714r768b762],
2	a	DT	O	a	det	4	SENT_216	[p18l783t726r810b762],
3	former	JJ	O	former	amod	4	SENT_216	[p18l827t710r1019b762],
4	employee	NN	O	employee	_	0	SENT_216	[p18l1034t711r1315b776],
5	of	IN	O	of	_	0	SENT_216	[p18l1330t710r1389b762],
6	Inpharmatica	NNP	LOCATION	Inpharmatica	prep_of	4	SENT_216	[p18l1402t711r1790b775],
7	.	.	O	.	_	0	SENT_216	[p18l1402t711r1790b775],

1	D.G.d.C.	NNP	O	D.G.d.C.	nsubj	13	SENT_217	[p18l1808t711r2024b762],
2	is	VBZ	O	be	cop	4	SENT_217	[p18l10t800r47b848],
3	an	DT	O	a	det	4	SENT_217	[p18l63t812r128b848],
4	employee	NN	O	employee	_	0	SENT_217	[p18l146t797r427b862],
5	of	IN	O	of	_	0	SENT_217	[p18l442t797r501b848],
6	the	DT	O	the	det	10	SENT_217	[p18l510t797r602b848],
7	Royal	NNP	ORGANIZATION	Royal	nn	10	SENT_217	[p18l621t797r767b862],
8	Marsden	NNP	ORGANIZATION	Marsden	nn	10	SENT_217	[p18l787t797r1029b848],
9	Foundation	NNP	ORGANIZATION	Foundation	nn	10	SENT_217	[p18l1050t797r1372b848],
10	Trust	NNP	ORGANIZATION	Trust	prep_of	4	SENT_217	[p18l1384t800r1525b848],
11	and	CC	O	and	_	0	SENT_217	[p18l1539t797r1643b848],
12	has	VBZ	O	have	aux	13	SENT_217	[p18l1663t797r1755b848],
13	received	VBN	O	receive	conj_and	4	SENT_217	[p18l1773t797r2007b848],
14	honoraria	NN	O	honorarium	dobj	13	SENT_217	[p18l11t884r281b935],
15	from	IN	O	from	_	0	SENT_217	[p18l297t883r429b935],
16	AstraZeneca	NNP	ORGANIZATION	AstraZeneca	prep_from	13	SENT_217	[p18l446t886r811b943],
17	,	,	O	,	_	0	SENT_217	[p18l446t886r811b943],
18	Roche	NNP	ORGANIZATION	Roche	nn	19	SENT_217	[p18l830t884r1002b935],
19	Products	NNPS	ORGANIZATION	Products	conj_and	16	SENT_217	[p18l1020t884r1279b942],
20	,	,	O	,	_	0	SENT_217	[p18l1020t884r1279b942],
21	Roche	NNP	ORGANIZATION	Roche	nn	23	SENT_217	[p18l1298t884r1469b935],
22	Molecular	JJ	ORGANIZATION	molecular	amod	23	SENT_217	[p18l1486t884r1767b935],
23	Systems	NNPS	ORGANIZATION	Systems	prep_from	13	SENT_217	[p18l1781t885r2024b949],
24	,	,	O	,	_	0	SENT_217	[p18l1781t885r2024b949],
25	GSK	NNP	ORGANIZATION	GSK	prep_from	13	SENT_217	[p18l8t971r135b1028],
26	,	,	O	,	_	0	SENT_217	[p18l8t971r135b1028],
27	Boehringer	NNP	PERSON	Boehringer	nn	28	SENT_217	[p18l153t969r468b1034],
28	Ingelheim	NNP	PERSON	Ingelheim	conj_and	16	SENT_217	[p18l485t969r782b1034],
29	,	,	O	,	_	0	SENT_217	[p18l485t969r782b1034],
30	and	CC	O	and	_	0	SENT_217	[p18l798t969r901b1020],
31	GE	NNP	ORGANIZATION	GE	nn	32	SENT_217	[p18l919t971r994b1020],
32	Healthcare	NNP	ORGANIZATION	Healthcare	conj_and	16	SENT_217	[p18l1012t969r1328b1020],
33	.	.	O	.	_	0	SENT_217	[p18l1012t969r1328b1020],

1	©	RB	O	©	dep	2	SENT_218	[p18l8t1161r48b1202],
2	2013	CD	DATE	2013	dep	4	SENT_218	[p18l64t1160r191b1204],
3	American	NNP	ORGANIZATION	American	nn	4	SENT_218	[p18l207t1159r461b1204],
4	Society	NNP	ORGANIZATION	Society	_	0	SENT_218	[p18l480t1159r674b1218],
5	for	IN	ORGANIZATION	for	_	0	SENT_218	[p18l687t1157r760b1204],
6	Clinical	JJ	ORGANIZATION	clinical	amod	7	SENT_218	[p18l774t1157r963b1204],
7	Pharmacology	NN	ORGANIZATION	pharmacology	prep_for	4	SENT_218	[p18l983t1157r1370b1218],
8	and	CC	ORGANIZATION	and	_	0	SENT_218	[p18l1384t1157r1481b1204],
9	Therapeutics	NNS	ORGANIZATION	therapeutics	prep_for	4	SENT_218	[p18l1494t1157r1842b1216],

1	1	LS	NUMBER	1	_	0	SENT_219	[p18l12t1336r50b1382],
2	.	.	O	.	_	0	SENT_219	[p18l12t1336r50b1382],

1	Collins	NNP	PERSON	Collins	nsubj	9	SENT_220	[p18l130t1332r314b1390],
2	,	,	O	,	_	0	SENT_220	[p18l130t1332r314b1390],
3	I.	NNP	ORGANIZATION	I.	nsubj	9	SENT_220	[p18l331t1335r353b1382],
4	&	CC	ORGANIZATION	&	_	0	SENT_220	[p18l367t1332r682b1390],
5	Workman	NNP	ORGANIZATION	Workman	nsubj	9	SENT_220	[p18l367t1332r682b1390],
6	,	,	O	,	_	0	SENT_220	[p18l367t1332r682b1390],
7	P.	NNP	O	P.	nn	8	SENT_220	[p18l699t1334r730b1382],
8	New	NNP	O	New	appos	1	SENT_220	[p18l747t1335r863b1382],
9	approaches	VBZ	O	approach	_	0	SENT_220	[p18l876t1332r1182b1395],
10	to	TO	O	to	_	0	SENT_220	[p18l1195t1340r1248b1382],
11	molecular	JJ	O	molecular	amod	13	SENT_220	[p18l1265t1332r1525b1382],
12	cancer	NN	O	cancer	nn	13	SENT_220	[p18l1539t1347r1711b1382],
13	therapeutics	NNS	O	therapeutics	prep_to	9	SENT_220	[p18l1723t1332r2065b1395],
14	.	.	O	.	_	0	SENT_220	[p18l1723t1332r2065b1395],

1	Nat	NN	PERSON	nat	_	0	SENT_221	[p18l131t1412r231b1458],
2	.	.	O	.	_	0	SENT_221	[p18l131t1412r231b1458],

1	Chem	NNP	O	Chem	_	0	SENT_222	[p18l248t1409r404b1458],
2	.	.	O	.	_	0	SENT_222	[p18l248t1409r404b1458],

1	Biol	NNP	O	Biol	_	0	SENT_223	[p18l419t1409r520b1458],
2	.	.	O	.	_	0	SENT_223	[p18l419t1409r520b1458],

1	2	CD	NUMBER	2	_	0	SENT_224	[p18l537t1412r581b1466],
2	,	,	O	,	_	0	SENT_224	[p18l537t1412r581b1466],
3	689-700	CD	NUMBER	689-700	number	4	SENT_224	[p18l596t1412r820b1458],
4	(	CD	NUMBER	(	appos	1	SENT_224	[p18l836t1410r1010b1466],
5	2006	CD	DATE	2006	num	6	SENT_224	[p18l836t1410r1010b1466],
6	)	NN	O	)	dep	4	SENT_224	[p18l836t1410r1010b1466],
7	.	.	O	.	_	0	SENT_224	[p18l836t1410r1010b1466],

1	2	LS	NUMBER	2	_	0	SENT_225	[p18l9t1490r50b1537],
2	.	.	O	.	_	0	SENT_225	[p18l9t1490r50b1537],

1	Yap	NNP	PERSON	Yap	nn	14	SENT_226	[p18l128t1490r348b1550],
2	,	,	O	,	_	0	SENT_226	[p18l128t1490r348b1550],
3	T.A.	NNP	LOCATION	T.A.	conj_and	1	SENT_226	[p18l128t1490r348b1550],
4	,	,	O	,	_	0	SENT_226	[p18l128t1490r348b1550],
5	Sandhu	NNP	PERSON	Sandhu	nn	14	SENT_226	[p18l363t1487r575b1545],
6	,	,	O	,	_	0	SENT_226	[p18l363t1487r575b1545],
7	S.K.	NNP	LOCATION	S.K.	nn	14	SENT_226	[p18l590t1489r692b1545],
8	,	,	O	,	_	0	SENT_226	[p18l590t1489r692b1545],
9	Workman	NNP	PERSON	Workman	nn	14	SENT_226	[p18l703t1487r971b1545],
10	,	,	O	,	_	0	SENT_226	[p18l703t1487r971b1545],
11	P.	NNP	PERSON	P.	conj_and	1	SENT_226	[p18l988t1489r1020b1537],
12	&	CC	PERSON	&	_	0	SENT_226	[p18l1034t1489r1071b1537],
13	de	NNP	PERSON	de	conj_and	1	SENT_226	[p18l1083t1487r1148b1537],
14	Bono	NNP	PERSON	Bono	_	0	SENT_226	[p18l1164t1489r1309b1545],
15	,	,	O	,	_	0	SENT_226	[p18l1164t1489r1309b1545],
16	J.S.	NNP	PERSON	J.S.	appos	14	SENT_226	[p18l1322t1489r1400b1537],
17	Envisioning	VBG	PERSON	envision	partmod	16	SENT_226	[p18l1417t1490r1716b1550],
18	the	DT	DATE	the	det	19	SENT_226	[p18l1731t1487r1817b1537],
19	future	NN	DATE	future	dobj	17	SENT_226	[p18l1830t1487r1989b1537],
20	of	IN	O	of	_	0	SENT_226	[p18l2004t1487r2058b1537],
21	early	JJ	O	early	amod	24	SENT_226	[p18l131t1565r257b1629],
22	anticancer	JJ	O	anticancer	amod	24	SENT_226	[p18l270t1568r545b1615],
23	drug	NN	O	drug	nn	24	SENT_226	[p18l558t1565r679b1628],
24	development	NN	O	development	prep_of	19	SENT_226	[p18l695t1565r1062b1628],
25	.	.	O	.	_	0	SENT_226	[p18l695t1565r1062b1628],

1	Nat	NN	PERSON	nat	_	0	SENT_227	[p18l1076t1568r1177b1615],
2	.	.	O	.	_	0	SENT_227	[p18l1076t1568r1177b1615],

1	Rev.	NNP	O	Rev.	nn	2	SENT_228	[p18l1191t1567r1287b1615],
2	Cancer	NNP	O	Cancer	_	0	SENT_228	[p18l1303t1567r1480b1615],
3	10	CD	NUMBER	10	num	2	SENT_228	[p18l1494t1569r1571b1623],
4	,	,	O	,	_	0	SENT_228	[p18l1494t1569r1571b1623],
5	514-523	CD	NUMBER	514-523	num	2	SENT_228	[p18l1585t1568r1807b1615],
6	(	CD	NUMBER	(	num	8	SENT_228	[p18l1825t1566r1999b1623],
7	2010	CD	DATE	2010	num	8	SENT_228	[p18l1825t1566r1999b1623],
8	)	NN	O	)	dep	2	SENT_228	[p18l1825t1566r1999b1623],
9	.	.	O	.	_	0	SENT_228	[p18l1825t1566r1999b1623],

1	3	LS	NUMBER	3	_	0	SENT_229	[p18l8t1646r50b1693],
2	.	.	O	.	_	0	SENT_229	[p18l8t1646r50b1693],

1	Zhang	NNP	PERSON	Zhang	_	0	SENT_230	[p18l129t1643r310b1706],
2	,	,	O	,	_	0	SENT_230	[p18l129t1643r310b1706],
3	J.	NNP	O	J.	nn	7	SENT_230	[p18l323t1646r369b1701],
4	,	,	O	,	_	0	SENT_230	[p18l323t1646r369b1701],
5	Yang	NNP	PERSON	Yang	appos	7	SENT_230	[p18l380t1646r521b1706],
6	,	,	O	,	_	0	SENT_230	[p18l380t1646r521b1706],
7	PL	NNP	O	PL	appos	1	SENT_230	[p18l538t1645r612b1693],
8	.	.	O	.	_	0	SENT_230	[p18l538t1645r612b1693],

1	&	CC	O	&	cc	4	SENT_231	[p18l626t1645r663b1693],
2	Gray	NNP	O	Gray	nn	4	SENT_231	[p18l676t1645r804b1707],
3	,	,	O	,	_	0	SENT_231	[p18l676t1645r804b1707],
4	N.S.	NNP	O	N.S.	nsubj	6	SENT_231	[p18l821t1645r1173b1706],
5	Targeting	NN	O	targeting	nn	6	SENT_231	[p18l821t1645r1173b1706],
6	cancer	NN	O	cancer	_	0	SENT_231	[p18l1189t1658r1362b1693],
7	with	IN	O	with	_	0	SENT_231	[p18l1374t1643r1487b1693],
8	small	JJ	O	small	amod	11	SENT_231	[p18l1504t1643r1636b1693],
9	molecule	NN	O	molecule	nn	11	SENT_231	[p18l1656t1643r1895b1693],
10	kinase	NN	O	kinase	nn	11	SENT_231	[p18l1912t1643r2075b1693],
11	inhibitors	NNS	O	inhibitor	prep_with	6	SENT_231	[p18l133t1720r392b1769],
12	.	.	O	.	_	0	SENT_231	[p18l133t1720r392b1769],

1	Nat	NN	PERSON	nat	_	0	SENT_232	[p18l406t1723r507b1769],
2	.	.	O	.	_	0	SENT_232	[p18l406t1723r507b1769],

1	Rev.	NNP	O	Rev.	nn	2	SENT_233	[p18l522t1722r618b1769],
2	Cancer	NNP	O	Cancer	_	0	SENT_233	[p18l634t1722r811b1769],
3	9	CD	NUMBER	9	num	2	SENT_233	[p18l821t1723r866b1777],
4	,	,	O	,	_	0	SENT_233	[p18l821t1723r866b1777],
5	28-39	CD	NUMBER	28-39	num	2	SENT_233	[p18l881t1723r1039b1769],
6	(	CD	NUMBER	(	num	8	SENT_233	[p18l1055t1721r1229b1777],
7	2009	CD	DATE	2009	num	8	SENT_233	[p18l1055t1721r1229b1777],
8	)	NN	O	)	dep	2	SENT_233	[p18l1055t1721r1229b1777],
9	.	.	O	.	_	0	SENT_233	[p18l1055t1721r1229b1777],

1	4	LS	NUMBER	4	_	0	SENT_234	[p18l6t1802r50b1848],
2	.	.	O	.	_	0	SENT_234	[p18l6t1802r50b1848],

1	Giamas	NNP	PERSON	Giamas	_	0	SENT_235	[p18l130t1800r334b1856],
2	,	,	O	,	_	0	SENT_235	[p18l130t1800r334b1856],
3	G.	NNP	O	G.	nn	4	SENT_235	[p18l348t1800r399b1848],
4	etal	NN	O	etal	appos	1	SENT_235	[p18l413t1798r525b1848],
5	.	.	O	.	_	0	SENT_235	[p18l413t1798r525b1848],

1	Kinases	NNS	O	kinase	_	0	SENT_236	[p18l544t1801r735b1848],
2	as	IN	O	as	_	0	SENT_236	[p18l750t1813r802b1848],
3	targets	NNS	O	target	prep_as	1	SENT_236	[p18l815t1806r998b1861],
4	in	IN	O	in	_	0	SENT_236	[p18l1014t1801r1057b1847],
5	the	DT	O	the	det	6	SENT_236	[p18l1072t1798r1158b1848],
6	treatment	NN	O	treatment	prep_in	3	SENT_236	[p18l1171t1806r1435b1848],
7	of	IN	O	of	_	0	SENT_236	[p18l1449t1798r1503b1848],
8	solid	JJ	O	solid	amod	9	SENT_236	[p18l1513t1798r1632b1848],
9	tumors	NNS	O	tumor	prep_of	1	SENT_236	[p18l1648t1806r1848b1848],
10	.	.	O	.	_	0	SENT_236	[p18l1648t1806r1848b1848],

1	Cell	NN	O	cell	_	0	SENT_237	[p18l1863t1798r1961b1848],
2	.	.	O	.	_	0	SENT_237	[p18l1863t1798r1961b1848],

1	Signal	NN	O	signal	_	0	SENT_238	[p18l1975t1798r2142b1861],
2	.	.	O	.	_	0	SENT_238	[p18l1975t1798r2142b1861],

1	5	CD	NUMBER	5	_	0	SENT_239	[p18l8t1957r50b2003],
2	.	.	O	.	_	0	SENT_239	[p18l8t1957r50b2003],

1	Gaulton	NNP	PERSON	Gaulton	_	0	SENT_240	[p18l130t1953r352b2011],
2	,	,	O	,	_	0	SENT_240	[p18l130t1953r352b2011],
3	A.	NNP	O	A.	nn	4	SENT_240	[p18l366t1956r415b2003],
4	etal	NNP	O	etal	appos	1	SENT_240	[p18l429t1953r541b2003],
5	.	.	O	.	_	0	SENT_240	[p18l429t1953r541b2003],

1	ChEMBL	NNP	O	ChEMBL	_	0	SENT_241	[p18l557t1953r786b2003],
2	:	:	O	:	_	0	SENT_241	[p18l557t1953r786b2003],
3	a	DT	O	a	det	8	SENT_241	[p18l801t1968r826b2003],
4	large	JJ	O	large	amod	8	SENT_241	[p18l844t1953r1124b2016],
5	—	CD	NUMBER	—	num	8	SENT_241	[p18l844t1953r1124b2016],
6	scale	NN	O	scale	nn	8	SENT_241	[p18l844t1953r1124b2016],
7	bioactivity	NN	O	bioactivity	nn	8	SENT_241	[p18l1140t1953r1415b2017],
8	database	NN	O	database	dep	1	SENT_241	[p18l1428t1953r1666b2003],
9	for	IN	O	for	_	0	SENT_241	[p18l1679t1953r1751b2003],
10	drug	NN	O	drug	nn	11	SENT_241	[p18l1764t1953r1886b2016],
11	discovery	NN	O	discovery	prep_for	8	SENT_241	[p18l131t2031r390b2095],
12	.	.	O	.	_	0	SENT_241	[p18l131t2031r390b2095],

1	NucleicAcids	NNS	O	nucleicacid	_	0	SENT_242	[p18l405t2031r730b2081],
2	Res	NNP	O	Res	dep	1	SENT_242	[p18l742t2033r834b2081],
3	.	.	O	.	_	0	SENT_242	[p18l742t2033r834b2081],

1	40	CD	NUMBER	40	_	0	SENT_243	[p18l850t2034r931b2089],
2	,	,	O	,	_	0	SENT_243	[p18l850t2034r931b2089],
3	D1	NN	O	d1	appos	1	SENT_243	[p18l948t2033r1007b2081],
4	100	CD	NUMBER	100	num	3	SENT_243	[p18l1025t2033r1212b2081],
5	.	.	O	.	_	0	SENT_243	[p18l1025t2033r1212b2081],

1	—	NN	O	—	_	0	SENT_244	[p18l1025t2033r1212b2081],
2	.	.	O	.	_	0	SENT_244	[p18l1025t2033r1212b2081],

1	D1	NN	O	d1	_	0	SENT_245	[p18l1025t2033r1212b2081],
2	107	CD	NUMBER	107	number	3	SENT_245	[p18l1230t2034r1319b2081],
3	(	CD	NUMBER	(	dep	1	SENT_245	[p18l1336t2032r1510b2089],
4	2012	CD	DATE	2012	num	5	SENT_245	[p18l1336t2032r1510b2089],
5	)	NN	O	)	dep	3	SENT_245	[p18l1336t2032r1510b2089],
6	.	.	O	.	_	0	SENT_245	[p18l1336t2032r1510b2089],

1	6	CD	NUMBER	6	_	0	SENT_246	[p18l8t2113r50b2159],
2	.	.	O	.	_	0	SENT_246	[p18l8t2113r50b2159],

1	Ha	FW	O	ha	_	0	SENT_247	[p18l132t2109r518b2172],
2	|	FW	O	|	nn	4	SENT_247	[p18l132t2109r518b2172],
3	|	FW	O	|	nn	4	SENT_247	[p18l132t2109r518b2172],
4	ing	NN	O	ing	dep	1	SENT_247	[p18l132t2109r518b2172],
5	.	.	O	.	_	0	SENT_247	[p18l132t2109r518b2172],

1	—	NN	O	—	_	0	SENT_248	[p18l132t2109r518b2172],
2	.	.	O	.	_	0	SENT_248	[p18l132t2109r518b2172],

1	Brown	NNP	PERSON	Brown	_	0	SENT_249	[p18l132t2109r518b2172],
2	,	,	O	,	_	0	SENT_249	[p18l132t2109r518b2172],
3	M.D.	NNP	O	M.D.	conj_and	1	SENT_249	[p18l533t2111r659b2167],
4	,	,	O	,	_	0	SENT_249	[p18l533t2111r659b2167],
5	Bulusu	NNP	LOCATION	Bulusu	conj_and	1	SENT_249	[p18l676t2109r861b2167],
6	,	,	O	,	_	0	SENT_249	[p18l676t2109r861b2167],
7	K.C.	NNP	LOCATION	K.C.	conj_and	1	SENT_249	[p18l879t2111r984b2167],
8	,	,	O	,	_	0	SENT_249	[p18l879t2111r984b2167],
9	Patel	NNP	PERSON	Patel	conj_and	1	SENT_249	[p18l1001t2109r1137b2167],
10	,	,	O	,	_	0	SENT_249	[p18l1001t2109r1137b2167],
11	M.	NNP	O	M.	conj_and	1	SENT_249	[p18l1153t2112r1358b2173],
12	,	,	O	,	_	0	SENT_249	[p18l1153t2112r1358b2173],
13	Tym	NNP	O	Tym	conj_and	1	SENT_249	[p18l1153t2112r1358b2173],
14	,	,	O	,	_	0	SENT_249	[p18l1153t2112r1358b2173],
15	J.E.	NNP	O	J.E.	conj_and	1	SENT_249	[p18l1371t2112r1449b2159],
16	&	CC	O	&	_	0	SENT_249	[p18l1463t2111r1500b2159],
17	A	NNP	O	A	conj_and	1	SENT_249	[p18l1512t2109r1809b2167],
18	|	NN	O	|	dep	1	SENT_249	[p18l1512t2109r1809b2167],
19	.	.	O	.	_	0	SENT_249	[p18l1512t2109r1809b2167],

1	—	NN	O	—	_	0	SENT_250	[p18l1512t2109r1809b2167],
2	.	.	O	.	_	0	SENT_250	[p18l1512t2109r1809b2167],

1	Lazikani	NNP	PERSON	Lazikani	_	0	SENT_251	[p18l1512t2109r1809b2167],
2	,	,	O	,	_	0	SENT_251	[p18l1512t2109r1809b2167],
3	B.	NNP	O	B.	nn	4	SENT_251	[p18l1826t2111r1866b2159],
4	canSAR	NNP	O	canSAR	appos	1	SENT_251	[p18l1881t2111r2089b2159],
5	:	:	O	:	_	0	SENT_251	[p18l1881t2111r2089b2159],

1	an	DT	O	a	nsubj	2	SENT_252	[p18l131t2202r191b2237],
2	integrated	VBN	O	integrate	_	0	SENT_252	[p18l209t2187r478b2250],
3	cancer	NN	O	cancer	nn	6	SENT_252	[p18l495t2202r668b2237],
4	public	JJ	O	public	amod	6	SENT_252	[p18l683t2187r844b2250],
5	translational	JJ	O	translational	amod	6	SENT_252	[p18l856t2187r1181b2237],
6	research	NN	O	research	dobj	2	SENT_252	[p18l1200t2187r1415b2237],
7	and	CC	O	and	_	0	SENT_252	[p18l1432t2187r1528b2237],
8	drug	NN	O	drug	nn	10	SENT_252	[p18l1544t2187r1666b2250],
9	discovery	NN	O	discovery	nn	10	SENT_252	[p18l1683t2187r1933b2251],
10	resource	NN	O	resource	conj_and	6	SENT_252	[p18l133t2279r367b2313],
11	.	.	O	.	_	0	SENT_252	[p18l133t2279r367b2313],

1	NucleicAcids	NNS	O	nucleicacid	_	0	SENT_253	[p18l381t2264r706b2313],
2	Res	NNP	O	Res	dep	1	SENT_253	[p18l718t2266r811b2313],
3	.	.	O	.	_	0	SENT_253	[p18l718t2266r811b2313],

1	40	CD	NUMBER	40	_	0	SENT_254	[p18l827t2267r907b2321],
2	,	,	O	,	_	0	SENT_254	[p18l827t2267r907b2321],
3	D947-D956	NN	O	d947-d956	appos	1	SENT_254	[p18l924t2266r1231b2313],
4	(	CD	NUMBER	(	num	3	SENT_254	[p18l1247t2265r1421b2321],
5	2012	CD	DATE	2012	num	6	SENT_254	[p18l1247t2265r1421b2321],
6	)	NN	O	)	dep	3	SENT_254	[p18l1247t2265r1421b2321],
7	.	.	O	.	_	0	SENT_254	[p18l1247t2265r1421b2321],

1	7	CD	NUMBER	7	_	0	SENT_255	[p18l9t2346r50b2392],
2	.	.	O	.	_	0	SENT_255	[p18l9t2346r50b2392],

1	Patel	NNP	PERSON	Patel	nn	2	SENT_256	[p18l132t2342r253b2392],
2	M.	NNP	O	M.	_	0	SENT_256	[p18l272t2345r344b2400],
3	,	,	O	,	_	0	SENT_256	[p18l272t2345r344b2400],
4	Ha	NNP	O	Ha	nn	6	SENT_256	[p18l360t2342r746b2405],
5	|	CD	NUMBER	|	num	6	SENT_256	[p18l360t2342r746b2405],
6	ling	NN	O	ling	appos	2	SENT_256	[p18l360t2342r746b2405],
7	.	.	O	.	_	0	SENT_256	[p18l360t2342r746b2405],

1	—	NN	O	—	_	0	SENT_257	[p18l360t2342r746b2405],
2	.	.	O	.	_	0	SENT_257	[p18l360t2342r746b2405],

1	Brown	NNP	PERSON	Brown	_	0	SENT_258	[p18l360t2342r746b2405],
2	,	,	O	,	_	0	SENT_258	[p18l360t2342r746b2405],
3	M.D.	NNP	O	M.D.	conj_and	1	SENT_258	[p18l762t2344r1021b2406],
4	,	,	O	,	_	0	SENT_258	[p18l762t2344r1021b2406],
5	Tym	NNP	O	Tym	conj_and	1	SENT_258	[p18l762t2344r1021b2406],
6	,	,	O	,	_	0	SENT_258	[p18l762t2344r1021b2406],
7	J.E.	NNP	PERSON	J.E.	conj_and	1	SENT_258	[p18l1033t2345r1124b2400],
8	,	,	O	,	_	0	SENT_258	[p18l1033t2345r1124b2400],
9	Workman	NNP	PERSON	Workman	conj_and	1	SENT_258	[p18l1135t2342r1404b2400],
10	,	,	O	,	_	0	SENT_258	[p18l1135t2342r1404b2400],
11	P.	NNP	O	P.	conj_and	1	SENT_258	[p18l1421t2344r1452b2392],
12	&	CC	O	&	_	0	SENT_258	[p18l1466t2344r1503b2392],
13	A	NNP	O	A	conj_and	1	SENT_258	[p18l1515t2342r1812b2400],
14	|	NN	O	|	dep	1	SENT_258	[p18l1515t2342r1812b2400],
15	.	.	O	.	_	0	SENT_258	[p18l1515t2342r1812b2400],

1	—	NN	O	—	_	0	SENT_259	[p18l1515t2342r1812b2400],
2	.	.	O	.	_	0	SENT_259	[p18l1515t2342r1812b2400],

1	Lazikani	NNP	PERSON	Lazikani	_	0	SENT_260	[p18l1515t2342r1812b2400],
2	,	,	O	,	_	0	SENT_260	[p18l1515t2342r1812b2400],
3	B.	NNP	O	B.	appos	1	SENT_260	[p18l1829t2344r1870b2392],

1	Objective	NN	O	objective	nn	2	SENT_261	[p18l131t2420r381b2484],
2	assessment	NN	O	assessment	_	0	SENT_261	[p18l396t2428r698b2470],
3	of	IN	O	of	_	0	SENT_261	[p18l711t2420r766b2470],
4	cancer	NN	O	cancer	nn	5	SENT_261	[p18l775t2435r948b2470],
5	genes	NNS	O	gene	prep_of	2	SENT_261	[p18l961t2435r1117b2484],
6	for	IN	O	for	_	0	SENT_261	[p18l1130t2420r1202b2470],
7	drug	NN	O	drug	nn	8	SENT_261	[p18l1215t2420r1337b2484],
8	discovery	NN	O	discovery	prep_for	2	SENT_261	[p18l1354t2420r1613b2484],
9	.	.	O	.	_	0	SENT_261	[p18l1354t2420r1613b2484],

1	Nat	NN	PERSON	nat	_	0	SENT_262	[p18l1627t2423r1728b2470],
2	.	.	O	.	_	0	SENT_262	[p18l1627t2423r1728b2470],

1	Rev.	NNP	O	Rev.	nn	2	SENT_263	[p18l1743t2423r1839b2470],
2	Drug	NNP	O	Drug	_	0	SENT_263	[p18l1854t2423r1989b2484],
3	.	.	O	.	_	0	SENT_263	[p18l1854t2423r1989b2484],

1	Discov	NNP	O	Discov	_	0	SENT_264	[p18l131t2499r303b2547],
2	.	.	O	.	_	0	SENT_264	[p18l131t2499r303b2547],

1	12	CD	NUMBER	12	_	0	SENT_265	[p18l334t2501r410b2554],
2	,	,	O	,	_	0	SENT_265	[p18l334t2501r410b2554],
3	35-50	CD	NUMBER	35-50	number	4	SENT_265	[p18l426t2501r584b2547],
4	(	CD	NUMBER	(	appos	1	SENT_265	[p18l600t2498r774b2554],
5	2012	CD	DATE	2012	num	6	SENT_265	[p18l600t2498r774b2554],
6	)	NN	O	)	dep	4	SENT_265	[p18l600t2498r774b2554],
7	.	.	O	.	_	0	SENT_265	[p18l600t2498r774b2554],

1	8	CD	NUMBER	8	_	0	SENT_266	[p18l8t2579r50b2625],
2	.	.	O	.	_	0	SENT_266	[p18l8t2579r50b2625],

1	Futreal	NNP	PERSON	Futreal	_	0	SENT_267	[p18l132t2575r321b2633],
2	,	,	O	,	_	0	SENT_267	[p18l132t2575r321b2633],
3	P.A.	NNP	O	P.A.	nn	4	SENT_267	[p18l337t2577r421b2625],
4	etal	NN	O	etal	appos	1	SENT_267	[p18l435t2575r547b2625],
5	.	.	O	.	_	0	SENT_267	[p18l435t2575r547b2625],

1	A	DT	O	a	det	2	SENT_268	[p18l563t2578r599b2624],
2	census	NN	O	census	_	0	SENT_268	[p18l613t2590r790b2625],
3	of	IN	O	of	_	0	SENT_268	[p18l805t2575r859b2625],
4	human	JJ	O	human	amod	6	SENT_268	[p18l871t2575r1053b2625],
5	cancer	NN	O	cancer	nn	6	SENT_268	[p18l1069t2590r1242b2625],
6	genes	NNS	O	gene	prep_of	2	SENT_268	[p18l1255t2590r1424b2639],
7	.	.	O	.	_	0	SENT_268	[p18l1255t2590r1424b2639],

1	Nat	NN	PERSON	nat	_	0	SENT_269	[p18l1437t2578r1538b2625],
2	.	.	O	.	_	0	SENT_269	[p18l1437t2578r1538b2625],

1	Rev.	NNP	O	Rev.	_	0	SENT_270	[p18l1553t2577r1649b2625],
2	Cancer	NNP	O	Cancer	dep	1	SENT_270	[p18l1665t2577r1842b2625],
3	4	CD	NUMBER	4	num	2	SENT_270	[p18l1852t2579r1897b2633],
4	,	,	O	,	_	0	SENT_270	[p18l1852t2579r1897b2633],
5	177-183	CD	NUMBER	177-183	num	2	SENT_270	[p18l1916t2579r2133b2625],

1	9	CD	NUMBER	9	_	0	SENT_271	[p18l8t2734r50b2780],
2	.	.	O	.	_	0	SENT_271	[p18l8t2734r50b2780],

1	Knapp	NNP	PERSON	Knapp	nn	3	SENT_272	[p18l132t2733r311b2793],
2	,	,	O	,	_	0	SENT_272	[p18l132t2733r311b2793],
3	S.B.J.	NNP	O	S.B.J.	_	0	SENT_272	[p18l326t2732r461b2788],
4	,	,	O	,	_	0	SENT_272	[p18l326t2732r461b2788],
5	etal	NN	O	etal	appos	3	SENT_272	[p18l475t2730r587b2780],
6	.	.	O	.	_	0	SENT_272	[p18l475t2730r587b2780],

1	A	DT	O	a	det	3	SENT_273	[p18l603t2733r640b2780],
2	public	JJ	O	public	amod	3	SENT_273	[p18l656t2730r1021b2793],
3	—	NN	O	—	_	0	SENT_273	[p18l656t2730r1021b2793],
4	private	JJ	O	private	amod	5	SENT_273	[p18l656t2730r1021b2793],
5	partnership	NN	O	partnership	dep	3	SENT_273	[p18l1037t2730r1341b2793],
6	to	TO	O	to	_	0	SENT_273	[p18l1354t2738r1407b2780],
7	unlockthe	JJ	O	unlockthe	amod	9	SENT_273	[p18l1424t2730r1695b2780],
8	untargeted	JJ	O	untargeted	amod	9	SENT_273	[p18l1712t2730r2002b2794],
9	kinome	NN	O	kinome	prep_to	5	SENT_273	[p18l133t2807r341b2857],
10	.	.	O	.	_	0	SENT_273	[p18l133t2807r341b2857],

1	Nat	NN	PERSON	nat	_	0	SENT_274	[p18l355t2810r456b2857],
2	.	.	O	.	_	0	SENT_274	[p18l355t2810r456b2857],

1	Chem	NNP	O	Chem	_	0	SENT_275	[p18l472t2807r628b2857],
2	.	.	O	.	_	0	SENT_275	[p18l472t2807r628b2857],

1	Biol	NNP	O	Biol	_	0	SENT_276	[p18l643t2807r744b2857],
2	.	.	O	.	_	0	SENT_276	[p18l643t2807r744b2857],

1	9	CD	NUMBER	9	_	0	SENT_277	[p18l761t2811r805b2864],
2	,	,	O	,	_	0	SENT_277	[p18l761t2811r805b2864],
3	3-6	CD	NUMBER	3-6	number	4	SENT_277	[p18l821t2811r913b2857],
4	(	CD	NUMBER	(	appos	1	SENT_277	[p18l930t2808r1103b2864],
5	2013	CD	DATE	2013	num	6	SENT_277	[p18l930t2808r1103b2864],
6	)	NN	O	)	dep	4	SENT_277	[p18l930t2808r1103b2864],
7	.	.	O	.	_	0	SENT_277	[p18l930t2808r1103b2864],

1	10	CD	NUMBER	10	_	0	SENT_278	[p18l12t2889r82b2935],
2	.	.	O	.	_	0	SENT_278	[p18l12t2889r82b2935],

1	Edwards	NNP	PERSON	Edwards	nn	17	SENT_279	[p18l132t2885r364b2943],
2	,	,	O	,	_	0	SENT_279	[p18l132t2885r364b2943],
3	A.M.	NNP	O	A.M.	appos	17	SENT_279	[p18l378t2888r504b2943],
4	,	,	O	,	_	0	SENT_279	[p18l378t2888r504b2943],
5	Isserlin	NNP	LOCATION	Isserlin	appos	17	SENT_279	[p18l520t2885r710b2943],
6	,	,	O	,	_	0	SENT_279	[p18l520t2885r710b2943],
7	R.	NNP	O	R.	appos	17	SENT_279	[p18l727t2887r781b2943],
8	,	,	O	,	_	0	SENT_279	[p18l727t2887r781b2943],
9	Bader	NNP	O	Bader	appos	17	SENT_279	[p18l798t2885r955b2943],
10	,	,	O	,	_	0	SENT_279	[p18l798t2885r955b2943],
11	G.D.	NNP	PERSON	G.D.	appos	17	SENT_279	[p18l970t2887r1086b2943],
12	,	,	O	,	_	0	SENT_279	[p18l970t2887r1086b2943],
13	Frye	NNP	PERSON	Frye	appos	17	SENT_279	[p18l1103t2888r1222b2949],
14	,	,	O	,	_	0	SENT_279	[p18l1103t2888r1222b2949],
15	S.V.	NNP	LOCATION	S.V.	appos	17	SENT_279	[p18l1237t2885r1663b2943],
16	,	,	O	,	_	0	SENT_279	[p18l1237t2885r1663b2943],
17	Wi	NNP	O	Wi	nsubj	31	SENT_279	[p18l1237t2885r1663b2943],
18	|	VBD	O	|	rcmod	17	SENT_279	[p18l1237t2885r1663b2943],
19	|	CD	NUMBER	|	num	20	SENT_279	[p18l1237t2885r1663b2943],
20	son	NN	O	son	dobj	18	SENT_279	[p18l1237t2885r1663b2943],
21	,	,	O	,	_	0	SENT_279	[p18l1237t2885r1663b2943],
22	T.M.	NNP	PERSON	T.M.	appos	20	SENT_279	[p18l1237t2885r1663b2943],
23	&	CC	PERSON	&	_	0	SENT_279	[p18l1677t2887r1798b2943],
24	Yu	NNP	PERSON	Yu	appos	20	SENT_279	[p18l1677t2887r1798b2943],
25	,	,	O	,	_	0	SENT_279	[p18l1677t2887r1798b2943],
26	F.H.	NNP	O	F.H.	nn	27	SENT_279	[p18l1815t2888r2006b2935],
27	Too	NNP	O	Too	appos	20	SENT_279	[p18l1815t2888r2006b2935],
28	many	JJ	O	many	amod	29	SENT_279	[p18l133t2978r277b3027],
29	roads	NNS	O	road	npadvmod	30	SENT_279	[p18l292t2963r433b3013],
30	not	RB	O	not	advmod	20	SENT_279	[p18l450t2971r536b3013],
31	taken	VBN	O	take	_	0	SENT_279	[p18l548t2963r707b3013],
32	.	.	O	.	_	0	SENT_279	[p18l548t2963r707b3013],

1	Nature	NNP	O	Nature	_	0	SENT_280	[p18l722t2966r895b3013],
2	470	CD	NUMBER	470	num	1	SENT_280	[p18l907t2967r1023b3021],
3	,	,	O	,	_	0	SENT_280	[p18l907t2967r1023b3021],
4	163-165	CD	NUMBER	163-165	num	1	SENT_280	[p18l1042t2967r1260b3013],
5	(	NN	O	(	dep	1	SENT_280	[p18l1278t2964r1378b3021],
6	201	CD	NUMBER	201	number	7	SENT_280	[p18l1278t2964r1378b3021],
7	1	CD	NUMBER	1	num	8	SENT_280	[p18l1397t2964r1452b3021],
8	)	NN	O	)	dep	5	SENT_280	[p18l1397t2964r1452b3021],
9	.	.	O	.	_	0	SENT_280	[p18l1397t2964r1452b3021],

1	11	CD	NUMBER	11	_	0	SENT_281	[p18l12t3045r82b3091],
2	.	.	O	.	_	0	SENT_281	[p18l12t3045r82b3091],

1	Hoelder	NNP	PERSON	Hoelder	_	0	SENT_282	[p18l132t3041r347b3099],
2	,	,	O	,	_	0	SENT_282	[p18l132t3041r347b3099],
3	S.	NNP	O	S.	conj_and	1	SENT_282	[p18l362t3043r415b3099],
4	,	,	O	,	_	0	SENT_282	[p18l362t3043r415b3099],
5	Clarke	NNP	PERSON	Clarke	conj_and	1	SENT_282	[p18l430t3041r603b3099],
6	,	,	O	,	_	0	SENT_282	[p18l430t3041r603b3099],
7	P.A.	NNP	ORGANIZATION	P.A.	conj_and	1	SENT_282	[p18l620t3043r704b3091],
8	&	CC	ORGANIZATION	&	_	0	SENT_282	[p18l718t3041r1032b3099],
9	Workman	NNP	ORGANIZATION	Workman	conj_and	1	SENT_282	[p18l718t3041r1032b3099],
10	,	,	O	,	_	0	SENT_282	[p18l718t3041r1032b3099],
11	P.	NNP	O	P.	nn	12	SENT_282	[p18l1050t3043r1081b3091],
12	Discovery	NNP	O	Discovery	appos	1	SENT_282	[p18l1098t3043r1353b3105],
13	of	IN	O	of	_	0	SENT_282	[p18l1365t3041r1420b3091],
14	small	JJ	O	small	amod	17	SENT_282	[p18l1430t3041r1562b3091],
15	molecule	NN	O	molecule	nn	17	SENT_282	[p18l1581t3041r1821b3091],
16	cancer	NN	O	cancer	nn	17	SENT_282	[p18l1835t3056r2008b3091],
17	drugs	NNS	O	drug	prep_of	12	SENT_282	[p18l131t3119r293b3183],
18	:	:	O	:	_	0	SENT_282	[p18l131t3119r293b3183],
19	successes	NNS	O	success	dep	1	SENT_282	[p18l308t3134r572b3177],
20	,	,	O	,	_	0	SENT_282	[p18l308t3134r572b3177],
21	challenges	NNS	O	challenge	conj_and	19	SENT_282	[p18l586t3119r866b3183],
22	and	CC	O	and	_	0	SENT_282	[p18l881t3119r977b3169],
23	opportunities	NNS	O	opportunity	conj_and	19	SENT_282	[p18l993t3122r1366b3182],
24	.	.	O	.	_	0	SENT_282	[p18l993t3122r1366b3182],

1	Mol	NNP	O	Mol	_	0	SENT_283	[p18l1379t3119r1484b3169],
2	.	.	O	.	_	0	SENT_283	[p18l1379t3119r1484b3169],

1	Oncol	NN	O	oncol	_	0	SENT_284	[p18l1500t3119r1656b3169],
2	.	.	O	.	_	0	SENT_284	[p18l1500t3119r1656b3169],

1	6	CD	NUMBER	6	_	0	SENT_285	[p18l1672t3123r1717b3177],
2	,	,	O	,	_	0	SENT_285	[p18l1672t3123r1717b3177],
3	155-176	CD	NUMBER	155-176	number	4	SENT_285	[p18l1736t3123r1956b3169],
4	(	CD	NUMBER	(	appos	1	SENT_285	[p18l1972t3120r2146b3177],
5	2012	CD	DATE	2012	num	6	SENT_285	[p18l1972t3120r2146b3177],
6	)	NN	O	)	dep	4	SENT_285	[p18l1972t3120r2146b3177],
7	.	.	O	.	_	0	SENT_285	[p18l1972t3120r2146b3177],

1	12	CD	NUMBER	12	_	0	SENT_286	[p18l12t3201r82b3247],
2	.	.	O	.	_	0	SENT_286	[p18l12t3201r82b3247],

1	Peeters	NNP	PERSON	Peeters	_	0	SENT_287	[p18l132t3199r332b3255],
2	,	,	O	,	_	0	SENT_287	[p18l132t3199r332b3255],
3	M.	NNP	O	M.	nn	4	SENT_287	[p18l348t3200r407b3247],
4	etal	NNP	O	etal	appos	1	SENT_287	[p18l422t3197r533b3247],
5	.	.	O	.	_	0	SENT_287	[p18l422t3197r533b3247],

1	Randomized	VBN	O	randomize	_	0	SENT_288	[p18l553t3197r879b3247],
2	phase	NN	O	phase	nn	4	SENT_288	[p18l897t3197r1051b3260],
3	III	CD	NUMBER	iii	num	4	SENT_288	[p18l1068t3200r1104b3247],
4	study	NN	O	study	dobj	1	SENT_288	[p18l1122t3197r1266b3261],
5	of	IN	O	of	_	0	SENT_288	[p18l1279t3197r1333b3247],
6	panitumumab	NN	O	panitumumab	prep_of	4	SENT_288	[p18l1345t3197r1721b3260],
7	with	IN	O	with	prep	1	SENT_288	[p18l1735t3197r1848b3247],

1	ﬂuorouracil	NN	O	ﬂuorouracil	nsubj	10	SENT_289	[p18l130t3275r442b3333],
2	,	,	O	,	_	0	SENT_289	[p18l130t3275r442b3333],
3	leucovorin	NN	O	leucovorin	nsubj	10	SENT_289	[p18l459t3275r747b3333],
4	,	,	O	,	_	0	SENT_289	[p18l459t3275r747b3333],
5	and	CC	O	and	_	0	SENT_289	[p18l761t3275r857b3325],
6	irinotecan	NN	O	irinotecan	nsubj	10	SENT_289	[p18l875t3278r1135b3325],
7	(	CD	NUMBER	(	num	8	SENT_289	[p18l1154t3276r1383b3333],
8	FOLFIRI	NNP	O	FOLFIRI	dep	1	SENT_289	[p18l1154t3276r1383b3333],
9	)	CD	NUMBER	)	num	8	SENT_289	[p18l1154t3276r1383b3333],
10	compared	VBN	O	compare	_	0	SENT_289	[p18l1399t3275r1664b3338],
11	with	IN	O	with	_	0	SENT_289	[p18l1680t3275r1793b3325],
12	FOLFIRI	NN	O	folfirus	prep_with	10	SENT_289	[p18l1812t3277r2003b3325],
13	alone	RB	O	alone	advmod	10	SENT_289	[p18l131t3353r275b3403],
14	as	IN	O	as	_	0	SENT_289	[p18l289t3368r341b3403],
15	second	JJ	ORDINAL	second	amod	18	SENT_289	[p18l356t3353r660b3403],
16	—	NN	O	—	nn	18	SENT_289	[p18l356t3353r660b3403],
17	line	NN	O	line	nn	18	SENT_289	[p18l356t3353r660b3403],
18	treatment	NN	O	treatment	prep_as	10	SENT_289	[p18l673t3361r937b3403],
19	in	IN	O	in	_	0	SENT_289	[p18l952t3356r995b3403],
20	patients	NNS	O	patient	prep_in	18	SENT_289	[p18l1013t3356r1223b3416],
21	with	IN	O	with	_	0	SENT_289	[p18l1236t3353r1350b3403],
22	metastatic	JJ	O	metastatic	amod	24	SENT_289	[p18l1368t3356r1640b3403],
23	colorectal	JJ	O	colorectal	amod	24	SENT_289	[p18l1655t3353r1909b3403],
24	cancer	NN	O	cancer	prep_with	10	SENT_289	[p18l1926t3368r2107b3403],
25	.	.	O	.	_	0	SENT_289	[p18l1926t3368r2107b3403],

1	J.	NNP	PERSON	J.	nn	2	SENT_290	[p18l127t3433r161b3480],
2	Clin	NNP	PERSON	Clin	_	0	SENT_290	[p18l177t3430r282b3480],
3	.	.	O	.	_	0	SENT_290	[p18l177t3430r282b3480],

1	Oncol	NN	O	oncol	_	0	SENT_291	[p18l298t3430r454b3480],
2	.	.	O	.	_	0	SENT_291	[p18l298t3430r454b3480],

1	28	CD	NUMBER	28	_	0	SENT_292	[p18l471t3434r551b3487],
2	,	,	O	,	_	0	SENT_292	[p18l471t3434r551b3487],
3	4706-4713	CD	DURATION	4706-4713	number	4	SENT_292	[p18l564t3434r853b3480],
4	(	CD	NUMBER	(	appos	1	SENT_292	[p18l871t3431r1045b3487],
5	2010	CD	DATE	2010	num	6	SENT_292	[p18l871t3431r1045b3487],
6	)	NN	O	)	dep	4	SENT_292	[p18l871t3431r1045b3487],
7	.	.	O	.	_	0	SENT_292	[p18l871t3431r1045b3487],

1	13	CD	NUMBER	13	_	0	SENT_293	[p18l12t3512r82b3558],
2	.	.	O	.	_	0	SENT_293	[p18l12t3512r82b3558],

1	Van	NNP	PERSON	Van	nn	2	SENT_294	[p18l128t3511r223b3558],
2	Cutsem	NNP	PERSON	Cutsem	_	0	SENT_294	[p18l239t3510r451b3566],
3	,	,	O	,	_	0	SENT_294	[p18l239t3510r451b3566],
4	E.	NNP	O	E.	nn	5	SENT_294	[p18l468t3511r506b3558],
5	etal	NN	O	etal	appos	2	SENT_294	[p18l520t3508r632b3558],
6	.	.	O	.	_	0	SENT_294	[p18l520t3508r632b3558],

1	Cetuximab	NN	PERSON	cetuximab	_	0	SENT_295	[p18l649t3508r934b3558],
2	plus	CC	O	plus	prep	1	SENT_295	[p18l950t3508r1056b3571],
3	irinotecan	NN	O	irinotecan	dep	2	SENT_295	[p18l1072t3511r1347b3566],
4	,	,	O	,	_	0	SENT_295	[p18l1072t3511r1347b3566],
5	ﬂuorouracil	NN	O	ﬂuorouracil	dep	2	SENT_295	[p18l1360t3508r1673b3566],
6	,	,	O	,	_	0	SENT_295	[p18l1360t3508r1673b3566],
7	and	CC	O	and	_	0	SENT_295	[p18l1687t3508r1783b3558],
8	leucovorin	NN	O	leucovorin	dep	2	SENT_295	[p18l1802t3508r2075b3558],
9	as	IN	O	as	_	0	SENT_295	[p18l131t3601r183b3636],
10	ﬁrst	NN	O	ﬁrst	nn	14	SENT_295	[p18l196t3586r410b3636],
11	—	CD	NUMBER	—	num	14	SENT_295	[p18l196t3586r410b3636],
12	|	NN	O	|	nn	14	SENT_295	[p18l196t3586r410b3636],
13	ine	NN	O	ine	nn	14	SENT_295	[p18l196t3586r410b3636],
14	treatment	NN	O	treatment	prep_as	3	SENT_295	[p18l423t3594r687b3636],
15	for	IN	O	for	_	0	SENT_295	[p18l699t3586r772b3636],
16	metastatic	JJ	O	metastatic	amod	18	SENT_295	[p18l786t3589r1058b3636],
17	colorectal	JJ	O	colorectal	amod	18	SENT_295	[p18l1073t3586r1327b3636],
18	cancer	NN	O	cancer	prep_for	1	SENT_295	[p18l1344t3601r1529b3636],
19	:	:	O	:	_	0	SENT_295	[p18l1344t3601r1529b3636],
20	updated	VBN	O	update	amod	21	SENT_295	[p18l1546t3586r1764b3649],
21	analysis	NN	O	analysis	dep	1	SENT_295	[p18l1780t3586r1982b3650],
22	of	IN	O	of	_	0	SENT_295	[p18l1997t3586r2052b3636],
23	overall	JJ	O	overall	amod	24	SENT_295	[p18l131t3664r302b3714],
24	survival	NN	O	survival	prep_of	21	SENT_295	[p18l319t3664r516b3714],
25	according	VBG	O	accord	_	0	SENT_295	[p18l533t3664r791b3728],
26	to	TO	O	to	prepc_according_to	24	SENT_295	[p18l806t3672r859b3714],
27	tumor	NN	O	tumor	nn	28	SENT_295	[p18l873t3672r1036b3714],
28	KRAS	NNS	ORGANIZATION	kra	pobj	24	SENT_295	[p18l1052t3666r1184b3714],
29	and	CC	O	and	_	0	SENT_295	[p18l1200t3664r1296b3714],
30	BRAF	NN	O	braf	nn	32	SENT_295	[p18l1314t3666r1447b3714],
31	mutation	NN	O	mutation	nn	32	SENT_295	[p18l1464t3667r1702b3714],
32	status	NN	O	status	conj_and	28	SENT_295	[p18l1719t3667r1929b3714],
33	.	.	O	.	_	0	SENT_295	[p18l1719t3667r1929b3714],

1	J.	NNP	O	J.	nn	2	SENT_296	[p18l1719t3667r1929b3714],
2	C/in	NNP	O	C/in	_	0	SENT_296	[p18l1945t3664r2050b3714],
3	.	.	O	.	_	0	SENT_296	[p18l1945t3664r2050b3714],

1	Oncol	NN	O	oncol	_	0	SENT_297	[p18l132t3741r288b3791],
2	.	.	O	.	_	0	SENT_297	[p18l132t3741r288b3791],

1	29	CD	NUMBER	29	_	0	SENT_298	[p18l305t3745r385b3798],
2	,	,	O	,	_	0	SENT_298	[p18l305t3745r385b3798],
3	201	CD	NUMBER	201	num	5	SENT_298	[p18l400t3745r483b3791],
4	1-2019	CD	NUMBER	1-2019	num	5	SENT_298	[p18l502t3745r689b3791],
5	(	NN	O	(	appos	1	SENT_298	[p18l705t3742r805b3798],
6	201	CD	NUMBER	201	number	7	SENT_298	[p18l705t3742r805b3798],
7	1	CD	NUMBER	1	num	8	SENT_298	[p18l824t3742r879b3798],
8	)	NN	O	)	dep	5	SENT_298	[p18l824t3742r879b3798],
9	.	.	O	.	_	0	SENT_298	[p18l824t3742r879b3798],

1	Fukuoka	NNP	LOCATION	Fukuoka	_	0	SENT_299	[p19l132t17r364b75],
2	,	,	O	,	_	0	SENT_299	[p19l132t17r364b75],
3	M.	NNP	O	M.	nn	4	SENT_299	[p19l380t20r439b67],
4	etal	NNP	O	etal	appos	1	SENT_299	[p19l454t17r566b67],
5	.	.	O	.	_	0	SENT_299	[p19l454t17r566b67],

1	Biomarker	NN	O	biomarker	nn	2	SENT_300	[p19l585t17r851b67],
2	analyses	NNS	O	analysis	nsubj	7	SENT_300	[p19l864t17r1084b81],
3	and	CC	O	and	_	0	SENT_300	[p19l1099t17r1195b67],
4	ﬁnal	JJ	O	ﬁnal	amod	6	SENT_300	[p19l1210t17r1319b67],
5	overall	JJ	O	overall	amod	6	SENT_300	[p19l1336t17r1507b67],
6	survival	NN	O	survival	conj_and	2	SENT_300	[p19l1524t17r1721b67],
7	results	VBZ	O	result	_	0	SENT_300	[p19l1740t17r1907b67],
8	from	IN	O	from	_	0	SENT_300	[p19l1921t17r2043b67],
9	a	DT	O	a	det	10	SENT_300	[p19l131t110r156b145],
10	phase	NN	O	phase	prep_from	7	SENT_300	[p19l174t95r328b158],
11	III	CD	NUMBER	iii	num	10	SENT_300	[p19l345t98r397b153],
12	,	,	O	,	_	0	SENT_300	[p19l345t98r397b153],
13	randomized	VBN	O	randomize	dep	7	SENT_300	[p19l413t95r740b153],
14	,	,	O	,	_	0	SENT_300	[p19l413t95r740b153],
15	open	JJ	O	open	acomp	13	SENT_300	[p19l754t95r1049b158],
16	—	CD	NUMBER	—	number	17	SENT_300	[p19l754t95r1049b158],
17	|	CD	NUMBER	|	num	19	SENT_300	[p19l754t95r1049b158],
18	abe	NN	O	abe	nn	19	SENT_300	[p19l754t95r1049b158],
19	|	NN	O	|	dep	15	SENT_300	[p19l754t95r1049b158],
20	,	,	O	,	_	0	SENT_300	[p19l754t95r1049b158],
21	ﬁrst	IN	O	ﬁrst	_	0	SENT_300	[p19l1062t95r1276b145],
22	—	CD	NUMBER	—	number	23	SENT_300	[p19l1062t95r1276b145],
23	|	CD	NUMBER	|	num	25	SENT_300	[p19l1062t95r1276b145],
24	ine	NN	O	ine	nn	25	SENT_300	[p19l1062t95r1276b145],
25	study	NN	O	study	prep_ﬁrst	13	SENT_300	[p19l1291t95r1435b159],
26	of	IN	O	of	_	0	SENT_300	[p19l1448t95r1503b145],
27	geﬁtinib	NN	O	geﬁtinib	prep_of	25	SENT_300	[p19l1512t95r1731b159],
28	versus	CC	O	versus	prep	27	SENT_300	[p19l1745t110r1910b145],
29	carboplatin/paclitaxel	NN	O	carboplatin/paclitaxel	dep	28	SENT_300	[p19l131t174r703b236],
30	in	IN	O	in	_	0	SENT_300	[p19l721t176r764b223],
31	clinically	RB	O	clinically	advmod	32	SENT_300	[p19l780t174r1005b237],
32	selected	VBN	O	select	amod	33	SENT_300	[p19l1018t174r1233b223],
33	patients	NNS	O	patient	prep_in	29	SENT_300	[p19l1252t176r1461b236],
34	with	IN	O	with	_	0	SENT_300	[p19l1475t174r1588b223],
35	advanced	JJ	O	advanced	amod	38	SENT_300	[p19l1605t174r1858b223],
36	nonsmall-cell	JJ	O	nonsmall-cell	amod	38	SENT_300	[p19l1877t188r1996b223, p19l131t252r374b301],
37	lung	NN	O	lung	nn	38	SENT_300	[p19l393t252r506b315],
38	cancer	NN	O	cancer	prep_with	29	SENT_300	[p19l523t266r695b301],
39	in	IN	O	in	_	0	SENT_300	[p19l710t254r753b301],
40	Asia	NNP	LOCATION	Asia	prep_in	38	SENT_300	[p19l768t254r873b301],
41	(	CD	NUMBER	(	num	40	SENT_300	[p19l890t253r1124b309],
42	|	CD	NUMBER	|	num	44	SENT_300	[p19l890t253r1124b309],
43	PASS	NN	O	pass	nn	44	SENT_300	[p19l890t253r1124b309],
44	)	NN	O	)	dep	29	SENT_300	[p19l890t253r1124b309],
45	.	.	O	.	_	0	SENT_300	[p19l890t253r1124b309],

1	J.	NNP	PERSON	J.	nn	2	SENT_301	[p19l890t253r1124b309],
2	Clin	NNP	PERSON	Clin	_	0	SENT_301	[p19l1140t252r1245b301],
3	.	.	O	.	_	0	SENT_301	[p19l1140t252r1245b301],

1	Oncol	NN	O	oncol	_	0	SENT_302	[p19l1260t252r1417b301],
2	.	.	O	.	_	0	SENT_302	[p19l1260t252r1417b301],

1	29	CD	NUMBER	29	_	0	SENT_303	[p19l1434t255r1514b309],
2	,	,	O	,	_	0	SENT_303	[p19l1434t255r1514b309],
3	2866-2874	CD	DATE	2866-2874	num	4	SENT_303	[p19l1528t255r1818b301],
4	(	NN	O	(	appos	1	SENT_303	[p19l1833t253r1934b309],
5	201	CD	NUMBER	201	number	6	SENT_303	[p19l1833t253r1934b309],
6	1	CD	NUMBER	1	num	7	SENT_303	[p19l1952t253r2007b309],
7	)	NN	O	)	dep	4	SENT_303	[p19l1952t253r2007b309],
8	.	.	O	.	_	0	SENT_303	[p19l1952t253r2007b309],

1	Mok	NNP	PERSON	Mok	_	0	SENT_304	[p19l131t330r349b387],
2	,	,	O	,	_	0	SENT_304	[p19l131t330r349b387],
3	T.S.	NNP	O	T.S.	nn	4	SENT_304	[p19l131t330r349b387],
4	etal	NN	O	etal	appos	1	SENT_304	[p19l363t330r475b379],
5	.	.	O	.	_	0	SENT_304	[p19l363t330r475b379],

1	Geﬁtinib	NN	O	geﬁtinib	_	0	SENT_305	[p19l492t329r717b379],
2	or	CC	O	or	_	0	SENT_305	[p19l732t344r785b379],
3	carboplatin-paclitaxel	NN	O	carboplatin-paclitaxel	conj_or	1	SENT_305	[p19l798t330r1367b392],
4	in	IN	O	in	_	0	SENT_305	[p19l1385t332r1428b379],
5	pulmonary	JJ	O	pulmonary	amod	6	SENT_305	[p19l1446t330r1735b393],
6	adenocarcinoma	NN	O	adenocarcinoma	prep_in	1	SENT_305	[p19l131t408r586b457],
7	.	.	O	.	_	0	SENT_305	[p19l131t408r586b457],

1	N.	NNP	O	N.	nn	2	SENT_306	[p19l600t410r648b457],
2	Engl	NNP	O	Engl	_	0	SENT_306	[p19l662t408r781b471],
3	.	.	O	.	_	0	SENT_306	[p19l662t408r781b471],

1	J.	NNP	O	J.	nn	2	SENT_307	[p19l792t410r826b457],
2	Med	NNP	O	Med	_	0	SENT_307	[p19l840t408r960b457],
3	.	.	O	.	_	0	SENT_307	[p19l840t408r960b457],

1	361	CD	NUMBER	361	_	0	SENT_308	[p19l977t411r1092b465],
2	,	,	O	,	_	0	SENT_308	[p19l977t411r1092b465],
3	947-957	CD	NUMBER	947-957	number	4	SENT_308	[p19l1106t411r1329b457],
4	(	CD	NUMBER	(	appos	1	SENT_308	[p19l1346t409r1520b465],
5	2009	CD	DATE	2009	num	6	SENT_308	[p19l1346t409r1520b465],
6	)	NN	O	)	dep	4	SENT_308	[p19l1346t409r1520b465],
7	.	.	O	.	_	0	SENT_308	[p19l1346t409r1520b465],

1	Rosell	NNP	PERSON	Rosell	_	0	SENT_309	[p19l132t486r294b543],
2	,	,	O	,	_	0	SENT_309	[p19l132t486r294b543],
3	R.	NNP	O	R.	nn	4	SENT_309	[p19l311t488r352b535],
4	etal	NN	O	etal	appos	1	SENT_309	[p19l366t486r478b535],
5	.	.	O	.	_	0	SENT_309	[p19l366t486r478b535],

1	Erlotinib	NNP	O	Erlotinib	nsubj	17	SENT_310	[p19l497t486r715b535],
2	versus	CC	O	versus	prep	1	SENT_310	[p19l728t500r894b535],
3	standard	JJ	O	standard	amod	4	SENT_310	[p19l909t486r1137b535],
4	chemotherapy	NN	O	chemotherapy	dep	2	SENT_310	[p19l1154t486r1541b549],
5	as	IN	O	as	_	0	SENT_310	[p19l1554t500r1605b535],
6	ﬁrst-line	JJ	O	ﬁrst-line	amod	7	SENT_310	[p19l1618t485r1832b535],
7	treatment	NN	O	treatment	prep_as	4	SENT_310	[p19l1845t493r2109b535],
8	for	IN	O	for	_	0	SENT_310	[p19l129t563r202b613],
9	European	JJ	MISC	european	amod	10	SENT_310	[p19l217t566r464b626],
10	patients	NNS	O	patient	prep_for	7	SENT_310	[p19l483t566r692b626],
11	with	IN	O	with	_	0	SENT_310	[p19l706t564r819b613],
12	advanced	JJ	O	advanced	amod	13	SENT_310	[p19l835t564r1089b613],
13	EGFR	NN	ORGANIZATION	egfr	prep_with	10	SENT_310	[p19l1108t566r1240b613],
14	mutation-positive	JJ	O	mutation-positive	amod	17	SENT_310	[p19l1256t566r1724b626],
15	non-small-cell	JJ	O	non-small-cell	amod	17	SENT_310	[p19l1740t564r2106b613],
16	lung	NN	O	lung	nn	17	SENT_310	[p19l133t642r246b705],
17	cancer	NN	O	cancer	_	0	SENT_310	[p19l262t656r435b691],
18	(	CD	NUMBER	(	num	19	SENT_310	[p19l450t643r704b699],
19	EURTAC	NN	O	eurtac	dep	17	SENT_310	[p19l450t643r704b699],
20	)	CD	NUMBER	)	dep	17	SENT_310	[p19l450t643r704b699],
21	:	:	O	:	_	0	SENT_310	[p19l450t643r704b699],
22	a	DT	O	a	det	29	SENT_310	[p19l718t656r744b691],
23	multicentre	JJ	O	multicentre	amod	29	SENT_310	[p19l762t642r1075b699],
24	,	,	O	,	_	0	SENT_310	[p19l762t642r1075b699],
25	open	JJ	O	open	amod	29	SENT_310	[p19l1089t642r1385b704],
26	—	CD	NUMBER	—	number	27	SENT_310	[p19l1089t642r1385b704],
27	|	CD	NUMBER	|	num	29	SENT_310	[p19l1089t642r1385b704],
28	abe	NN	O	abe	nn	29	SENT_310	[p19l1089t642r1385b704],
29	|	NN	O	|	dep	17	SENT_310	[p19l1089t642r1385b704],
30	,	,	O	,	_	0	SENT_310	[p19l1089t642r1385b704],
31	randomised	JJ	O	randomised	amod	34	SENT_310	[p19l1401t642r1711b691],
32	phase	NN	O	phase	dep	31	SENT_310	[p19l1730t642r1884b704],
33	3	CD	NUMBER	3	num	32	SENT_310	[p19l1899t645r1925b691],
34	trial	NN	O	trial	dobj	17	SENT_310	[p19l1940t642r2052b691],
35	.	.	O	.	_	0	SENT_310	[p19l1940t642r2052b691],

1	Lancet	NNP	O	Lancet	nn	2	SENT_311	[p19l131t721r301b768],
2	Oncol	NNP	O	Oncol	_	0	SENT_311	[p19l311t719r467b768],
3	.	.	O	.	_	0	SENT_311	[p19l311t719r467b768],

1	13	CD	NUMBER	13	_	0	SENT_312	[p19l487t722r564b775],
2	,	,	O	,	_	0	SENT_312	[p19l487t722r564b775],
3	239-246	CD	NUMBER	239-246	number	4	SENT_312	[p19l579t722r803b768],
4	(	CD	NUMBER	(	appos	1	SENT_312	[p19l818t720r993b775],
5	2012	CD	DATE	2012	num	6	SENT_312	[p19l818t720r993b775],
6	)	NN	O	)	dep	4	SENT_312	[p19l818t720r993b775],
7	.	.	O	.	_	0	SENT_312	[p19l818t720r993b775],

1	VOLUME	NN	O	volume	_	0	SENT_313	[p19l592t926r816b968],
2	93	CD	NUMBER	93	num	1	SENT_313	[p19l834t927r890b968],
3	NUMBER	NN	O	number	nn	6	SENT_313	[p19l911t926r1136b968],
4	3	CD	NUMBER	3	num	6	SENT_313	[p19l1153t927r1178b968],
5	|	NN	O	|	nn	6	SENT_313	[p19l1200t922r1204b983],
6	MARCH	NN	DATE	march	dep	1	SENT_313	[p19l1226t926r1417b968],
7	2013	CD	DATE	2013	num	9	SENT_313	[p19l1437t927r1555b968],
8	|	CD	NUMBER	|	num	9	SENT_313	[p19l1577t922r1581b983],
9	www.nature.com/cpt	NN	O	www.nature.com/cpt	dep	1	SENT_313	[p19l1600t926r2152b979],

1	Chapman	NNP	PERSON	Chapman	nn	4	SENT_314	[p19l125t1264r385b1324],
2	,	,	O	,	_	0	SENT_314	[p19l125t1264r385b1324],
3	P.B.	NNP	O	P.B.	appos	4	SENT_314	[p19l401t1266r477b1312],
4	etal.	NNP	O	etal.	_	0	SENT_314	[p19l491t1264r614b1319],
5	;	:	O	;	_	0	SENT_314	[p19l491t1264r614b1319],
6	BR	NNP	O	BR	nn	8	SENT_314	[p19l630t1266r805b1312],
7	|	CD	NUMBER	|	num	8	SENT_314	[p19l630t1266r805b1312],
8	M	NN	O	m	dep	4	SENT_314	[p19l630t1266r805b1312],
9	—	NN	O	—	nn	12	SENT_314	[p19l630t1266r805b1312],
10	3	CD	NUMBER	3	num	12	SENT_314	[p19l630t1266r805b1312],
11	Study	NNP	O	Study	nn	12	SENT_314	[p19l821t1264r967b1325],
12	Group	NNP	O	Group	dep	8	SENT_314	[p19l979t1266r1149b1324],
13	.	.	O	.	_	0	SENT_314	[p19l979t1266r1149b1324],

1	Improved	VBN	O	improve	_	0	SENT_315	[p19l1165t1264r1407b1324],
2	survival	NN	O	survival	dobj	1	SENT_315	[p19l1424t1264r1615b1312],
3	with	IN	O	with	_	0	SENT_315	[p19l1630t1264r1740b1312],
4	vemurafenib	NN	O	vemurafenib	prep_with	1	SENT_315	[p19l1755t1263r2079b1312],
5	in	IN	O	in	_	0	SENT_315	[p19l128t1341r169b1386],
6	melanoma	NN	O	melanoma	prep_in	4	SENT_315	[p19l187t1339r456b1387],
7	with	IN	O	with	_	0	SENT_315	[p19l471t1339r581b1387],
8	BRAF	NN	O	braf	nn	10	SENT_315	[p19l599t1341r727b1387],
9	V600E	NN	O	v600e	nn	10	SENT_315	[p19l738t1341r896b1387],
10	mutation	NN	O	mutation	prep_with	1	SENT_315	[p19l912t1341r1157b1387],
11	.	.	O	.	_	0	SENT_315	[p19l912t1341r1157b1387],

1	N.	NNP	MISC	N.	nn	2	SENT_316	[p19l1171t1341r1217b1387],
2	EngI	NNP	MISC	EngI	_	0	SENT_316	[p19l1232t1339r1520b1400],
3	.	.	O	.	_	0	SENT_316	[p19l1232t1339r1520b1400],

1	J.	NNP	O	J.	nn	2	SENT_317	[p19l1232t1339r1520b1400],
2	Med	NNP	O	Med	_	0	SENT_317	[p19l1232t1339r1520b1400],
3	.	.	O	.	_	0	SENT_317	[p19l1232t1339r1520b1400],

1	364	CD	NUMBER	364	_	0	SENT_318	[p19l1536t1342r1647b1394],
2	,	,	O	,	_	0	SENT_318	[p19l1536t1342r1647b1394],
3	2507-2516	CD	DATE	2507-2516	num	4	SENT_318	[p19l1662t1342r1942b1387],
4	(	NN	O	(	appos	1	SENT_318	[p19l128t1415r225b1469],
5	201	CD	NUMBER	201	number	6	SENT_318	[p19l128t1415r225b1469],
6	1	CD	NUMBER	1	num	7	SENT_318	[p19l243t1415r297b1469],
7	)	NN	O	)	dep	4	SENT_318	[p19l243t1415r297b1469],
8	.	.	O	.	_	0	SENT_318	[p19l243t1415r297b1469],

1	Hauschild	NNP	O	Hauschild	_	0	SENT_319	[p19l127t1489r387b1544],
2	,	,	O	,	_	0	SENT_319	[p19l127t1489r387b1544],
3	A.	NNP	O	A.	nn	4	SENT_319	[p19l401t1491r448b1537],
4	etal	NNP	O	etal	appos	1	SENT_319	[p19l462t1489r570b1537],
5	.	.	O	.	_	0	SENT_319	[p19l462t1489r570b1537],

1	Dabrafenib	NNP	O	Dabrafenib	_	0	SENT_320	[p19l589t1488r870b1537],
2	in	IN	O	in	_	0	SENT_320	[p19l885t1491r927b1536],
3	BRAF-mutated	JJ	O	braf-mutated	amod	5	SENT_320	[p19l945t1489r1312b1537],
4	metastatic	JJ	O	metastatic	amod	5	SENT_320	[p19l1330t1491r1594b1537],
5	melanoma	NN	O	melanoma	prep_in	1	SENT_320	[p19l1610t1489r1893b1537],
6	:	:	O	:	_	0	SENT_320	[p19l1610t1489r1893b1537],
7	a	DT	O	a	det	14	SENT_320	[p19l1907t1503r1931b1537],
8	multicentre	JJ	O	multicentre	amod	14	SENT_320	[p19l128t1564r432b1619],
9	,	,	O	,	_	0	SENT_320	[p19l128t1564r432b1619],
10	open	JJ	O	open	amod	14	SENT_320	[p19l446t1564r732b1624],
11	—	CD	NUMBER	—	number	12	SENT_320	[p19l446t1564r732b1624],
12	|	CD	NUMBER	|	dep	10	SENT_320	[p19l446t1564r732b1624],
13	abe	NN	O	abe	nn	14	SENT_320	[p19l446t1564r732b1624],
14	|	NN	O	|	dep	1	SENT_320	[p19l446t1564r732b1624],
15	,	,	O	,	_	0	SENT_320	[p19l446t1564r732b1624],
16	phase	NN	O	phase	npadvmod	18	SENT_320	[p19l748t1564r897b1624],
17	3	CD	NUMBER	3	num	16	SENT_320	[p19l912t1567r937b1612],
18	randomised	JJ	O	randomised	amod	20	SENT_320	[p19l955t1564r1256b1612],
19	controlled	JJ	O	controlled	amod	20	SENT_320	[p19l1272t1564r1530b1612],
20	trial	NN	O	trial	appos	14	SENT_320	[p19l1545t1564r1653b1612],
21	.	.	O	.	_	0	SENT_320	[p19l1545t1564r1653b1612],

1	Lancet	NNP	O	Lancet	_	0	SENT_321	[p19l1667t1566r1832b1612],
2	380	CD	NUMBER	380	num	1	SENT_321	[p19l1843t1567r1954b1619],
3	,	,	O	,	_	0	SENT_321	[p19l1843t1567r1954b1619],
4	358-365	CD	NUMBER	358-365	num	1	SENT_321	[p19l127t1642r342b1687],
5	(	CD	NUMBER	(	num	7	SENT_321	[p19l359t1640r528b1694],
6	2012	CD	DATE	2012	num	7	SENT_321	[p19l359t1640r528b1694],
7	)	NN	O	)	dep	1	SENT_321	[p19l359t1640r528b1694],
8	.	.	O	.	_	0	SENT_321	[p19l359t1640r528b1694],

1	Vardiman	NNP	PERSON	Vardiman	_	0	SENT_322	[p19l123t1714r380b1769],
2	,	,	O	,	_	0	SENT_322	[p19l123t1714r380b1769],
3	J.W.	NNP	PERSON	J.W.	nn	4	SENT_322	[p19l393t1716r487b1762],
4	etal	NNP	O	etal	appos	1	SENT_322	[p19l501t1714r609b1762],
5	.	.	O	.	_	0	SENT_322	[p19l501t1714r609b1762],

1	The	DT	O	the	det	3	SENT_323	[p19l620t1714r714b1762],
2	2008	CD	DATE	2008	num	3	SENT_323	[p19l729t1717r851b1762],
3	revision	NN	O	revision	_	0	SENT_323	[p19l867t1716r1061b1762],
4	of	IN	O	of	_	0	SENT_323	[p19l1077t1713r1130b1762],
5	the	DT	O	the	det	9	SENT_323	[p19l1138t1714r1221b1762],
6	World	NNP	ORGANIZATION	World	nn	9	SENT_323	[p19l1231t1714r1381b1762],
7	Health	NNP	ORGANIZATION	Health	nn	9	SENT_323	[p19l1399t1714r1561b1762],
8	Organization	NNP	ORGANIZATION	Organization	nn	9	SENT_323	[p19l1577t1715r1905b1775],
9	(	NNP	O	(	prep_of	3	SENT_323	[p19l128t1790r294b1844],
10	WHO	WP	O	who	nsubj	11	SENT_323	[p19l128t1790r294b1844],
11	)	VBP	O	)	rcmod	3	SENT_323	[p19l128t1790r294b1844],
12	classiﬁcation	NN	O	classiﬁcation	dobj	11	SENT_323	[p19l310t1788r631b1837],
13	of	IN	O	of	_	0	SENT_323	[p19l647t1788r700b1837],
14	myeloid	JJ	O	myeloid	amod	15	SENT_323	[p19l711t1789r911b1850],
15	neoplasms	NNS	O	neoplasm	prep_of	12	SENT_323	[p19l929t1789r1202b1849],
16	and	CC	O	and	_	0	SENT_323	[p19l1216t1789r1309b1837],
17	acute	JJ	O	acute	amod	18	SENT_323	[p19l1326t1796r1464b1837],
18	leukemia	NN	O	leukemia	prep_of	12	SENT_323	[p19l1480t1789r1722b1837],
19	:	:	O	:	_	0	SENT_323	[p19l1480t1789r1722b1837],
20	rationale	NN	O	rationale	dep	3	SENT_323	[p19l1738t1789r1959b1837],
21	and	CC	O	and	_	0	SENT_323	[p19l1973t1789r2066b1837],
22	important	JJ	O	important	amod	23	SENT_323	[p19l128t1866r385b1924],
23	changes	NNS	O	change	conj_and	20	SENT_323	[p19l398t1864r622b1925],
24	.	.	O	.	_	0	SENT_323	[p19l398t1864r622b1925],

1	Blood	NN	O	blood	_	0	SENT_324	[p19l636t1864r779b1912],
2	1	CD	NUMBER	1	number	3	SENT_324	[p19l792t1868r811b1911],
3	14	CD	NUMBER	14	dep	1	SENT_324	[p19l827t1868r901b1919],
4	,	,	O	,	_	0	SENT_324	[p19l827t1868r901b1919],
5	937-951	CD	NUMBER	937-951	number	6	SENT_324	[p19l915t1867r1123b1912],
6	(	CD	NUMBER	(	appos	1	SENT_324	[p19l1148t1865r1317b1919],
7	2009	CD	DATE	2009	num	8	SENT_324	[p19l1148t1865r1317b1919],
8	)	NN	O	)	dep	6	SENT_324	[p19l1148t1865r1317b1919],
9	.	.	O	.	_	0	SENT_324	[p19l1148t1865r1317b1919],

1	Thway	NNP	O	Thway	_	0	SENT_325	[p19l123t1939r299b2000],
2	,	,	O	,	_	0	SENT_325	[p19l123t1939r299b2000],
3	K.	NNP	O	K.	nn	4	SENT_325	[p19l315t1941r356b1987],
4	etal	NN	O	etal	appos	1	SENT_325	[p19l370t1939r478b1987],
5	.	.	O	.	_	0	SENT_325	[p19l370t1939r478b1987],

1	Utility	NN	O	utility	_	0	SENT_326	[p19l497t1939r646b2000],
2	of	IN	O	of	_	0	SENT_326	[p19l658t1938r711b1987],
3	sarcoma	NN	O	sarcoma	nn	6	SENT_326	[p19l721t1938r1144b1999],
4	—	CD	NUMBER	—	num	6	SENT_326	[p19l721t1938r1144b1999],
5	speciﬁc	NN	O	speciﬁc	nn	6	SENT_326	[p19l721t1938r1144b1999],
6	fusion	NN	O	fusion	prep_of	1	SENT_326	[p19l1157t1938r1311b1987],
7	gene	NN	O	gene	nn	8	SENT_326	[p19l1327t1953r1454b2000],
8	analysis	NN	O	analysis	dep	1	SENT_326	[p19l1468t1939r1664b2000],
9	in	IN	O	in	_	0	SENT_326	[p19l1680t1941r1721b1986],
10	parafﬁn	NN	O	parafﬁn	npadvmod	12	SENT_326	[p19l1739t1938r1952b1999],
11	—	CD	NUMBER	—	num	10	SENT_326	[p19l1739t1938r1952b1999],
12	embedded	JJ	O	embedded	amod	13	SENT_326	[p19l126t2014r405b2062],
13	material	NN	O	material	prep_in	8	SENT_326	[p19l423t2014r626b2062],
14	for	IN	O	for	_	0	SENT_326	[p19l641t2013r711b2062],
15	routine	JJ	O	routine	amod	16	SENT_326	[p19l725t2016r907b2062],
16	diagnosis	NN	O	diagnosis	prep_for	13	SENT_326	[p19l921t2014r1161b2075],
17	at	IN	O	at	_	0	SENT_326	[p19l1175t2021r1222b2062],
18	a	DT	O	a	det	20	SENT_326	[p19l1236t2028r1260b2062],
19	specialist	NN	O	specialist	nn	20	SENT_326	[p19l1276t2014r1508b2074],
20	centre	NN	O	centre	prep_at	16	SENT_326	[p19l1522t2016r1736b2062],
21	.	.	O	.	_	0	SENT_326	[p19l1522t2016r1736b2062],

1	J.	NNP	PERSON	J.	nn	2	SENT_327	[p19l1522t2016r1736b2062],
2	Clin	NNP	PERSON	Clin	_	0	SENT_327	[p19l1751t2014r1853b2062],
3	.	.	O	.	_	0	SENT_327	[p19l1751t2014r1853b2062],

1	Pathol	NN	PERSON	pathol	_	0	SENT_328	[p19l1867t2014r2034b2062],
2	.	.	O	.	_	0	SENT_328	[p19l1867t2014r2034b2062],

1	63	CD	NUMBER	63	_	0	SENT_329	[p19l126t2092r204b2144],
2	,	,	O	,	_	0	SENT_329	[p19l126t2092r204b2144],
3	508-51	CD	NUMBER	508-51	number	4	SENT_329	[p19l218t2092r394b2137],
4	2	CD	NUMBER	2	appos	1	SENT_329	[p19l408t2092r434b2136],
5	(	CD	NUMBER	(	num	7	SENT_329	[p19l451t2090r619b2144],
6	2010	CD	DATE	2010	num	7	SENT_329	[p19l451t2090r619b2144],
7	)	NN	O	)	dep	4	SENT_329	[p19l451t2090r619b2144],
8	.	.	O	.	_	0	SENT_329	[p19l451t2090r619b2144],

1	Gonzalez	NNP	PERSON	Gonzalez	nn	3	SENT_330	[p19l125t2164r370b2219],
2	,	,	O	,	_	0	SENT_330	[p19l125t2164r370b2219],
3	D.	NNP	O	D.	_	0	SENT_330	[p19l386t2166r432b2212],
4	et	FW	O	et	nn	5	SENT_330	[p19l446t2171r493b2212],
5	al.	FW	O	al.	dep	3	SENT_330	[p19l502t2164r554b2212],
6	.	.	O	.	_	0	SENT_330	[p19l502t2164r554b2212],

1	Mutational	JJ	O	mutational	amod	2	SENT_331	[p19l572t2164r845b2212],
2	status	NN	O	status	_	0	SENT_331	[p19l862t2171r1011b2212],
3	of	IN	O	of	_	0	SENT_331	[p19l1025t2163r1078b2212],
4	the	DT	O	the	det	6	SENT_331	[p19l1086t2164r1169b2212],
5	TP53	NN	O	tp53	nn	6	SENT_331	[p19l1178t2166r1302b2212],
6	gene	NN	O	gene	prep_of	2	SENT_331	[p19l1318t2178r1444b2225],
7	as	IN	O	as	_	0	SENT_331	[p19l1458t2178r1509b2212],
8	a	DT	O	a	det	9	SENT_331	[p19l1523t2178r1547b2212],
9	predictor	NN	O	predictor	prep_as	6	SENT_331	[p19l1565t2164r1798b2224],
10	of	IN	O	of	_	0	SENT_331	[p19l1810t2163r1863b2212],
11	response	NN	O	response	prep_of	9	SENT_331	[p19l128t2253r356b2299],
12	and	CC	O	and	_	0	SENT_331	[p19l370t2239r463b2287],
13	survival	NN	O	survival	conj_and	11	SENT_331	[p19l480t2239r671b2287],
14	in	IN	O	in	_	0	SENT_331	[p19l689t2241r730b2286],
15	patients	NNS	O	patient	prep_in	2	SENT_331	[p19l748t2241r951b2299],
16	with	IN	O	with	_	0	SENT_331	[p19l964t2239r1074b2287],
17	chronic	JJ	O	chronic	amod	19	SENT_331	[p19l1090t2239r1278b2287],
18	lymphocytic	JJ	O	lymphocytic	amod	19	SENT_331	[p19l1294t2239r1607b2300],
19	leukemia	NN	O	leukemia	prep_with	15	SENT_331	[p19l1623t2239r1864b2287],
20	:	:	O	:	_	0	SENT_331	[p19l1623t2239r1864b2287],
21	results	NNS	O	result	dep	2	SENT_331	[p19l1880t2239r2043b2287],
22	from	IN	O	from	_	0	SENT_331	[p19l125t2313r243b2362],
23	the	DT	O	the	det	27	SENT_331	[p19l258t2314r341b2362],
24	LRF	NN	O	lrf	nn	27	SENT_331	[p19l358t2316r443b2361],
25	CLL4	NN	O	cll4	nn	27	SENT_331	[p19l458t2315r581b2362],
26	tria	NN	O	trium	nn	27	SENT_331	[p19l593t2314r745b2362],
27	|	NN	O	|	prep_from	21	SENT_331	[p19l593t2314r745b2362],
28	.	.	O	.	_	0	SENT_331	[p19l593t2314r745b2362],

1	J.	NNP	PERSON	J.	nn	2	SENT_332	[p19l593t2314r745b2362],
2	Clin	NNP	PERSON	Clin	_	0	SENT_332	[p19l760t2314r862b2362],
3	.	.	O	.	_	0	SENT_332	[p19l760t2314r862b2362],

1	Oncol	NN	O	oncol	_	0	SENT_333	[p19l877t2314r1029b2362],
2	.	.	O	.	_	0	SENT_333	[p19l877t2314r1029b2362],

1	29	CD	NUMBER	29	_	0	SENT_334	[p19l1045t2317r1122b2369],
2	,	,	O	,	_	0	SENT_334	[p19l1045t2317r1122b2369],
3	2223-2229	CD	DATE	2223-2229	num	4	SENT_334	[p19l1137t2317r1417b2362],
4	(	NN	O	(	appos	1	SENT_334	[p19l1433t2315r1530b2369],
5	201	CD	NUMBER	201	number	6	SENT_334	[p19l1433t2315r1530b2369],
6	1	CD	NUMBER	1	num	7	SENT_334	[p19l1548t2315r1601b2369],
7	)	NN	O	)	dep	4	SENT_334	[p19l1548t2315r1601b2369],
8	.	.	O	.	_	0	SENT_334	[p19l1548t2315r1601b2369],

1	Pospisilova	NNP	PERSON	Pospisilova	_	0	SENT_335	[p19l127t2389r418b2449],
2	,	,	O	,	_	0	SENT_335	[p19l127t2389r418b2449],
3	S.	NNP	O	S.	nn	4	SENT_335	[p19l433t2390r472b2437],
4	etal	NNP	O	etal	appos	1	SENT_335	[p19l486t2389r594b2437],
5	.	.	O	.	_	0	SENT_335	[p19l486t2389r594b2437],

1	ERIC	NNP	ORGANIZATION	ERIC	nn	2	SENT_336	[p19l613t2390r720b2437],
2	recommendations	NNS	O	recommendation	_	0	SENT_336	[p19l737t2389r1202b2437],
3	on	IN	O	on	_	0	SENT_336	[p19l1217t2403r1279b2437],
4	TP53	NN	O	tp53	nn	6	SENT_336	[p19l1290t2391r1414b2437],
5	mutation	NN	O	mutation	nn	6	SENT_336	[p19l1432t2391r1662b2437],
6	analysis	NN	O	analysis	prep_on	2	SENT_336	[p19l1678t2389r1874b2450],
7	in	IN	O	in	_	0	SENT_336	[p19l1890t2391r1932b2436],
8	chronic	JJ	O	chronic	amod	10	SENT_336	[p19l126t2464r314b2512],
9	lymphocytic	JJ	O	lymphocytic	amod	10	SENT_336	[p19l330t2464r643b2525],
10	leukemia	NN	O	leukemia	prep_in	2	SENT_336	[p19l659t2464r901b2512],
11	.	.	O	.	_	0	SENT_336	[p19l659t2464r901b2512],

1	Leukemia	NN	O	leukemia	_	0	SENT_337	[p19l915t2464r1149b2512],
2	26	CD	NUMBER	26	num	1	SENT_337	[p19l1163t2467r1240b2519],
3	,	,	O	,	_	0	SENT_337	[p19l1163t2467r1240b2519],
4	1458-1461	CD	DATE	1458-1461	number	5	SENT_337	[p19l1258t2467r1525b2512],
5	(	CD	NUMBER	(	appos	1	SENT_337	[p19l1550t2465r1719b2519],
6	2012	CD	DATE	2012	num	7	SENT_337	[p19l1550t2465r1719b2519],
7	)	NN	O	)	dep	5	SENT_337	[p19l1550t2465r1719b2519],
8	.	.	O	.	_	0	SENT_337	[p19l1550t2465r1719b2519],

1	Oscier	NNP	O	Oscier	_	0	SENT_338	[p19l125t2540r290b2594],
2	,	,	O	,	_	0	SENT_338	[p19l125t2540r290b2594],
3	D.	NNP	O	D.	nn	4	SENT_338	[p19l307t2541r352b2587],
4	etal	NNP	O	etal	appos	1	SENT_338	[p19l366t2539r475b2587],
5	.	.	O	.	_	0	SENT_338	[p19l366t2539r475b2587],

1	Prognostic	JJ	O	prognostic	amod	2	SENT_339	[p19l493t2541r762b2600],
2	factors	NNS	O	factor	nsubj	3	SENT_339	[p19l774t2538r945b2587],
3	identiﬁed	VBD	O	identiﬁed	_	0	SENT_339	[p19l961t2538r1201b2587],
4	three	CD	NUMBER	three	num	6	SENT_339	[p19l1216t2539r1349b2587],
5	risk	NN	O	risk	nn	6	SENT_339	[p19l1365t2539r1450b2587],
6	groups	NNS	O	group	dobj	3	SENT_339	[p19l1461t2553r1639b2600],
7	in	IN	O	in	_	0	SENT_339	[p19l1655t2541r1696b2586],
8	the	DT	O	the	det	11	SENT_339	[p19l1711t2539r1794b2587],
9	LRF	NN	ORGANIZATION	lrf	nn	11	SENT_339	[p19l1810t2541r1896b2586],
10	CLL4	NN	O	cll4	nn	11	SENT_339	[p19l1910t2540r2033b2587],
11	trial	NN	O	trial	prep_in	3	SENT_339	[p19l125t2614r234b2669],
12	,	,	O	,	_	0	SENT_339	[p19l125t2614r234b2669],
13	independent	JJ	O	independent	appos	11	SENT_339	[p19l249t2614r580b2674],
14	of	IN	O	of	_	0	SENT_339	[p19l593t2613r645b2662],
15	treatment	NN	O	treatment	nn	16	SENT_339	[p19l654t2621r909b2662],
16	allocation	NN	O	allocation	prep_of	13	SENT_339	[p19l923t2614r1184b2662],
17	.	.	O	.	_	0	SENT_339	[p19l923t2614r1184b2662],

1	Haematologica	NNP	PERSON	Haematologica	_	0	SENT_340	[p19l1198t2614r1578b2675],
2	95	CD	NUMBER	95	num	1	SENT_340	[p19l1590t2617r1668b2669],
3	,	,	O	,	_	0	SENT_340	[p19l1590t2617r1668b2669],
4	1705-1712	CD	DATE	1705-1712	num	1	SENT_340	[p19l1686t2617r1962b2662],
5	(	CD	NUMBER	(	num	7	SENT_340	[p19l128t2690r297b2744],
6	2010	CD	DATE	2010	num	7	SENT_340	[p19l128t2690r297b2744],
7	)	NN	O	)	dep	1	SENT_340	[p19l128t2690r297b2744],
8	.	.	O	.	_	0	SENT_340	[p19l128t2690r297b2744],

1	Gonzalez	NNP	PERSON	Gonzalez	_	0	SENT_341	[p19l125t2764r370b2819],
2	,	,	O	,	_	0	SENT_341	[p19l125t2764r370b2819],
3	D.	NNP	O	D.	nn	4	SENT_341	[p19l386t2766r432b2812],
4	etal	NNP	O	etal	appos	1	SENT_341	[p19l446t2764r554b2812],
5	.	.	O	.	_	0	SENT_341	[p19l446t2764r554b2812],

1	CLLU1	NN	O	cllu1	nn	2	SENT_342	[p19l570t2765r720b2812],
2	expression	NN	O	expression	nsubj	3	SENT_342	[p19l744t2766r1015b2824],
3	has	VBZ	O	have	_	0	SENT_342	[p19l1033t2764r1115b2812],
4	prognostic	JJ	O	prognostic	amod	5	SENT_342	[p19l1131t2766r1404b2825],
5	value	NN	O	value	dobj	3	SENT_342	[p19l1416t2764r1552b2812],
6	in	IN	O	in	_	0	SENT_342	[p19l1567t2766r1609b2811],
7	CLL	NN	O	cll	prep_in	5	SENT_342	[p19l1625t2765r1716b2812],
8	after	IN	O	after	_	0	SENT_342	[p19l1729t2763r1846b2812],
9	ﬁrst	NN	O	ﬁrst	nn	13	SENT_342	[p19l125t2838r332b2887],
10	—	CD	NUMBER	—	num	13	SENT_342	[p19l125t2838r332b2887],
11	|	NN	O	|	nn	13	SENT_342	[p19l125t2838r332b2887],
12	ine	NN	O	ine	nn	13	SENT_342	[p19l125t2838r332b2887],
13	therapy	NN	O	therapy	prep_after	3	SENT_342	[p19l345t2839r543b2901],
14	in	IN	O	in	_	0	SENT_342	[p19l557t2841r598b2886],
15	younger	JJR	O	younger	amod	16	SENT_342	[p19l613t2853r828b2900],
16	patients	NNS	O	patient	prep_in	3	SENT_342	[p19l843t2841r1045b2899],
17	and	CC	O	and	_	0	SENT_342	[p19l1060t2839r1153b2887],
18	those	DT	O	those	conj_and	16	SENT_342	[p19l1168t2839r1309b2887],
19	with	IN	O	with	_	0	SENT_342	[p19l1322t2839r1432b2887],
20	mutated	VBN	O	mutate	amod	22	SENT_342	[p19l1450t2839r1663b2887],
21	IGHV	NN	O	ighv	nn	22	SENT_342	[p19l1682t2841r1808b2887],
22	genes	NNS	O	gene	prep_with	18	SENT_342	[p19l1820t2853r1982b2900],
23	.	.	O	.	_	0	SENT_342	[p19l1820t2853r1982b2900],

1	Haematologica	NNP	PERSON	Haematologica	_	0	SENT_343	[p19l126t2914r518b2975],
2	,	,	O	,	_	0	SENT_343	[p19l126t2914r518b2975],
3	(	CD	NUMBER	(	num	5	SENT_343	[p19l533t2915r702b2969],
4	2012	CD	DATE	2012	num	5	SENT_343	[p19l533t2915r702b2969],
5	)	NN	O	)	appos	1	SENT_343	[p19l533t2915r702b2969],
6	;	:	O	;	_	0	SENT_343	[p19l533t2915r702b2969],
7	e	SYM	O	e	dep	9	SENT_343	[p19l716t2914r868b2974],
8	—	CD	NUMBER	—	num	9	SENT_343	[p19l716t2914r868b2974],
9	pub	NN	O	pub	dep	1	SENT_343	[p19l716t2914r868b2974],
10	ahead	RB	O	ahead	_	0	SENT_343	[p19l882t2914r1036b2962],
11	of	IN	O	of	_	0	SENT_343	[p19l1052t2913r1105b2962],
12	print	NN	O	print	nn	14	SENT_343	[p19l1116t2916r1235b2974],
13	16	CD	DATE	16	num	14	SENT_343	[p19l1253t2917r1308b2962],
14	August	NNP	DATE	August	prep_ahead_of	1	SENT_343	[p19l1322t2916r1504b2975],
15	201	CD	NUMBER	201	number	16	SENT_343	[p19l1517t2917r1599b2962],
16	2	CD	NUMBER	2	dep	14	SENT_343	[p19l1612t2917r1652b2962],
17	.	.	O	.	_	0	SENT_343	[p19l1612t2917r1652b2962],

1	Paik	NNP	PERSON	Paik	nn	3	SENT_344	[p19l127t2989r239b3044],
2	,	,	O	,	_	0	SENT_344	[p19l127t2989r239b3044],
3	S.	NNP	O	S.	_	0	SENT_344	[p19l253t2990r292b3037],
4	et	FW	O	et	nn	5	SENT_344	[p19l306t2996r353b3037],
5	al.	FW	O	al.	dep	3	SENT_344	[p19l361t2989r414b3037],
6	.	.	O	.	_	0	SENT_344	[p19l361t2989r414b3037],

1	A	DT	O	a	det	3	SENT_345	[p19l430t2991r465b3036],
2	multigene	JJ	O	multigene	amod	3	SENT_345	[p19l480t2989r740b3050],
3	assay	NN	O	assay	nsubj	10	SENT_345	[p19l754t3003r889b3050],
4	to	TO	O	to	aux	5	SENT_345	[p19l900t2996r951b3037],
5	predict	VB	O	predict	infmod	3	SENT_345	[p19l967t2989r1146b3049],
6	recurrence	NN	O	recurrence	dobj	5	SENT_345	[p19l1161t3003r1431b3037],
7	of	IN	O	of	_	0	SENT_345	[p19l1445t2988r1498b3037],
8	tamoxifen	NN	O	tamoxifen	nn	9	SENT_345	[p19l1506t2988r1980b3044],
9	—	NN	O	—	prep_of	6	SENT_345	[p19l1506t2988r1980b3044],
10	treated	VBN	O	treat	_	0	SENT_345	[p19l1506t2988r1980b3044],
11	,	,	O	,	_	0	SENT_345	[p19l1506t2988r1980b3044],
12	node	NN	O	node	dep	16	SENT_345	[p19l128t3064r501b3125],
13	—	CD	NUMBER	—	num	16	SENT_345	[p19l128t3064r501b3125],
14	negative	JJ	O	negative	amod	16	SENT_345	[p19l128t3064r501b3125],
15	breast	NN	O	breast	nn	16	SENT_345	[p19l517t3064r672b3112],
16	cancer	NN	O	cancer	ccomp	10	SENT_345	[p19l685t3078r861b3112],
17	.	.	O	.	_	0	SENT_345	[p19l685t3078r861b3112],

1	N.	NNP	O	N.	nn	2	SENT_346	[p19l874t3066r921b3112],
2	Engl	NNP	O	Engl	_	0	SENT_346	[p19l935t3064r1050b3125],
3	.	.	O	.	_	0	SENT_346	[p19l935t3064r1050b3125],

1	J.	NNP	O	J.	nn	2	SENT_347	[p19l1060t3066r1094b3112],
2	Med	NNP	O	Med	_	0	SENT_347	[p19l1107t3064r1223b3112],
3	.	.	O	.	_	0	SENT_347	[p19l1107t3064r1223b3112],

1	351	CD	NUMBER	351	_	0	SENT_348	[p19l1239t3067r1351b3119],
2	,	,	O	,	_	0	SENT_348	[p19l1239t3067r1351b3119],
3	281	CD	NUMBER	281	number	4	SENT_348	[p19l1365t3067r1447b3112],
4	7-2826	CD	NUMBER	7-2826	appos	1	SENT_348	[p19l1461t3067r1646b3112],
5	(	CD	NUMBER	(	num	7	SENT_348	[p19l1661t3065r1830b3119],
6	2004	CD	DATE	2004	num	7	SENT_348	[p19l1661t3065r1830b3119],
7	)	NN	O	)	dep	4	SENT_348	[p19l1661t3065r1830b3119],
8	.	.	O	.	_	0	SENT_348	[p19l1661t3065r1830b3119],

1	Glas	NNP	O	Glas	_	0	SENT_349	[p19l125t3139r241b3194],
2	,	,	O	,	_	0	SENT_349	[p19l125t3139r241b3194],
3	A.M.	NNP	O	A.M.	nn	4	SENT_349	[p19l255t3141r365b3187],
4	etal	NN	O	etal	appos	1	SENT_349	[p19l378t3139r487b3187],
5	.	.	O	.	_	0	SENT_349	[p19l378t3139r487b3187],

1	Converting	VBG	O	convert	_	0	SENT_350	[p19l503t3140r785b3200],
2	a	DT	O	a	det	6	SENT_350	[p19l801t3153r825b3187],
3	breast	NN	O	breast	nn	6	SENT_350	[p19l843t3139r998b3187],
4	cancer	NN	O	cancer	nn	6	SENT_350	[p19l1011t3153r1179b3187],
5	microarray	NN	O	microarray	nn	6	SENT_350	[p19l1193t3141r1464b3201],
6	signature	NN	O	signature	dobj	1	SENT_350	[p19l1477t3141r1715b3200],
7	into	IN	O	into	_	0	SENT_350	[p19l1730t3141r1827b3187],
8	a	DT	O	a	det	11	SENT_350	[p19l1841t3153r1865b3187],
9	highthroughput	JJ	O	highthroughput	amod	11	SENT_350	[p19l1883t3139r2014b3200, p19l125t3214r424b3275],
10	diagnostic	JJ	O	diagnostic	amod	11	SENT_350	[p19l437t3214r701b3275],
11	test	NN	O	test	prep_into	1	SENT_350	[p19l714t3221r819b3262],
12	.	.	O	.	_	0	SENT_350	[p19l714t3221r819b3262],

1	BMC	NNP	O	BMC	nn	2	SENT_351	[p19l833t3216r948b3262],
2	Genomics	NNPS	O	Genomics	_	0	SENT_351	[p19l957t3216r1199b3262],
3	7	CD	NUMBER	7	dep	2	SENT_351	[p19l1213t3218r1255b3269],
4	,	,	O	,	_	0	SENT_351	[p19l1213t3218r1255b3269],
5	278	CD	NUMBER	278	number	6	SENT_351	[p19l1269t3217r1360b3262],
6	(	CD	NUMBER	(	appos	3	SENT_351	[p19l1376t3215r1545b3269],
7	2006	CD	DATE	2006	num	8	SENT_351	[p19l1376t3215r1545b3269],
8	)	NN	O	)	dep	6	SENT_351	[p19l1376t3215r1545b3269],
9	.	.	O	.	_	0	SENT_351	[p19l1376t3215r1545b3269],

1	Bartlett	NNP	PERSON	Bartlett	nn	3	SENT_352	[p19l127t3289r324b3344],
2	,	,	O	,	_	0	SENT_352	[p19l127t3289r324b3344],
3	J.M.	NNP	O	J.M.	_	0	SENT_352	[p19l336t3291r432b3337],
4	et	FW	O	et	nn	5	SENT_352	[p19l446t3296r493b3337],
5	al.	FW	O	al.	dep	3	SENT_352	[p19l502t3289r554b3337],
6	.	.	O	.	_	0	SENT_352	[p19l502t3289r554b3337],

1	Mammostrat	NNP	PERSON	Mammostrat	_	0	SENT_353	[p19l571t3291r899b3337],
2	as	IN	O	as	_	0	SENT_353	[p19l912t3303r962b3337],
3	an	DT	O	a	det	6	SENT_353	[p19l976t3303r1035b3337],
4	Immunohistochemical	JJ	O	immunohistochemical	amod	6	SENT_353	[p19l1053t3289r1623b3337],
5	Multigene	JJ	O	multigene	amod	6	SENT_353	[p19l1641t3289r1900b3350],
6	Assay	NN	O	assay	prep_as	1	SENT_353	[p19l1913t3291r2056b3350],
7	for	IN	O	for	_	0	SENT_353	[p19l125t3363r195b3412],
8	Prediction	NN	O	prediction	prep_for	6	SENT_353	[p19l210t3364r464b3412],
9	of	IN	O	of	_	0	SENT_353	[p19l480t3363r533b3412],
10	Early	JJ	O	early	amod	12	SENT_353	[p19l545t3364r664b3425],
11	Relapse	NN	O	relapse	nn	12	SENT_353	[p19l679t3364r872b3424],
12	Risk	NN	O	risk	prep_of	1	SENT_353	[p19l888t3364r986b3412],
13	in	IN	O	in	_	0	SENT_353	[p19l1000t3366r1040b3411],
14	theTamoxifen	NNP	O	theTamoxifen	nn	22	SENT_353	[p19l1055t3363r1411b3412],
15	Versus	NNP	O	Versus	nn	22	SENT_353	[p19l1422t3366r1587b3412],
16	Exemestane	NNP	O	Exemestane	nn	22	SENT_353	[p19l1603t3366r1909b3412],
17	Adjuvant	JJ	O	adjuvant	amod	22	SENT_353	[p19l126t3439r358b3500],
18	Mu	NN	O	mu	nn	22	SENT_353	[p19l372t3439r776b3487],
19	|	NN	O	|	nn	22	SENT_353	[p19l372t3439r776b3487],
20	ticenterTrial	JJ	O	ticentertrial	amod	22	SENT_353	[p19l372t3439r776b3487],
21	Pathology	NN	O	pathology	nn	22	SENT_353	[p19l794t3439r1051b3500],
22	Study	NN	O	study	prep_in	12	SENT_353	[p19l1064t3439r1218b3500],
23	.	.	O	.	_	0	SENT_353	[p19l1064t3439r1218b3500],

1	J.	NNP	PERSON	J.	nn	2	SENT_354	[p19l1228t3441r1261b3487],
2	Clin	NNP	PERSON	Clin	_	0	SENT_354	[p19l1277t3439r1379b3487],
3	.	.	O	.	_	0	SENT_354	[p19l1277t3439r1379b3487],

1	Oncol	NN	O	oncol	_	0	SENT_355	[p19l1394t3439r1545b3487],
2	.	.	O	.	_	0	SENT_355	[p19l1394t3439r1545b3487],

1	(	RB	O	(	dep	3	SENT_356	[p19l1563t3440r1732b3494],
2	2012	CD	DATE	2012	num	3	SENT_356	[p19l1563t3440r1732b3494],
3	)	NN	O	)	_	0	SENT_356	[p19l1563t3440r1732b3494],
4	;	:	O	;	_	0	SENT_356	[p19l1563t3440r1732b3494],
5	e	SYM	O	e	dep	3	SENT_356	[p19l1746t3439r1898b3499],
6	—	CD	NUMBER	—	num	7	SENT_356	[p19l1746t3439r1898b3499],
7	pub	NN	O	pub	npadvmod	5	SENT_356	[p19l1746t3439r1898b3499],
8	ahead	RB	O	ahead	_	0	SENT_356	[p19l1912t3439r2066b3487],
9	of	IN	O	of	_	0	SENT_356	[p19l126t3513r179b3562],
10	print	NN	O	print	prep_ahead_of	5	SENT_356	[p19l190t3516r309b3574],
11	8	CD	DATE	8	num	10	SENT_356	[p19l323t3517r351b3562],
12	October	NNP	DATE	October	tmod	10	SENT_356	[p19l365t3514r574b3562],
13	2012	CD	DATE	2012	num	12	SENT_356	[p19l587t3517r722b3562],
14	.	.	O	.	_	0	SENT_356	[p19l587t3517r722b3562],

1	Cuzick	NNP	O	Cuzick	_	0	SENT_357	[p19l124t3589r301b3644],
2	,	,	O	,	_	0	SENT_357	[p19l124t3589r301b3644],
3	J.	NNP	O	J.	nn	4	SENT_357	[p19l313t3591r346b3637],
4	etal	NNP	O	etal	appos	1	SENT_357	[p19l359t3589r468b3637],
5	.	.	O	.	_	0	SENT_357	[p19l359t3589r468b3637],

1	Prognostic	JJ	O	prognostic	amod	2	SENT_358	[p19l486t3591r755b3650],
2	value	NN	O	value	dep	24	SENT_358	[p19l767t3589r903b3637],
3	of	IN	O	of	_	0	SENT_358	[p19l917t3588r970b3637],
4	a	DT	O	a	det	7	SENT_358	[p19l979t3603r1004b3637],
5	combined	JJ	O	combined	amod	7	SENT_358	[p19l1020t3589r1276b3637],
6	estrogen	NN	O	estrogen	nn	7	SENT_358	[p19l1292t3596r1515b3650],
7	receptor	NN	O	receptor	prep_of	2	SENT_358	[p19l1533t3596r1754b3649],
8	,	,	O	,	_	0	SENT_358	[p19l1533t3596r1754b3649],
9	progesterone	NN	O	progesterone	nn	10	SENT_358	[p19l128t3670r470b3724],
10	receptor	NN	O	receptor	prep_of	2	SENT_358	[p19l486t3670r707b3723],
11	,	,	O	,	_	0	SENT_358	[p19l486t3670r707b3723],
12	Ki	NN	O	kus	prep_of	2	SENT_358	[p19l724t3665r861b3719],
13	—	CD	NUMBER	—	number	14	SENT_358	[p19l724t3665r861b3719],
14	67	CD	NUMBER	67	dep	12	SENT_358	[p19l724t3665r861b3719],
15	,	,	O	,	_	0	SENT_358	[p19l724t3665r861b3719],
16	and	CC	O	and	_	0	SENT_358	[p19l875t3663r968b3711],
17	human	JJ	O	human	amod	20	SENT_358	[p19l986t3663r1163b3711],
18	epidermal	JJ	O	epidermal	amod	20	SENT_358	[p19l1178t3663r1435b3723],
19	growth	NN	O	growth	nn	20	SENT_358	[p19l1451t3663r1633b3724],
20	factor	NN	O	factor	conj_and	7	SENT_358	[p19l1648t3662r1797b3711],
21	receptor	NN	O	receptor	dep	24	SENT_358	[p19l128t3745r341b3799],
22	2	CD	NUMBER	2	num	21	SENT_358	[p19l354t3741r381b3786],
23	immunohistochemical	JJ	O	immunohistochemical	amod	24	SENT_358	[p19l398t3738r967b3786],
24	score	NN	NUMBER	score	_	0	SENT_358	[p19l984t3752r1116b3786],
25	and	CC	O	and	_	0	SENT_358	[p19l1130t3738r1223b3786],
26	comparison	NN	O	comparison	conj_and	24	SENT_358	[p19l1239t3740r1538b3798],
27	with	IN	O	with	_	0	SENT_358	[p19l1553t3738r1663b3786],
28	the	DT	O	the	det	29	SENT_358	[p19l1678t3738r1761b3786],
29	Genomic	JJ	MISC	genomic	prep_with	24	SENT_358	[p19l1775t3740r2005b3786],

1	Health	NNP	O	Health	nn	3	SENT_359	[p20l128t14r290b62],
2	recurrence	NN	O	recurrence	nn	3	SENT_359	[p20l308t28r578b62],
3	score	NN	NUMBER	score	_	0	SENT_359	[p20l592t28r724b62],
4	in	IN	O	in	_	0	SENT_359	[p20l740t16r781b62],
5	early	JJ	O	early	amod	7	SENT_359	[p20l797t14r919b76],
6	breast	NN	O	breast	nn	7	SENT_359	[p20l934t14r1089b62],
7	cancer	NN	O	cancer	prep_in	3	SENT_359	[p20l1102t28r1278b62],
8	.	.	O	.	_	0	SENT_359	[p20l1102t28r1278b62],

1	J.	NNP	PERSON	J.	nn	2	SENT_360	[p20l1287t16r1321b62],
2	Clin	NNP	PERSON	Clin	_	0	SENT_360	[p20l1336t14r1438b62],
3	.	.	O	.	_	0	SENT_360	[p20l1336t14r1438b62],

1	Oncol	NN	O	oncol	_	0	SENT_361	[p20l1453t14r1605b62],
2	.	.	O	.	_	0	SENT_361	[p20l1453t14r1605b62],

1	29	CD	NUMBER	29	_	0	SENT_362	[p20l1621t17r1698b70],
2	,	,	O	,	_	0	SENT_362	[p20l1621t17r1698b70],
3	4273-4278	CD	DURATION	4273-4278	num	4	SENT_362	[p20l1711t17r1993b62],
4	(	NN	O	(	appos	1	SENT_362	[p20l128t90r225b145],
5	201	CD	NUMBER	201	number	6	SENT_362	[p20l128t90r225b145],
6	1	CD	NUMBER	1	num	7	SENT_362	[p20l243t90r296b144],
7	)	NN	O	)	dep	4	SENT_362	[p20l243t90r296b144],
8	.	.	O	.	_	0	SENT_362	[p20l243t90r296b144],

1	29	CD	NUMBER	29	_	0	SENT_363	[p20l7t167r79b212],
2	.	.	O	.	_	0	SENT_363	[p20l7t167r79b212],

1	Kantarjian	NNP	MISC	Kantarjian	_	0	SENT_364	[p20l127t166r395b225],
2	,	,	O	,	_	0	SENT_364	[p20l127t166r395b225],
3	H.M.	NNP	PERSON	H.M.	nn	4	SENT_364	[p20l411t166r521b212],
4	etal	NNP	O	etal	appos	1	SENT_364	[p20l535t164r643b212],
5	.	.	O	.	_	0	SENT_364	[p20l535t164r643b212],

1	Dasatinib	NN	O	dasatinib	_	0	SENT_365	[p20l661t164r898b212],
2	or	CC	O	or	_	0	SENT_365	[p20l913t178r964b212],
3	imatinib	NN	O	imatinib	conj_or	1	SENT_365	[p20l978t164r1187b212],
4	in	IN	O	in	_	0	SENT_365	[p20l1203t166r1244b212],
5	newly	RB	O	newly	advmod	6	SENT_365	[p20l1262t164r1412b226],
6	diagnosed	VBN	O	diagnose	amod	8	SENT_365	[p20l1424t164r1690b225],
7	chronic	JJ	O	chronic	amod	8	SENT_365	[p20l1706t164r2067b224],
8	—	NN	O	—	prep_in	1	SENT_365	[p20l1706t164r2067b224],
9	phase	NN	O	phase	dep	1	SENT_365	[p20l1706t164r2067b224],
10	chronic	JJ	O	chronic	amod	12	SENT_365	[p20l126t239r314b287],
11	myeloid	JJ	O	myeloid	amod	12	SENT_365	[p20l330t239r530b301],
12	leukemia	NN	O	leukemia	dep	9	SENT_365	[p20l548t239r790b287],
13	:	:	O	:	_	0	SENT_365	[p20l548t239r790b287],
14	2	CD	NUMBER	2	num	15	SENT_365	[p20l804t238r1216b301],
15	—	CD	NUMBER	—	dep	1	SENT_365	[p20l804t238r1216b301],
16	yearfo	JJ	O	yearfo	amod	17	SENT_365	[p20l804t238r1216b301],
17	|	NN	O	|	dep	15	SENT_365	[p20l804t238r1216b301],
18	low	JJ	O	low	amod	17	SENT_365	[p20l804t238r1216b301],
19	—	CD	NUMBER	—	tmod	18	SENT_365	[p20l804t238r1216b301],
20	up	IN	O	up	advmod	17	SENT_365	[p20l804t238r1216b301],
21	from	IN	O	from	_	0	SENT_365	[p20l1229t238r1348b287],
22	a	DT	O	a	det	26	SENT_365	[p20l1363t253r1388b287],
23	randomized	JJ	O	randomized	amod	26	SENT_365	[p20l1406t239r1708b287],
24	phase	NN	O	phase	nn	26	SENT_365	[p20l1726t239r1875b300],
25	3	CD	NUMBER	3	num	26	SENT_365	[p20l1889t242r1915b287],
26	trial	NN	O	trial	prep_from	20	SENT_365	[p20l1930t239r2024b287],
27	(	CD	NUMBER	(	num	28	SENT_365	[p20l128t314r701b370],
28	DAS	NNP	O	DAS	dep	17	SENT_365	[p20l128t314r701b370],
29	|	CD	NUMBER	|	num	28	SENT_365	[p20l128t314r701b370],
30	SlON	NNP	O	SlON	dep	28	SENT_365	[p20l128t314r701b370],
31	)	CD	NUMBER	)	num	30	SENT_365	[p20l128t314r701b370],
32	.	.	O	.	_	0	SENT_365	[p20l128t314r701b370],

1	BIood119	NN	O	biood119	_	0	SENT_366	[p20l128t314r701b370],
2	,	,	O	,	_	0	SENT_366	[p20l128t314r701b370],
3	1	CD	NUMBER	1	number	4	SENT_366	[p20l719t318r733b362],
4	123-1	CD	NUMBER	123-1	appos	1	SENT_366	[p20l750t317r891b362],
5	129	CD	NUMBER	129	num	6	SENT_366	[p20l908t317r995b362],
6	(	CD	NUMBER	(	dep	4	SENT_366	[p20l1011t315r1180b369],
7	2012	CD	DATE	2012	num	8	SENT_366	[p20l1011t315r1180b369],
8	)	NN	O	)	dep	4	SENT_366	[p20l1011t315r1180b369],
9	.	.	O	.	_	0	SENT_366	[p20l1011t315r1180b369],

1	30	CD	NUMBER	30	_	0	SENT_367	[p20l7t392r82b437],
2	.	.	O	.	_	0	SENT_367	[p20l7t392r82b437],

1	Kantarjian	NNP	LOCATION	Kantarjian	nn	3	SENT_368	[p20l127t391r407b450],
2	,	,	O	,	_	0	SENT_368	[p20l127t391r407b450],
3	H.M.	NNP	O	H.M.	_	0	SENT_368	[p20l426t391r539b437],
4	et	FW	O	et	nn	5	SENT_368	[p20l556t396r604b437],
5	al.	FW	O	al.	dep	3	SENT_368	[p20l615t389r670b437],
6	.	.	O	.	_	0	SENT_368	[p20l615t389r670b437],

1	Nilotinib	NN	MISC	nilotinib	_	0	SENT_369	[p20l691t389r917b437],
2	versus	CC	O	versus	prep	1	SENT_369	[p20l933t403r1099b437],
3	imatinib	NN	O	imatinib	dep	2	SENT_369	[p20l1118t389r1335b437],
4	for	IN	O	for	_	0	SENT_369	[p20l1350t388r1423b437],
5	the	DT	O	the	det	6	SENT_369	[p20l1436t389r1522b437],
6	treatment	NN	O	treatment	prep_for	1	SENT_369	[p20l1537t396r1803b437],
7	of	IN	O	of	_	0	SENT_369	[p20l1819t388r1873b437],
8	patients	NNS	O	patient	prep_of	1	SENT_369	[p20l128t466r340b524],
9	with	IN	O	with	_	0	SENT_369	[p20l355t464r469b512],
10	newly	RB	O	newly	advmod	11	SENT_369	[p20l490t464r645b526],
11	diagnosed	VBN	O	diagnose	amod	13	SENT_369	[p20l660t464r935b525],
12	chronic	JJ	O	chronic	amod	13	SENT_369	[p20l954t464r1149b512],
13	phase	NN	O	phase	prep_with	1	SENT_369	[p20l1167t464r1334b524],
14	,	,	O	,	_	0	SENT_369	[p20l1167t464r1334b524],
15	Philadelphia	NNP	LOCATION	Philadelphia	dep	27	SENT_369	[p20l1353t464r1678b525],
16	chromosomepositive	JJ	O	chromosomepositive	amod	20	SENT_369	[p20l1696t464r2068b512, p20l128t541r346b599],
17	,	,	O	,	_	0	SENT_369	[p20l1696t464r2068b512, p20l128t541r346b599],
18	chronic	JJ	O	chronic	amod	20	SENT_369	[p20l363t539r559b587],
19	myeloid	JJ	O	myeloid	amod	20	SENT_369	[p20l577t539r784b601],
20	leukaemia	NN	O	leukaemia	dep	27	SENT_369	[p20l805t539r1089b587],
21	:	:	O	:	_	0	SENT_369	[p20l805t539r1089b587],
22	24-month	JJ	DURATION	24-month	amod	27	SENT_369	[p20l1106t539r1364b587],
23	minimum	JJ	O	minimum	amod	27	SENT_369	[p20l1385t541r1637b587],
24	fo	JJ	O	fo	amod	27	SENT_369	[p20l1654t538r1908b599],
25	|	NN	O	|	nn	27	SENT_369	[p20l1654t538r1908b599],
26	|	NN	O	|	nn	27	SENT_369	[p20l1654t538r1908b599],
27	ow	NN	O	ow	appos	13	SENT_369	[p20l1654t538r1908b599],
28	—	CD	NUMBER	—	dep	27	SENT_369	[p20l1654t538r1908b599],
29	up	RP	O	up	prep	28	SENT_369	[p20l1654t538r1908b599],
30	ofthe	NN	O	ofthe	nn	31	SENT_369	[p20l126t613r276b662],
31	phase	NN	O	phase	dep	29	SENT_369	[p20l295t614r448b674],
32	3	CD	NUMBER	3	num	35	SENT_369	[p20l465t617r491b662],
33	randomised	JJ	O	randomised	amod	35	SENT_369	[p20l511t614r823b662],
34	ENESTnd	NN	O	enestnd	nn	35	SENT_369	[p20l844t614r1073b662],
35	trial	NN	O	trial	dep	27	SENT_369	[p20l1090t614r1205b662],
36	.	.	O	.	_	0	SENT_369	[p20l1090t614r1205b662],

1	Lancet	NNP	O	Lancet	nn	2	SENT_370	[p20l1221t616r1393b662],
2	Oncol	NNP	O	Oncol	_	0	SENT_370	[p20l1405t614r1562b662],
3	.	.	O	.	_	0	SENT_370	[p20l1405t614r1562b662],

1	12	CD	NUMBER	12	_	0	SENT_371	[p20l1584t617r1661b670],
2	,	,	O	,	_	0	SENT_371	[p20l1584t617r1661b670],
3	841	CD	NUMBER	841	number	4	SENT_371	[p20l1677t617r1762b662],
4	-851	CD	NUMBER	-851	num	5	SENT_371	[p20l1776t617r1893b662],
5	(	NN	O	(	appos	1	SENT_371	[p20l128t690r229b745],
6	201	CD	NUMBER	201	number	7	SENT_371	[p20l128t690r229b745],
7	1	CD	NUMBER	1	num	8	SENT_371	[p20l247t690r304b744],
8	)	NN	O	)	dep	5	SENT_371	[p20l247t690r304b744],
9	.	.	O	.	_	0	SENT_371	[p20l247t690r304b744],

1	31	CD	NUMBER	31	_	0	SENT_372	[p20l7t767r79b812],
2	.	.	O	.	_	0	SENT_372	[p20l7t767r79b812],

1	Schrappe	NNP	PERSON	Schrappe	nn	3	SENT_373	[p20l125t764r376b825],
2	,	,	O	,	_	0	SENT_373	[p20l125t764r376b825],
3	M.	NNP	O	M.	_	0	SENT_373	[p20l392t766r449b812],
4	et	FW	O	et	nn	5	SENT_373	[p20l462t771r510b812],
5	al.	FW	O	al.	dep	3	SENT_373	[p20l519t764r571b812],
6	.	.	O	.	_	0	SENT_373	[p20l519t764r571b812],

1	Late	RB	O	late	advmod	3	SENT_374	[p20l590t766r693b812],
2	MRD	NN	O	mrd	nn	3	SENT_374	[p20l709t766r827b812],
3	response	NN	O	response	_	0	SENT_374	[p20l844t778r1071b825],
4	determines	VBZ	O	determine	rcmod	3	SENT_374	[p20l1085t764r1374b812],
5	relapse	NN	O	relapse	nn	6	SENT_374	[p20l1390t764r1569b825],
6	risk	NN	O	risk	dobj	4	SENT_374	[p20l1585t764r1670b812],
7	overall	JJ	O	overall	advmod	4	SENT_374	[p20l1682t764r1847b812],
8	and	CC	O	and	_	0	SENT_374	[p20l1864t764r1957b812],
9	in	IN	O	in	advmod	4	SENT_374	[p20l1975t766r2016b812],
10	subsets	NNS	O	subset	pobj	9	SENT_374	[p20l126t839r316b887],
11	of	IN	O	of	_	0	SENT_374	[p20l330t838r383b887],
12	childhood	NN	O	childhood	nn	13	SENT_374	[p20l392t839r649b887],
13	T	NN	O	t	prep_of	10	SENT_374	[p20l660t839r791b887],
14	—	CD	NUMBER	—	num	16	SENT_374	[p20l660t839r791b887],
15	ce	NN	O	ce	nn	16	SENT_374	[p20l660t839r791b887],
16	|	NN	O	|	dep	3	SENT_374	[p20l660t839r791b887],
17	|	CD	NUMBER	|	num	18	SENT_374	[p20l660t839r791b887],
18	ALL	NN	O	all	dep	16	SENT_374	[p20l806t841r912b887],
19	:	:	O	:	_	0	SENT_374	[p20l806t841r912b887],
20	results	NNS	O	result	dep	3	SENT_374	[p20l928t839r1090b887],
21	of	IN	O	of	_	0	SENT_374	[p20l1104t838r1157b887],
22	the	DT	O	the	det	25	SENT_374	[p20l1165t839r1248b887],
23	A	NN	O	a	nn	25	SENT_374	[p20l1262t841r1662b887],
24	|	NN	O	|	nn	25	SENT_374	[p20l1262t841r1662b887],
25	EOP	NN	ORGANIZATION	eop	prep_of	20	SENT_374	[p20l1262t841r1662b887],
26	.	.	O	.	_	0	SENT_374	[p20l1262t841r1662b887],

1	—	NN	O	—	_	0	SENT_375	[p20l1262t841r1662b887],
2	.	.	O	.	_	0	SENT_375	[p20l1262t841r1662b887],

1	BFM	NNP	O	BFM	_	0	SENT_376	[p20l1262t841r1662b887],
2	.	.	O	.	_	0	SENT_376	[p20l1262t841r1662b887],

1	—	NN	O	—	_	0	SENT_377	[p20l1262t841r1662b887],
2	.	.	O	.	_	0	SENT_377	[p20l1262t841r1662b887],

1	ALL	NN	O	all	_	0	SENT_378	[p20l1262t841r1662b887],
2	2000	CD	DATE	2000	num	3	SENT_378	[p20l1676t842r1799b887],
3	study	NN	O	study	dep	1	SENT_378	[p20l1813t839r1962b901],
4	.	.	O	.	_	0	SENT_378	[p20l1813t839r1962b901],

1	Blood	NN	O	blood	_	0	SENT_379	[p20l126t914r269b962],
2	1	CD	NUMBER	1	number	3	SENT_379	[p20l283t918r302b962],
3	18	CD	NUMBER	18	dep	1	SENT_379	[p20l317t917r391b970],
4	,	,	O	,	_	0	SENT_379	[p20l317t917r391b970],
5	2077-2084	CD	DATE	2077-2084	num	6	SENT_379	[p20l406t917r687b962],
6	(	NN	O	(	appos	1	SENT_379	[p20l702t915r799b969],
7	201	CD	NUMBER	201	number	8	SENT_379	[p20l702t915r799b969],
8	1	CD	NUMBER	1	num	9	SENT_379	[p20l817t915r870b969],
9	)	NN	O	)	dep	6	SENT_379	[p20l817t915r870b969],
10	.	.	O	.	_	0	SENT_379	[p20l817t915r870b969],

1	32	CD	NUMBER	32	_	0	SENT_380	[p20l7t992r79b1037],
2	.	.	O	.	_	0	SENT_380	[p20l7t992r79b1037],

1	Conter	NNP	O	Conter	nn	3	SENT_381	[p20l124t991r304b1045],
2	,	,	O	,	_	0	SENT_381	[p20l124t991r304b1045],
3	V.	NNP	O	V.	_	0	SENT_381	[p20l314t991r356b1037],
4	et	FW	O	et	nn	5	SENT_381	[p20l369t996r417b1037],
5	al.	FW	O	al.	dep	3	SENT_381	[p20l425t989r478b1037],
6	.	.	O	.	_	0	SENT_381	[p20l425t989r478b1037],

1	Molecular	JJ	O	molecular	amod	2	SENT_382	[p20l496t989r747b1037],
2	response	NN	O	response	_	0	SENT_382	[p20l762t1003r990b1049],
3	to	TO	O	to	_	0	SENT_382	[p20l1002t996r1054b1037],
4	treatment	NN	O	treatment	nn	5	SENT_382	[p20l1066t996r1322b1037],
5	redeﬁnes	NNS	O	redeﬁnes	prep_to	2	SENT_382	[p20l1338t988r1570b1037],
6	all	DT	O	all	det	8	SENT_382	[p20l1584t989r1636b1037],
7	prognostic	JJ	O	prognostic	amod	8	SENT_382	[p20l1655t991r1927b1050],
8	factors	NNS	O	factor	dep	19	SENT_382	[p20l125t1063r296b1112],
9	in	IN	O	in	_	0	SENT_382	[p20l312t1066r354b1112],
10	children	NNS	O	child	prep_in	8	SENT_382	[p20l370t1064r574b1112],
11	and	CC	O	and	_	0	SENT_382	[p20l590t1064r683b1112],
12	adolescents	NNS	O	adolescent	conj_and	10	SENT_382	[p20l699t1064r1000b1112],
13	with	IN	O	with	_	0	SENT_382	[p20l1014t1064r1123b1112],
14	B	NN	O	b	prep_with	10	SENT_382	[p20l1142t1064r1274b1112],
15	—	CD	NUMBER	—	num	16	SENT_382	[p20l1142t1064r1274b1112],
16	ce	NN	O	ce	dep	19	SENT_382	[p20l1142t1064r1274b1112],
17	|	CD	NUMBER	|	num	19	SENT_382	[p20l1142t1064r1274b1112],
18	|	NN	O	|	nn	19	SENT_382	[p20l1142t1064r1274b1112],
19	precursor	NN	O	precursor	dep	2	SENT_382	[p20l1292t1078r1533b1124],
20	acute	JJ	O	acute	amod	22	SENT_382	[p20l1546t1071r1685b1112],
21	lymphoblastic	JJ	O	lymphoblastic	amod	22	SENT_382	[p20l1701t1064r2060b1126],
22	leukemia	NN	O	leukemia	dep	19	SENT_382	[p20l128t1139r370b1187],
23	:	:	O	:	_	0	SENT_382	[p20l128t1139r370b1187],
24	results	NNS	O	result	dep	2	SENT_382	[p20l386t1139r548b1187],
25	in	IN	O	in	_	0	SENT_382	[p20l563t1141r605b1187],
26	3184	CD	DATE	3184	num	27	SENT_382	[p20l621t1142r745b1187],
27	patients	NNS	O	patient	prep_in	24	SENT_382	[p20l760t1141r963b1199],
28	of	IN	O	of	_	0	SENT_382	[p20l977t1138r1030b1187],
29	the	DT	O	the	det	32	SENT_382	[p20l1038t1139r1121b1187],
30	A	NN	O	a	nn	32	SENT_382	[p20l1135t1141r1418b1187],
31	|	NN	O	|	nn	32	SENT_382	[p20l1135t1141r1418b1187],
32	EOP	NN	ORGANIZATION	eop	prep_of	27	SENT_382	[p20l1135t1141r1418b1187],
33	.	.	O	.	_	0	SENT_382	[p20l1135t1141r1418b1187],

1	—	NN	O	—	_	0	SENT_383	[p20l1135t1141r1418b1187],
2	.	.	O	.	_	0	SENT_383	[p20l1135t1141r1418b1187],

1	BFM	NNP	O	BFM	nn	2	SENT_384	[p20l1135t1141r1418b1187],
2	ALL	NN	O	all	_	0	SENT_384	[p20l1433t1141r1527b1187],
3	2000	CD	DATE	2000	num	4	SENT_384	[p20l1541t1142r1663b1187],
4	study	NN	O	study	dep	2	SENT_384	[p20l1677t1139r1826b1201],
5	.	.	O	.	_	0	SENT_384	[p20l1677t1139r1826b1201],

1	Blood	NN	O	blood	_	0	SENT_385	[p20l1840t1139r1983b1187],
2	115	CD	NUMBER	115	num	1	SENT_385	[p20l129t1218r238b1270],
3	,	,	O	,	_	0	SENT_385	[p20l129t1218r238b1270],
4	3206-3214	CD	DURATION	3206-3214	num	5	SENT_385	[p20l252t1217r533b1262],
5	(	NN	O	(	appos	1	SENT_385	[p20l548t1215r645b1269],
6	201	CD	NUMBER	201	num	8	SENT_385	[p20l548t1215r645b1269],
7	o	NN	O	o	nn	8	SENT_385	[p20l659t1215r717b1269],
8	)	NN	O	)	dep	5	SENT_385	[p20l659t1215r717b1269],
9	.	.	O	.	_	0	SENT_385	[p20l659t1215r717b1269],

1	33	CD	NUMBER	33	_	0	SENT_386	[p20l7t1292r79b1337],
2	.	.	O	.	_	0	SENT_386	[p20l7t1292r79b1337],

1	Mattocks	NNP	PERSON	Mattocks	nn	4	SENT_387	[p20l126t1289r368b1345],
2	,	,	O	,	_	0	SENT_387	[p20l126t1289r368b1345],
3	C.J.	NNP	O	C.J.	appos	4	SENT_387	[p20l381t1291r461b1337],
4	etal.	NNP	O	etal.	_	0	SENT_387	[p20l474t1289r598b1344],
5	;	:	O	;	_	0	SENT_387	[p20l474t1289r598b1344],
6	EuroGentest	NNP	ORGANIZATION	EuroGentest	nn	8	SENT_387	[p20l614t1291r927b1337],
7	Validation	NNP	ORGANIZATION	Validation	nn	8	SENT_387	[p20l936t1289r1190b1337],
8	Group	NNP	ORGANIZATION	Group	dep	4	SENT_387	[p20l1206t1291r1376b1349],
9	.	.	O	.	_	0	SENT_387	[p20l1206t1291r1376b1349],

1	A	DT	O	a	det	3	SENT_388	[p20l1390t1291r1425b1337],
2	standardized	JJ	O	standardized	amod	3	SENT_388	[p20l1439t1289r1766b1337],
3	framework	NN	O	framework	_	0	SENT_388	[p20l1781t1288r2059b1337],
4	for	IN	O	for	_	0	SENT_388	[p20l124t1364r195b1412],
5	the	DT	O	the	det	6	SENT_388	[p20l206t1364r289b1412],
6	validation	NN	O	validation	prep_for	3	SENT_388	[p20l302t1364r552b1412],
7	and	CC	O	and	_	0	SENT_388	[p20l568t1364r662b1412],
8	veriﬁcation	NN	O	veriﬁcation	prep_for	3	SENT_388	[p20l676t1364r959b1412],
9	of	IN	O	of	_	0	SENT_388	[p20l975t1364r1027b1412],
10	clinical	JJ	O	clinical	amod	13	SENT_388	[p20l1037t1364r1207b1412],
11	molecular	JJ	O	molecular	amod	13	SENT_388	[p20l1226t1364r1479b1412],
12	genetic	JJ	O	genetic	amod	13	SENT_388	[p20l1491t1367r1681b1425],
13	tests	NNS	O	test	prep_of	6	SENT_388	[p20l1693t1372r1822b1412],
14	.	.	O	.	_	0	SENT_388	[p20l1693t1372r1822b1412],

1	Eur	NNP	O	Eur	_	0	SENT_389	[p20l1836t1367r1922b1412],
2	.	.	O	.	_	0	SENT_389	[p20l1836t1367r1922b1412],

1	J.	NNP	O	J.	nn	2	SENT_390	[p20l1933t1367r1965b1412],
2	Hum	NNP	O	Hum	_	0	SENT_390	[p20l126t1442r254b1487],
3	.	.	O	.	_	0	SENT_390	[p20l126t1442r254b1487],

1	Genet	NNP	PERSON	Genet	_	0	SENT_391	[p20l269t1441r422b1487],
2	.	.	O	.	_	0	SENT_391	[p20l269t1441r422b1487],

1	18	CD	NUMBER	18	_	0	SENT_392	[p20l442t1442r516b1495],
2	,	,	O	,	_	0	SENT_392	[p20l442t1442r516b1495],
3	1276-1288	CD	DATE	1276-1288	number	4	SENT_392	[p20l534t1442r811b1487],
4	(	CD	NUMBER	(	appos	1	SENT_392	[p20l827t1440r995b1495],
5	2010	CD	DATE	2010	num	6	SENT_392	[p20l827t1440r995b1495],
6	)	NN	O	)	dep	4	SENT_392	[p20l827t1440r995b1495],
7	.	.	O	.	_	0	SENT_392	[p20l827t1440r995b1495],

1	34	CD	NUMBER	34	_	0	SENT_393	[p20l7t1517r79b1562],
2	.	.	O	.	_	0	SENT_393	[p20l7t1517r79b1562],

1	Kimura	NNP	PERSON	Kimura	_	0	SENT_394	[p20l127t1517r364b1570],
2	,	,	O	,	_	0	SENT_394	[p20l127t1517r364b1570],
3	T.	NNP	O	T.	nn	4	SENT_394	[p20l127t1517r364b1570],
4	etal	NNP	O	etal	appos	1	SENT_394	[p20l378t1514r486b1562],
5	.	.	O	.	_	0	SENT_394	[p20l378t1514r486b1562],

1	Clinical	JJ	O	clinical	amod	2	SENT_395	[p20l503t1514r681b1562],
2	beneﬁt	NN	O	beneﬁt	nsubj	14	SENT_395	[p20l700t1514r879b1562],
3	of	IN	O	of	_	0	SENT_395	[p20l892t1514r944b1562],
4	high	JJ	O	high	amod	6	SENT_395	[p20l956t1514r1345b1576],
5	—	NN	O	—	nn	6	SENT_395	[p20l956t1514r1345b1576],
6	sensitivity	NN	O	sensitivity	prep_of	2	SENT_395	[p20l956t1514r1345b1576],
7	KRAS	NNP	ORGANIZATION	KRAS	nn	9	SENT_395	[p20l1360t1516r1488b1562],
8	mutation	NN	O	mutation	nn	9	SENT_395	[p20l1505t1517r1735b1562],
9	testing	NN	O	testing	dep	6	SENT_395	[p20l1750t1517r1925b1575],
10	in	IN	O	in	_	0	SENT_395	[p20l127t1592r169b1637],
11	metastatic	JJ	O	metastatic	amod	13	SENT_395	[p20l187t1592r450b1637],
12	colorectal	JJ	O	colorectal	amod	13	SENT_395	[p20l464t1589r711b1637],
13	cancer	NN	O	cancer	prep_in	9	SENT_395	[p20l727t1603r895b1637],
14	treated	VBN	O	treat	_	0	SENT_395	[p20l906t1589r1088b1637],
15	with	IN	O	with	_	0	SENT_395	[p20l1103t1589r1212b1637],
16	anti	JJ	O	anti	prep_with	14	SENT_395	[p20l1228t1591r1476b1637],
17	.	.	O	.	_	0	SENT_395	[p20l1228t1591r1476b1637],

1	—	NN	O	—	_	0	SENT_396	[p20l1228t1591r1476b1637],
2	.	.	O	.	_	0	SENT_396	[p20l1228t1591r1476b1637],

1	EGFR	NN	ORGANIZATION	egfr	_	0	SENT_397	[p20l1228t1591r1476b1637],
2	antibody	NN	O	antibody	nn	3	SENT_397	[p20l1489t1589r1719b1651],
3	therapy	NN	O	therapy	dep	1	SENT_397	[p20l1730t1589r1937b1651],
4	.	.	O	.	_	0	SENT_397	[p20l1730t1589r1937b1651],

1	Oncology	NNP	O	Oncology	_	0	SENT_398	[p20l126t1664r364b1726],
2	82	CD	NUMBER	82	num	1	SENT_398	[p20l374t1667r452b1720],
3	,	,	O	,	_	0	SENT_398	[p20l374t1667r452b1720],
4	298-304	CD	NUMBER	298-304	num	1	SENT_398	[p20l466t1667r684b1712],
5	(	NN	O	(	dep	1	SENT_398	[p20l699t1665r796b1720],
6	201	CD	NUMBER	201	number	7	SENT_398	[p20l699t1665r796b1720],
7	2	CD	NUMBER	2	num	8	SENT_398	[p20l810t1665r868b1720],
8	)	NN	O	)	dep	5	SENT_398	[p20l810t1665r868b1720],
9	.	.	O	.	_	0	SENT_398	[p20l810t1665r868b1720],

1	35	CD	NUMBER	35	_	0	SENT_399	[p20l7t1742r81b1787],
2	.	.	O	.	_	0	SENT_399	[p20l7t1742r81b1787],

1	Su	FW	O	su	_	0	SENT_400	[p20l125t1741r199b1795],
2	,	,	O	,	_	0	SENT_400	[p20l125t1741r199b1795],
3	K.Y.	NNP	PERSON	K.Y.	appos	1	SENT_400	[p20l217t1742r301b1787],
4	et	FW	O	et	nn	5	SENT_400	[p20l317t1747r365b1787],
5	al.	FW	O	al.	dep	3	SENT_400	[p20l375t1739r430b1787],
6	.	.	O	.	_	0	SENT_400	[p20l375t1739r430b1787],

1	Pretreatment	NN	O	pretreatment	nsubj	11	SENT_401	[p20l450t1741r795b1787],
2	epidermal	JJ	O	epidermal	amod	5	SENT_401	[p20l810t1739r1074b1800],
3	growth	NN	O	growth	nn	5	SENT_401	[p20l1092t1739r1279b1800],
4	factor	NN	O	factor	nn	5	SENT_401	[p20l1295t1739r1449b1787],
5	receptor	NN	O	receptor	dep	1	SENT_401	[p20l1465t1747r1685b1800],
6	(	CD	NUMBER	(	num	7	SENT_401	[p20l1701t1740r1867b1795],
7	EGFR	NN	ORGANIZATION	egfr	dep	1	SENT_401	[p20l1701t1740r1867b1795],
8	)	CD	NUMBER	)	num	10	SENT_401	[p20l1701t1740r1867b1795],
9	T790M	NN	O	t790m	nn	10	SENT_401	[p20l1880t1742r2056b1787],
10	mutation	NN	O	mutation	dep	7	SENT_401	[p20l128t1817r365b1862],
11	predicts	VBZ	O	predict	_	0	SENT_401	[p20l385t1814r593b1875],
12	shorter	JJR	O	shorter	amod	14	SENT_401	[p20l610t1814r798b1862],
13	EGFR	NN	ORGANIZATION	egfr	nn	14	SENT_401	[p20l815t1816r945b1862],
14	tyrosine	NN	O	tyrosine	dobj	11	SENT_401	[p20l960t1817r1171b1876],
15	kinase	NN	O	kinase	nn	18	SENT_401	[p20l1189t1814r1351b1862],
16	inhibitor	NN	O	inhibitor	nn	18	SENT_401	[p20l1369t1814r1593b1862],
17	response	NN	O	response	nn	18	SENT_401	[p20l1610t1828r1844b1875],
18	duration	NN	O	duration	dep	11	SENT_401	[p20l1860t1814r2082b1862],
19	in	IN	O	in	dep	18	SENT_401	[p20l127t1892r170b1937],
20	patients	NNS	O	patient	pobj	19	SENT_401	[p20l189t1892r399b1950],
21	with	IN	O	with	dep	18	SENT_401	[p20l414t1889r527b1937],
22	non	JJ	O	non	amod	28	SENT_401	[p20l547t1889r914b1937],
23	—	JJ	O	—	amod	28	SENT_401	[p20l547t1889r914b1937],
24	small	JJ	O	small	amod	28	SENT_401	[p20l547t1889r914b1937],
25	—	NN	O	—	nn	28	SENT_401	[p20l547t1889r914b1937],
26	cell	NN	O	cell	nn	28	SENT_401	[p20l547t1889r914b1937],
27	lung	NN	O	lung	nn	28	SENT_401	[p20l934t1889r1046b1950],
28	cancer	NN	O	cancer	pobj	21	SENT_401	[p20l1064t1903r1245b1937],
29	.	.	O	.	_	0	SENT_401	[p20l1064t1903r1245b1937],

1	J.	NNP	PERSON	J.	nn	2	SENT_402	[p20l1257t1892r1292b1937],
2	Clin	NNP	PERSON	Clin	_	0	SENT_402	[p20l1309t1889r1414b1937],
3	.	.	O	.	_	0	SENT_402	[p20l1309t1889r1414b1937],

1	Oncol	NN	O	oncol	_	0	SENT_403	[p20l1431t1889r1588b1937],
2	.	.	O	.	_	0	SENT_403	[p20l1431t1889r1588b1937],

1	30	CD	NUMBER	30	_	0	SENT_404	[p20l1605t1892r1685b1945],
2	,	,	O	,	_	0	SENT_404	[p20l1605t1892r1685b1945],
3	433-440	CD	NUMBER	433-440	number	4	SENT_404	[p20l1699t1892r1924b1937],
4	(	CD	NUMBER	(	appos	1	SENT_404	[p20l127t1965r302b2020],
5	2012	CD	DATE	2012	num	6	SENT_404	[p20l127t1965r302b2020],
6	)	NN	O	)	dep	4	SENT_404	[p20l127t1965r302b2020],
7	.	.	O	.	_	0	SENT_404	[p20l127t1965r302b2020],

1	36	CD	NUMBER	36	_	0	SENT_405	[p20l7t2042r79b2087],
2	.	.	O	.	_	0	SENT_405	[p20l7t2042r79b2087],

1	Gerlinger	NNP	O	Gerlinger	_	0	SENT_406	[p20l124t2039r370b2100],
2	,	,	O	,	_	0	SENT_406	[p20l124t2039r370b2100],
3	M.	NNP	O	M.	nn	4	SENT_406	[p20l385t2042r443b2087],
4	etal	NNP	O	etal	appos	1	SENT_406	[p20l456t2039r565b2087],
5	.	.	O	.	_	0	SENT_406	[p20l456t2039r565b2087],

1	Intratumor	JJ	O	intratumor	amod	2	SENT_407	[p20l583t2042r858b2087],
2	heterogeneity	NN	O	heterogeneity	_	0	SENT_407	[p20l872t2039r1232b2101],
3	and	CC	O	and	_	0	SENT_407	[p20l1245t2039r1338b2087],
4	branched	VBD	O	branch	amod	5	SENT_407	[p20l1356t2039r1595b2087],
5	evolution	NN	O	evolution	conj_and	2	SENT_407	[p20l1611t2039r1850b2087],
6	revealed	VBN	O	reveal	partmod	2	SENT_407	[p20l1869t2039r2081b2087],
7	by	IN	O	by	_	0	SENT_407	[p20l128t2114r188b2176],
8	multiregion	JJ	O	multiregion	amod	9	SENT_407	[p20l202t2114r496b2175],
9	sequencing	NN	O	sequencing	agent	6	SENT_407	[p20l512t2117r820b2175],
10	.	.	O	.	_	0	SENT_407	[p20l512t2117r820b2175],

1	N.	NNP	O	N.	nn	2	SENT_408	[p20l834t2117r880b2162],
2	Engl	NNP	O	Engl	_	0	SENT_408	[p20l895t2114r1009b2175],
3	.	.	O	.	_	0	SENT_408	[p20l895t2114r1009b2175],

1	J.	NNP	O	J.	nn	2	SENT_409	[p20l1020t2117r1053b2162],
2	Med	NNP	O	Med	_	0	SENT_409	[p20l1066t2114r1183b2162],
3	.	.	O	.	_	0	SENT_409	[p20l1066t2114r1183b2162],

1	366	CD	NUMBER	366	_	0	SENT_410	[p20l1199t2117r1310b2170],
2	,	,	O	,	_	0	SENT_410	[p20l1199t2117r1310b2170],
3	883-892	CD	NUMBER	883-892	number	4	SENT_410	[p20l1324t2117r1540b2162],
4	(	CD	NUMBER	(	appos	1	SENT_410	[p20l1557t2115r1726b2170],
5	2012	CD	DATE	2012	num	6	SENT_410	[p20l1557t2115r1726b2170],
6	)	NN	O	)	dep	4	SENT_410	[p20l1557t2115r1726b2170],
7	.	.	O	.	_	0	SENT_410	[p20l1557t2115r1726b2170],

1	37	CD	NUMBER	37	_	0	SENT_411	[p20l7t2192r79b2237],
2	.	.	O	.	_	0	SENT_411	[p20l7t2192r79b2237],

1	Anderson	NNP	PERSON	Anderson	nn	3	SENT_412	[p20l124t2189r384b2245],
2	,	,	O	,	_	0	SENT_412	[p20l124t2189r384b2245],
3	K.	NNP	O	K.	_	0	SENT_412	[p20l400t2192r441b2237],
4	et	FW	O	et	nn	5	SENT_412	[p20l455t2197r502b2237],
5	al.	FW	O	al.	dep	3	SENT_412	[p20l511t2189r563b2237],
6	.	.	O	.	_	0	SENT_412	[p20l511t2189r563b2237],

1	Genetic	JJ	O	genetic	amod	2	SENT_413	[p20l579t2191r775b2237],
2	variegation	NN	O	variegation	_	0	SENT_413	[p20l787t2192r1074b2250],
3	of	IN	O	of	_	0	SENT_413	[p20l1090t2189r1143b2237],
4	clonal	JJ	O	clonal	amod	5	SENT_413	[p20l1152t2189r1301b2237],
5	architecture	NN	O	architecture	prep_of	2	SENT_413	[p20l1317t2189r1623b2237],
6	and	CC	O	and	_	0	SENT_413	[p20l1637t2189r1730b2237],
7	propagating	VBG	O	propagate	amod	8	SENT_413	[p20l1748t2192r2061b2250],
8	cells	NNS	O	cell	conj_and	5	SENT_413	[p20l126t2264r233b2312],
9	in	IN	O	in	_	0	SENT_413	[p20l249t2267r290b2312],
10	leukaemia	NN	O	leukaemia	prep_in	8	SENT_413	[p20l308t2264r581b2312],
11	.	.	O	.	_	0	SENT_413	[p20l308t2264r581b2312],

1	Nature	NNP	O	Nature	_	0	SENT_414	[p20l595t2267r763b2312],
2	469	CD	NUMBER	469	num	1	SENT_414	[p20l774t2267r887b2320],
3	,	,	O	,	_	0	SENT_414	[p20l774t2267r887b2320],
4	356-361	CD	NUMBER	356-361	num	1	SENT_414	[p20l902t2267r1109b2312],
5	(	NN	O	(	dep	1	SENT_414	[p20l1134t2265r1231b2320],
6	201	CD	NUMBER	201	number	7	SENT_414	[p20l1134t2265r1231b2320],
7	1	CD	NUMBER	1	num	8	SENT_414	[p20l1249t2265r1303b2320],
8	)	NN	O	)	dep	5	SENT_414	[p20l1249t2265r1303b2320],
9	.	.	O	.	_	0	SENT_414	[p20l1249t2265r1303b2320],

1	CLINICAL	JJ	O	clinical	amod	2	SENT_415	[p20l8t2476r249b2517],
2	PHARMACOLOGY	NNP	O	PHARMACOLOGY	_	0	SENT_415	[p20l267t2476r720b2517],
3	&	CC	O	&	_	0	SENT_415	[p20l735t2476r1179b2517],
4	THERAPEUT	NNP	O	THERAPEUT	nn	6	SENT_415	[p20l735t2476r1179b2517],
5	|	CD	NUMBER	|	num	6	SENT_415	[p20l735t2476r1179b2517],
6	CS	NNP	O	CS	conj_and	2	SENT_415	[p20l735t2476r1179b2517],
7	|	NNP	O	|	nn	8	SENT_415	[p20l1199t2472r1437b2532],
8	VOLUME	NNP	O	VOLUME	dep	2	SENT_415	[p20l1199t2472r1437b2532],
9	93	CD	NUMBER	93	num	10	SENT_415	[p20l1454t2477r1509b2518],
10	NUMBER	NN	O	number	dep	8	SENT_415	[p20l1530t2476r1747b2518],
11	3	CD	NUMBER	3	num	13	SENT_415	[p20l1763t2477r1788b2518],
12	|	NN	O	|	nn	13	SENT_415	[p20l1809t2472r1813b2532],
13	MARCH	NN	DATE	march	dep	2	SENT_415	[p20l1834t2476r2019b2518],
14	2013	CD	DATE	2013	num	15	SENT_415	[p20l2039t2477r2153b2518],
15	38	CD	DATE	38	dep	13	SENT_415	[p20l9t2549r83b2596],
16	.	.	O	.	_	0	SENT_415	[p20l9t2549r83b2596],

1	Colombino	NNP	O	Colombino	_	0	SENT_416	[p20l130t2546r433b2604],
2	,	,	O	,	_	0	SENT_416	[p20l130t2546r433b2604],
3	M.	NNP	O	M.	nn	4	SENT_416	[p20l449t2549r508b2596],
4	etal	NNP	O	etal	appos	1	SENT_416	[p20l522t2546r634b2596],
5	.	.	O	.	_	0	SENT_416	[p20l522t2546r634b2596],

1	BRAF/NRAS	NN	O	braf/nras	nn	3	SENT_417	[p20l653t2548r954b2598],
2	mutation	NN	O	mutation	nn	3	SENT_417	[p20l971t2549r1209b2596],
3	frequencies	NNS	O	frequency	nsubj	13	SENT_417	[p20l1225t2546r1531b2609],
4	among	IN	O	among	_	0	SENT_417	[p20l1545t2561r1730b2609],
5	primary	JJ	O	primary	amod	6	SENT_417	[p20l1748t2549r1952b2610],
6	tumors	NNS	O	tumor	prep_among	3	SENT_417	[p20l1964t2554r2151b2596],
7	and	CC	O	and	_	0	SENT_417	[p20l131t2624r227b2674],
8	metastases	NNS	O	metastase	prep_among	3	SENT_417	[p20l246t2632r536b2674],
9	in	IN	O	in	_	0	SENT_417	[p20l552t2627r595b2673],
10	patients	NNS	O	patient	prep_in	6	SENT_417	[p20l613t2627r823b2687],
11	with	IN	O	with	_	0	SENT_417	[p20l836t2624r949b2674],
12	me	PRP	O	I	prep_with	10	SENT_417	[p20l968t2624r1305b2674],
13	|	VBP	O	|	_	0	SENT_417	[p20l968t2624r1305b2674],
14	anoma	NN	O	anoma	dobj	13	SENT_417	[p20l968t2624r1305b2674],
15	.	.	O	.	_	0	SENT_417	[p20l968t2624r1305b2674],

1	J.	NNP	PERSON	J.	nn	2	SENT_418	[p20l968t2624r1305b2674],
2	Clin	NNP	PERSON	Clin	_	0	SENT_418	[p20l1321t2624r1426b2674],
3	.	.	O	.	_	0	SENT_418	[p20l1321t2624r1426b2674],

1	Oncol	NN	O	oncol	_	0	SENT_419	[p20l1441t2624r1598b2674],
2	.	.	O	.	_	0	SENT_419	[p20l1441t2624r1598b2674],

1	30	CD	NUMBER	30	_	0	SENT_420	[p20l1615t2627r1694b2682],
2	,	,	O	,	_	0	SENT_420	[p20l1615t2627r1694b2682],
3	2522-2529	CD	DATE	2522-2529	number	4	SENT_420	[p20l1709t2627r1998b2674],
4	(	CD	NUMBER	(	appos	1	SENT_420	[p20l133t2702r307b2758],
5	2012	CD	DATE	2012	num	6	SENT_420	[p20l133t2702r307b2758],
6	)	NN	O	)	dep	4	SENT_420	[p20l133t2702r307b2758],
7	.	.	O	.	_	0	SENT_420	[p20l133t2702r307b2758],

1	39	CD	NUMBER	39	_	0	SENT_421	[p20l9t2782r83b2829],
2	.	.	O	.	_	0	SENT_421	[p20l9t2782r83b2829],

1	Perkins	NNP	PERSON	Perkins	_	0	SENT_422	[p20l132t2779r329b2837],
2	,	,	O	,	_	0	SENT_422	[p20l132t2779r329b2837],
3	G.	NNP	O	G.	nn	4	SENT_422	[p20l344t2781r395b2829],
4	etal	NN	O	etal	appos	1	SENT_422	[p20l408t2779r520b2829],
5	.	.	O	.	_	0	SENT_422	[p20l408t2779r520b2829],

1	Mu	NN	O	mu	nn	4	SENT_423	[p20l538t2779r910b2842],
2	|	CD	NUMBER	|	num	4	SENT_423	[p20l538t2779r910b2842],
3	ti	NN	O	ti	nn	4	SENT_423	[p20l538t2779r910b2842],
4	—	NN	O	—	nn	5	SENT_423	[p20l538t2779r910b2842],
5	purpose	NN	O	purpose	_	0	SENT_423	[p20l538t2779r910b2842],
6	utility	NN	O	utility	dep	5	SENT_423	[p20l927t2779r1075b2843],
7	of	IN	O	of	_	0	SENT_423	[p20l1087t2779r1142b2829],
8	circulating	VBG	O	circulate	prepc_of	6	SENT_423	[p20l1152t2779r1425b2842],
9	plasma	NN	O	plasma	nn	11	SENT_423	[p20l1443t2779r1627b2842],
10	DNA	NN	O	dna	nn	11	SENT_423	[p20l1645t2781r1763b2829],
11	testing	NN	O	testing	dobj	8	SENT_423	[p20l1776t2782r1955b2842],
12	in	IN	O	in	_	0	SENT_423	[p20l1974t2782r2016b2828],
13	patients	NNS	O	patient	prep_in	11	SENT_423	[p20l133t2860r343b2920],
14	with	IN	O	with	_	0	SENT_423	[p20l356t2857r470b2907],
15	advanced	JJ	O	advanced	amod	16	SENT_423	[p20l486t2857r739b2907],
16	cancers	NNS	O	cancer	prep_with	13	SENT_423	[p20l756t2872r965b2907],
17	.	.	O	.	_	0	SENT_423	[p20l756t2872r965b2907],

1	PLoS	NN	O	plo	_	0	SENT_424	[p20l979t2859r1099b2907],
2	ONE	CD	NUMBER	one	number	3	SENT_424	[p20l1110t2859r1223b2907],
3	7	CD	NUMBER	7	amod	1	SENT_424	[p20l1234t2861r1277b2915],
4	,	,	O	,	_	0	SENT_424	[p20l1234t2861r1277b2915],
5	e47020	NN	O	e47020	appos	1	SENT_424	[p20l1292t2860r1483b2907],
6	(	CD	NUMBER	(	num	5	SENT_424	[p20l1500t2858r1674b2915],
7	2012	CD	DATE	2012	num	8	SENT_424	[p20l1500t2858r1674b2915],
8	)	NN	O	)	dep	5	SENT_424	[p20l1500t2858r1674b2915],
9	.	.	O	.	_	0	SENT_424	[p20l1500t2858r1674b2915],

1	40	CD	NUMBER	40	_	0	SENT_425	[p20l7t2938r82b2985],
2	.	.	O	.	_	0	SENT_425	[p20l7t2938r82b2985],

1	Tejpar	NNP	PERSON	Tejpar	nn	5	SENT_426	[p20l127t2938r297b2998],
2	,	,	O	,	_	0	SENT_426	[p20l127t2938r297b2998],
3	S.	NNP	O	S.	appos	5	SENT_426	[p20l312t2937r365b2993],
4	,	,	O	,	_	0	SENT_426	[p20l312t2937r365b2993],
5	Celik	NNP	O	Celik	_	0	SENT_426	[p20l380t2935r518b2993],
6	,	,	O	,	_	0	SENT_426	[p20l380t2935r518b2993],
7	|	CD	NUMBER	|	appos	5	SENT_426	[p20l534t2938r569b2993],
8	.	.	O	.	_	0	SENT_426	[p20l534t2938r569b2993],

1	,	,	O	,	_	0	SENT_427	[p20l534t2938r569b2993],
2	Schlichting	NNP	PERSON	Schlichting	dep	18	SENT_427	[p20l584t2935r887b2998],
3	,	,	O	,	_	0	SENT_427	[p20l584t2935r887b2998],
4	M.	NNP	O	M.	nn	15	SENT_427	[p20l903t2938r975b2993],
5	,	,	O	,	_	0	SENT_427	[p20l903t2938r975b2993],
6	Sartorius	NNP	PERSON	Sartorius	nn	15	SENT_427	[p20l990t2937r1234b2993],
7	,	,	O	,	_	0	SENT_427	[p20l990t2937r1234b2993],
8	U.	NNP	O	U.	nn	15	SENT_427	[p20l1251t2938r1310b2993],
9	,	,	O	,	_	0	SENT_427	[p20l1251t2938r1310b2993],
10	Bokemeyer	NNP	PERSON	Bokemeyer	nn	15	SENT_427	[p20l1327t2935r1629b2999],
11	,	,	O	,	_	0	SENT_427	[p20l1327t2935r1629b2999],
12	C.	NNP	ORGANIZATION	C.	nn	15	SENT_427	[p20l1643t2937r1690b2985],
13	&	CC	ORGANIZATION	&	_	0	SENT_427	[p20l1704t2937r1845b2985],
14	Van	NNP	ORGANIZATION	Van	nn	15	SENT_427	[p20l1704t2937r1845b2985],
15	Cutsem	NNP	ORGANIZATION	Cutsem	appos	2	SENT_427	[p20l1861t2937r2073b2993],
16	,	,	O	,	_	0	SENT_427	[p20l1861t2937r2073b2993],
17	E.	NNP	ORGANIZATION	E.	nn	18	SENT_427	[p20l133t3016r171b3063],
18	Association	NNP	ORGANIZATION	Association	nsubj	33	SENT_427	[p20l185t3016r483b3063],
19	of	IN	ORGANIZATION	of	_	0	SENT_427	[p20l500t3013r554b3063],
20	KRAS	NNP	ORGANIZATION	KRAS	nn	24	SENT_427	[p20l566t3015r699b3063],
21	G1	NN	O	g1	nn	24	SENT_427	[p20l714t3015r774b3063],
22	3D	NN	O	3d	nn	24	SENT_427	[p20l789t3015r859b3063],
23	tumor	NN	O	tumor	nn	24	SENT_427	[p20l873t3021r1037b3063],
24	mutations	NNS	O	mutation	prep_of	18	SENT_427	[p20l1052t3016r1317b3063],
25	with	IN	O	with	_	0	SENT_427	[p20l1330t3013r1444b3063],
26	outcome	NN	O	outcome	prep_with	18	SENT_427	[p20l1460t3021r1695b3063],
27	in	IN	O	in	_	0	SENT_427	[p20l1711t3016r1754b3062],
28	patients	NNS	O	patient	prep_in	26	SENT_427	[p20l1773t3016r1982b3076],
29	with	IN	O	with	_	0	SENT_427	[p20l1996t3013r2109b3063],
30	metastatic	JJ	O	metastatic	amod	32	SENT_427	[p20l133t3094r405b3141],
31	colorectal	JJ	O	colorectal	amod	32	SENT_427	[p20l419t3091r674b3141],
32	cancer	NN	O	cancer	prep_with	28	SENT_427	[p20l691t3106r864b3141],
33	treated	VBN	O	treat	conj_or	33	SENT_427	[p20l876t3091r1062b3141],
34	with	IN	O	with	_	0	SENT_427	[p20l1078t3091r1191b3141],
35	ﬁrst	NN	O	ﬁrst	nn	39	SENT_427	[p20l1206t3091r1420b3141],
36	—	CD	NUMBER	—	num	39	SENT_427	[p20l1206t3091r1420b3141],
37	|	NN	O	|	nn	39	SENT_427	[p20l1206t3091r1420b3141],
38	ine	NN	O	ine	nn	39	SENT_427	[p20l1206t3091r1420b3141],
39	chemotherapy	NN	O	chemotherapy	prep_with	33	SENT_427	[p20l1434t3091r1821b3155],
40	with	IN	O	with	_	0	SENT_427	[p20l1833t3091r1946b3141],
41	or	CC	O	or	_	0	SENT_427	[p20l1963t3106r2017b3141],
42	without	IN	O	without	_	0	SENT_427	[p20l130t3168r337b3218],
43	cetuximab	NN	O	cetuximab	prep_with	33	SENT_427	[p20l351t3168r639b3218],
44	.	.	O	.	_	0	SENT_427	[p20l351t3168r639b3218],

1	J.	NNP	PERSON	J.	nn	2	SENT_428	[p20l649t3171r684b3218],
2	Clin	NNP	PERSON	Clin	_	0	SENT_428	[p20l700t3168r804b3218],
3	.	.	O	.	_	0	SENT_428	[p20l700t3168r804b3218],

1	Oncol	NN	O	oncol	_	0	SENT_429	[p20l820t3168r977b3218],
2	.	.	O	.	_	0	SENT_429	[p20l820t3168r977b3218],

1	30	CD	NUMBER	30	_	0	SENT_430	[p20l994t3172r1073b3225],
2	,	,	O	,	_	0	SENT_430	[p20l994t3172r1073b3225],
3	3570-3577	CD	DURATION	3570-3577	number	4	SENT_430	[p20l1088t3172r1376b3218],
4	(	CD	NUMBER	(	appos	1	SENT_430	[p20l1393t3169r1567b3225],
5	2012	CD	DATE	2012	num	6	SENT_430	[p20l1393t3169r1567b3225],
6	)	NN	O	)	dep	4	SENT_430	[p20l1393t3169r1567b3225],
7	.	.	O	.	_	0	SENT_430	[p20l1393t3169r1567b3225],

1	41	CD	NUMBER	41	_	0	SENT_431	[p20l7t3250r82b3296],
2	.	.	O	.	_	0	SENT_431	[p20l7t3250r82b3296],

1	Blanke	NNP	PERSON	Blanke	nn	2	SENT_432	[p20l132t3246r303b3296],
2	C.D.	NNP	O	C.D.	_	0	SENT_432	[p20l317t3248r417b3296],
3	etal	NN	O	etal	dep	2	SENT_432	[p20l431t3246r543b3296],
4	.	.	O	.	_	0	SENT_432	[p20l431t3246r543b3296],

1	Long	JJ	O	long	amod	3	SENT_433	[p20l562t3249r835b3310],
2	—	NN	O	—	nn	3	SENT_433	[p20l562t3249r835b3310],
3	term	NN	O	term	nsubj	4	SENT_433	[p20l562t3249r835b3310],
4	results	VBZ	O	result	conj_versus	4	SENT_433	[p20l854t3246r1021b3296],
5	from	IN	O	from	_	0	SENT_433	[p20l1034t3246r1156b3296],
6	a	DT	O	a	det	10	SENT_433	[p20l1173t3261r1198b3296],
7	randomized	JJ	O	randomized	amod	10	SENT_433	[p20l1216t3246r1528b3296],
8	phase	NN	O	phase	nn	10	SENT_433	[p20l1547t3246r1700b3309],
9	II	CD	NUMBER	ii	num	10	SENT_433	[p20l1717t3249r1739b3295],
10	trial	NN	O	trial	prep_from	4	SENT_433	[p20l1754t3246r1852b3296],
11	of	IN	O	of	_	0	SENT_433	[p20l131t3324r185b3374],
12	standard	JJ	O	standard	amod	13	SENT_433	[p20l195t3324r446b3374],
13	—	CD	NUMBER	—	prep_of	4	SENT_433	[p20l195t3324r446b3374],
14	versus	CC	O	versus	_	0	SENT_433	[p20l459t3339r624b3374],
15	higher	JJR	O	higher	advmod	4	SENT_433	[p20l641t3324r957b3388],
16	—	CD	NUMBER	—	num	19	SENT_433	[p20l641t3324r957b3388],
17	dose	NN	O	dose	nn	19	SENT_433	[p20l641t3324r957b3388],
18	imatinib	NN	O	imatinib	nn	19	SENT_433	[p20l973t3324r1188b3374],
19	mesylate	NN	O	mesylate	npadvmod	4	SENT_433	[p20l1205t3324r1437b3388],
20	for	IN	O	for	_	0	SENT_433	[p20l1450t3324r1522b3374],
21	patients	NNS	O	patient	prep_for	19	SENT_433	[p20l1537t3327r1747b3387],
22	with	IN	O	with	_	0	SENT_433	[p20l1760t3324r1873b3374],
23	unresectable	JJ	O	unresectable	amod	28	SENT_433	[p20l133t3402r471b3452],
24	or	CC	O	or	_	0	SENT_433	[p20l485t3417r539b3452],
25	metastatic	JJ	O	metastatic	amod	28	SENT_433	[p20l554t3405r826b3452],
26	gastrointestinal	JJ	O	gastrointestinal	amod	28	SENT_433	[p20l840t3402r1245b3466],
27	stromal	JJ	O	stromal	amod	28	SENT_433	[p20l1262t3402r1456b3452],
28	tumors	NNS	O	tumor	prep_with	4	SENT_433	[p20l1472t3410r1659b3452],
29	expressing	VBG	O	express	xcomp	4	SENT_433	[p20l1674t3405r1953b3466],
30	KIT	NN	O	kit	dobj	29	SENT_433	[p20l1972t3405r2056b3452],
31	.	.	O	.	_	0	SENT_433	[p20l1972t3405r2056b3452],

1	J.	NNP	PERSON	J.	nn	2	SENT_434	[p20l127t3482r161b3529],
2	Clin	NNP	PERSON	Clin	_	0	SENT_434	[p20l177t3479r282b3529],
3	.	.	O	.	_	0	SENT_434	[p20l177t3479r282b3529],

1	Oncol	NN	O	oncol	_	0	SENT_435	[p20l298t3479r454b3529],
2	.	.	O	.	_	0	SENT_435	[p20l298t3479r454b3529],

1	26	CD	NUMBER	26	_	0	SENT_436	[p20l471t3483r551b3536],
2	,	,	O	,	_	0	SENT_436	[p20l471t3483r551b3536],
3	620-625	CD	NUMBER	620-625	number	4	SENT_436	[p20l565t3483r787b3529],
4	(	CD	NUMBER	(	appos	1	SENT_436	[p20l806t3480r979b3536],
5	2008	CD	DATE	2008	num	6	SENT_436	[p20l806t3480r979b3536],
6	)	NN	O	)	dep	4	SENT_436	[p20l806t3480r979b3536],
7	.	.	O	.	_	0	SENT_436	[p20l806t3480r979b3536],

1	Verweij	NNP	O	Verweij	_	0	SENT_437	[p21l128t20r334b81],
2	,	,	O	,	_	0	SENT_437	[p21l128t20r334b81],
3	J.	NNP	O	J.	nn	4	SENT_437	[p21l347t20r380b67],
4	etal	NNP	O	etal	appos	1	SENT_437	[p21l394t17r506b67],
5	.	.	O	.	_	0	SENT_437	[p21l394t17r506b67],

1	Progression	NN	O	progression	npadvmod	3	SENT_438	[p21l526t17r952b81],
2	—	CD	NUMBER	—	num	1	SENT_438	[p21l526t17r952b81],
3	free	JJ	O	free	amod	4	SENT_438	[p21l526t17r952b81],
4	survival	NN	O	survival	_	0	SENT_438	[p21l966t17r1164b67],
5	in	IN	O	in	_	0	SENT_438	[p21l1182t20r1225b66],
6	gastrointestinal	JJ	O	gastrointestinal	amod	8	SENT_438	[p21l1241t17r1647b81],
7	stromal	JJ	O	stromal	amod	8	SENT_438	[p21l1664t17r1857b67],
8	tumours	NNS	O	tumour	prep_in	4	SENT_438	[p21l1873t25r2095b67],
9	with	IN	O	with	_	0	SENT_438	[p21l130t95r243b145],
10	high	JJ	O	high	amod	13	SENT_438	[p21l262t95r526b159],
11	—	NN	O	—	nn	13	SENT_438	[p21l262t95r526b159],
12	dose	NN	O	dose	nn	13	SENT_438	[p21l262t95r526b159],
13	imatinib	NN	O	imatinib	prep_with	8	SENT_438	[p21l542t95r770b145],
14	:	:	O	:	_	0	SENT_438	[p21l542t95r770b145],
15	randomised	JJ	O	randomised	amod	16	SENT_438	[p21l786t95r1097b145],
16	trial	NN	O	trial	dep	4	SENT_438	[p21l1112t95r1224b145],
17	.	.	O	.	_	0	SENT_438	[p21l1112t95r1224b145],

1	Lancet	NNP	O	Lancet	_	0	SENT_439	[p21l1238t98r1409b145],
2	364	CD	NUMBER	364	num	1	SENT_439	[p21l1419t99r1534b153],
3	,	,	O	,	_	0	SENT_439	[p21l1419t99r1534b153],
4	1127-1	CD	NUMBER	1127-1	num	1	SENT_439	[p21l1554t99r1730b145],
5	134	CD	NUMBER	134	number	6	SENT_439	[p21l1749t99r1839b145],
6	(	CD	NUMBER	(	dep	1	SENT_439	[p21l1855t96r2029b153],
7	2004	CD	DATE	2004	num	8	SENT_439	[p21l1855t96r2029b153],
8	)	NN	O	)	dep	6	SENT_439	[p21l1855t96r2029b153],
9	.	.	O	.	_	0	SENT_439	[p21l1855t96r2029b153],

1	Kim	NNP	PERSON	Kim	_	0	SENT_440	[p21l132t176r242b231],
2	,	,	O	,	_	0	SENT_440	[p21l132t176r242b231],
3	E.S.	NNP	LOCATION	E.S.	nn	4	SENT_440	[p21l259t175r341b223],
4	etal	NNP	O	etal	appos	1	SENT_440	[p21l355t173r467b223],
5	.	.	O	.	_	0	SENT_440	[p21l355t173r467b223],

1	The	DT	O	the	det	3	SENT_441	[p21l479t173r576b223],
2	BATTLE	NN	O	battle	nn	3	SENT_441	[p21l593t175r782b223],
3	trial	NN	O	trial	_	0	SENT_441	[p21l795t173r908b223],
4	:	:	O	:	_	0	SENT_441	[p21l795t173r908b223],
5	personalizing	VBG	O	personalize	amod	6	SENT_441	[p21l925t173r1274b237],
6	therapy	NN	O	therapy	dep	3	SENT_441	[p21l1289t173r1494b237],
7	for	IN	O	for	_	0	SENT_441	[p21l1505t173r1577b223],
8	lung	NN	O	lung	nn	9	SENT_441	[p21l1592t173r1705b237],
9	cancer	NN	O	cancer	prep_for	6	SENT_441	[p21l1722t188r1903b223],
10	.	.	O	.	_	0	SENT_441	[p21l1722t188r1903b223],

1	Cancer	NNP	O	Cancer	nn	2	SENT_442	[p21l1918t175r2095b223],
2	Discov	NNP	O	Discov	_	0	SENT_442	[p21l131t252r304b300],
3	.	.	O	.	_	0	SENT_442	[p21l131t252r304b300],

1	1	CD	NUMBER	1	_	0	SENT_443	[p21l324t254r365b307],
2	,	,	O	,	_	0	SENT_443	[p21l324t254r365b307],
3	44-53	CD	NUMBER	44-53	num	4	SENT_443	[p21l378t254r536b300],
4	(	NN	O	(	appos	1	SENT_443	[p21l554t251r654b307],
5	201	CD	NUMBER	201	number	6	SENT_443	[p21l554t251r654b307],
6	1	CD	NUMBER	1	num	7	SENT_443	[p21l673t251r728b307],
7	)	NN	O	)	dep	4	SENT_443	[p21l673t251r728b307],
8	.	.	O	.	_	0	SENT_443	[p21l673t251r728b307],

1	Dietrich	NNP	PERSON	Dietrich	nn	14	SENT_444	[p21l132t327r349b384],
2	,	,	O	,	_	0	SENT_444	[p21l132t327r349b384],
3	S.	NNP	O	S.	conj_and	14	SENT_444	[p21l363t329r416b384],
4	,	,	O	,	_	0	SENT_444	[p21l363t329r416b384],
5	Glimm	NNP	O	Glimm	conj_and	14	SENT_444	[p21l431t327r618b384],
6	,	,	O	,	_	0	SENT_444	[p21l431t327r618b384],
7	H.	NNP	O	H.	conj_and	14	SENT_444	[p21l634t330r696b384],
8	,	,	O	,	_	0	SENT_444	[p21l634t330r696b384],
9	Andrulis	NNP	PERSON	Andrulis	conj_and	14	SENT_444	[p21l710t327r939b384],
10	,	,	O	,	_	0	SENT_444	[p21l710t327r939b384],
11	M.	NNP	O	M.	conj_and	14	SENT_444	[p21l955t330r1027b384],
12	,	,	O	,	_	0	SENT_444	[p21l955t330r1027b384],
13	von	NNP	PERSON	von	conj_and	14	SENT_444	[p21l1040t342r1136b377],
14	Kalle	NNP	PERSON	Kalle	_	0	SENT_444	[p21l1155t327r1289b384],
15	,	,	O	,	_	0	SENT_444	[p21l1155t327r1289b384],
16	C.	NNP	O	C.	conj_and	14	SENT_444	[p21l1303t329r1362b384],
17	,	,	O	,	_	0	SENT_444	[p21l1303t329r1362b384],
18	Ho	NNP	O	Ho	conj_and	14	SENT_444	[p21l1380t330r1461b384],
19	,	,	O	,	_	0	SENT_444	[p21l1380t330r1461b384],
20	A.D.	NNP	ORGANIZATION	A.D.	conj_and	14	SENT_444	[p21l1475t329r1577b377],
21	&	CC	ORGANIZATION	&	_	0	SENT_444	[p21l1591t329r1628b377],
22	Zenz	NNP	ORGANIZATION	Zenz	conj_and	14	SENT_444	[p21l1640t330r1828b384],
23	,	,	O	,	_	0	SENT_444	[p21l1640t330r1828b384],
24	T.	NNP	O	T.	nn	26	SENT_444	[p21l1640t330r1828b384],
25	BRAF	NNP	O	BRAF	nn	26	SENT_444	[p21l1845t329r1977b376],
26	inhibition	NN	O	inhibition	appos	14	SENT_444	[p21l133t405r382b455],
27	in	IN	O	in	_	0	SENT_444	[p21l401t408r443b454],
28	refractory	JJ	O	refractory	amod	34	SENT_444	[p21l462t405r716b469],
29	hairy	JJ	O	hairy	amod	34	SENT_444	[p21l731t405r966b469],
30	—	NN	O	—	nn	34	SENT_444	[p21l731t405r966b469],
31	ce	NN	O	ce	nn	34	SENT_444	[p21l731t405r966b469],
32	|	NN	O	|	nn	34	SENT_444	[p21l731t405r966b469],
33	l	NN	O	l	nn	34	SENT_444	[p21l731t405r966b469],
34	leukemia	NN	O	leukemia	prep_in	26	SENT_444	[p21l985t405r1234b455],
35	.	.	O	.	_	0	SENT_444	[p21l985t405r1234b455],

1	N.	NNP	O	N.	nn	2	SENT_445	[p21l1249t408r1296b455],
2	Engl	NNP	O	Engl	_	0	SENT_445	[p21l1311t405r1429b469],
3	.	.	O	.	_	0	SENT_445	[p21l1311t405r1429b469],

1	J.	NNP	O	J.	nn	2	SENT_446	[p21l1440t408r1475b455],
2	Med	NNP	O	Med	_	0	SENT_446	[p21l1488t405r1608b455],
3	.	.	O	.	_	0	SENT_446	[p21l1488t405r1608b455],

1	366	CD	NUMBER	366	_	0	SENT_447	[p21l1625t409r1740b463],
2	,	,	O	,	_	0	SENT_447	[p21l1625t409r1740b463],
3	2038-2040	CD	DATE	2038-2040	number	4	SENT_447	[p21l1755t409r2044b455],
4	(	CD	NUMBER	(	appos	1	SENT_447	[p21l133t483r307b539],
5	2012	CD	DATE	2012	num	6	SENT_447	[p21l133t483r307b539],
6	)	NN	O	)	dep	4	SENT_447	[p21l133t483r307b539],
7	.	.	O	.	_	0	SENT_447	[p21l133t483r307b539],

1	Prahallad	NNP	O	Prahallad	_	0	SENT_448	[p21l132t560r384b618],
2	,	,	O	,	_	0	SENT_448	[p21l132t560r384b618],
3	A.	NNP	O	A.	nn	4	SENT_448	[p21l398t563r447b610],
4	etal	NNP	O	etal	appos	1	SENT_448	[p21l461t560r573b610],
5	.	.	O	.	_	0	SENT_448	[p21l461t560r573b610],

1	Unresponsiveness	NN	O	unresponsiveness	_	0	SENT_449	[p21l592t563r1066b623],
2	of	IN	O	of	_	0	SENT_449	[p21l1080t560r1135b610],
3	colon	NN	O	colon	nn	4	SENT_449	[p21l1144t560r1287b610],
4	cancer	NN	O	cancer	prep_of	1	SENT_449	[p21l1304t575r1476b610],
5	to	TO	O	to	_	0	SENT_449	[p21l1488t568r1541b610],
6	BRAF	NN	O	braf	nn	10	SENT_449	[p21l1558t561r1893b618],
7	(	CD	NUMBER	(	num	10	SENT_449	[p21l1558t561r1893b618],
8	V600E	NN	O	v600e	nn	10	SENT_449	[p21l1558t561r1893b618],
9	)	NN	O	)	nn	10	SENT_449	[p21l1558t561r1893b618],
10	inhibition	NN	O	inhibition	prep_to	1	SENT_449	[p21l133t638r382b688],
11	through	IN	O	through	_	0	SENT_449	[p21l398t638r611b702],
12	feedback	NN	O	feedback	nn	13	SENT_449	[p21l626t638r869b688],
13	activation	NN	O	activation	prep_through	1	SENT_449	[p21l880t641r1137b688],
14	of	IN	O	of	_	0	SENT_449	[p21l1154t638r1208b688],
15	EGFR	NN	ORGANIZATION	egfr	prep_of	13	SENT_449	[p21l1220t640r1365b688],
16	.	.	O	.	_	0	SENT_449	[p21l1220t640r1365b688],

1	Nature	NNP	O	Nature	_	0	SENT_450	[p21l1379t641r1552b688],
2	483	CD	NUMBER	483	num	1	SENT_450	[p21l1564t642r1680b696],
3	,	,	O	,	_	0	SENT_450	[p21l1564t642r1680b696],
4	100-103	CD	NUMBER	100-103	num	1	SENT_450	[p21l1699t642r1917b688],
5	(	CD	NUMBER	(	num	7	SENT_450	[p21l1935t639r2109b696],
6	2012	CD	DATE	2012	num	7	SENT_450	[p21l1935t639r2109b696],
7	)	NN	O	)	dep	1	SENT_450	[p21l1935t639r2109b696],
8	.	.	O	.	_	0	SENT_450	[p21l1935t639r2109b696],

1	A	DT	O	a	det	2	SENT_451	[p21l129t716r441b774],
2	|	NN	O	|	_	0	SENT_451	[p21l129t716r441b774],
3	.	.	O	.	_	0	SENT_451	[p21l129t716r441b774],

1	—	NN	O	—	_	0	SENT_452	[p21l129t716r441b774],
2	.	.	O	.	_	0	SENT_452	[p21l129t716r441b774],

1	Lazikani	NNP	PERSON	Lazikani	_	0	SENT_453	[p21l129t716r441b774],
2	,	,	O	,	_	0	SENT_453	[p21l129t716r441b774],
3	B.	NNP	O	B.	conj_and	1	SENT_453	[p21l460t719r516b774],
4	,	,	O	,	_	0	SENT_453	[p21l460t719r516b774],
5	Banerji	NNP	PERSON	Banerji	conj_and	1	SENT_453	[p21l535t718r734b780],
6	,	,	O	,	_	0	SENT_453	[p21l535t718r734b780],
7	U.	NNP	ORGANIZATION	U.	conj_and	1	SENT_453	[p21l754t719r801b766],
8	&	CC	ORGANIZATION	&	_	0	SENT_453	[p21l818t716r1145b774],
9	Workman	NNP	ORGANIZATION	Workman	conj_and	1	SENT_453	[p21l818t716r1145b774],
10	,	,	O	,	_	0	SENT_453	[p21l818t716r1145b774],
11	P.	NNP	O	P.	nn	14	SENT_453	[p21l1164t719r1197b766],
12	Combinatorial	NNP	O	Combinatorial	nn	14	SENT_453	[p21l1214t716r1601b766],
13	drug	NN	O	drug	nn	14	SENT_453	[p21l1621t716r1746b780],
14	therapy	NN	O	therapy	appos	1	SENT_453	[p21l130t794r342b858],
15	for	IN	O	for	_	0	SENT_453	[p21l356t794r431b844],
16	cancer	NN	O	cancer	prep_for	14	SENT_453	[p21l446t809r625b844],
17	in	IN	O	in	_	0	SENT_453	[p21l643t797r686b843],
18	the	DT	O	the	det	22	SENT_453	[p21l704t794r793b844],
19	post	NN	O	post	npadvmod	21	SENT_453	[p21l812t797r1192b858],
20	—	CD	NUMBER	—	num	19	SENT_453	[p21l812t797r1192b858],
21	genomic	JJ	O	genomic	amod	22	SENT_453	[p21l812t797r1192b858],
22	era	NN	O	era	prep_in	16	SENT_453	[p21l1209t809r1305b844],
23	.	.	O	.	_	0	SENT_453	[p21l1209t809r1305b844],

1	Nat	NN	PERSON	nat	_	0	SENT_454	[p21l1322t797r1426b844],
2	.	.	O	.	_	0	SENT_454	[p21l1322t797r1426b844],

1	Biotechnol	NNP	O	Biotechnol	_	0	SENT_455	[p21l1444t794r1735b844],
2	.	.	O	.	_	0	SENT_455	[p21l1444t794r1735b844],

1	30	CD	NUMBER	30	_	0	SENT_456	[p21l1754t798r1837b852],
2	,	,	O	,	_	0	SENT_456	[p21l1754t798r1837b852],
3	679-692	CD	NUMBER	679-692	number	4	SENT_456	[p21l1853t798r2084b844],
4	(	CD	NUMBER	(	appos	1	SENT_456	[p21l133t872r315b928],
5	2012	CD	DATE	2012	num	6	SENT_456	[p21l133t872r315b928],
6	)	NN	O	)	dep	4	SENT_456	[p21l133t872r315b928],
7	.	.	O	.	_	0	SENT_456	[p21l133t872r315b928],

1	Garraway	NNP	ORGANIZATION	Garraway	nn	2	SENT_457	[p21l130t951r378b1013],
2	L.A.	NNP	ORGANIZATION	L.A.	_	0	SENT_457	[p21l393t952r482b999],
3	&	CC	ORGANIZATION	&	_	0	SENT_457	[p21l496t951r699b999],
4	Janne	NNP	ORGANIZATION	Janne	conj_and	2	SENT_457	[p21l496t951r699b999],
5	PA.	NNP	ORGANIZATION	PA.	dep	2	SENT_457	[p21l716t951r799b999],
6	.	.	O	.	_	0	SENT_457	[p21l716t951r799b999],

1	Circumventing	VBG	O	circumvent	amod	4	SENT_458	[p21l814t951r1200b1013],
2	cancer	NN	O	cancer	nn	4	SENT_458	[p21l1216t964r1389b999],
3	drug	NN	O	drug	nn	4	SENT_458	[p21l1402t949r1523b1013],
4	resistance	NN	O	resistance	_	0	SENT_458	[p21l1542t952r1800b999],
5	in	IN	O	in	_	0	SENT_458	[p21l1816t952r1859b999],
6	the	DT	O	the	det	7	SENT_458	[p21l1874t949r1960b999],
7	era	NN	O	era	prep_in	4	SENT_458	[p21l1974t964r2052b999],
8	of	IN	O	of	_	0	SENT_458	[p21l2068t949r2122b999],
9	personalized	JJ	O	personalized	amod	10	SENT_458	[p21l133t1027r464b1090],
10	medicine	NN	O	medicine	prep_of	7	SENT_458	[p21l483t1027r736b1077],
11	.	.	O	.	_	0	SENT_458	[p21l483t1027r736b1077],

1	CancerDiscov	NNP	O	CancerDiscov	_	0	SENT_459	[p21l751t1029r1109b1077],
2	.	.	O	.	_	0	SENT_459	[p21l751t1029r1109b1077],

1	2	CD	NUMBER	2	_	0	SENT_460	[p21l1126t1031r1170b1085],
2	,	,	O	,	_	0	SENT_460	[p21l1126t1031r1170b1085],
3	214-226	CD	NUMBER	214-226	num	4	SENT_460	[p21l1185t1031r1409b1077],
4	(	NN	O	(	appos	1	SENT_460	[p21l1425t1028r1525b1085],
5	201	CD	NUMBER	201	number	6	SENT_460	[p21l1425t1028r1525b1085],
6	2	CD	NUMBER	2	num	7	SENT_460	[p21l1540t1028r1599b1085],
7	)	NN	O	)	dep	4	SENT_460	[p21l1540t1028r1599b1085],
8	.	.	O	.	_	0	SENT_460	[p21l1540t1028r1599b1085],

1	Workman	NN	PERSON	workman	_	0	SENT_461	[p21l128t1106r397b1163],
2	,	,	O	,	_	0	SENT_461	[p21l128t1106r397b1163],
3	P.	NNP	O	P.	nn	7	SENT_461	[p21l414t1108r446b1155],
4	&	CC	O	&	_	0	SENT_461	[p21l459t1107r496b1155],
5	Clarke	NNP	PERSON	Clarke	nn	7	SENT_461	[p21l509t1106r683b1163],
6	,	,	O	,	_	0	SENT_461	[p21l509t1106r683b1163],
7	P.A.	NNP	O	P.A.	appos	1	SENT_461	[p21l700t1108r783b1155],
8	Resisting	VBG	O	resist	partmod	7	SENT_461	[p21l800t1108r1030b1169],
9	targeted	VBN	O	target	dep	8	SENT_461	[p21l1045t1106r1269b1169],
10	therapy	NN	O	therapy	dobj	9	SENT_461	[p21l1284t1106r1501b1169],
11	:	:	O	:	_	0	SENT_461	[p21l1284t1106r1501b1169],
12	ﬁfty	NN	O	ﬁfty	nn	13	SENT_461	[p21l1514t1105r1617b1169],
13	ways	NNS	O	way	nsubj	15	SENT_461	[p21l1629t1120r1757b1169],
14	to	TO	O	to	aux	15	SENT_461	[p21l1771t1113r1824b1155],
15	leave	VB	O	leave	parataxis	9	SENT_461	[p21l1840t1106r1973b1155],
16	your	PRP$	O	you	poss	17	SENT_461	[p21l1986t1120r2105b1169],
17	EGFR	NN	ORGANIZATION	egfr	dobj	15	SENT_461	[p21l133t1185r278b1232],
18	.	.	O	.	_	0	SENT_461	[p21l133t1185r278b1232],

1	Cancer	NN	O	cancer	_	0	SENT_462	[p21l293t1184r470b1232],
2	Cell	NN	O	cell	dep	1	SENT_462	[p21l480t1183r578b1232],
3	.	.	O	.	_	0	SENT_462	[p21l480t1183r578b1232],

1	19	CD	NUMBER	19	_	0	SENT_463	[p21l598t1186r674b1239],
2	,	,	O	,	_	0	SENT_463	[p21l598t1186r674b1239],
3	437-440	CD	NUMBER	437-440	num	4	SENT_463	[p21l687t1186r913b1232],
4	(	NN	O	(	appos	1	SENT_463	[p21l929t1184r1029b1239],
5	201	CD	NUMBER	201	number	6	SENT_463	[p21l929t1184r1029b1239],
6	1	CD	NUMBER	1	num	7	SENT_463	[p21l1048t1184r1103b1239],
7	)	NN	O	)	dep	4	SENT_463	[p21l1048t1184r1103b1239],
8	.	.	O	.	_	0	SENT_463	[p21l1048t1184r1103b1239],

1	Postel-Vinay	NNP	O	Postel-Vinay	_	0	SENT_464	[p21l132t1261r459b1324],
2	,	,	O	,	_	0	SENT_464	[p21l132t1261r459b1324],
3	S.	NNP	ORGANIZATION	S.	conj_and	1	SENT_464	[p21l474t1262r514b1310],
4	&	CC	ORGANIZATION	&	_	0	SENT_464	[p21l529t1262r566b1310],
5	Ashworth	NNP	ORGANIZATION	Ashworth	conj_and	1	SENT_464	[p21l578t1261r846b1318],
6	,	,	O	,	_	0	SENT_464	[p21l578t1261r846b1318],
7	A.	NNP	O	A.	nn	8	SENT_464	[p21l859t1263r908b1310],
8	AXL	NNP	ORGANIZATION	AXL	appos	1	SENT_464	[p21l922t1263r1024b1310],
9	and	CC	O	and	_	0	SENT_464	[p21l1037t1261r1134b1310],
10	acquired	VBN	O	acquire	amod	11	SENT_464	[p21l1150t1261r1377b1323],
11	resistance	NN	O	resistance	appos	1	SENT_464	[p21l1396t1263r1654b1310],
12	to	TO	O	to	_	0	SENT_464	[p21l1667t1268r1720b1310],
13	EGFR	NN	ORGANIZATION	egfr	nn	14	SENT_464	[p21l1737t1263r1869b1310],
14	inhibitors	NNS	O	inhibitor	prep_to	11	SENT_464	[p21l1884t1261r2144b1310],
15	.	.	O	.	_	0	SENT_464	[p21l1884t1261r2144b1310],

1	Nat	NN	PERSON	nat	_	0	SENT_465	[p21l131t1340r231b1387],
2	.	.	O	.	_	0	SENT_465	[p21l131t1340r231b1387],

1	Genet	NNP	PERSON	Genet	_	0	SENT_466	[p21l248t1340r405b1387],
2	.	.	O	.	_	0	SENT_466	[p21l248t1340r405b1387],

1	44	CD	NUMBER	44	_	0	SENT_467	[p21l421t1342r502b1394],
2	,	,	O	,	_	0	SENT_467	[p21l421t1342r502b1394],
3	835-836	CD	NUMBER	835-836	number	4	SENT_467	[p21l516t1341r741b1387],
4	(	CD	NUMBER	(	appos	1	SENT_467	[p21l757t1339r930b1394],
5	2012	CD	DATE	2012	num	6	SENT_467	[p21l757t1339r930b1394],
6	)	NN	O	)	dep	4	SENT_467	[p21l757t1339r930b1394],
7	.	.	O	.	_	0	SENT_467	[p21l757t1339r930b1394],

1	Bivona	NNP	PERSON	Bivona	_	0	SENT_468	[p21l132t1418r422b1473],
2	,	,	O	,	_	0	SENT_468	[p21l132t1418r422b1473],
3	T.G.	NNP	O	T.G.	nn	4	SENT_468	[p21l132t1418r422b1473],
4	etal	NNP	O	etal	appos	1	SENT_468	[p21l436t1416r548b1465],
5	.	.	O	.	_	0	SENT_468	[p21l436t1416r548b1465],

1	FAS	NN	O	fa	nn	4	SENT_469	[p21l567t1417r657b1465],
2	and	CC	O	and	_	0	SENT_469	[p21l672t1416r768b1465],
3	NF-KB	NN	MISC	nf-kb	nn	4	SENT_469	[p21l787t1418r939b1465],
4	signalling	NN	O	signalling	nsubj	5	SENT_469	[p21l954t1416r1204b1479],
5	modulate	VBP	O	modulate	_	0	SENT_469	[p21l1223t1416r1474b1465],
6	dependence	NN	O	dependence	dobj	5	SENT_469	[p21l1488t1416r1819b1478],
7	of	IN	O	of	_	0	SENT_469	[p21l1834t1415r1888b1465],
8	lung	NN	O	lung	nn	9	SENT_469	[p21l1900t1416r2013b1479],
9	cancers	NNS	O	cancer	prep_of	6	SENT_469	[p21l131t1507r327b1542],
10	on	IN	O	on	_	0	SENT_469	[p21l342t1507r406b1542],
11	mutant	JJ	O	mutant	amod	12	SENT_469	[p21l425t1500r616b1542],
12	EGFR	NN	ORGANIZATION	egfr	prep_on	9	SENT_469	[p21l632t1495r777b1542],
13	.	.	O	.	_	0	SENT_469	[p21l632t1495r777b1542],

1	Nature	NNP	O	Nature	_	0	SENT_470	[p21l791t1495r964b1542],
2	471	CD	NUMBER	471	num	1	SENT_470	[p21l977t1497r1093b1549],
3	,	,	O	,	_	0	SENT_470	[p21l977t1497r1093b1549],
4	523-526	CD	NUMBER	523-526	num	1	SENT_470	[p21l1107t1496r1331b1542],
5	(	NN	O	(	dep	1	SENT_470	[p21l1347t1494r1448b1549],
6	201	CD	NUMBER	201	number	7	SENT_470	[p21l1347t1494r1448b1549],
7	1	CD	NUMBER	1	num	8	SENT_470	[p21l1466t1494r1521b1549],
8	)	NN	O	)	dep	5	SENT_470	[p21l1466t1494r1521b1549],
9	.	.	O	.	_	0	SENT_470	[p21l1466t1494r1521b1549],

1	Sequist	NNP	O	Sequist	_	0	SENT_471	[p21l130t1572r343b1633],
2	,	,	O	,	_	0	SENT_471	[p21l130t1572r343b1633],
3	L.V.	NNP	PERSON	L.V.	nn	4	SENT_471	[p21l362t1573r448b1620],
4	etal	NNP	O	etal	appos	1	SENT_471	[p21l465t1571r583b1620],
5	.	.	O	.	_	0	SENT_471	[p21l465t1571r583b1620],

1	Genotypic	JJ	MISC	genotypic	amod	4	SENT_472	[p21l603t1573r884b1634],
2	and	CC	O	and	_	0	SENT_472	[p21l901t1571r999b1620],
3	histological	JJ	O	histological	conj_and	1	SENT_472	[p21l1021t1571r1331b1634],
4	evolution	NN	O	evolution	_	0	SENT_472	[p21l1351t1571r1608b1620],
5	of	IN	O	of	_	0	SENT_472	[p21l1627t1570r1683b1620],
6	lung	NN	O	lung	nn	7	SENT_472	[p21l1697t1571r1814b1634],
7	cancers	NNS	O	cancer	prep_of	4	SENT_472	[p21l131t1663r335b1698],
8	acquiring	VBG	O	acquire	partmod	4	SENT_472	[p21l352t1651r608b1712],
9	resistance	NN	O	resistance	dobj	8	SENT_472	[p21l629t1651r899b1698],
10	to	TO	O	to	_	0	SENT_472	[p21l914t1656r969b1698],
11	EGFR	NN	ORGANIZATION	egfr	nn	12	SENT_472	[p21l988t1651r1125b1698],
12	inhibitors	NNS	O	inhibitor	prep_to	8	SENT_472	[p21l1142t1649r1415b1698],
13	.	.	O	.	_	0	SENT_472	[p21l1142t1649r1415b1698],

1	Sci	NNP	O	Sci	_	0	SENT_473	[p21l1430t1650r1515b1698],
2	.	.	O	.	_	0	SENT_473	[p21l1430t1650r1515b1698],

1	Trans	NNP	MISC	Trans	nn	2	SENT_474	[p21l1534t1649r1698b1698],
2	]	NNP	O	]	_	0	SENT_474	[p21l1534t1649r1698b1698],
3	.	.	O	.	_	0	SENT_474	[p21l1534t1649r1698b1698],

1	Med	NNP	O	Med	_	0	SENT_475	[p21l1714t1649r1837b1698],
2	.	.	O	.	_	0	SENT_475	[p21l1714t1649r1837b1698],

1	3	CD	NUMBER	3	_	0	SENT_476	[p21l1857t1652r1902b1706],
2	,	,	O	,	_	0	SENT_476	[p21l1857t1652r1902b1706],
3	75ra26	CD	NUMBER	75ra26	num	4	SENT_476	[p21l1921t1652r2104b1698],
4	(	NN	O	(	appos	1	SENT_476	[p21l133t1727r237b1782],
5	201	CD	NUMBER	201	number	6	SENT_476	[p21l133t1727r237b1782],
6	1	CD	NUMBER	1	num	7	SENT_476	[p21l257t1727r315b1782],
7	)	NN	O	)	dep	4	SENT_476	[p21l257t1727r315b1782],
8	.	.	O	.	_	0	SENT_476	[p21l257t1727r315b1782],

1	Rekhtman	NNP	MISC	Rekhtman	_	0	SENT_477	[p21l132t1804r417b1861],
2	,	,	O	,	_	0	SENT_477	[p21l132t1804r417b1861],
3	N.	NNP	O	N.	nn	4	SENT_477	[p21l435t1806r484b1853],
4	etal	NN	O	etal	appos	1	SENT_477	[p21l500t1804r615b1853],
5	.	.	O	.	_	0	SENT_477	[p21l500t1804r615b1853],

1	Clarifying	VBG	O	clarify	_	0	SENT_478	[p21l633t1803r885b1867],
2	the	DT	O	the	det	3	SENT_478	[p21l902t1804r989b1853],
3	spectrum	NN	O	spectrum	dobj	1	SENT_478	[p21l1005t1811r1255b1866],
4	of	IN	O	of	_	0	SENT_478	[p21l1274t1803r1328b1853],
5	driver	NN	O	driver	nn	7	SENT_478	[p21l1339t1804r1495b1853],
6	oncogene	NN	O	oncogene	nn	7	SENT_478	[p21l1509t1818r1778b1867],
7	mutations	NNS	O	mutation	prep_of	3	SENT_478	[p21l1795t1806r2066b1853],
8	in	IN	O	in	_	0	SENT_478	[p21l133t1884r176b1931],
9	biomarker-veriﬁed	JJ	O	biomarker-veriﬁed	amod	11	SENT_478	[p21l195t1881r689b1931],
10	squamous	JJ	O	squamous	amod	11	SENT_478	[p21l707t1896r982b1944],
11	carcinoma	NN	O	carcinoma	prep_in	7	SENT_478	[p21l999t1884r1275b1931],
12	of	IN	O	of	_	0	SENT_478	[p21l1292t1881r1348b1931],
13	lung	NN	O	lung	prep_of	11	SENT_478	[p21l1361t1882r1491b1945],
14	:	:	O	:	_	0	SENT_478	[p21l1361t1882r1491b1945],
15	lack	NN	O	lack	dep	3	SENT_478	[p21l1509t1882r1612b1931],
16	of	IN	O	of	_	0	SENT_478	[p21l1625t1881r1680b1931],
17	EGFR/KRAS	NN	O	egfr/kras	prep_of	15	SENT_478	[p21l1693t1883r1991b1934],
18	and	CC	O	and	_	0	SENT_478	[p21l2007t1882r2104b1931],
19	presence	NN	O	presence	conj_and	17	SENT_478	[p21l133t1974r372b2022],
20	of	IN	O	of	_	0	SENT_478	[p21l388t1959r443b2009],
21	P	NN	O	p	nn	24	SENT_478	[p21l456t1961r800b2012],
22	|	CD	NUMBER	|	num	24	SENT_478	[p21l456t1961r800b2012],
23	K3CA/AKT1	NN	O	k3ca/akt1	nn	24	SENT_478	[p21l456t1961r800b2012],
24	mutations	NNS	O	mutation	prep_of	15	SENT_478	[p21l828t1962r1111b2009],
25	.	.	O	.	_	0	SENT_478	[p21l828t1962r1111b2009],

1	Clin	NNP	O	Clin	_	0	SENT_479	[p21l1128t1960r1235b2009],
2	.	.	O	.	_	0	SENT_479	[p21l1128t1960r1235b2009],

1	Cancer	NN	O	cancer	_	0	SENT_480	[p21l1252t1961r1432b2009],
2	Res	NNP	O	Res	dep	1	SENT_480	[p21l1442t1962r1536b2009],
3	.	.	O	.	_	0	SENT_480	[p21l1442t1962r1536b2009],

1	18	CD	NUMBER	18	_	0	SENT_481	[p21l1558t1963r1636b2017],
2	,	,	O	,	_	0	SENT_481	[p21l1558t1963r1636b2017],
3	1	CD	NUMBER	1	num	4	SENT_481	[p21l1656t1964r1670b2009],
4	167-1	CD	NUMBER	167-1	appos	1	SENT_481	[p21l1689t1963r1836b2009],
5	176	CD	NUMBER	176	number	6	SENT_481	[p21l1855t1963r1946b2009],
6	(	CD	NUMBER	(	dep	4	SENT_481	[p21l1963t1961r2141b2017],
7	2012	CD	DATE	2012	num	8	SENT_481	[p21l1963t1961r2141b2017],
8	)	NN	O	)	dep	6	SENT_481	[p21l1963t1961r2141b2017],
9	.	.	O	.	_	0	SENT_481	[p21l1963t1961r2141b2017],

1	Voulgari	NNP	PERSON	Voulgari	dep	11	SENT_482	[p21l127t2038r359b2101],
2	,	,	O	,	_	0	SENT_482	[p21l127t2038r359b2101],
3	A.	NNP	ORGANIZATION	A.	appos	1	SENT_482	[p21l373t2040r422b2087],
4	&	CC	ORGANIZATION	&	_	0	SENT_482	[p21l436t2039r473b2087],
5	Pintzas	NNP	ORGANIZATION	Pintzas	conj_and	3	SENT_482	[p21l488t2040r680b2095],
6	,	,	O	,	_	0	SENT_482	[p21l488t2040r680b2095],
7	A.	NN	PERSON	a.	appos	1	SENT_482	[p21l694t2040r743b2087],
8	Epithe	NNP	PERSON	Epithe	dep	11	SENT_482	[p21l760t2038r1386b2101],
9	|	CD	NUMBER	|	num	11	SENT_482	[p21l760t2038r1386b2101],
10	ial	JJ	O	ial	amod	11	SENT_482	[p21l760t2038r1386b2101],
11	—	NN	O	—	dep	18	SENT_482	[p21l760t2038r1386b2101],
12	mesenchymal	JJ	O	mesenchymal	amod	13	SENT_482	[p21l760t2038r1386b2101],
13	transition	NN	O	transition	dep	11	SENT_482	[p21l1402t2040r1650b2087],
14	in	IN	O	in	_	0	SENT_482	[p21l1668t2040r1711b2087],
15	cancer	NN	O	cancer	nn	16	SENT_482	[p21l1728t2052r1900b2087],
16	metastasis	NN	O	metastasis	prep_in	13	SENT_482	[p21l133t2118r419b2165],
17	:	:	O	:	_	0	SENT_482	[p21l133t2118r419b2165],
18	mechanisms	NNS	O	mechanism	_	0	SENT_482	[p21l435t2116r775b2173],
19	,	,	O	,	_	0	SENT_482	[p21l435t2116r775b2173],
20	markers	NNS	O	marker	conj_and	18	SENT_482	[p21l791t2116r998b2165],
21	and	CC	O	and	_	0	SENT_482	[p21l1012t2116r1109b2165],
22	strategies	NNS	O	strategy	conj_and	18	SENT_482	[p21l1126t2118r1378b2179],
23	to	TO	O	to	aux	24	SENT_482	[p21l1391t2123r1444b2165],
24	overcome	VB	O	overcome	infmod	18	SENT_482	[p21l1459t2130r1720b2165],
25	drug	NN	O	drug	nn	26	SENT_482	[p21l1734t2116r1856b2179],
26	resistance	NN	O	resistance	dobj	24	SENT_482	[p21l1874t2118r2132b2165],
27	in	IN	O	in	_	0	SENT_482	[p21l133t2196r175b2243],
28	the	DT	O	the	det	29	SENT_482	[p21l190t2194r276b2243],
29	clinic	NN	O	clinic	prep_in	24	SENT_482	[p21l290t2194r435b2243],
30	.	.	O	.	_	0	SENT_482	[p21l290t2194r435b2243],

1	Biochim	NNP	O	Biochim	_	0	SENT_483	[p21l450t2194r665b2243],
2	.	.	O	.	_	0	SENT_483	[p21l450t2194r665b2243],

1	Biophys	NNS	O	biophy	_	0	SENT_484	[p21l680t2194r886b2257],
2	.	.	O	.	_	0	SENT_484	[p21l680t2194r886b2257],

1	Acta	NNP	O	Acta	_	0	SENT_485	[p21l898t2196r1014b2243],
2	1796	CD	DATE	1796	num	1	SENT_485	[p21l1031t2197r1179b2251],
3	,	,	O	,	_	0	SENT_485	[p21l1031t2197r1179b2251],
4	75-90	CD	NUMBER	75-90	num	1	SENT_485	[p21l1194t2197r1352b2243],
5	(	CD	NUMBER	(	num	7	SENT_485	[p21l1368t2195r1542b2251],
6	2009	CD	DATE	2009	num	7	SENT_485	[p21l1368t2195r1542b2251],
7	)	NN	O	)	dep	1	SENT_485	[p21l1368t2195r1542b2251],
8	.	.	O	.	_	0	SENT_485	[p21l1368t2195r1542b2251],

1	Nurwidya	NNP	O	Nurwidya	_	0	SENT_486	[p21l132t2272r396b2335],
2	,	,	O	,	_	0	SENT_486	[p21l132t2272r396b2335],
3	F.	NNP	O	F.	conj_and	1	SENT_486	[p21l413t2272r740b2329],
4	,	,	O	,	_	0	SENT_486	[p21l413t2272r740b2329],
5	Takahashi	NNP	PERSON	Takahashi	conj_and	1	SENT_486	[p21l413t2272r740b2329],
6	,	,	O	,	_	0	SENT_486	[p21l413t2272r740b2329],
7	F.	NNP	O	F.	conj_and	1	SENT_486	[p21l756t2274r801b2329],
8	,	,	O	,	_	0	SENT_486	[p21l756t2274r801b2329],
9	Murakami	NNP	PERSON	Murakami	conj_and	1	SENT_486	[p21l817t2272r1092b2329],
10	,	,	O	,	_	0	SENT_486	[p21l817t2272r1092b2329],
11	A.	NNP	ORGANIZATION	A.	conj_and	1	SENT_486	[p21l1106t2274r1155b2321],
12	&	CC	ORGANIZATION	&	_	0	SENT_486	[p21l1169t2272r1486b2329],
13	Takahashi	NNP	ORGANIZATION	Takahashi	conj_and	1	SENT_486	[p21l1169t2272r1486b2329],
14	,	,	O	,	_	0	SENT_486	[p21l1169t2272r1486b2329],
15	K.	NNP	O	K.	nn	18	SENT_486	[p21l1503t2274r1545b2321],
16	Epithelial	JJ	O	epithelial	amod	18	SENT_486	[p21l1562t2272r1799b2334],
17	mesenchymal	JJ	O	mesenchymal	amod	18	SENT_486	[p21l133t2350r494b2413],
18	transition	NN	O	transition	appos	1	SENT_486	[p21l510t2352r758b2399],
19	in	IN	O	in	_	0	SENT_486	[p21l777t2352r819b2399],
20	drug	NN	O	drug	nn	21	SENT_486	[p21l836t2350r957b2413],
21	resistance	NN	O	resistance	prep_in	18	SENT_486	[p21l976t2352r1234b2399],
22	and	CC	O	and	_	0	SENT_486	[p21l1248t2350r1345b2399],
23	metastasis	NN	O	metastasis	conj_and	21	SENT_486	[p21l1363t2352r1636b2399],
24	of	IN	O	of	_	0	SENT_486	[p21l1650t2349r1705b2399],
25	lung	NN	O	lung	nn	26	SENT_486	[p21l1717t2350r1830b2413],
26	cancer	NN	O	cancer	prep_of	18	SENT_486	[p21l1846t2364r2027b2399],
27	.	.	O	.	_	0	SENT_486	[p21l1846t2364r2027b2399],

1	Cancer	NN	O	cancer	_	0	SENT_487	[p21l132t2428r308b2476],
2	Res	NNP	O	Res	dep	1	SENT_487	[p21l317t2429r409b2476],
3	.	.	O	.	_	0	SENT_487	[p21l317t2429r409b2476],

1	Treat	VB	O	treat	_	0	SENT_488	[p21l427t2429r560b2476],
2	.	.	O	.	_	0	SENT_488	[p21l427t2429r560b2476],

1	44	CD	NUMBER	44	_	0	SENT_489	[p21l576t2431r657b2483],
2	,	,	O	,	_	0	SENT_489	[p21l576t2431r657b2483],
3	151-156	CD	NUMBER	151-156	number	4	SENT_489	[p21l676t2430r896b2476],
4	(	CD	NUMBER	(	appos	1	SENT_489	[p21l912t2428r1085b2483],
5	2012	CD	DATE	2012	num	6	SENT_489	[p21l912t2428r1085b2483],
6	)	NN	O	)	dep	4	SENT_489	[p21l912t2428r1085b2483],
7	.	.	O	.	_	0	SENT_489	[p21l912t2428r1085b2483],

1	Huang	NNP	PERSON	Huang	_	0	SENT_490	[p21l132t2507r322b2568],
2	,	,	O	,	_	0	SENT_490	[p21l132t2507r322b2568],
3	S.	NNP	O	S.	nn	4	SENT_490	[p21l340t2506r381b2554],
4	etal	NNP	O	etal	appos	1	SENT_490	[p21l398t2505r516b2554],
5	.	.	O	.	_	0	SENT_490	[p21l398t2505r516b2554],

1	MED12	NN	O	med12	nsubj	2	SENT_491	[p21l537t2507r726b2554],
2	controls	VBZ	O	control	_	0	SENT_491	[p21l744t2505r964b2554],
3	the	DT	O	the	det	4	SENT_491	[p21l980t2505r1068b2554],
4	response	NN	O	response	dobj	2	SENT_491	[p21l1087t2519r1331b2567],
5	to	TO	O	to	_	0	SENT_491	[p21l1347t2512r1401b2554],
6	multiple	JJ	O	multiple	amod	8	SENT_491	[p21l1420t2505r1645b2567],
7	cancer	NN	O	cancer	nn	8	SENT_491	[p21l1662t2519r1842b2554],
8	drugs	NNS	O	drug	prep_to	4	SENT_491	[p21l1857t2505r2011b2568],
9	through	IN	O	through	_	0	SENT_491	[p21l130t2583r350b2646],
10	regulation	NN	O	regulation	nn	13	SENT_491	[p21l371t2583r649b2646],
11	ofTGF-B	NN	O	oftgf-b	nn	13	SENT_491	[p21l668t2582r892b2645],
12	receptor	NN	O	receptor	nn	13	SENT_491	[p21l911t2590r1140b2645],
13	signaling	NN	O	signaling	prep_through	2	SENT_491	[p21l1156t2583r1417b2646],
14	.	.	O	.	_	0	SENT_491	[p21l1156t2583r1417b2646],

1	Cell	NN	O	cell	_	0	SENT_492	[p21l1435t2583r1530b2632],
2	151	CD	NUMBER	151	num	1	SENT_492	[p21l1547t2587r1663b2640],
3	,	,	O	,	_	0	SENT_492	[p21l1547t2587r1663b2640],
4	937-950	CD	NUMBER	937-950	number	5	SENT_492	[p21l1680t2586r1912b2632],
5	(	CD	NUMBER	(	appos	1	SENT_492	[p21l1931t2584r2112b2640],
6	2012	CD	DATE	2012	num	7	SENT_492	[p21l1931t2584r2112b2640],
7	)	NN	O	)	dep	5	SENT_492	[p21l1931t2584r2112b2640],
8	.	.	O	.	_	0	SENT_492	[p21l1931t2584r2112b2640],

1	Miller	NNP	PERSON	Miller	nn	3	SENT_493	[p21l131t2661r284b2718],
2	,	,	O	,	_	0	SENT_493	[p21l131t2661r284b2718],
3	V.A.	NNP	O	V.A.	dep	4	SENT_493	[p21l294t2663r390b2711],
4	etal	JJ	O	etal	_	0	SENT_493	[p21l404t2661r516b2711],
5	.	.	O	.	_	0	SENT_493	[p21l404t2661r516b2711],

1	Afatinib	NNP	O	Afatinib	dep	15	SENT_494	[p21l532t2660r738b2711],
2	versus	CC	O	versus	prep	1	SENT_494	[p21l751t2676r916b2711],
3	placebo	NN	O	placebo	dep	2	SENT_494	[p21l933t2661r1140b2723],
4	for	IN	O	for	_	0	SENT_494	[p21l1153t2660r1226b2711],
5	patients	NNS	O	patient	prep_for	3	SENT_494	[p21l1240t2663r1450b2723],
6	with	IN	O	with	_	0	SENT_494	[p21l1464t2661r1577b2711],
7	advanced	JJ	O	advanced	amod	12	SENT_494	[p21l1593t2661r1861b2718],
8	,	,	O	,	_	0	SENT_494	[p21l1593t2661r1861b2718],
9	metastatic	JJ	O	metastatic	amod	12	SENT_494	[p21l1878t2663r2150b2711],
10	non-small	JJ	O	non-small	amod	12	SENT_494	[p21l133t2739r499b2789],
11	—	NN	O	—	nn	12	SENT_494	[p21l133t2739r499b2789],
12	cell	NN	O	cell	prep_with	5	SENT_494	[p21l133t2739r499b2789],
13	lung	NN	O	lung	dep	15	SENT_494	[p21l518t2739r631b2802],
14	cancer	NN	O	cancer	nn	15	SENT_494	[p21l647t2754r820b2789],
15	afterfailure	NN	O	afterfailure	dep	34	SENT_494	[p21l833t2738r1129b2789],
16	of	IN	O	of	_	0	SENT_494	[p21l1143t2738r1198b2789],
17	erlotinib	NN	O	erlotinib	prep_of	15	SENT_494	[p21l1207t2739r1440b2796],
18	,	,	O	,	_	0	SENT_494	[p21l1207t2739r1440b2796],
19	geﬁtinib	NN	O	geﬁtinib	conj_or	17	SENT_494	[p21l1454t2738r1685b2802],
20	,	,	O	,	_	0	SENT_494	[p21l1454t2738r1685b2802],
21	or	CC	O	or	_	0	SENT_494	[p21l1699t2754r1752b2789],
22	both	DT	O	both	advmod	17	SENT_494	[p21l1767t2739r1902b2796],
23	,	,	O	,	_	0	SENT_494	[p21l1767t2739r1902b2796],
24	and	CC	O	and	_	0	SENT_494	[p21l1916t2739r2013b2789],
25	one	CD	NUMBER	one	conj_and	17	SENT_494	[p21l2030t2754r2128b2789],
26	or	CC	O	or	_	0	SENT_494	[p21l131t2832r184b2867],
27	two	CD	NUMBER	two	num	28	SENT_494	[p21l196t2824r296b2867],
28	lines	NNS	O	line	conj_or	15	SENT_494	[p21l313t2817r429b2867],
29	of	IN	O	of	_	0	SENT_494	[p21l443t2816r498b2867],
30	chemotherapy	NN	O	chemotherapy	nn	32	SENT_494	[p21l507t2817r894b2880],
31	(	CD	NUMBER	(	num	32	SENT_494	[p21l909t2818r1178b2880],
32	LUX-Lung	NN	O	lux-lung	prep_of	28	SENT_494	[p21l909t2818r1178b2880],
33	1	CD	NUMBER	1	num	34	SENT_494	[p21l1199t2818r1254b2874],
34	)	NN	O	)	dep	39	SENT_494	[p21l1199t2818r1254b2874],
35	:	:	O	:	_	0	SENT_494	[p21l1199t2818r1254b2874],
36	a	DT	O	a	det	38	SENT_494	[p21l1268t2832r1294b2867],
37	phase	NN	O	phase	nn	38	SENT_494	[p21l1312t2817r1466b2879],
38	2b/3	NN	O	2b/3	nsubj	39	SENT_494	[p21l1481t2817r1598b2869],
39	randomised	VBD	O	randomise	_	0	SENT_494	[p21l1616t2817r1926b2867],
40	trial	NN	O	trial	dobj	39	SENT_494	[p21l1941t2817r2054b2867],
41	.	.	O	.	_	0	SENT_494	[p21l1941t2817r2054b2867],

1	Lancet	NNP	O	Lancet	nn	2	SENT_495	[p21l131t2896r301b2943],
2	Oncol	NNP	O	Oncol	_	0	SENT_495	[p21l311t2894r467b2943],
3	.	.	O	.	_	0	SENT_495	[p21l311t2894r467b2943],

1	13	CD	NUMBER	13	_	0	SENT_496	[p21l487t2897r564b2950],
2	,	,	O	,	_	0	SENT_496	[p21l487t2897r564b2950],
3	528-538	CD	NUMBER	528-538	number	4	SENT_496	[p21l579t2897r802b2943],
4	(	CD	NUMBER	(	appos	1	SENT_496	[p21l818t2895r993b2950],
5	2012	CD	DATE	2012	num	6	SENT_496	[p21l818t2895r993b2950],
6	)	NN	O	)	dep	4	SENT_496	[p21l818t2895r993b2950],
7	.	.	O	.	_	0	SENT_496	[p21l818t2895r993b2950],

1	Chmielecki	NNP	PERSON	Chmielecki	nn	3	SENT_497	[p21l129t2972r432b3029],
2	,	,	O	,	_	0	SENT_497	[p21l129t2972r432b3029],
3	J.	NNP	O	J.	_	0	SENT_497	[p21l444t2974r478b3022],
4	et	FW	O	et	nn	5	SENT_497	[p21l492t2979r541b3022],
5	al.	FW	O	al.	dep	3	SENT_497	[p21l550t2972r604b3022],
6	.	.	O	.	_	0	SENT_497	[p21l550t2972r604b3022],

1	Optimization	NN	O	optimization	_	0	SENT_498	[p21l620t2973r962b3034],
2	of	IN	O	of	_	0	SENT_498	[p21l979t2971r1033b3022],
3	dosing	NN	O	dosing	prep_of	1	SENT_498	[p21l1043t2972r1219b3035],
4	for	IN	O	for	_	0	SENT_498	[p21l1234t2971r1306b3022],
5	EGFR-mutant	JJ	O	egfr-mutant	amod	9	SENT_498	[p21l1322t2974r1670b3022],
6	non-small	JJ	O	non-small	amod	9	SENT_498	[p21l1685t2972r1942b3022],
7	cell	NN	O	cell	nn	9	SENT_498	[p21l1958t2972r2042b3022],
8	lung	NN	O	lung	nn	9	SENT_498	[p21l133t3050r246b3113],
9	cancer	NN	O	cancer	prep_for	1	SENT_498	[p21l262t3064r435b3099],
10	with	IN	O	with	_	0	SENT_498	[p21l447t3050r560b3099],
11	evolutionary	JJ	O	evolutionary	amod	13	SENT_498	[p21l577t3050r910b3114],
12	cancer	NN	O	cancer	nn	13	SENT_498	[p21l924t3064r1096b3099],
13	modeling	NN	O	modeling	prep_with	1	SENT_498	[p21l1111t3050r1374b3113],
14	.	.	O	.	_	0	SENT_498	[p21l1111t3050r1374b3113],

1	Sci	NNP	O	Sci	_	0	SENT_499	[p21l1387t3052r1468b3099],
2	.	.	O	.	_	0	SENT_499	[p21l1387t3052r1468b3099],

1	Trans	NNP	MISC	Trans	nn	2	SENT_500	[p21l1485t3050r1640b3099],
2	]	NNP	O	]	_	0	SENT_500	[p21l1485t3050r1640b3099],
3	.	.	O	.	_	0	SENT_500	[p21l1485t3050r1640b3099],

1	Med	NNP	O	Med	_	0	SENT_501	[p21l1654t3050r1774b3099],
2	.	.	O	.	_	0	SENT_501	[p21l1654t3050r1774b3099],

1	3	CD	NUMBER	3	_	0	SENT_502	[p21l1790t3053r1835b3107],
2	,	,	O	,	_	0	SENT_502	[p21l1790t3053r1835b3107],
3	90ra59	NN	O	90ra59	nn	4	SENT_502	[p21l1850t3053r2027b3099],
4	(	NN	O	(	appos	1	SENT_502	[p21l132t3128r233b3183],
5	201	CD	NUMBER	201	number	6	SENT_502	[p21l132t3128r233b3183],
6	1	CD	NUMBER	1	num	7	SENT_502	[p21l251t3128r306b3183],
7	)	NN	O	)	dep	4	SENT_502	[p21l251t3128r306b3183],
8	.	.	O	.	_	0	SENT_502	[p21l251t3128r306b3183],

1	Yap	NNP	PERSON	Yap	_	0	SENT_503	[p21l128t3207r334b3267],
2	,	,	O	,	_	0	SENT_503	[p21l128t3207r334b3267],
3	T.A.	NNP	ORGANIZATION	T.A.	conj_and	1	SENT_503	[p21l128t3207r334b3267],
4	&	CC	ORGANIZATION	&	_	0	SENT_503	[p21l349t3205r664b3262],
5	Workman	NNP	ORGANIZATION	Workman	conj_and	1	SENT_503	[p21l349t3205r664b3262],
6	,	,	O	,	_	0	SENT_503	[p21l349t3205r664b3262],
7	P.	NNP	O	P.	appos	1	SENT_503	[p21l680t3207r712b3255],
8	Exploiting	VBG	O	exploit	partmod	7	SENT_503	[p21l729t3205r989b3268],
9	the	DT	O	the	det	11	SENT_503	[p21l1004t3205r1090b3255],
10	cancer	NN	O	cancer	nn	11	SENT_503	[p21l1104t3220r1277b3255],
11	genome	NN	O	genome	dobj	8	SENT_503	[p21l1290t3220r1522b3268],
12	:	:	O	:	_	0	SENT_503	[p21l1290t3220r1522b3268],
13	strategies	NNS	O	strategy	appos	1	SENT_503	[p21l1537t3207r1789b3268],
14	for	IN	O	for	_	0	SENT_503	[p21l1802t3204r1875b3255],
15	the	DT	O	the	det	16	SENT_503	[p21l1886t3205r1972b3255],
16	discovery	NN	O	discovery	prep_for	13	SENT_503	[p21l131t3283r381b3347],
17	and	CC	O	and	_	0	SENT_503	[p21l394t3283r490b3333],
18	clinical	JJ	O	clinical	amod	19	SENT_503	[p21l507t3283r682b3332],
19	development	NN	O	development	conj_and	7	SENT_503	[p21l700t3283r1053b3345],
20	of	IN	O	of	_	0	SENT_503	[p21l1067t3282r1122b3332],
21	targeted	VBN	O	target	amod	23	SENT_503	[p21l1130t3283r1353b3346],
22	molecular	JJ	O	molecular	amod	23	SENT_503	[p21l1372t3283r1632b3332],
23	therapeutics	NNS	O	therapeutics	prep_of	19	SENT_503	[p21l1644t3283r2145b3345],
24	.	.	O	.	_	0	SENT_503	[p21l1644t3283r2145b3345],

1	Annu	NNP	PERSON	Annu	_	0	SENT_504	[p21l1644t3283r2145b3345],
2	.	.	O	.	_	0	SENT_504	[p21l1644t3283r2145b3345],

1	Rev.	NNP	O	Rev.	nn	2	SENT_505	[p21l130t3362r226b3409],
2	Pharmacol	NNP	PERSON	Pharmacol	_	0	SENT_505	[p21l241t3360r526b3409],
3	.	.	O	.	_	0	SENT_505	[p21l241t3360r526b3409],

1	Toxicol	NNP	O	Toxicol	_	0	SENT_506	[p21l543t3360r723b3409],
2	.	.	O	.	_	0	SENT_506	[p21l543t3360r723b3409],

1	52	CD	NUMBER	52	_	0	SENT_507	[p21l740t3363r819b3416],
2	,	,	O	,	_	0	SENT_507	[p21l740t3363r819b3416],
3	549-573	CD	NUMBER	549-573	number	4	SENT_507	[p21l834t3363r1056b3409],
4	(	CD	NUMBER	(	appos	1	SENT_507	[p21l1074t3361r1248b3416],
5	2012	CD	DATE	2012	num	6	SENT_507	[p21l1074t3361r1248b3416],
6	)	NN	O	)	dep	4	SENT_507	[p21l1074t3361r1248b3416],
7	.	.	O	.	_	0	SENT_507	[p21l1074t3361r1248b3416],

1	Chen	NNP	PERSON	Chen	_	0	SENT_508	[p21l129t3438r278b3495],
2	,	,	O	,	_	0	SENT_508	[p21l129t3438r278b3495],
3	R.	NNP	O	R.	nn	4	SENT_508	[p21l295t3440r336b3487],
4	etal	NN	O	etal	appos	1	SENT_508	[p21l350t3438r462b3487],
5	.	.	O	.	_	0	SENT_508	[p21l350t3438r462b3487],

1	Personal	JJ	O	personal	amod	2	SENT_509	[p21l481t3438r698b3487],
2	omics	NNS	O	omic	nsubj	4	SENT_509	[p21l715t3440r868b3488],
3	proﬁling	VBG	O	proﬁling	partmod	2	SENT_509	[p21l884t3437r1102b3501],
4	reveals	VBZ	O	reveal	_	0	SENT_509	[p21l1120t3438r1299b3487],
5	dynamic	JJ	O	dynamic	amod	6	SENT_509	[p21l1313t3438r1538b3502],
6	molecular	JJ	O	molecular	dobj	4	SENT_509	[p21l1555t3438r1815b3487],
7	and	CC	O	and	_	0	SENT_509	[p21l1828t3438r1924b3487],
8	medical	JJ	O	medical	amod	9	SENT_509	[p21l1943t3438r2145b3487],
9	phenotypes	NNS	O	phenotype	dobj	4	SENT_509	[p21l133t3516r458b3579],
10	.	.	O	.	_	0	SENT_509	[p21l133t3516r458b3579],

1	Cell	NN	O	cell	_	0	SENT_510	[p21l473t3516r565b3566],
2	148	CD	NUMBER	148	num	1	SENT_510	[p21l579t3519r691b3573],
3	,	,	O	,	_	0	SENT_510	[p21l579t3519r691b3573],
4	1293-1307	CD	DATE	1293-1307	number	5	SENT_510	[p21l710t3519r994b3566],
5	(	CD	NUMBER	(	appos	1	SENT_510	[p21l1011t3517r1185b3573],
6	2012	CD	DATE	2012	num	7	SENT_510	[p21l1011t3517r1185b3573],
7	)	NN	O	)	dep	5	SENT_510	[p21l1011t3517r1185b3573],
8	.	.	O	.	_	0	SENT_510	[p21l1011t3517r1185b3573],

1	i	LS	O	i	dep	5	SENT_511	[p22l131t95r132b102],
2	This	DT	O	this	det	3	SENT_511	[p22l430t45r589b109],
3	work	NN	O	work	nsubjpass	5	SENT_511	[p22l652t45r850b109],
4	is	VBZ	O	be	auxpass	5	SENT_511	[p22l913t47r967b109],
5	licensed	VBN	O	license	_	0	SENT_511	[p22l1034t45r1356b109],
6	under	IN	O	under	_	0	SENT_511	[p22l1426t45r1658b109],
7	a	DT	O	a	det	12	SENT_511	[p22l1721t64r1757b109],
8	Creative	JJ	MISC	creative	amod	12	SENT_511	[p22l1824t47r2152b109],
9	"	``	O	"	punct	12	SENT_511	[p22l236t168r253b185],
10	*	CD	NUMBER	*	num	12	SENT_511	[p22l316t148r377b185],
11	Commons	NNPS	O	Commons	nn	12	SENT_511	[p22l432t152r828b213],
12	Attribution-NonCommercial-No	NN	O	attribution-noncommercial-no	prep_under	5	SENT_511	[p22l875t150r2152b213],

1	Derivative	JJ	O	derivative	amod	2	SENT_512	[p22l13t256r389b317],
2	Works	NNP	O	Works	_	0	SENT_512	[p22l404t254r633b317],
3	3.0	CD	NUMBER	3.0	num	4	SENT_512	[p22l653t259r761b317],
4	License	NNP	O	License	dep	2	SENT_512	[p22l784t256r1073b317],
5	.	.	O	.	_	0	SENT_512	[p22l784t256r1073b317],

1	To	TO	O	to	aux	2	SENT_513	[p22l1087t257r1172b317],
2	view	VB	O	view	_	0	SENT_513	[p22l1190t256r1364b317],
3	a	DT	O	a	det	4	SENT_513	[p22l1382t273r1419b317],
4	copy	NN	O	copy	dobj	2	SENT_513	[p22l1440t273r1618b335],
5	of	IN	O	of	dep	13	SENT_513	[p22l1636t254r1712b317],
6	this	DT	O	this	det	7	SENT_513	[p22l1725t254r1860b317],
7	license	NN	O	license	pobj	5	SENT_513	[p22l1882t254r2152b327],
8	,	,	O	,	_	0	SENT_513	[p22l1882t254r2152b327],
9	visit	NN	O	visit	nn	10	SENT_513	[p22l8t351r160b412],
10	http://creativecommons.org/	NN	O	http://creativecommons.org/	appos	7	SENT_513	[p22l186t349r2098b430],
11	|	CD	NUMBER	|	num	12	SENT_513	[p22l186t349r2098b430],
12	icenses/by-nc-nd/3	NN	O	icenses/by-nc-nd/3	dep	10	SENT_513	[p22l186t349r2098b430],
13	.0	CD	NUMBER	.0	dep	2	SENT_513	[p22l186t349r2098b430],
14	/	:	O	/	punct	13	SENT_513	[p22l186t349r2098b430],

